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 I 
Abstract  
Duchenne muscular dystrophy (DMD) is an X chromosome-linked disease caused by the 
absence of the sarcolemmal protein dystrophin. The skeletal muscles of DMD have disrupted 
dystrophin-glycoprotein complex (DGC) and impaired sarcolemma integrity. In this study, we 
show that clonally derived dystrophin-deficient myoblasts PD50A are differentiation impaired. 
Coculture with osteoblasts improves the differentiation efficiency of PD50A myoblasts. We 
also establish that supplementation of combinations of IGF-1/IGF-2, IGF-1/LIF and IGF-
2/LIF in cultured PD50A myoblasts ameliorates the differentiation impairment. We establish 
that there are elevated levels of Cav-3 and Cav-1 proteins in dystrophin-deficient myoblasts 
and mdx mouse embryos and that Cav-3 and Cav-1 form heterooligomers in adult skeletal 
muscles. We show that overexpression of Pax7 suppresses Cav-3 in dystrophin-deficient 
myoblasts. Using a genetic mouse model (mdx/cav3+/-) embryo we further establish that 
immunohistochemistry staining of Cav-1 and Cav-3 coincides with the mouse heart 
development. The DGC of skeletal muscles plays a role in signal transduction and mechanical 
response. Here we show that AKT/mTOR and IGF-2/p57kip2 (but not ERK) signalling 
pathways are upregulated in dystrophin-deficient myoblasts and mouse embryos. Using 
atomic force microscope we show that Cav-1 helps maintain the stiffness of dystrophin-
deficient myotubes while Cav-3 help maintain that of dystrophin-deficient myoblasts. This 
study suggests that Cav-1 and Cav-3 have both compensatory and compromising roles in mdx.  
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Chapter 1. Introduction 
Both the skeletal muscles of DMD patients and mdx mice [mouse model of Duchenne 
Muscular Dystrophy (DMD)] have elevated levels of caveolin-3 (Cav-3) (Merrick et al., 2009; 
Repetto et al., 1999; Vaghy et al., 1998). The muscle stem cells isolated from DMD patients 
or from adult mdx mice have been suggested to differentiate less efficiently than wild-type (wt) 
controls in culture (Blau et al., 1983; Delaporte et al., 1984; Schuierer et al., 2005). Primary 
muscle stem cells isolated from mdx and cav3-/- [mouse model of Limb Girdle Muscular 
Dystrophy type 1C (LGMD-1C)] mouse embryos have elevated rates of proliferation coupled 
with elevated apoptosis, suggesting aberrant behaviour of the muscle stem cells (Merrick et 
al., 2009). There is attrition of Pax7-positive cells in mdx embryos and this attrition is 
exacerbated by reducing the Cav-3 levels in mdx mice (mdxcav-3+/-) (Merrick et al., 2009). 
The aim of this project is to understand whether up-regulation of Cav-3 in mdx plays a 
compensatory or pathological role in the progress of pathology.  
 
1.1. Myogenesis  
1.1.1. Origin of skeletal muscle during embryogenesis 
With the exception of the head muscles, the embryonic skeletal muscles of the vertebrate 
body are derived from the myotome, which is differentiated from the dorsal part of somite 
(Kahane et al., 1998; Venters et al., 1999) (Figure 1.1). The dorsal part of the somite in mouse 
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embryos differentiates into the dermomyotome, and dorsal-medial cells then delaminate from 
the dermomyotome and migrate underneath to form the primitive skeletal muscle, myotome 
(Venters et al., 1999) (Figure 1.1). Formation of myotome in chick embryos involves two 
sequential steps (Gros et al., 2004). In the first phase, progenitors delaminate from the dorsal-
medial lip of dermomyotome, migrate underneath the dermomyotome and elongate 
bidirectionally (Gros et al., 2004; Kahane et al., 1998). In the second phase, the myocytes 
arise from boarders of the dermomyotome in the sequence of caudal border, rostral border and 
ventral-lateral lip (Gros et al., 2004; Kahane et al., 1998) (Figure 1.1).  
 
Figure 1.1 Schematic representation of myotome specification and the 
siganlling underpin this process.  
The specification of myotome from dermomyotome is in response to the 
coordinate signals from the dorsal neural tube (BMP4, Wnt1 and Noggin), 
notochord (Shh), lateral ectoderm (Wnt7a) and lateral mesoderm (BMP4). 
(Modified from Marcelle et al., 1997 and Cossu and Borello, 1999)..(Cossu and 
Borello, 1999) 
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Synthesis of laminin α1 in response to Shh signalling, together with laminin β1γ1, helps the 
formation of basement membrane in the myotome, thus defining the structural boundary of 
the myotome (Anderson et al., 2009). The molecular markers of the dermomyotome have 
been investigated which include Pax3 and Pax7 (paired-typed homeobox transcription factors) 
(refer to section 1.2.2 for detail introduction of Pax3 and Pax7) (Goulding et al., 1991; 
Stockdale et al., 2000). The somites (both mice and chicks) respond to sonic hedgehog (Shh) 
from the notochord; Wnt (wingless) family from dorsal neural tube and dorsal ectoderm, and 
BMP4 (bone morphogenetic protein 4) from the lateral mesoderm such that they differentiate 
into the dermomyotome and the myotome (Borycki et al., 1999a; Jones et al., 1991; Marcelle 
et al., 1997; Pourquie et al., 1996; Spence et al., 1996; Tajbakhsh et al., 1998) (Figure 1.1). 
MyoD is a downstream target of Myf5 in progenitors of both epaxial and hypaxial 
musculature (Kablar et al., 1997; Tajbakhsh et al., 1997). In mouse and chick embryos, Wnt1 
signalling from the dorsal neural tube, which is under the induction of BMP4, activates Myf5 
in the expaxial region of newly formed somites; Wnt7a signalling from dorsal ectoderm can 
activate MyoD in the hypaxial region with a two-day delay (Cossu et al., 1996; Marcelle et al., 
1997; Tajbakhsh et al., 1998) (refer to section 1.2.5 for detailed introduction of Myf5 and 
MyoD) (Figure 1.1). Wnt family proteins have been shown to induce the expression of Myf5 
and MyoD in somites by in vitro culture of Wnt-expressing cells with the unsegmented 
paraxial mesoderm (UPM; from E9.5 mouse embryos); this UPM expresses myosin heavy 
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chain (MyHC) after 5 days in culture (Tajbakhsh et al., 1998). In both chick and mouse 
embryos, the Shh and Wnts signalling pathways also activate Noggin expression in the medial 
somites, which antagonises the BMP4 activity from neural tube and lateral mesoderm to form 
the barrier, contributing to the formation of dermomyotome (Cossu and Borello, 1999; 
Hirsinger et al., 1997; Marcelle et al., 1997; Pourquie et al., 1996) (Figure 1.1). From the 
study of chick embryos, it has been demonstrated that deep back muscles originate from the 
epaxial dermomyotome (proximal somite) while muscles of the limbs, abdomen and 
diaphragm come from the hypaxial dermomyotome (distal somite) (Denetclaw et al., 1997; 
Ordahl and Le Douarin, 1992) (Figure 1.1). 
The morphogenetic processes of skeletal muscles in limb buds begin when muscle precursor 
cells first delaminate from the epithelium of the hypaxial dermomyotome and migrate into the 
limb buds (Buckingham et al., 2003). In the mouse embryos, expression of Pax3/Lbx1 (a 
homeo-domain containing transcription factor), c-Met receptor tyrosine kinase and Scatter 
factor/hepatocyte growth factor (SF/HGF, ligand of c-Met) from embryonic day 9.5 (E9.5) 
regulates myoblast specification and migration (from E10.5) from hypaxial dermomyotome 
into the limb buds (Dietrich et al., 1999). Appendicular muscle precursor cells in mouse 
embryos (E10.5) with Lbx1－/＋and Lbx1－/－ lose their ability to laterally migrate from the 
dermomyotome to limb buds as do those which are deficient in Pax-3 (Gross et al., 2000; 
Tremblay et al., 1998). Once migration of cells stops, the myoblasts begin to differentiate and 
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fuse to form multinucleated muscle fibres. 
 
1.1.2. Two waves of myogenesis 
During embryonic myogenesis there are two waves of myognesis, primary and secondary 
myogenesis (Fredette and Landmesser, 1991; Harris et al., 1989; Ross et al., 1987). In mouse 
embryos, the formation of primary myotubes begins at E9.5 while formation of secondary 
myotubes commences from E13.5 and continues postnatally (Ashby et al., 1993; Harris et al., 
1989; Merrick et al., 2007). It has been suggested that primary and secondary myotubes come 
from distinct precursors (Fredette and Landmesser, 1991; George-Weinstein et al., 1993; 
Miller and Stockdale, 1986). Primary myoblasts fuse to form primary myotubes which 
secondary myoblasts use as the basis for attachment and as the surface for formation of 
secondary myotubes (Wigmore and Dunglison, 1998). Primary myotubes are distinguished 
from secondary myotubes in that they are shorter in size but fatter and doughnut-shaped in 
cross section (Pedrosa-Domellof and Thornell, 1994; Wigmore and Stickland, 1983). Primary 
myotubes express the slow embryonic isoform of myosin heavy chain (MyHC) whilst 
secondary myotubes express developmental (embryonic and neonatal) as well as adult fast 
MyHC isoforms (Refer to section 1.1.3 for myosin heavy chain isoforms) (Cho et al., 1994; 
Merrick et al., 2007; Miller et al., 1985; Pedrosa-Domellof and Thornell, 1994). In addition to 
MyHC isoform typing, secondary myotubes in chick embryos can also be identified with the 
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presence of fast Ca2+-ATPase in these myotubes (Fredette and Landmesser, 1991). 
 
1.1.3. Myosin heavy chain isoforms of skeletal muscles  
Four major MyHC isoforms have been identified in adult mammalian skeletal muscles; one 
slow type (MyHCβ) and three fast types (MyHCIIa, MyHCIId/x and MyHCIIb) (Pette and 
Staron, 2000). Appropriate localisation of slow and fast MyHC isoforms to different myotubes 
defines the specificity of individual skeletal muscle groups (Harridge, 2007; Pette and Staron, 
2000). The MyHC compositions reflect the function of skeletal muscles (Pette and Staron, 
2000). The fast muscle fibres have fast rates of contraction and relaxation and they are rich in 
enzymes for glycolytic metabolism, such as creatine kinase and glycerol 3-phosphate 
dehydrogenase (Okumura et al., 2005; Scott et al., 2001; Vitorino et al., 2007). In postnatal 
mice, the fast-twitch extensor digitorum longus (EDL) muscle (the lower anterior limb muscle) 
contains 87% of MyHCIIb with only 9% of MyHCIId/x and 4% of slow MyHC (Agbulut et 
al., 2003). In contrast, the slow muscle fibres have slow rates of contraction and relaxation 
and they are rich in proteins for oxidative metabolism, such as myoglobin and TCA cycle 
enzymes (Okumura et al., 2005; Scott et al., 2001; Vitorino et al., 2007). In postnatal mice, 
the slow-twitch soleus muscle (the lower posterior limb muscle) consists of about 54% 
MyHCβ, 31% MyHCIIa and 15% fast MyHCIId/x (Agbulut et al., 2003). Muscle fibres 
expressing different types of MyHC have different sizes (Mantilla et al., 2008; Pullen, 1977). 
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In adult rat EDL muscle, which consists of type I, IIa and IIb fibres, the cross-section areas of 
these three fibre types are IIb, I and IIa in the order of large to small (Pullen, 1977). Similarly, 
in adult rat soleus muscle which consists of type I and IIa fibres, cross-section areas of type I 
fibres are larger than those of type IIa fibres (Pullen, 1977).    
In mammalian embryos, the expression of developmental (embryonic and neonatal) MyHC 
isoforms is concomitant with adult fast myosin isoforms (Cho et al., 1994; Merrick et al., 
2007). In later stages of embryogenesis, down-regulation and elimination of developmental 
myosin isoforms are accompanied with replacement by adult MyHC isoforms in a muscle 
type-specific pattern (fibre type specification), a process that begins in the embryo (E15.5) 
and is not completed until several weeks after birth (Agbulut et al., 2003; Merrick et al., 
2007). Overexpression of insulin-like growth factor 2 (IGF-2) in mouse has been shown to 
increase the number of fast MyHC (FMyHC) positive myotubes in mouse from E15.5 to just 
after birth (P1) (Merrick et al., 2007) (Refer to section 1.7 for detailed introduction of IGF-2 
and myogenesis).  
  
1.2. Muscle Stem Cells  
Stem cells are characterised by their ability to self-renew and their potential to differentiate 
into specialized cells. Based on their origin, stem cells can be divided into several categories 
comprising; embryonic stem (ES) cells, which are derived from the inner cell mass (ICM) of 
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the blastocysts; embryo-derived stem cells (such as mesoangioblasts and embryonic 
myoblasts); adult stem cells; and induced pluripotent stem (iPS) cells derived from 
reprogramming the somatic cells (Merrick et al., 2010; Minasi et al., 2002; Okita et al., 2007; 
Passier and Mummery, 2003; Smith and Schofield, 1997). Somatic and adult stem cells are 
largely tissue specific and reside in specific niches within those tissues; examples of tissue 
specific adult stem cells are the neural stem cells and skeletal muscle stem cells (SMSCs; also 
referred to as myoblasts, muscle progenitors and satellite cells) (Kim and Morshead, 2003; 
Qu-Petersen et al., 2002; Smith and Schofield, 1997; Zammit et al., 2006a). In prenatal 
muscle development, the transcription factor Pax3 is important for the function of embryonic 
muscle stem cells; however, Pax7 is important for postnatal myogenesis (Refer to section 
1.2.2 for detailed introduction of Pax7 and Pax3 in myogenesis) (Hutcheson et al., 2009; 
Kassar-Duchossoy et al., 2005; von Maltzahn et al., 2013). 
 
1.2.1. Satellite cells 
Postnatal muscle growth, maintenance and repair after injury depend primarily on the muscle 
stem cell population (Mauro, 1961; Zammit et al., 2006a). Satellite cells are characterised by 
their anatomic position between the sarcolemma and basement membrane of muscle fibres 
(Figure 1.3) (Hawke and Garry, 2001). Quiescent satellite cells are reported to be wedge-
shaped whilst activated satellite cells are elongated (Figure 1.2) (Hawke and Garry, 2001). To 
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activate the regeneration response in muscles, quiescent satellite cells are activated to 
differentiate and fuse to complete muscle regeneration (Collins et al., 2005; Mauro, 1961). As 
a source for muscle growth and repair, satellite cells exhibit the ability to self-renew to 
maintain the stem cell pool (Collins et al., 2005; Zammit et al., 2004). 
 
Figure 1.2 Anatomic identification of satellite cells within muscle fibres.  
Satellite cells reside between the basal lamina and sarcolemma and are smaller in 
size than myonuclei. Quiescent satellite cells are wedge-shaped, whereas 
activated satellite cells are elongated in shapes. Scale bar: 1 μm (Taken from 
Hawke and Garry, 2001). 
In mouse neonatal skeletal muscles, satellite cells constitute about 30% of the total myonuclei 
and the number decreases with maturation with only about 1-4% in adult skeletal muscles 
(Hawke and Garry, 2001; Snow, 1977). The muscle stem cell population is heterogeneous 
both in terms of the markers expressed by these cells and their proliferative response. Based 
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upon their proliferation behaviour, myoblasts are divided into the producer satellite cells 
which are active in fusion and the reserve (nonfusion) satellite cells which have prolonged 
cell-cycle duration (Collins et al., 2005; Schultz, 1996). Through single fiber analysis of the 
mitotic satellite cells from adult rat continuously infused with BrdU up to fourteen days, it has 
been suggested that the producer satellite cells occupy about 80% of the satellite cell pool and 
reserve satellite cells make up the rest 20% of the pool (Schultz, 1996).  
 
1.2.2. Paired-Type Homeobox Transcription Factor (Pax7 and Pax3) and satellite cells 
One common molecular marker used to identify satellite cells in adult muscles is the paired-
type homeobox transcription factor Pax7 which is observed both in quiescent and activated 
satellite cells in adult muscles (Fukada et al., 2007; Gnocchi et al., 2009; Seale et al., 2000). 
However, expression of Pax7 decreases in activated satellite cells (Fukada et al., 2007; 
Gnocchi et al., 2009; Seale et al., 2000). A recent study indicates distinct roles of Pax7 and 
the related, Pax3 in postnatal and prenatal limb muscle development. In this study Pax3+Pax7- 
myogenic progenitor cells in mouse embryos were found to give rise to Pax3-derived Pax7+ 
cells; ablation of these Pax7+ cells compromises limb fetal myogenesis (Hutcheson et al., 
2009). Pax3, like Pax7, is also expressed in quiescent and activated satellite cells in adult 
muscles (Kassar-Duchossoy et al., 2005; Relaix et al., 2006). About 88% of the Pax7-positive 
myogenic population in diaphragm expresses Pax3 and about 20% of the Pax7-positive 
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myogenic population in limb muscles is also Pax3 positive (Relaix et al., 2006). See next 
section for detailed introduction of functions for Pax7 and Pax3 in myogenesis. 
 
Paired-Type Homeobox Transcription Factor (Pax7 and Pax3): 
The paired-type homeobox transcription factors Pax3 and Pax7 play crucial roles in 
myogenesis in which they show overlapping functions in most parts of the embryos, including 
somite, neural tube, and neural crest (Relaix et al., 2004). However, the functions of Pax3 in 
delamination, migration and proliferation of progenitor cells designated to form limbs are not 
replaced by Pax7 (Relaix et al., 2004). During embryogenesis, Pax3 is essential for the 
development of dermomyotome and myotome (Goulding et al., 1994; Tremblay et al., 1998). 
Pax3 deficient mice, the Splotch mouse, have muscle precursor cells but these cells do not 
migrate. Consequently the mice lack hypaxial musculature (limb, trunk and diaphragm 
muscles) (Tremblay et al., 1998). In addition, the Splotch mouse embryos also show fused 
bones (Tremblay et al., 1998). During embryogenesis, Pax3 is crucial for the survival of 
somatic cell; somites of Splotch mouse embryos have elevated levels of apoptosis (Borycki et 
al., 1999b). It has been reported that, Pax3, homeoproteins Six1 and Six4 are essential for the 
expression of Lbx1, c-Met, MRFs and even Pax3; thus regulating cell migration from the 
dermomyotome (Dietrich et al., 1999; Grifone et al., 2005). Pax3 is also expressed by a small 
population (~3-10%) of muscle stem cells in juvenile diaphragm, triceps and hindlimb 
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muscles (Relaix et al., 2006; Young and Wagers, 2010). Overexpression of Pax3 in this 
muscle stem cell population can promote their differentiation (Young and Wagers, 2010).     
In mouse embryos at E9.5-10, Pax7 expresses in the closed neural tube and in the 
dermomyotome (Horst et al., 2006; Jostes et al., 1990). The expression of Pax7 in dorsal 
neural tube and the anterior regions of somites is inhibited by Pax3 such that Pax7 is found in 
the medial region of neural tubes and the central region of dorsal dermomyotome (Borycki et 
al., 1999b; Horst et al., 2006; Jostes et al., 1990). In Splotch mice, Pax7 misexpresses in the 
dorsal neural tube and dorsomedial lip of dermomyotome where Pax3 normally expresses in 
the wt mice (Borycki et al., 1999b). In the absence of Pax7 (Pax7−/− mice), about 97% of the 
Pax7−/− mice die within three weeks after birth with no obvious reason (Mansouri et al., 
1996). Juvenile Pax7−/− mice show reduction of satellite cell number and increased satellite 
cell apoptosis, suggesting the role of Pax7 for the survival of adult satellite cells (Oustanina et 
al., 2004; Relaix et al., 2006; Seale et al., 2000). In addition, Pax7−/− mice exhibit defects of 
the skeletal structures derived from cephalic neural crest cells, such as shorter upper jaw 
(Mansouri et al., 1996). A recent report using Tamoxifen-inducible NICDOE (overexpression 
of constitutive activated Notch 1 intracellular domain) mice suggests that constitutive 
activation of Notch induces Pax7 expression in satellite cells leading to impairment of muscle 
regeneration after injury (Wen et al., 2012).  
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1.2.3. Heterogeneity of muscle stem cells 
The heterogeneity of muscle stem cells is represented by the diverse expression of their 
molecular markers. It has been suggested that two distinct populations of muscle precursor 
cells take part in the formation of myotome during embryogenesis; one population expresses 
both Myf-5 and MyoD while the other population expresses MyoD (Gensch et al., 2008; Ott 
et al., 1991; Tajbakhsh et al., 1996). Using immunolabeling together with in situ hybridization 
of single mouse muscle fibers, the established hematopoietic stem cell marker CD34 and the 
myoblast marker Myf-5 were identified as markers for quiescent satellite cells in adult 
muscles, some of which also expresses MyoD (Beauchamp et al., 2000). M-cadherin and c-
met are also identified to be candidate markers for adult muscle stem cells (Cornelison and 
Wold, 1997; Irintchev et al., 1994). However, satellite cells expressing M-cadherin, Myf5 and 
CD34 represent only about 80% of total quiescent satellite cells within the muscle fibre 
(Beauchamp et al., 2000). The expression of Myf5 and CD34 in satellite cells declines in 
activated satellite cells while the expression of M-cadherin increases in activated satellite 
cells (Beauchamp et al., 2000; Cornelison and Wold, 1997) (Refer to section 1.2.5 for detail 
introduction of Myf-5 and MyoD). It has been reported that muscle stem cells isolated from 
mouse skeletal muscles using SM/C-2.6 antibody (antigen: VCAM) are also CD34 positive 
but they make up only about 18% of the CD34 positive muscle stem cell population (Fukada 
et al., 2004; Fukada et al., 2007). The receptor for HGF/SF, c-met, is present in quiescent 
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muscle stem cells and its expression continues when the muscle stem cells are activated 
(Cornelison and Wold, 1997; Tatsumi et al., 1998). Expression patterns of these markers in 
postnatal myoblasts and the population of myoblasts expressing them are summarised in table 
1.1.  
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Molecular 
marker 
Quiescent 
satellite 
cells 
Activated 
satellite 
cells 
Proportion of 
myoblasts expressing  
Reference 
Caveolin-1 ++ + Also express Pax7 Gnocchi et al., 2009; Volonte et 
al., 2005 
CD34 ++ + Also express Myf5 and M-cadherin; 80% of 
satellite cells 
Beauchamp et al., 2000;  
c-met ++ ++ Also express M-
cadherin and syndecan 
Cornelison and Wold, 1997; 
Tatsumi et al., 1998 
CTR + + 
Emerin ++ ++ 
Integrin α7 ++ ++ 
Also express Pax7 
Jagged-1 － ++ Also express MyoD 
Lamin A/C ++ ++ Also express Pax7 
Gnocchi et al., 2009 
 
M-cadherin + ++ 
Also express Myf5, 
CD34 and c-met; 80% 
of satellite cells 
Cornelison and Wold, 1997; 
Irintchev et al., 1994 
MRF4 － ++  Cornelison and Wold, 1997 
Myf5 ++ + 
Also express CD34 and 
M-cadherin; 80% of 
satellite cells 
Beauchamp et al., 2000; 
Cornelison and Wold, 1997; Ott 
et al., 1991; Gensch et al., 2008; 
Tajbakhsh et al., 1996 ; 
Gayraud-Morel et al., 2012 
MyoD + ++ Also express Pax7 Cornelison and Wold, 1997; Gnocchi et al., 2009; Ott et al., 
1991; Gensch et al., 2008 
myogenin － ++ Also express myoD Cornelison and Wold, 1997; 
Gnocchi et al., 2009 
     NCAM － ++ Also express syndecan Capkovic et al., 2008 
Pax3 ++ － 10% of Pax7(+) cells Relaix et al., 2006 
Pax7 ++ + 
90% of these cells 
express Myf5 
Gnocchi et al., 2009; Fukada et 
al., 2004; Seale et al., 2000; 
Gayraud-Morel et al., 2012 
SM/C-2.6 
(antigen: 
VCAM) 
++  
Express in 18% of the 
CD34 positive satellite 
cells 
Fukada et al., 2004; Fukada et 
al., 2007 
Syndecan-3 
and 
Syndecan-4 
++ ++ 
Also express c-met 
Cornelison et al., 2001 
Table 1.1 The expression of some common molecular markers found in quiescent and 
activated satellite cells in adult muscle.  
The absence of individual marker is marked by “－”  whereas their presence is marked by 
“ +.” The number of “+” indicates increased or decreased expression of individual marker. 
Although Pax3 and Pax7 are expressed in activated satellite cells, their expression is down-
regulated once the activated satellite cells are committed to differentiation.   
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1.2.4. Other Markers for quiescent and activated muscle stem cells 
Expression pattern of the following markers and the cell population expressing them are 
summarised in table 1.1. The c-met positive quiescent and activated satellite cells also express 
two heparan sulfate proteoglycans (syndecan-3 and syndecan-4) (Cornelison et al., 2001). In 
that report, the authors suggested that proliferation and differentiation of satellite cells of 
isolated muscle fibres induced by HGF/SF and FGF require the formation of a complex which 
comprises the growth factors, their receptors and the syndecans (Cornelison et al., 2001). 
Caveolin-1 (Cav-1), integrin α7, calcitonin receptor (CTR) and two nuclear envelope proteins 
lamin A/C and emerin are also expressed in Pax7-positive muscle stem cells; they are present 
in both quiescent and activated satellite cells (Gnocchi et al., 2009). 90% of these Pax7-
positive cells also express Myf5 (Gayraud-Morel et al., 2012). Although the protein levels of 
Cav-1 and CTR decrease in activated satellite cells, the level of Cav-1 recovers from day 
three onward after induction of differentiation and it is also present in myotubes (Gnocchi et 
al., 2009; Volonte et al., 2005). NCAM and Jagged-1 (the Notch ligand) are expressed in 
activated satellite cells only, and thus can be used as markers for activated satellite cells in 
addition to MyoD, myogenin and MRF4 (Capkovic et al., 2008; Cornelison and Wold, 1997; 
Gnocchi et al., 2009). For a more detailed review of MyoD, MRF4 and myogenin see section 
1.2.5. 
Another population of the myogenic stem cells (called muscle-derived stem cells or MDSC) 
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isolated from subpopulation of reserve satellite cells is characterised by long-term 
proliferative capacity, strong self-renewal ability and multipontent differentiation (Gussoni et 
al., 1999; Qu-Petersen et al., 2002). The MDSCs are divided, according to Hoechst 33342 
(H33342) staining and fluorescence activated cell sorting (FACS) method, into a population 
of stem cells with low H33342 staining which was called side population (SP) to distinguish 
from the brightly stained main population (MP) (Gussoni et al., 1999). This population of 
muscle stem cells is not well understood.  
 
1.2.5. Myogenic Regulatory Factors (MRFs) and Myogenesis 
Myoblast differentiation begins with cell cycle withdrawal which is followed by expression of 
contractile proteins and ends when syncytial myotubes are formed (Figure 1.3) (Andres and 
Walsh, 1996). The skeletal muscle differentiation process requires the expression of muscle 
specific genes (such as MyHC) under the control of myogenic regulatory factors (MRFs) in 
cooperation with myocyte enhance factors (MEFs) (Blais et al., 2005; Molkentin et al., 1995; 
Pownall et al., 2002). The MRFs, including Myf5, MyoD, myogenin and MRF4, are 
transcription factors that share conserved basic helix-loop-helix (bHLH) DNA binding motifs 
and recognize E-box (consensus sequence of E-box is CANNTG) (Blackwell and Weintraub, 
1990; Davis et al., 1987; Rhodes and Konieczny, 1989; Wright et al., 1989). MRFs cooperate 
with E proteins (including HEB/HTF4, E2-2/ITF-2, and E12/E47) and the myocyte enhancer 
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factors (MEFs; e.g. MEF2) to regulate the expression of genes specific for myogenesis and to 
promote myogenic differentiation (Blackwell and Weintraub, 1990; Blais et al., 2005; 
Molkentin et al., 1995). Myogenesis can be negatively regulated by helix-loop-helix Id 
proteins; Id dimerizes with E protein through its helix-loop-helix domain which then disrupts 
the transcriptional activity of MRFs and inhibits myogenesis (Jen et al., 1992; Sun et al., 
1991). 
 
Figure 1.3 Expression of MRFs during myoblast differentiation.  
Expression of Myf5 and MyoD preceding MRF4 and myogenin leads to myoblast 
differentiation. Myf5 levels regulate renewal of satellite cells. Myogenin expression 
regulates terminal differentiation of myoblasts to myotubes. (Modified from Zammit 
et al., 2006)  
Forced expression of Myf5, MyoD, myogenin and MRF4 in fibroblasts can drive these cells 
to commit to the myogenic lineage (Braun et al., 1989; Davis et al., 1987; Rhodes and 
Konieczny, 1989; Wright et al., 1989). Myf5 and MyoD express early before myoblasts 
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undergo myogenesis and promote the determination of myoblasts whereas MRF4 and 
myogenin take part in fusion during myoblast differentiation (Figure 1.3) (Ferri et al., 2009; 
Pownall et al., 2002). MyoD has been reported to mediate the transition between quiescent 
satellite cells to activated myogenic precursor cells during postnatal myogenesis (Figure 1.3) 
(Sabourin et al., 1999). Levels of Myf5 protein correlate with cell fate decision of myoblasts; 
such that wild-type myoblasts undergo differentiation whereas myoblasts with Myf5 
heterozygous knock-out commit to self-renewal, which maintains a reservoir of 
undifferentiated satellite cells (Gayraud-Morel et al., 2012) (Figure 1.3). In C2C12 myoblasts, 
MRFs (Myf5, MyoD, myogenin and MRF4) can be detected in the cytosol of non-
differentiated myoblasts; these MRFs translocate into the nucleus to act as transcription 
factors when myoblasts enter differentiation (Ferri et al., 2009). This cytoplasmic-nuclear 
shuttling mechanism during myogenesis has been reported in NIH3T3 fibroblasts to be 
orchestrated via I-mf (inhibitor of MyoD family) in that I-mf proteins retain MRFs in the 
cytoplasm by masking the NLS signals of MRFs (Chen et al., 1996). I-mf is also employed in 
the sclerotome portion (precursor of skeleton) of the somite to prevent muscle differentiation 
(Chen et al., 1996). 
 
Myf5: 
During vertebrate embryonic myogenesis, Myf5 is the first expressed myogenic regulatory 
 20 
factor (MRF) (at about E8.0 in mouse embryos) and expression of Myf5 controls specification 
of the embryonic myogenic stem cell lineage (Ott et al., 1991; Tajbakhsh et al., 1996) (Figure 
1.4). 
 
Figure 1.4 Time table of the expression of MRFs during mouse embryogenesis.  
Primary myogenesis begins at E9.5 while secondary myogenesis begins at E13.5 
and continues after birth. Expression of Myf5 begins at E8.0; expression of 
myogenin begins at E8.5; and expression of MyoD begins at E10.5. Expression of 
MRF4 begins at E9.0; it disappears from E12 to E15 and express again from E15. 
(Adapted from Bober et al., 1991; Ott et al., 1991; Sassoon et al., 1989; 
Summerbell et al., 2002 ) 
Expression of Myf5 in hypaxial muscle progenitor cells is activated by the binding of Pax3 to 
Myf5 promoter. In contrast, its expression in epaxial muscle precursors is modulated by Gli 
transcription factor under the stimulation of Shh produced by notochord (Bajard et al., 2006; 
Borycki et al., 1999a; Buchberger et al., 2007; Gustafsson et al., 2002). The transition 
between activator forms of Gli2 (Cli2A)/Gli3 (Gli3A) and repressor forms (Gli2R and Gli3R) 
play vital roles in regulating Myf5 expression during skeletal muscle formation (McDermott 
et al., 2005). In cultured myoblasts (C2C12), Myf5 protein levels cycle with the cell cycle 
because of its role in determining the differentiation of myoblasts (Dedieu et al., 2002; 
Lindon et al., 1998). Myf5 protein levels decrease when cells enter the cell cycle (G1), 
 21 
increase at G2 to levels comparable to cells at G0 and then decrease at G2/M transition 
(Dedieu et al., 2002; Lindon et al., 1998). Cytosol-to-nucleus translocation of Myf5 during 
differentiation may correlate with the regulation of Myf5 activity; ubiquitination and 
proteosomoe degradation of nuclear Myf5 is triggered by phosphorylation of Myf5 by 
CDK1/cyclinB (Doucet et al., 2005; Ferri et al., 2009).  
 
MyoD: 
MyoD which is critical for the development of epaxial (trunk) and hypaxial (limb and 
branchial arch muscles) muscles during embryonic myogenesis is activated by both Myf5 and 
Pax3 (Berkes and Tapscott, 2005; Tajbakhsh et al., 1997). It is first detected in mouse 
embryos at E10.5 in myotomes and at E11.5 in limb buds (Sassoon et al., 1989) (Figure 1.4). 
In C2C12 myoblasts, MyoD expression is up-regulated by codependent binding of Pax3/7 and 
FoxO3 to the promoter element of MyoD during myoblast fusion (Dedieu et al., 2002; Hu et 
al., 2008). MyoD up-regulates the expression of the muscle specific genes Desmin (Des), 
Myosin Light Chains 1 and 2 (Myl1, Myl2), and embryonic myosin heavy chain (MyH3) by 
binding coordinately with MEF2 (myocyte enhancer factor 2) to the promoter regions of these 
genes via a feed-forward signalling in which MyoD promotes expression and activates p38 
mitogen-activated protein kinase (MAPK), which in turn promotes binding of MyoD and 
MEF2 to promoters of muscle specific genes (Figure 1.5) (Penn et al., 2004). 
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Figure 1.5 MyoD generates feed-forward signalling to regulate expression of muscle 
specific genes during myogenesis. 
 
MyoD/MEF2 activity in non-differentiated C2C12 myoblasts is inhibited by the 
transcriptional repressor prohibitin 2 (PHB2); this inhibition is released when Akt binds to 
PHB2 during myoblast differentiation (Sun et al., 2004). MyoD-dependent transcription of 
genes with E-boxes during C2C12 myoblasts differentiation is assisted by binding of 
transcriptional coactivator P300/BPC and histone acetyltransferase PCAF (Puri et al., 1997; 
Yuan et al., 1996). Studies on myoD-/- primary myoblasts show that MyoD induced expression 
of microRNA-1 (miR-1)/miR-206 down-regulates Pax3 and this causes down-regulation of 
anti-apoptotic factors Bcl-2 and Bcl-xL, leading to elevated apoptosis in myoblasts 
undergoing differentiation (Hirai et al., 2010). 
 
Myogenin: 
Myogenin becomes expressed in myotomes at E8.5 (two days prior to MyoD in myotomes 
and 12 hours later than Myf5), and is subsequently expressed in limb buds at E11.5 (Ott et al., 
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1991; Sassoon et al., 1989) (Figure 1.4). Expression of myogenin in embryos or in myoblasts 
during myogenesis is triggered by cooperative binding of MyoD and calcineurin (a 
calcium/calmodulin-dependent protein phosphatase)-NFAT3c (nuclear factor of activated T 
cells isoform 3c) to the promoter region of myogenin (Armand et al., 2008). Upon occupying 
the promoter region of myogenin, MyoD associates with histone deacetylase 1 (HDAC1) to 
repress the expression of myogenin in proliferating C2C12 myoblasts and works with PCAF 
(histone acetyltransferase) to up-regulate myogenin expression during C2C12 myoblast 
differentiation (Mal and Harter, 2003). Unlike myf5-/- and myoD-/- mice, myogenin null mice 
die neonatally; these mice exhibit a severe reduction of myotubes and extensive loss of 
skeletal muscle fibres although they have abundant mononucleate myogenic cells comparable 
to the residual myoblast population in wt counterparts (Hasty et al., 1993; Nabeshima et al., 
1993). This suggests that myogenin plays a key role in the fusion stage of embryonic skeletal 
muscle differentiation (Hasty et al., 1993; Nabeshima et al., 1993). During C2C12 myoblast 
differentiation, myogenin expression precedes the MyoD–induced expression of Cyclin-
dependent kinase inhibitors (p21CIP1 and p57KIP2) that promote cell cycle withdrawal, a 
process required for myogenic differentiation (Andres and Walsh, 1996; Busanello et al., 2012; 
Guo et al., 1995; Halevy et al., 1995; Zhang et al., 1999).  
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MRF4: 
MRF4 becomes expressed at E9.0 in somites and the expression of MRF4 is undetectable 
between E12-15 in mouse embryos (Bober et al., 1991; Kassar-Duchossoy et al., 2004; 
Summerbell et al., 2002) (Figure 1.4). MRF4 has not been identified in the hypaxial muscles 
of mouse embryos (Bober et al., 1991). The levels of MRF4 are high in differentiated 
myofibers and also in adult skeletal muscles compared to the other three MRFs (MyoD, Myf5 
and myogenin) (Hinterberger et al., 1991; Rhodes and Konieczny, 1989; Sambasivan et al., 
2013). In myf5-/- mouse embryos, MRF4 expression precedes and is required for the 
expression of MyoD (Kassar-Duchossoy et al., 2004). Expression of MRF4 in mfy5:myoD 
double null mice is required for skeletal muscle formation as myf5 null mice with no MRF4 
have no myogenesis, suggesting its role in determination of myogenic lineage (Kassar-
Duchossoy et al., 2004). Expression of MRF4 can be regulated by MyoD, Myf5 and 
myogenin; these MRFs recognize an E-box in the MRF4 promoter region and work 
synergistically with MEF2 to activate MRF4 transcription (Naidu et al., 1995).  
 
1.3. Dystrophin-glycoprotein complex 
The dystrophin-glycoprotein complex (DGC) is a transmembrane structure in the sarcolemma 
(plasma membrane of skeletal muscles) that links the extracellular matrix (ECM) through 
dystroglycan and actin cytoskeleton via dystrophin (Ervasti and Campbell, 1993). This pivotal 
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positioning of the DGC enables it to play roles both in sarcolemmal stabilization and in 
signalling modulation, such as signals from Neuronal Nitric Oxide Synthase (nNOS) and the 
PI3K/AKT pathway (Glass, 2005; Judge et al., 2006; Langenbach and Rando, 2002; 
Rybakova et al., 2000). Dystrophin, the largest gene in the mammalian genome, is encoded by 
14-Kb (kilo-base) cDNA spanning 2.4 Mb (mega-base) of chromosome Xp21 and consisting 
of 79 exons (Blake et al., 2002; Lapidos et al., 2004). The N-terminus of dystrophin protein 
consists of F-actin binding site, followed by a rod domain of 24 spectrin-like repeats, a 
cysteine-rich domain and the C-terminal domain (Blake et al., 2002) (Figure 1.6 A). Other 
components of the DGC include the glycoproteins dystroglycan, sarcoglycan and sarcospan 
(Figure 1.6 B) (Lovering et al., 2005). Dystrophin associates with β-subunit of dystroglycan 
through the carboxyl terminal WW domain (a protein-protein interaction motif containing two 
conserved tryptophan residues) (Lovering et al., 2005; Suzuki et al., 1992). 
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Figure 1.6 Dystrophin-glycoprotein complex (DGC) in sarcolemma.  
(A) The dystrophin and utrophin proteins share common features, including N-
terminal actin binding domain, spectrin-like rod repeats, cysteine-rich domain and 
C-terminal coiled-coil (CC) domain. The cysteine-rich regions contain WW 
domains, EF domains and ZZ domains all of which are able to bind to β-
dystroglycan (DG). (B) DGC links cytoskeleton F-actin within cells and laminin 
of the extracellular matrix (ECM) to provide integrity of sarcolemma. (C) Without 
dystrophin, β-dystroglycan is subject to tyrosine phosphorylation at position 892. 
Phosphorylated β-dystroglycan undergoes ubiquitination and degradation, 
accompanied by the elevation of caveolin-3 (Cav3) levels. SYN: syntrophin; DFB: 
dystrophin family binding site (Figure A is adapted from Blake et al., 2002; 
Bonuccelli et al., 2003; Ilsley et al., 2001)  
Dystrophin: 
The expression of dystrophin in mouse embryos begins at E9.0 in the heart and subsequently 
in the myotome at E9.5 (Houzelstein et al., 1992). In zebrafish, absence of dystrophin leads to 
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the detachment of muscle fibres and apoptosis of the detached muscle fibres, an indication of 
its role in stabilizing the myotendinous junctions (Bassett et al., 2003). Interaction between 
dystrophin and β-dystroglycan is mediated by the binding of WW-domain in dystrophin to 
two PPXY motifs (WW-binding domain) in β-dystroglycan; phosphorylation of the tyrosine 
residue in the WW-binding domain of dystrophin abrogates the interaction between 
dystrophin and β-dystroglycan (Ilsley et al., 2001; Yatsenko et al., 2007) (Figure 1.6 B and C). 
Cav-3 also interacts with β-dystroglycan through the WW domain (Sotgia et al., 2000) (refer 
to section 1.6 for Cav-3). The stability of dystrophin-glycoprotein complex is regulated by the 
phosphorylation status of WW-binding domain in β-dystroglycan (Sotgia et al., 2001). In the 
presence of dystrophin, the phosphorylation site on β-dystroglycan is covered by dystrophin 
and the whole complex remains stable whereas in the absence of dystrophin, Src-family 
tyrosine kinases phosphorylate β-dystroglycan and induce ubiquitination and degradation of 
β-dystroglycan through proteasome (Bonuccelli et al., 2003; Ilsley et al., 2001; Sotgia et al., 
2001). The consequences of β-dystroglycan degradation are the disruption of DGC complex 
(Bonuccelli et al., 2003) (Figure 1.6 B and C).  
 
Utrophin: 
Utrophin, an autosomal homologue of dystrophin, is localized to human chromosome 6q21 
and encoded by a cDNA of 13 kb (Love et al., 1989). Utrophin protein is very similar in 
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structure to dystrophin, consisting of an N-terminal actin binding domain, central rod-like 
repeats and a C-terminal coiled-coil domain; there is an 80% sequence homology between 
dystrophin and utrophin in the N-terminal actin binding domain and C-terminus region (Blake 
et al., 2002; Tinsley et al., 1992) (Figure 1.6 A). The greatest variation between utrophin and 
dystrophin lies in the rod domain which in utrophin lacks the domains corresponding to the 
actin-binding domain (spectrin-like repeats 15 and 19) in dystrophin (Amann et al., 1999; 
Pearce et al., 1993). During mouse embryonic development, utrophin is first identified in the 
neural groove at E8.5 and is later expressed in most tissues of the embryos, including brain, 
smooth muscle and both skeletal and cardiac muscles (Schofield et al., 1993). Utrophin 
localises around the sarcolemma in embryonic skeletal muscles (Schofield et al., 1993). In 
adult skeletal muscles, utrophin is largely absent from the sarcolemma (except for in 
regenerating fibres) becoming restricted exclusively to the neuromuscular junction in the 
sarcolemma and to the myotendinous junction, blood vessels, brain and peripheral nerves 
found between and within muscle fibres (Khurana et al., 1990; Khurana et al., 1991; 
Ohlendieck et al., 1991; Pons et al., 1991). Like dystrophin, utrophin also interacts with the β-
dystroglycan complex in the neuromuscular junction and sarcolemma (Matsumura et al., 
1992). Expression of utrophin proteins is upregulated in regenerating muscle fibers of both 
non-dystrophic and dystrophic subjects [Duchenne muscular dystrophy (DMD) and the mouse 
model mdx] (Refer to section 1.4 for muscular dystrophy) (Galvagni et al., 2002; Helliwell et 
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al., 1992; Khurana et al., 1991; Rigoletto et al., 1995; Weir et al., 2004). The level of utrophin 
in DMD can be negatively correlated with the clinical severity of the disease (i.e. age at 
becoming wheelchair-bound), suggesting a possible role for utrophin in compensation for the 
lack of dystrophin (Kleopa et al., 2006). Mice lacking both dystrophin and utrophin (dko mice) 
have muscular dystrophy phenotype, including reduced body weight, delayed bone healing, 
kyphosis (curvature of the spine, causing hunchback phenotype), slack posture, weak hind 
limbs, laboured breathing, fibrosis, cardiomyopathy and premature death (by 20 weeks of age) 
(Deconinck et al., 1997; Grady et al., 1997; Janssen et al., 2005). 
 
1.4. Duchenne Muscular Dystrophy (DMD), Limb Girdle Muscular Dystrophy type 1C 
(LGMD-1C) and their animal models 
Dysfunction of components of the trans-sarcolemmal DGC (Figure 1.6) results in a series of 
heritable Muscular Dystrophies (MD), including Becker Muscular Dystrophy (BMD; 
Dystrophin rod truncation mutation), sarcoglycanopathies (Limb Girdle Muscular Dystrophy 
type 2; LGMD 2A, 2B, 2C and 2D) and the severest (and commonest) form, Duchenne 
Muscular Dystrophy (DMD) (Lovering et al., 2005). DMD is caused by the complete lack of 
function of the dystrophin protein (stop codon mutation) and is characterised by progressive 
loss of function of the entire skeletal musculature (Lovering et al., 2005). The disruption of 
skeletal muscle function in DMD begins early from about four years of age; patients suffer 
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from progressive muscle weakness leading to wheelchair confinement (Parker et al., 2005; 
Sanyal et al., 1978). A recent study on mouse model of DMD, the mdx mice, suggests an 
embryonic origin of this disease (Refer to section 1.4.1 for animal models of DMD) (Merrick 
et al., 2009). The muscles of hips, shoulders, legs and the heart are affected in DMD patients 
(Brooke et al., 1989). Patients also suffer from scoliosis (lateral curvature of the spine) caused 
by muscle weakness (Brooke et al., 1989). Eventually respiratory failure and/or 
cardiomyopathy cause death of DMD patients in their adolescence (Parker et al., 2005). A 
majority of DMD patients die of complications of respiratory muscle failure; however, 98% of 
DMD patients who receive ventilation support develop overt cardiomyopathy by 18 years of 
age which progresses and causes the death of 40% of patients between 10 to 30 years of age 
(Gnecchi-Ruscone et al., 1999; Melacini et al., 1996; Parker et al., 2005). The skeletal 
muscles of DMD and mdx mice have elevated levels of caveolin-3 (Cav-3), suggesting the 
contribution of Cav-3 to the pathology of the disease (Refer to section 1.4.1 and 1.6 for 
further discussion of Cav-3) (Merrick et al., 2009; Repetto et al., 1999). LGMD-1C (limb 
girdle muscular dystrophy type 1C), an early onset skeletal muscle dystrophy affecting 
hypaxial muscles particularly in the limb and limb girdle, is caused by loss of function of 
Cav-3 (Refer to section 1.6 for Cav-3) (Minetti et al., 2002; Minetti et al., 1998). LGMD-1C 
patients show muscle pain, weakness of upper and lower limb muscles, hypertrophy, and 
elevated levels of serum creatine kinase (Aboumousa et al., 2008). Unlike DMD, LGMD-1C 
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patients show no cardiomyopathy although cardiomyopathy is reported in some Cav-3 
deficient mice (2-4 months of age), including the mutant used in this study (Aboumousa et al., 
2008; Merrick et al., 2009; Woodman et al., 2002).   
 
1.4.1. Animal models for DMD 
X chromosome-linked muscular dystrophy (Mdx) in mice:  
The mdx mouse, a spontaneously originating X chromosome-linked mutant, is a murine 
model of DMD and was found in a screening program for discovering enzymatic activity 
mutants of glycolysis (Bulfield et al., 1984). The mdx mouse has a nonsense point mutation in 
exon 23 of dystrophin gene that creates a premature stop codon in the dystrophin transcript 
(Ryder-Cook et al., 1988; Sicinski et al., 1989). mdx mice show pathologies similar to DMD, 
particularly in the diaphragm muscles and juvenile growth phase (Stedman et al., 1991). 
Pathology includes severe fibrosis, fatty infiltration, reduced muscle strength and fiber length 
(Stedman et al., 1991; Torres and Duchen, 1987). The muscles of mdx mice of more than 3 
weeks old have more number of centrally nucleated muscle fibres in limb and diaphragm 
muscles compared to non-dystrophic counterparts, suggesting muscle regeneration of mdx 
mice (Niebrqj-Dobosz et al., 1997; Tanabe et al., 1986; Torres and Duchen, 1987). In addition, 
the number of small-sized fibres increases in mdx diaphragm and limb muscles compared to 
non-dystrophic mice, suggesting impairment of the regenerative capacity in mdx mice 
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(Niebrqj-Dobosz et al., 1997; Tanabe et al., 1986; Torres and Duchen, 1987). Detail analysis 
of the skeletal muscle function on mdx mice, such as locomotion and muscle strength (specific 
force and absolute power output) tests, shows significant muscle function impairment 
compared to age-matched non-dystrophic mice (Lynch et al., 2001; Rafael et al., 2000). 
Impairment of muscle function has also been shown by identifying the branched fibres in 
aged (6-7 months) mdx EDL muscles; these muscles have reduced specific force after 
lengthening contraction (Refer to section 1.5 for mechanical properties of muscle fibres) 
(Chan et al., 2007). 
 
Embryonic origin of muscular dystrophy: 
Recently, it has been shown that pathology of the mdx mouse originates early in embryos 
(Merrick et al., 2009). Pax7-positive cell attrition is evident in the proximal limbs of both mdx 
and mdxcav3+/- mouse embryos at E15.5 to E17.5 (Merrick et al., 2009). Myf-5 positive 
myoblasts isolated from E11.5-E17.5 mdx embryos exhibit elevated rates of apoptosis and 
proliferation compared to age-matched non-dystrophic embryos (Merrick et al., 2009). 
Muscle fibre splitting is observed in both mdx embryos and adult mdx skeletal muscles (Chan 
et al., 2007; Head, 2010; Merrick et al., 2009). The skeletal muscle fibres of mdx embryos 
show misalignment (Merrick et al., 2009). In addition, the ratio of fast myosin heavy chain 
(FMyHC) in mdx mice increases from E15.5 to E17.5 compared to non-dystrophic mouse 
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(Merrick et al., 2009). mdx mouse embryos at E13.5 to E17.5 also show dilation of the 
ventricular wall and abnormality in atrial trabecular formation, suggesting the development of 
cardiomyopathy in mdx embryos (Merrick et al., 2009).  
 
Canine X-linked Muscular Dystrophy (CXMD): 
Canine X-linked Muscular Dystrophy (CXMD) is the result of a point mutation in intron 6 of 
the dystrophin gene, which causes skipping of exon 7, resulting in a premature termination 
codon (Sharp et al., 1992). Like DMD and mdx, CXMD is characterised by elevated serum 
creatine kinase levels, progressive muscle degeneration and necrosis, fibrosis and fatty 
infiltration; additionally the dog has features not found in mdx such as distortion of the spinal 
column and thoracic wall (Cooper et al., 1988; Valentine et al., 1990; Valentine et al., 1988). 
Histopathologically, CXMD shows cytoplasmic disorganization, fiber size variation, 
alteration of fibre types (similar to DMD and mdx, regenerated muscle fibres of CXMD have 
predominance of type IIC fibres), severe fibrosis and fat infiltration (Valentine et al., 1990). 
Despite the pathological similarities between CXMD and DMD, this canine model exhibits 
variations in severity of clinical signs between different litters and it is expensive to raise this 
canine model (Cooper et al., 1988; Nakamura and Takeda, 2011).  
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1.4.2. Mouse models of LGMD-1C 
Cav-3 deficient (cav-3-/-) mice exhibit pathologies similar to LGMD-1C, including skeletal 
muscle degeneration and T-tubule defects (Galbiati et al., 2001a; Hagiwara et al., 2000; 
Herrmann et al., 2000; Minetti et al., 2002). Isolated Myf-5 positive embryonic myoblasts 
from E13.5 cav3-/- mouse embryos exhibit elevated rates of apoptosis and proliferation 
compared to age-matched wt embryos (Merrick et al., 2009). Adult cav-3-/- mice (5-30 weeks 
of age) have degeneration-regeneration cycles in their diaphragm and skeletal muscles 
(Hagiwara et al., 2000). Cav-3 null mice also show embryonic pathology comprising attrition 
of Pax7-positive cells (E15.5 to E17.5) and cardiomyopathy (dilation of the ventricular wall 
and abnormalities in atrial trabecular formation from E13.5 to E17.5) (Merrick et al., 2009). 
In contrast to mdx mice, however, the cav3-/- mouse embryos does not exhibit muscle fibre 
misalignment and splitting (refer to section 1.4.1 for mdx model) (Merrick et al., 2009). Nor 
does it have defects in movement and growth from 8-30 weeks (Hagiwara et al., 2000). In 
addition, protein levels of FMyHC in cav3-/- mouse embryos decrease from E15.5 to E17.5 
which is the opposite to that seen in mdx mice at E15.5-E17.5 where FMyHC is elevated 
(Merrick et al., 2009).  
 
1.5. The mechanical properties of dystrophic myoblasts and muscle fibres  
The muscle functions of mdx mice have been studied in various ways. The grip strength can 
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be easily measured and has been used to assess the muscle strength of mdx mice which show 
force impairment of their forelimbs (van Putten et al., 2012). The normalised isometric tetanic 
force and output power of mdx hindlimb muscles (EDL and soleus) are in average 15-30% 
and 33% less than non-dystrophic limb muscles respectively (Chan et al., 2007; Lynch et al., 
2001). The specific tetanic force of isolated diaphragm strips from mdx mice (9-12 weeks) is 
40% less than the age-matched controls (Stevens and Faulkner, 2000).   
In addition to the force measurements by grip test or electrical stimulation, the atomic force 
microscopy (AFM) has been used to measure the local mechanical properties (e.g. stiffness) 
of myoblasts and myotubes (Collinsworth et al., 2002). For example, the cortical stiffness of 
differentiating C2C12 myoblasts increases 4 fold from undifferentiated myoblasts to 
differentiated myotubes (Collinsworth et al., 2002). It has also been used with a glass stylus to 
measure the stiffness of mdx myotubes which is only 1/4 that of non-dystrophic myotubes 
(Pasternak et al., 1995), suggesting a potential role for dystrophin in response to mechanical 
stress in myotubes. In fibroblasts, response to mechanical stress is thought to be mediated 
through actin and microtubule remodelling (Heidemann et al., 1999). It has been reported that 
the change of cortical stiffness of muscle cells and fibres involves actin and microtubule 
remodelling (Collinsworth et al., 2002; Hofmann et al., 1997; Khairallah et al., 2012). In 
addition, impairment of microtubule remodelling in the skeletal muscles of mdx results in 
production of reactive oxygen species (ROS) after stretch, leading to increased influx of Ca2+ 
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(Claflin and Brooks, 2008; Khairallah et al., 2012; Suchyna and Sachs, 2007). Hindlimb 
muscles isolated from mdx mice show the longitudinal separation of muscle fibres after 
isometric tetanic contractions which is not observed in non-dystrophic controls, suggesting 
reduced coupling between intracellular cytoskeleton and extracellular matrix in mdx muscles 
(Claflin and Brooks, 2008). This stress-induced muscle fibre separation is correlated to the 
elevated intracellular Ca2+ concentration (Claflin and Brooks, 2008; Suchyna and Sachs, 
2007).  
 
1.6. Caveolins and caveolae mediated signalling 
Caveolae are small vesicular invaginations of plasma membrane with diameters of 50-100 nm 
(Severs, 1988). They play roles in transporting lipids (e.g. cholesterol and sphingolipids), 
endocytosis and concentrating signalling transducers, thus regulating signal transduction 
pathways (Kim and Bertics, 2002; Okamoto et al., 1998; Schlegel et al., 2000; Singh et al., 
2003). The principle components of caveolae are caveolins whose molecular weights are 17-
24 kDa (Glenney and Soppet, 1992). Three members of the caveolin protein family have been 
recognized; caveolin-1 (Cav-1), caveolin-2 (Cav-2) and caveolin-3 (Cav-3) (Couet et al., 
2001). Two isoforms of caveolin-1 (Cav-1α and Cav-1β) are derived from distinct 
transcription initiation (Kogo and Fujimoto, 2000). Cav-1β lacks the first 31 amino acid 
residues of the N-terminus which is present in Cav-1α (Kogo and Fujimoto, 2000; Scherer et 
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al., 1995). Cav-1α can form homo-oligomers and hetero-oligomers with Cav-2 or Cav-3 
through the scaffolding domain (amino acid residue 61-101) (Sargiacomo et al., 1995; Scherer 
et al., 1997; Volonte et al., 2008). Cav-1α and Cav-2 express in many types of cells, mainly 
adipocytes, fibroblasts and endothelial cells while Cav-3 is predominantly found in different 
types of muscle cells; skeletal, cardiac and smooth muscle cells (Scherer et al., 1997; Song et 
al., 1996). Levels of Cav-3 protein affect myotube formation such that down-regulation of 
Cav-3 inhibits both activation of focal adhesion kinase (FAK) and myotube formation 
(Galbiati et al., 1999; Quach et al., 2009; Volonte et al., 2003). In zebrafish, knocking down 
Cav-3 expression shows aberrant myofibril organization and impaired myoblast fusion (Nixon 
et al., 2005). This is consistent with the fact that expression of Cav-3 is linked to two types of 
muscular dystrophy, DMD and LGMD-1C (Refer to section 1.4 for muscular dystrophy).  
In addition to roles in regulating signalling pathways and endocytosis, caveolins also 
participate in the regulation of cell response to mechanical stress (refer to section 1.5 for 
introduction for mechanical properties of muscles). Phorbol ester induced contraction of 
vascular smooth muscle is mediated through binding between Cav-1α scaffold domain with 
protein kinase C (PKC), which in turn activates downstream ERK1/2 signalling pathway (Je 
et al., 2004). Activation of ERK1/2 pathway leads to the phosphorylation of actin-binding 
protein caldesmon (CaD) which releases from actin and leave actin for interaction with 
myosin (Je et al., 2004). Treating myoblasts with hypotonic solution or stretch causes 
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flattening of caveolae and this has been shown to be mediated by Cav-3 redistribution on the 
plasma membrane (Gervasio et al., 2011; Sinha et al., 2011). Stress-induced deformation of 
caveolae leads to Src activation (Gervasio et al., 2011). In skeletal muscles, Cav-3 has been 
demonstrated, via the WW domain, to bind to the PPXY motif in the c-terminal tail of β-
dystroglycan that also recognizes and binds to dystrophin, suggesting a competition between 
Cav-3 and dystrophin for β-dystroglycan (Jung et al., 1995; Sotgia et al., 2000).  
Misregulation of caveolin-1 has been shown to result in oncogenic transformation, but this 
role is cell type specific; Cav-1α protein levels increase in osteosarcoma but decrease in 
rhabdomyosarcoma (Sainz-Jaspeado et al., 2011). Transformed NIH3T3 fibroblasts show a 
reduction of Cav-1α protein levels compared to the normal NIH3T3 fibroblasts (Koleske et al., 
1995); on the other hand when Cav-1α is introduced into human breast cancer cells which 
have reduced level of Cav-1, growth of these tumor cells is inhibited (Lee et al., 1998). This 
implies Cav-1α can act as tumor suppressor. Missense mutations of Cav-1α (e.g. P132L, 
Y148S and Y148H) that resemble Cav-1 null mutation have been found in human breast 
cancer, especially those with estrogen receptor α-positive breast cancer (Li et al., 2006); loss 
of active Cav-1α in these breast cancer cells promotes their metastasis to lung in mouse 
(Williams et al., 2004). Overexpression of Cav-1α in CHO (Chinese hamster ovary) cells and 
NIH3T3 fibroblasts leads to cell cycle arrest of cells in G0 and G1 phases which is mediated 
via the p53 pathway leading to repression of cyclin D1 gene transcription (Galbiati et al., 
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2001b; Hulit et al., 2000). In addition, aortic smooth muscle cells isolated from Cav-1α 
knockout mice show elevated proliferation and migration compared to their wt counterparts 
(Hassan et al., 2006). This implies that Cav-1α, when over-expressed in fibroblasts, acts as a 
suppressor of proliferation in fibroblasts through regulating the cell cycle (Galbiati et al., 
2001b; Hulit et al., 2000; Volonte et al., 2002).  
  
1.7. Growth factors and myogenesis  
Expression of insulin-like growth factor-2 (IGF-2) and leukemia inhibitory factor (LIF) 
increases in mdx muscles, suggesting that IGF-2 and LIF may play a role in muscle 
regeneration in mdx mice (Porter et al., 2003; Reardon et al., 2000; Tkatchenko et al., 2000). 
IGF-2 acts as a survival factor for dystrophin-deficient myoblasts and plays key roles in the 
differentiation and survival pathways of skeletal muscles, particularly in embryos (DeChiara 
et al., 1990; Florini et al., 1991; Merrick et al., 2007; Prelle et al., 2000; Smith et al., 1995). 
Insulin-like growth factor-1 (IGF-1) is primarily a mitogen for the postnatal growth of mice 
(Baker et al., 1993). Leukemia inhibitory factor (LIF) has been reported to participate in the 
regeneration of rat muscle fibres after injury (Kami et al., 2000). Expression of LIF also 
increases immediately after exercise in human skeletal muscles and its level then decreases 
along with time (Broholm et al., 2008). 
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1.7.1. Insulin-Like Growth Factors (IGF-1, IGF-2)  
After binding to type I insulin-like growth factor receptor (IGF1R), IGFs (IGF-1 and IGF-2) 
signalling is passed down through the PI3K signalling pathway which exerts its effect by 
promoting the phosphorylation of Akt/protein kinase B (PKB), a serine-threonine kinase and 
therefore promotes myogenesis (Coolican et al., 1997; Jiang et al., 1999; Jiang et al., 1998; 
Kaliman et al., 1998). The known downstream targets of PI3K/Akt signalling cascades 
include FOXO (transcription factor forkhead box O), mTOR and GSK-3β (Glycogen synthase 
kinase-3β) (Puente et al., 2006; Shiojima and Walsh, 2006) (Figure 1.7).  
 
Figure 1.7 Signalling cascades downstream the IGF1R/PI3K/AKT.  
Whereas activation of mTOR by AKT promotes signals related to cell 
proliferation; phosphorylation of GSK3β inhibits its negative role on the target 
genes. FOXO, whose target genes participate in regulation of cell death is 
inactivated when phosphorylated by AKT. (Modified from Shiojima and Walsh, 
2006) (Shiojima and Walsh, 2006) 
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Differentiation of myoblasts is stimulated in the presence of IGF-1 when the negative role of 
GSK-3β is inhibited through phosphorylation by Akt/PKB which releases the inhibition of 
GSK-3β on NFAT and thus contributes to an increase in muscle size (van der Velden et al., 
2006; Vyas et al., 2002) (Figure 1.7). mTOR (mammalian target of rampmycin) signalling 
regulates muscle fibre hypertrophy by phosphorylation and activation of downstream 
ribosomal p70S6K and PHAS-1/4E-BP1; both genes are crucial for protein synthesis (Bodine et 
al., 2001; Pallafacchina et al., 2002). Moreover, myogenic differentiation can also be 
promoted through mTOR mediated IGF-2 expression during myogenesis (Erbay and Chen, 
2001; Erbay et al., 2003; Shu et al., 2002; Yoon and Chen, 2008) (Figure 1.7). 
Phosphorylation of FOXO by Akt/PKB disturbs its role in prompting p27kip1 expression; 
binding of p27kip1 to cyclin E/Cdk2 complex causes G0/G1 arrest and induces expression of 
BIM, leading to programmed cell death (Burgering and Medema, 2003; Gilley et al., 2003). 
Phosphorylated FOXO is exported from the nucleus and binds to 14-3-3 (Burgering and 
Medema, 2003). Phosphorylation status of FOXO also modulates myoblast differentiation in 
that FOXO1 induces degradation of Raptor, the component of mTOR complex 1 (mTORC1); 
this indicates that FOXO1 may regulate myogenesis by down-regulating IGF-2 (Hribal et al., 
2003; Wu et al., 2008) (Figure 1.7). 
In vitro administration of IGF-1 to L6E9 myoblasts demonstrates that IGF-1 plays a role in 
both proliferation and differentiation of myoblasts (Engert et al., 1996; Kaliman et al., 1998). 
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The mitogenic signalling from IGF-1 is mediated via the MAP kinase pathway and precedes 
the myogenic signalling mediated via the phophatidylinositol 3-kinase (PI3K) signalling 
pathway (Coolican et al., 1997; Engert et al., 1996; Kaliman et al., 1998). Muscle-specific 
expression of IGF-1 induces hypertrophy of mdx skeletal muscles (Barton et al., 2002). 
Systematic administration of IGF-1 in mdx mice (1 mg/kg/day for 8 weeks) improves the 
contractile function of mdx diaphragm muscles by 30% (Gregorevic et al., 2002; Schertzer et 
al., 2006). IGF-2 is a survival factor for dystrophin-deficient myoblasts; treating mdx mice or 
cultured myoblasts derived from mdx mice with IGF-2 (1-20 ng/mL) reduces apoptosis of 
dystrophin-deficient muscle stem cells (Smith et al., 1995). Apoptosis is also significantly 
reduced in a transgenic mouse model mdxBlast which overexpresses IGF-2; overexpression of 
IGF-2 ameliorates skeletal muscle programmed cell death of these dystrophin-deficient mice 
(Smith et al., 2000).  
IGF-2 is up-regulated during myogenesis induced by serum withdrawal via an auto-regulation 
loop involving IGF binding protein-5 (IGFBP5) and the mTOR signalling pathway (Figure 
1.8) (Erbay et al., 2003; Florini et al., 1991; Ren et al., 2008). Myoblasts under low mitogen 
have elevated levels of IGFBP5 protein which help concentrate IGF-2 to some threshold to 
trigger the signalling mediated via IGF1R/PI3K/AKT/mTOR pathway, leading to the 
expression of IGF-2 and myogenesis (Ren et al., 2008) (Figure 1.8). It has been reported that 
IGF-2 (290 ng/ml) administration in rat biceps after myotoxin damage delays the early 
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regeneration response (from day 1 ro day 4) but enhances the late regeneration stage, showing 
larger size of regenerated muscle fibres on day 7 (Kirk et al., 2003). In C2 myoblasts, signals 
from N-cadherin formation between adjacent cells can promote myoblast differentiation 
through activating kinase RhoA, followed by p38 MAPK activation and then IGF2 expression 
(Lovett et al., 2006).  
 
Figure 1.8 Auto-regulation loop of IGF-2 during myogenesis induced by low 
mitogen or nutrients.  
IGFBP5 proteins help concentrate IGF-2 such that the level of IGF-2 reaches the 
threshold to trigger signalling via the IGF-1 receptor (IGF1R)/PI3K/AKT 
pathway which in turn promotes the expression of IGF-2 and myogenesis. Low 
mitogen condition may also promote IGF-2 expression through the mTOR 
signalling pathway (Modified from Erbay et al., 2003 and Ren et al., 2008). 
 
1.7.2. Leukemia inhibitory factor (LIF)  
Leukemia inhibitory factor (LIF) is a member of the interleukin (IL)-6 cytokine family which 
consists of IL-6, LIF, ciliary neurotrophic factor (CNTF), oncostatin M (OSM) and 
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cardiotrophin-1 (CT-1); they share gp130 as a common receptor subunit (Heinrich et al., 
1998). These cytokines participate in various cellular processes, including gene regulation, 
proliferation and differentiation (Heinrich et al., 1998). It has been reported that continuous 
delivery of LIF (7 unit/μl for 7 days) in mdx mice via a catheter increases not only fibre size 
but also number of fibres in regenerating areas (Kurek et al., 1996a). In vivo analysis shows 
elevated LIF and IL-6 mRNA expression in mdx compared to wt mice in non-regenerating 
muscles; it also shows increased mRNA production of LIF and IL-6 in regenerating skeletal 
muscles after injury (Kurek et al., 1996b), suggesting participation of LIF in muscle 
regeneration. Involvement of LIF in muscle regeneration following injury is reinforced by 
data showing that LIF receptor (LIFR) mRNA is expressed in the nucleus of muscle precursor 
cells after muscle injury but is absent in myotubes (myonuclei) (Kami et al., 2000). In LIF-/- 
mouse, the size of regenerating muscle is only half of that in wt mice (Kurek et al., 1997). 
Though smaller body weights are found in LIF-/- mice than in wt mice, they appear normal in 
most respects with the exceptions that LIF-/- mice have reduced muscle regeneration after 
crush-injury and that female LIF-/- mice are sterile (Kurek et al., 1997; Stewart et al., 1992). 
Sterility of the female LIF-/- mice is due to the failure of blastocyst implantation and 
decidualisation which are attributed to the lack of maternal LIF signalling responses (Chen et 
al., 2000a; Mohamet et al., 2009; Stewart et al., 1992).  
Research on C2C12 myoblasts and isolated satellite cells indicates that the effect LIF exerts 
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on muscle regeneration is mainly through the promotion of cell proliferation (Spangenburg 
and Booth, 2002; Vakakis et al., 1995; Wang et al., 2008; White et al., 2001). The effect of 
LIF during muscle regeneration may be mediated through the ERK and the signal transducer 
and activator transcription 3 (STAT3) signalling pathways whose phosphorylation coincides 
with myoblast proliferation (Jo et al., 2005; Kami and Senba, 2002) (Figure 1.9). 
 
Figure 1.9 Signalling pathway mediated by LIF stimulation that promotes 
myogenesis.  
LIF exerts its effect through the JAK/STAT3 as well as the ERK signalling 
pathway. This pathway inhibits the expression of CDO/BOC and STAT3 can 
associate with MyoD. CDO/BOC and MyoD form a positive feedback loop to 
promote myogenesis. (Adapted from Jo et al., 2005; Kami and Senba, 2002; Yang 
et al., 2009; Kang et al., 2002; Snyder et al., 2008) 
Function of the STAT3 signalling pathway in muscle differentiation may be regulated via the 
interaction of STAT3 and MyoD since STAT3 has been reported to bind to MyoD (Yang et al., 
2009) (Figure 1.9). Furthermore, regulation of myoblast proliferation and differentiation can 
be mediated by direct targeting of STAT3 to CDO (CAM-related/downregulated by 
oncogenes; member of Ig/fibronectin type III repeat subfamily) and BOC (brother of CDO; 
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member of Ig/fibronectin type III repeat subfamily), which form complexes with N- and M-
cadherins during myoblast differentiation and promote myogenesis via a positive feedback 
loop with MyoD (Kang et al., 2003; Kang et al., 2002; Kang et al., 1998; Snyder et al., 2008) 
(Figure 1.10). LIF is also used to maintain pluripotency of embryonic stem cells and induced 
pluripotent stem (iPS) cells which is mediated through the STAT3 signalling pathway (Niwa 
et al., 1998; Smith et al., 1988; Takahashi and Yamanaka, 2006; Williams et al., 1988).  
 
1.8. Therapies for Muscular Dystrophy 
Several potential therapies for muscular dystrophy are proposed and have been investigated. 
The pharmacological strategies are to improve the phenotypes of muscular dystrophy (e.g. 
decrease inflammation) (Khurana and Davies, 2003). The molecular-based therapies involve 
delivery of dystrophin gene (full-length or truncated mini-/micro-dystrophin) or antisense 
RNA (that cause exon skipping) to replace or restore the defect dystrophin gene in dystrophin-
deficient muscles (Chakkalakal et al., 2005). Cell-based therapies require transplantation of 
cells that can differentiate into myogenic lineages into dystrophic recipients; it includes 
muscle stem cells, embryonic stem cells and iPS cells (Strober, 2006). There are alternative 
routes such as induction of utrophin expression or administration of growth factors (e.g. IGF-
1 and IGF-2) in dystrophin-deficient muscles (Krag et al., 2004; Smith et al., 2000). 
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1.8.1. Pharmacological therapies 
Treating DMD patients with glucocorticoids, such as the corticosteroid, prednisone and its 
analogue, deflazacort, has been shown to slow down the progress of DMD, retarding 
respiratory and ventricular dysfunctions (Biggar et al., 2001; Bonifati et al., 2000; Markham 
et al., 2008). Treating mdx mice with deflazacort and prednisone along with nitric oxide donor 
(NO donor, such as L-arginine, MyoNovin and isosorbide dinitrate) shows better efficacy than 
treatment of glucocorticoids alone (Archer et al., 2006; Mizunoya et al., 2011). In one report 
from two Canadian provinces of Nova Scotia and Prince Edward Island, better survival rate 
could be achieved in DMD patients treated with steroids (prednisone or deflazocort) along 
with bisphosphonate than in patients treated solely with steroids (Gordon et al., 2011). 
Oxandrolone, an anabolic steroid, has also been shown to be beneficial for slowing the 
progress and increasing the muscle strength of DMD patients, mainly through up-regulation 
of the anabolism of fast myosin heavy chains (Balagopal et al., 2006; Fenichel et al., 1997). 
Although treatment with corticosteroids causes significant side effects in patients, such as 
weight gain, hypertension and osteoporosis, a long-term study (14 years) of five DMD 
patients reports that early treatment (at the age of 2-4 years) of prednisone prolonged walking 
ability and preserved both pulmonary and cardiac functions for four of these DMD patients 
(Ames et al., 2005; Merlini et al., 2012).  
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There are several pharmacological therapies being tested in mdx mice. Intervention of IGF-1 
(1 mg/kg/day for 8 weeks) in mdx mice via osmotic pump improves the force output of treated 
mdx diaphragm muscles (Gregorevic et al., 2002). Application of IGF-1 as a therapy for DMD 
has been in phase 1 clinical trials in the U.S. since 2010 (ClinicalTrials.gov Identifier: 
NCT01207908; Children's Hospital Medical Center, Cincinnati). Mdx mice with an IGF-2 
transgene (MdxBlast) have reduced programmed cell death of myoblasts, improved 
maturation (decrease of centrally nucleated muscle fibres) and an ameliorated 
histopathological phenotype (Smith et al., 2000). Mdx mice injected with myostatin 
propeptide, which inhibits the activity of myostatin, also show ameliorated dystrophic 
pathology, especially in the improvement of muscle function as indicated by an increase in 
specific force (Bogdanovich et al., 2005). Mdx mice treated with an antibody (Remicade®) 
which specifically inhibits activity of tumor necrosis factor-α (TNFα) have decreased 
inflammatory cell infiltration and necrosis, indicating the therapeutic potential of this 
antibody therapy (Grounds and Torrisi, 2004). Administrating mdx mice with the small 
peptide heregulin has been reported to ameliorate the dystrophic phenotype of mdx, mainly 
via reduction of degeneration of muscle fibres (Krag et al., 2004). These pharmacological 
therapies slow down the pathologenesis and improve the life quality of DMD patients. 
Besides, they can be applied in concert with cell-based or molecular based therapies to obtain 
a synergistic efficacy (also refer to section 1.7 growth factors and myogenesis).  
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1.8.2. Molecular-based therapies 
In direct gene delivery therapy, a functional dystrophin gene is inserted into a viral delivery 
vector and directly introduced into dystrophin-deficient muscle (Xiao et al., 1996). Even 
though the recombinant adeno-associated virus (rAAV) vector shows long-term persistence in 
recipients, packing capacity of rAAV is only about 5 kb which is far less than the full length 
dystrophin cDNA of 14 kb (Lapidos et al., 2004; Xiao et al., 1996). The therapeutic potential 
of truncated forms of dystrophin (mini- and micro-dystrophin which lacks the majority of the 
central rod-domain) has been examined by expressing the truncated dystrophin in transgenic 
mdx mice and transiently transfecting into dystrophic mice or muscle explants from these 
mice (Fabb et al., 2002; Jorgensen et al., 2009; Phelps et al., 1995). There, however, exists a 
risk of causing an immune response against the newly expressed viral products and the 
product of the transferred gene while utilizing rAAV as the vector, which results in 
diminishment of transduced cells and thus limits the efficacy of this clinical application 
(Wang et al., 2007; Yang et al., 1996). An alternative gene delivery therapy is to correct the 
mutated dystrophin RNA transcript by antisense RNA which modulates pre-mRNA splicing 
by skipping the mutated exon containing the premature stop codon (Denti et al., 2006; 
Popplewell et al., 2010; van Deutekom et al., 2001). In addition to the antisense 
oligonucleotide-based exon skipping, treating mdx mice with aminoglycoside antibiotics 
gentamycin or the dipeptide antibiotic negamycin can also cause read-through of premature 
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stop codon and therefore recover part of dystrophin expression (Arakawa et al., 2003; Malik 
et al., 2010). Overexpression of utrophin in mdx mice has also been reported to improve 
phenotype of these mice (i.e. fibre regeneration, force development and resistance to stretch) 
(Tinsley et al., 1998). The main issues of these gene-therapies are low transfection and 
delivery efficiency of the therapeutic genes, short lasting period and immune responses of 
recipients against the gene products and/or the virus vectors (Uchida et al., 2005; Wang et al., 
2007; Yang et al., 1996).  
 
1.8.3. Cell-based therapies 
Intra-arterial injection of CD34+/Sca1+ stem cells derived from forelimb and hindlimb 
muscles of normal mice into mdx mice exhibits transplant efficiency of about 12% after 21 
days (Torrente et al., 2001). 20-71% of tibialis anterior (TA) muscles of mdx mice injected 
with a mdx-clonally derived muscle cell line (PD50A) are positive for incorporation of 
PD50A cells which persist up to 12 months after transplantation (Smith and Schofield, 1997). 
We used this PD50A cells in the present study. DMD patients who received 5 weeks of 
consecutive implantation of normal myoblasts to the biceps have an incorporation efficiency 
of mostly less than 1%; only one patient in twelve who received the transplantation had 
incorporation efficiency reached 10% after 12 month of implantation (Mendell et al., 1995). 
Immunosuppressive treatments have been administrated to recipients along with 
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transplantated human mesenchymal stem cells and human myoblasts to suppress an immune 
response; these treatments increase the efficacy of myoblast transplantation (De Bari et al., 
2003; Guerette et al., 1997; Mendell et al., 1995). Polymorphonuclear LFA-1 (lymphocyte 
fusion-associated antigen 1) positive T-cells are found among the infiltrating cells after 
myoblast transplantation and inhibition of these LFA-1 positive cells by anti-FLA-1 antibody 
can improve the survival of myoblast transplants (Guerette et al., 1997). Transplantation of 
cells other than myoblasts, such as embryonic stem cell-derived satellite-like cells (Pax7-
positive cells derived from embryoid bodies) and mesoangioblasts (vessel-associated stem 
cells capable of giving rise to most mesoderm cell types) has also been reported to promote 
better survival of the donor cells in immunocompetent mice (Chang et al., 2009; Sampaolesi 
et al., 2003). It has been reported that human mesenchymal stem cells fuse with myoblasts 
isolated from DMD patients and contribute to myotube formation of these dystrophic 
myoblasts in cell culture experiments (Goncalves et al., 2006). This suggests that 
transplantation of human mesenchymal stem cells can be a potential therapy for DMD. In one 
promising study, mesenchymal stem cells derived from the synovial membrane of adult 
human knee joints showed long-term persistence and contributed to the satellite cell pool after 
being transplanted into the TA muscles of nude mice, which suggests potential use of these 
cells in DMD therapy (De Bari et al., 2001; De Bari et al., 2003). 60% of the injected TA 
muscels are positive for the transplanted mesenchymal stem cells into the TA muscles 4 weeks 
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after transplantation (De Bari et al., 2003). A subset of Pax7-positive satellite cells, which are 
marked with CD45-Sca-1-Mac-1-CXCR4+β1-integrin+ (CSM4B; skeletal muscle precursor 
cells or SMPs) surface markers, show high efficiency in restoring dystrophin-positive 
myotubes and they are also found in the satellite cell niche when transplanted into mdx mice 
(Cerletti et al., 2008).  
 
1.8.4. Transplantation of embryonic stem (ES) cells and induced pluripotent stem (iPS) cells 
into mdx mice 
Embryonic stem (ES) cells are cells isolated from the inner cell mass (ICM) of blastocysts 
(Evans and Kaufman, 1981; Martin, 1981; Thomson et al., 1998). They are characterised by 
their ability to self-renew, known as pluripotency (Chambers and Smith, 2004; Nagy et al., 
1990). When mouse ES cells are aggregated with diploid or tetraploid embryos they form 
foetal cells of three germ layers (ectoderm, mesoderm and endoderm) but not the 
extraembryonic lineage (Chambers and Smith, 2004; Nagy et al., 1990). The ability to 
differentiate to cell types derived from three embryonic germ layers is also demonstrated by 
the formation of teratomas when ES cells are injected into severe combined immunodeficient 
(SCID) mice or when ES cells are cultured in specific conditions (Martin, 1981; Odorico et 
al., 2001; Reubinoff et al., 2000; Thomson et al., 1998). The pluripotency of ES cells makes 
them a candidate for transplantation therapy in DMD. However, isolation of ES cells involves 
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destruction of embryos which is considered unethical by some ethicists (Mertes et al., 2006). 
The main scientific concern of using ES cells for therapeutic purpose is their tumorigenicity, 
thus it is necessary to differentiate ES (and iPSc; see next section) into precursor cell types to 
eliminate ES cell tumourigenicity (Denker, 2006).  
Reprogramming patient specific somatic cells back to pluripotent status produces the induced 
pluripotent stem (iPS) cells which bypass the ethical issues (Holm, 2008). iPS cells have been 
successfully produced by virally introducing Oct3/4, Klf4, Sox2 and c-Myc into adult mouse 
and human fibroblasts (Meissner et al., 2007; Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006) and by introducing Oct4, Sox2, Nanog, Lin28 into human fibroblasts (Yu et 
al., 2007). iPS cells share morphological similarities with ES cells, including round shape, 
large nuclei and scant cytoplasm (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). iPS 
cells exhibit similar pluripotency to ES cells; they form teratomas comprising tissues from 
endoderm, mesoderm and ectoderm when injected into SCID mice; they can also be induced 
to differentiate into specific cell lineages such as neural cells and cardiomyocytes and skeletal 
muscle cells (Awaya et al., 2012; Kaichi et al., 2010; Meissner et al., 2007; Takahashi et al., 
2007; Takahashi and Yamanaka, 2006; Yu et al., 2007). The iPS cells derived from mdx have 
been genetically engineered to carry human artificial chromosome (HAC) with the full length 
dystrophin gene [mdx-iPS (DYS-HAC)] (Kazuki et al., 2009). Chimeric mice generated from 
these mdx-iPS (DYS-HAC) cells have been shown to express the full length dystrophin gene 
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in skeletal muscles (Kazuki et al., 2009). The clinical applications of iPS cells are still limited 
because of the poor understanding of the detailed mechanisms of how the reprogramming 
process is regulated. Duplication and deletion of chromosomes has been reported in mouse 
iPS cells (Pasi et al., 2011). In addition, the iPS cells may form tumors if the ectopic 
reprogramming factors (c-Myc, Klf4, Sox2 and Oct4) are not silenced since c-Myc is an 
oncogene (Okita et al., 2007; Ramos-Mejia et al., 2010). In addition, the products of 
correcting genes (e.g. full length dystrophin gene) carried by the iPS cells may also be 
recognised as an antigen and thus trigger an immune response (Fairchild, 2010; Mendell et al., 
2010).  
 
1.9. Aims and objectives of this project 
The main goal of this project is to understand whether elevated levels of Cav-3 play a 
compensatory or compromising role in dystrophin-deficient myoblasts and mouse embryos. 
(Figure 1.10). 
A novel way to differentiate dystrophin-deficient myoblasts (Figure 1.10) 
The first objective is to study the differentiation capacity of dystrophin-deficient myoblasts. In 
a previous study (unpublished data of Leah Foley and Dr. Janet Smith), preliminary data 
suggested that co-culture of C2C12 (the non-dystrophic myoblast cell line) with an osteoblast 
cell line (MC3T3-E1) promoted the differentiation of C2C12 cells. This promotion could also 
 55 
be seen, to a lesser extent, in co-cultures of MC3T3-E1 cells with PD50A myoblasts (a 
dystrophin-deficient myoblast line derived from mdx mouse). In this objective I develop the 
coculture protocol for differentiation of dystrophin-deficient myoblasts.  
 
Figure 1.10 Schematical description of the goal and objectives of this thesis. 
The goal of this project is to study the role of elevated Cav-3 in mdx. The first 
objective is to examine the differentiation capacity of the dystrophin-deficient 
myoblasts. The second objective is to investigate the protein levels of Pax7 and 
Cav-3 in differentiating dystrophin-deficient myoblasts and also in embryos. The 
third objective is to study the mechanical responses of dystrophin-deficient 
myoblasts and myotubes.   
 
The role of elevated Cav-3 in dystrophin-deficient myoblasts and mdx embryos (Figure 1.10) 
There are elevation of Cav-3 protein levels and attrition of Pax7-positive cells in mdx mouse 
embryos (Merrick et al., 2009); the second objective is to study roles of Pax7 and elevated 
Cav-3 in dystrophin-deficiency. This was achieved by using immunohistochemistry (IHC) and 
immunoblotting to examine the expression patterns of Cav-3 and Pax7 in dystrophin-deficient 
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myoblasts and mouse embryos. Molecular manipulation including overexpression and 
knockdown of genes of interest (Cav-3 or Pax7) in both wt and dystrophin-deficient 
myoblasts was also used to examine the relationships between Cav-3 and Pax7.    
 
Mechanical properties of dystrophin-deficient myoblasts and myotubes (Figure 1.10) 
It has been reported that there is impairment of the specific force of mdx skeletal muscles 
(Chan et al., 2007; Lynch et al., 2001; van Putten et al., 2012); the third objective is to 
examine the relations between the levels of caveolins and the function (mechanical 
response/the stiffness) of myoblasts/myotubes. This was achieved by using the atomic force 
microscope (AFM). The goal of this objective is to understand whether elevated levels of 
caveolin in dystrophin-deficient myoblasts have pathological or compensatory roles for 
dystrophin deficiency in terms of mechanical properties. 
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Chapter 2. Material and Methods 
2.1. Cell culture  
2.1.1. Cell lines and mouse strains:  
Myoblast cell lines used were C2C12, a subclone of adult mouse myoblast C2 cell line 
derived from thigh muscles of 2-month-old mice (Yaffe and Saxel, 1977); dfd13 derived from 
5-week-old mdx mouse and PD50A cells which are a clonal derivative of dfd13 cells (Smith 
and Schofield, 1994; Smith and Schofield, 1997). Osteoblast MC3T3-E1 cell line is a cell line 
derived from newborn mouse calvaria (Sudo et al., 1983). WT (C57BL/10), isogenic mdx and 
cav-3−/− mouse strains were used. mdx and C57BL/10 mice were generated in-house. The 
Cav-3 knockout (cav-3−/− dystrophic) mice on a C57BL/10 background were from Dr. 
Yoshito Hagiwara (Tokyo) (Hagiwara et al., 2000). Double mutant het mice (mdxcav-3+/− or 
DMhet) are null for dystrophin (mdx) and heterozygous for Cav-3 (cav-3+/−); this strain was 
generated by intercrossing mdx and cav-3−/− mice by Dr. Merrick during her PhD (Merrick, 
2006; Merrick et al., 2009). The mouse iPS cell line JBL6 4F3 which was made by 
introducing four transcription factors, Oct4, Sox2, cMyc and Klf4 into mouse embryonic 
fibroblasts (MEF from C57BL/6J mouse) and the MEF cells were gifts from Dr. James 
Dutton, Minnesota (iPS cell facility, Stem Cell Institute, University of Minnesota, USA). The 
mouse embryonic fibroblast cell line STO was used as the feeder cells for iPS cell culture. 
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2.1.2. Cell culture for myoblasts: 
Cell stocks were removed from liquid nitrogen and thawed briefly at 37°C in a water bath 
[Grants Instruments (Cambridge) Ltd, UK] prior to use. Cell solution was transferred into a 
15-ml falcon tube (Falcon; Becton Dickinson Labware, USA) containing 5 ml of fresh 
medium and spun at 1000 rpm (round per minute) for 3 minutes by centrifuge [labofuge 300 
Heraeus centrifuge (Kendro Laboratory Products, Germany)]. Dimethyl Sulphoxide (DMSO 
HYBRI-MAXR; Sigma-Aldrich, UK) was added in cell stock to help prevent formation of ice 
crystals and stabilize cell membrane when cells were frozen, but it is toxic when at 37°C. 
Supernatant was aspirated and the cell pellet was resuspended in 5 ml of appropriate culture 
medium. For murine C2C12 myoblasts, the medium employed was Dulbecco's Modified 
Eagles Medium (DMEM; Invitrogen Ltd, UK) with 10% FCS (Sigma-Aldrich, UK), 1% 
Penicillin/Streptomycin (P/S; Sigma-Aldrich, UK) and 1% L-Glutamine (Sigma-Aldrich, UK). 
Dulbecco's Modified Eagles Medium (DMEM-F12 or DF-12; Invitrogen Ltd, UK) with 10% 
FCS, 1% P/S and 1% L-Glutamine was used for dfd13 and PD50A cell lines. For MC3T3-E1 
cell line, the preferential medium is Minimum Essential Medium Alpha Modification (Alpha-
MEM; Sigma-Aldrich, UK) with 10% FCS, 1% P/S and 1% L-Glutamine. Cell suspension 
was placed in a 25 cm2 plastic culture flask (Nunc Plasticware, UK) and the flask was placed 
into a 37°C Heraeus incubator (5% CO2; Kenodro Laboratory Products, Germany). The 
following day after cells were plated, the medium was replaced with 10 ml of fresh medium. 
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2.1.3. Subculture cell lines: 
Cells were subcultured when they reached approximate 80% confluence. Old culture medium 
was first aspirated and cells were gently washed with warm PBS (phosphate buffered saline; 
see appendix 2 for recipe). After washing twice with PBS, 1 ml of trypsin (porcine trypsin in 
0.2% EDTA‧4Na, 0.9% Sodium Chloride; Sigma-Aldrich Company, UK) was added into 
the flask. The flask was placed for 2 to 3 minutes to allow trypsin time to act and cells were 
monitored by an inverted microscope (Leica DMIRB, Leica, UK) to determine when 
detachment and individual cell separation had taken place. Then 9 ml of prewarmed medium 
was added into the flask to stop the trypsinization. 1 ml of the cell mixture was transferred to 
a new flask with fresh medium to keep the cell line. Cell number of the rest cell mixture was 
determined (see section 2.2. for cell number determination) for further experiments. 
 
2.1.4. iPS (induced pluripotent stem) cell culture:  
Gelatin coated flask preparation: 
The flasks for iPS cell culture were first treated with 0.1% gelatin. 3 ml of 0.1% gelatin 
(Sigma-Aldrich, UK) was added into the flask and this flask was placed at 4°C for 15-30 
minutes; alternatively the flask could be placed at 37 °C for 1 hour. The solution was aspirated 
and the flask was used for iPS cell culture.   
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Feeder cell preparation: 
Mitotically inactivated STO cells were used as the feeder cells for iPS cell culture to provide 
essential factors. When STO cells cultured in a 25-cm2 flask reached confluence, they were 
treated with 10 μg/ml of mitomycin C (Sigma-Aldrich, UK) and the cells were placed at 37°C 
supplied with 5% CO2 for 2.5 hours. The medium was then aspirated and the cells were 
washed with PBS twice. 1 ml of trypsin was added into the flask to separate cells and the 
reaction was stopped by addition of 10 ml of DMEM with 10% FBS. 4×104 cells/cm2 was 
plated into the gelatin-treated flask; for a 25-cm2 flask 106 of the mitomycin C-treated STO 
cells were plated. Detail information for total cell number used in different sizes of culture 
flasks was listed in table 2.1. Cells were kept at 37°C supplied with 5% CO2 for a week and 
the medium was changed everyday. 
 
Plate/ Flask/ 
Chamber slide 
Volume of 
Culture Medium 
Surface area (cm2) 
Number of STO 
cells required 
96-well 
48-well 
24-well 
6-well 
3.5-cm dish 
6-cm dish 
10-cm dish 
Small (25 cm2) 
Medium (80 cm2) 
Large (175 cm2) 
50 µl  
200 µl 
500 µl 
1  ml 
1  ml 
1.5 ml 
5  ml  
5  ml 
10  ml 
15  ml  
0.5 
1 
2 
9.6 
8.8 
21.5 
56.7 
25 
75 
175 
2×104 
4×104 
8×104 
3.84×105 
3.52×105 
8.6×105 
2.3×106 
1×106 
3×106 
7×106 
Table 2.1 The number of STO cells needed for feeder cell preparation after 
mitomycin C treatment. STO cells were plated in 4×104 cells/cm2. 
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Mitomycin C is a carcinogen and therefore it must be handled carefully. Lab coat, goggle and 
two pairs of gloves were worn while handling mitomycin C. The whole process was 
performed in a spill tray covered with foil. All the wastes were treated with concentrated 
sodium hypochlorite (VWR, UK) for 24 hours and then collected in an autoclave bag. 
 
iPS cell culture  
iPS cell stock was brought up as normal cell culture method mentioned in section 2.1.2. These 
iPS cells were maintained on feeder cells (see section above for feeder cell preparation) in iPS 
cell culture medium [knockout-DMEM (KO-DMEM; Invitrogen Ltd., UK) supplemented 
with 10% knockout-Serum Replacer (KO-Serum Replacer; Invitrogen Ltd., UK), 10% FBS, 
1% MEM non-essential amino acids (Invitrogen Ltd., UK), 2-mercaptoethanol (2-ME; 3.5 μl 
in 500 ml medium; Sigma-Aldrich, UK), 1% P/S and leukemia inhibitory factor (ESGRO-LIF 
107 units; 1000 units/ml medium, Millipore Ltd., UK)]. The medium without LIF was filter 
sterile through Acrodisc 0.45 μm filter (PALL Life Sciences, UK), stored at 4°C and used 
within 10 days. Filtered medium added with LIF can be stored at 4°C and must be used within 
5 days. Medium of iPS cells was replenished everyday to get rid of the waste and provide the 
nutrients. The iPS cells formed compact cell clusters on the feeder cells (Figure 2.1).  
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Figure 2.1 Mouse iPS cells cultured on feeder cells.  
Mouse induced pluripotent stem (iPS) cells formed compact cell clusters in the 
presence of feeder cells (mitotic-inactiavted STO cells). 
 
iPS cell subculture 
The iPS cells were expanded and cultured in a larger flask when they reach confluence. 
Trypsinization followed the instruction of Dr. James Dutton. The old medium was aspirated 
and the cells were washed twice with PBS. Cells were incubated at 37°C for 2 minutes before 
the second wash of PBS was aspirated. 1 ml of trypsin was added into the flask and the cells 
were incubated at 37°C for 5 minutes. The cells were examined under the inverted microscope 
and trypsinization was stopped when the iPS cells were beginning to float free whereas the 
feeder cells were detaching. 9 ml of iPS cell culture medium was added into the flask to stop 
trypsinization and the cell clumps were broken down by gently pipetting the mixture multiple 
times. The cell mixture was then transferred into a proper size of flask with mitomycin C-
treated feeder cells and incubated at 37°C with 5% CO2. Medium was refreshed everyday to 
provide the iPS cells necessary nutrients and to remove the wastes.  
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2.1.5. Freezing down cell lines: 
Cells were separated into individual cells by subculture method (section 2.1.3.) when they 
reached about 80% of confluence. Single cell suspension was first spun at 1000 rpm for 3 
minutes and supernatant was aspirated.  The cell pellet was resuspended in 10 ml of freezing 
medium (10% DMSO in corresponding culture medium) and spun at 1000 rpm for further 3 
minutes. The supernatant was removed and the cell pellet was resuspended in appropriate 
amount of freezing medium. 0.5 ml of the cell suspension was aliquoted into each labelled 
CryoTubeTM vial (Nunc plasticware, UK). The vials were immediately frozen at -80°C 
overnight and then transferred to the liquid nitrogen in the following day for long term storage. 
For example (see table 2.2), cells in a large flask were divided into 8 labelled CryoTubeTM 
vials and immediately placed at -80°C overnight. The vials were transferred to liquid nitrogen 
the following day for long-term storage. 
Plate/ Flask/ 
Chamber slide 
Volume of 
Culture Medium PBS washes 
Volume of 
trypsin 
Number of freeze 
down CryoTubes 
96-well 
48-well 
24-well 
6-well 
Small (25 cm2) 
Medium (75 cm2) 
Large (175 cm2) 
Chamber well 
50 µl  
150 µl 
500 µl 
2 ml 
10 ml 
10 ml 
30 ml  
500 µl 
2×100 µl 
2×200 µl 
2×700 µl 
2×3 ml 
2×10 ml 
2×15 ml 
2×20 ml 
2×500 µl 
25 µl 
50 µl 
200 µl 
500 µl 
1 ml 
3 ml 
5 ml 
100 µl 
N/A 
N/A 
N/A 
1 
2 
4 
8 
N/A  
Table 2.2 Reagents needed to freeze down the expected number of vials 
according to the container used for cell culture. N/A= not applicable, as cell 
numbers were too low to freeze down (modified from the thesis of Dr. Deborah 
Merrick, P47, Table 2.1, 2006) 
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2.2. Determining cell number: 
Cell number was determined using a haemocytometer (Fisher Scientific Ltd, UK). The 
coverslip was mounted onto the haemocytometer base by a gentle, but firm, sliding action. 10 
μl of cell suspension was added to each counting chamber (Figure 2.2).  
 
Figure 2.2 Cell number determination using haemocytometer. 
Cell densities were determined by counting cells in the four squares on the 
haemocytometer. (A) Side view of haemocytometer. (B) Above view of 
haemocytometer and the sample loading site. (C) View of grids (counting 
chamber) under microscope. (D) Cell number calculation when using 
haemocytometer. 
Haemocytometer with cell suspension was placed on an inverted microscope to visualise the 
counting chamber. Cell suspension would be diluted so that cells in counting chamber should 
not overlap. There should be 100 or more cells in each chamber to obtain statistically 
significant counts. The final cell concentration was obtained by multiplying total number of 
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cells counted in the 4 large squares by 2500 to give a value of number of cells/ml (i.e. Total 
100 cells counted: 100×2500 = 2.5× 105 cells/ml) (Figure 2.2) 
 
2.2.1. Myoblast and osteoblast coculture and growth factor effect experiments: 
Cell number used for coculture experiment is based on Leah Foley’s preliminary experiment 
(unpublished data of Leah Foley and Dr. Janet Smith). 2.625×104 of MC3T3-E1 osteoblasts 
and 1.5×104 of myoblasts (C2C12 and PD50A cell lines respectively) were plated on acid-
etched coverslips (see section 2.3 for coverslip preparation) in 48-well plates (Nunc 
plasticware, UK) in the presence of Alpha-MEM with 10% FCS, 1% P/S and 1% L-
Glutamine. 1.5×104 of myoblasts were plated on coverslips in 48-well plates in the presence 
of growth medium (GM; DMEM + 10% FCS + 1% P/S + 1% L-Glutamine) as the negative 
control. Myoblasts in differentiation medium [DM; DMEM + 1% L-Glutamine + 1% P/S + 
2% Horse serum (HS batch tested; Sigma-Aldrich, UK)] serve as the positive control. Cells 
were also treated with MC3T3-E1 cell-conditioned medium (OCM; half osteoblast-
conditioned medium and half DM). Alpha-MEM with 10% FCS, 1% P/S and 1% L-
Glutamine were used to culture MC3T3-E1 cells; this conditioned medium was used to treat 
C2C12 and PD50A myoblasts when MC3T3-E1 cells reach >85% of confluence. Conditioned 
medium from coculture of C2C12 cells with MC3T3-E1 cells (CCM) or from coculture of 
PD50A cells with MC3T3-E1 cells (PDCM) were also tested (CCM and PDCM were 
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collected when cells reached  >85% of confluence). For growth factor test, myoblasts in DM 
were supplemented with 20 ng/ml of IGF-II (insulin-like growth factor-II; R & D systems, 
UK), 100 ng/ml of IGF-I (insulin-like growth factor-I; R & D systems, UK) or 1000 unit/ml 
LIF (Millipore Ltd, UK) respectively. For determining the number of myonuclei in fusing 
under different treatments, myoblats were plated directly in the 48-well plate for four days 
and stained with Leishman’s stain (Refer to section 2.6.2 for Leishman’s stain). Myoblasts in 
coculture experiment were also cultured for ten days, and the myotubes were labelled with 
anti-pan-myosin antibody (see section 2.6.3 for fluorescent immunostaining).  
 
2.2.2. Cell culture for protein assay: 
C2C12 and PD50A myoblasts were plated in 10-cm dishes (Nunc plasticware, UK) with 
8.5×105 cells per dish (1.5×104 cells/cm2) in growth medium. Cells were washed twice with 
PBS and serum starved for 30 minutes when they attached. Cells were then shifted to DM or 
OCM. Whole cell protein extracts from C2C12 and PD50A myoblasts were collected at 24-
hour intervals respectively for further immunoblotting analysis (see section 2.8 for protein 
assay and section 2.10 for immunoblotting). 
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2.2.3. Analysis of the effects of conditioned medium (OCM) and differentiation medium (DM) 
on total number of myoblasts: 
The effect of osteoblast conditioned medium on total cell number of myoblasts was analysed 
by plating 1.5×104 of myoblasts (both C2C12 and PD50A cell lines) in a 48-well plate. 
Myoblasts were cultured in GM, DM or OCM respectively for 4 days. Total cell number was 
determined at 24-hour intervals (Refer to section 2.2 for detailed method of cell number 
determination). 
 
2.2.4.Cell culture for mechanical property analysis: 
Myoblasts (non-dystrophic, dystrophin-deficient and transfected) were plated in 6-cm dishes 
(Nunc plasticware, UK) with 9.0×104 cells per dish (1.5×104 cells/cm2) in growth medium. 
Cells were cultured for four days and the mechanical properties were analised with the atomic 
force microscope (AFM). For investigating the mechanical property of myotubes, 
transfectants were first plated in 60-mm petri dishes. Cells were shifted to low mitogen 
medium (alpha-MEM with 1% P/S, 1% L-Glutamine and 2% horse serum) when they reached 
>80% of confluence. They were kept in low mitogen for 13-14 days for myotube formation 
because the AFM machine was heavily booked and time available for measurement was 
limited. These myotubes were then subjected to AFM for analysis of their mechanical 
properties. (Refer to section 2.11 for details of mechanical property analysis) 
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2.3. Coverslip preparation- acid etching method 
80 pieces of 9-mm2 coverslips (VWR International, UK) were placed in a 1-litre beaker 
without overlapping with each other. Approximate 5 ml of concentrated nitric acid (Fisher 
Scientific, UK) was carefully added into the beaker in a fumehood to etch the coverslips for 5 
minutes. After 5 minutes, nitric acid was transferred into a 2-litre beaker filled with water and 
poured off in the sink with copious water. Acid-etched coverslips were then placed under 
running water for at least 1 hour to wash off the residual nitric acid. Clean coverslips were 
soaked in small amount of methanol (100%; Fisher Scientific, UK) and then transferred onto 
a piece of clean tissue to allow complete evaporation of the methanol. These coverslips were 
transferred into a clean container and put into oven to finish sterilization.  
 
2.4. Generation of Pax7-mCherry expression plasmid: 
2.4.1. Mutagenesis Polymerase Chain Reaction (Mutagenesis PCR): 
Mutagenesis PCR was performed to introduce restriction enzyme site (AgeI site) to the 
Pax7/loxP-His-FLAG expression construct (kind gift from Dr. Michael A. Rudnicki; 
Department of Cellular and Molecular Medicine, University of Ottawa, Canada) so that it 
could be used to create the construct expressing fusion proteins with mCherry tag. In order to 
create the in frame mCherry construct the reverse primer was designed with addition of an 
extra nucleotide cytosine just ahead of AgeI restriction site. Also the ATC was substituted by 
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GGT in the forward primer to create the AgeI cutting site (the primers used are listed in table 
2.3).  
Primer name  Primer sequence 
Pax7-His/FLAG 
(Forward) 
5'CTACCTCGAGCATCACCATCCACCGGTACGATTATGATATTC 3' 
Pax7-His/FLAG 
(Reverse-insert C 
before AgeI site, 
ATC1554GGT) 
5'GAATATCATAATCGTACCGGTGGATGGTGATGCTCGAGGTAG 3’ 
Table 2.3 The forward and reverse primers used in the mutagenesis PCR for 
the generation of Pax7-mCherry expression plasmid. The AgeI restriction site 
is underlined, the insertion base is labeled in red and the substitution bases are in 
bold label (Primers were ordered from AltaBiosciences Ltd, UK). 
 
Pfu DNA polymerase (Promega, UK) was utilized to prevent mutations on the backbone of 
the plasmid during PCR amplification. 5 μl of DNA template (10 ng/μl) was added in a PCR 
tube followed by addition of 45 μl master mix to give total volume of 50 μl.   
 5 μl    -10×Buffer with MgSO4 (Promega, UK) 
 5 μl    -dNTP mix (10 mM dATP, dCTP, dGTP and dTTP respectively)(Qiagen) 
 1.5 μl  -each primer (10 μM) 
 1 μl    -Pfu DNA polymerase (Promega, UK) 
 31 μl   -dH2O 
Samples were placed in a PCR machine (Veriti® 96-Well Thermal Cycler; AB Applied 
Biosystems, UK) and the program started. The following program was used according to the 
instruction for PCR using Pfu DNA polymerase.  
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      1 cycle     -    95°C  for 2 minutes 
            -    annealing temp (50°C) for 30 seconds  
            -    72°C (2 minutes/kb; 13.6 mins)  
      20 cycles   -    95°C  for 30 seconds  
                 -    annealing temp (50°C) for 30 seconds  
            -    72°C (2 minutes/kb; 13.6 mins)  
      Final step   -    72°C  for 5 minutes 
 
2.4.2. E. Coli transformation and culture for plasmid amplification: 
2.4.2.1. Competent cell preparation 
Bacterial E. coli (DH5α strain) competent cell preparation was based on Chung’s method 
published in 1989 (Chung et al., 1989). Single colony was picked up from LB (Luria-Bertani) 
plate [for 250 ml LB agar, 9.25 g Luria Agar powder (Invitrogen, UK), add dH2O up to 250 
ml] and transferred into 3 ml of LB medium for 16 hours of incubation at 37°C in an 
incubator rotor (INNOVATM 433 refrigerated incubator shaker; New Brunswick Scientific). 
200 μl of medium containing bacteria was transferred into 20 ml of fresh LB medium and 
incubated at 37°C with vigorous shaking for 2 to 2.5 hours to reach 0.3-0.4 of OD600 value. 
Bacterial cultures were put in ice for 20 minutes before spun down with centrifugation at 
4,000 rpm (AvantiTM 30 centrifuge; Beckman Coulter, UK) at 4°C for 10 minutes. After 
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supernatant was removed, the pellet was resuspended with 2 ml of cold TSS [transformation 
and storage solution; 50 mM MgCl2 (BDH, UK), 85% LB medium (Invitrogen, UK), 10% 
PEG (Polyethylene glycol; molecular weight 8,000; Sigma-Aldrich, UK), 5% DMSO (Sigma-
Aldrich, UK), adjust pH to 6.5)]. The cell mixture was then aliquoted into 150 μl aliquot per 
Eppendorf tube and was stored at -80°C before use.  
 
2.4.2.2. E. coli Transformation 
Competent cells were removed from -80°C and thawed on ice prior to use. 5 μl of Pax7/loxP-
His-FLAG (see section 2.4.1 for mutagenesis PCR) PCR product was added into competent 
cells and the mixture was placed on ice for 30 minutes. Competent cells were then heat 
shocked at 45°C (Thermomixer; Eppendorf, UK) for 90 seconds and placed on ice for another 
2 minutes. 1 ml of fresh LB medium was added into the Eppendorf tube and competent cells 
were incubated at 37°C with vigorous shaking for 1 hour. The cells were then spun down by 
centrifugation at 13,000 rpm (Labofuge 300 Heraeus centrifuge; Kendro Laboratory Products 
Plc, UK). The cell pellet was resuspended with fresh LB medium and plated on LB plate with 
100 μg/ml ampicillin (Sigma-Aldrich, UK). The plate was placed in an incubator set at 37°C 
(Heraeus Incubator D-6450; Kendro Laboratory Products Plc, UK) for 14 to 16 hours for 
bacterial colony formation. 
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2.4.3. DNA purification:  
2.4.3.1. Small scale plasmid DNA purification using QIAprep Spin Miniprep Kit 
To obtain enough DNA of the mutagenesis product, a single bacteria colony was picked up 
from the transform plate and incubated in 3 ml of LB medium containing 100 μg/ml 
ampicillin for 12-16 hours at 37°C with vigorous shaking. Bacterial cells were collected in an 
Eppendorf tube by centrifugation at 13,000 rpm for 1 minute. The plasmid DNA was then 
purified using QIAprep Spin Miniprep Kit (QIAGEN, UK), following the manufacturer’s 
instruction. Bacterial cells were first resuspended in 250 μl of Buffer P1 and then lysed by 
adding 250 μl of Buffer P2. The mixture was mixed thoroughly by gently inverting the tube 
4–6 times and reaction was neutralized with 350 μl of Buffer N3 by inverting the tube 4–6 
times. Precipitate was spun down by centrifugation at 13,000 rpm for 10 minutes and 
supernatant was transferred directly into the QIAprep spin column. Column was centrifuged 
at 13,000 rpm for 1 minute and flow-through was discarded. Column was then washed with 
0.75 ml of Buffer PE and centrifuged for 1 minute. After flow-through was discarded, the 
column was centrifuged for another minute to remove the residual wash buffer. The QIAprep 
column was placed in a clean Eppendorf tube. Plasmid DNA was eluted by addition of 20 μl 
of ddH2O and centrifuged at 13,000 rpm for 1 minute. The elution step was repeated once to 
increase yield.  
 
 73 
2.4.3.2. Band purification for construction of Pax7 plasmids 
Pax7/loxP-His-FLAG mutagenetic plasmid and pmCherry-N1 plasmid were digested with 
restriction enzymes EcoRI and AgeI (New England BioLabs, UK) supplemented with 
NEBuffer 1 at 37°C for 8 hours. Digested Pax7 insert fragment and pmCherry-N1 vector were 
separated on 1% agarose (multi-purpose, molecular grade; BioLine Ltd, UK) gels [1 g 
Agarose dissolved in 100 ml TBE with a 750W microwave (Panasonic UK Ltd)] containing 
0.5 μg/ml of Ethidiun Bromide (10 mg/ml stock; Invitrogen, UK). Ethidium Bromide (a 
known carcinogen) was added with great care after gel had cooled down slightly at room 
temperature for 5 minutes. The gel was poured into a horizontal electrophoresis casting tray 
(HORIZON®58; Invitrogen, UK) and gel combs placed at one end. Gel was allowed to cool 
for about 30 minutes or until it had solidified. The gel was placed in an electrophoresis tank 
(HORIZON®58; Invitrogen, UK) and covered thoroughly in TBE [9.3 g Na2EDTA 
(Diaminoethanetetra-acetic acid disodium salt; Fisher Scientific, UK), 55 g Boric acid (Fisher 
Scientific, UK), 108 g Tris made up to 1 litre with dH2O]. To visualize the leading front of the 
sample, 6×loading buffer (2.5% Ficoll-400, 11 mM EDTA, 3.3 mM Tris-HCl pH 8.0, 0.017% 
SDS and 0.015% bromophenol blue; New England Biolabs, UK) was added to each sample. 
Samples were then loaded onto the 1% agarose gel. After separation for 1 hour at 130V at 
room temperature, gel was removed from the horizontal electrophoresis tank and visualized 
under uv light (uvitec, Jenkons Scientific Ltd, UK). The images were captured utilizing a 
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Sony gel imaging camera with video graphic printer (Sony, UK). The DNA band 
corresponding to the Pax7 fragment (~1.5 kb) was carefully excised with a clean, sharp 
scalpel (Swann-Morton, UK) and transferred to a pre-weighed Eppendorf tube. The Pax7 
insert fragment and pmCherry-N1 vector were recovered from agarose gel using QIAquick® 
Gel Extraction kit (QIAGEN, UK).  
The gel slice was weighed and 3 volumes of Buffer QG (QIAGEN, UK) was added (e.g. add 
300 μl of Buffer QG to each 100 mg of gel.). Gel slice was then incubated at 50°C for 10 
minutes and the tube was vortexed every 2-3 minutes until gel slice has completely dissolved. 
1 volume of isopropanol (2-propanol; Fisher Scientific, UK) was added into the sample to 
promote DNA precipitation and the mixture was thoroughly mixed by inverting the tube 
several times. The Sample was transferred onto a QIAquick column and centrifuged at 13,000 
rpm for 1 minute to let DNA bind to the resin. 0.75 ml of Buffer PE was added to the column 
and centrifuged at 13,000 rpm for 1 minute to wash the sample. The QIAquick column was 
further centrifuged at 13,000 rpm for 1 minute to remove the residual buffer. Column was 
then transferred to a clean Eppendorf tube. 15 μl of ddH2O was added onto the column and 
then centrifuged at 13,000 rpm for 1 minute to elute the DNA. The elution step was repeated 
once to obtain higher yield.  
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2.4.3.3. Plasmid ligation  
Digested Pax7 insert fragment and mCherry vector were ligated in a ratio of 4 versus 1 (ratio 
of molecules) to create the Pax7-mCherry expression plasmid (Figure 2.3 A). T4 DNA ligase 
(New England BioLab, UK) was used to ligate the fragments; the reaction was kept at 16 °C 
in a PCR machine overnight. Half of the ligation product was transformed into E. coli 
competent cells (Refer to section 2.4.2.2 for E. coli transformation) and the resulting colonies 
were picked and amplified to isolate plasmid DNA (see section 2.4.3.1 for small scale plasmid 
DNA purification using QIAprep Spin Miniprep Kit). 
Pax7-mCherry
6236 bp
pCMV EI
Kanr/Neor
mPax7d
mCherry
AgeI (2181)
Ase I (8)
BamHI (643)
Bsp EI (987)
EcoRI (630)
HpaI (3024)
NdeI (235)
NheI (592)
SalI (797)
XbaI (2915)
ApaLI (2254)
ApaLI (5865)
Bst BI (628)
BstBI (4943)
BstEII (2349)
BstEII (2520)
HindIII (623)
HindIII (2104)
XhoI (614)
XhoI (2164)
    
Figure 2.3 Pax7-mCherry expression plasmid construction.  
(A) The construct map of Pax7-mCherry. (B) The Pax7-mcherry was checked by 
BspEI and AseI restriction map analysis.   
DNA was digested to confirm the constructs were expected. DNA was digested by placing in 
a clean Eppendorf tube with enzyme, buffer and water (detailed in table 2.4 and Figure 2.3 B) 
and incubated at 37°C overnight. Samples were run on 1% agarose gels containing 0.5 μg/ml 
A B 
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of Ethidium Bromide. 
Pax7-mCherry 
Uncut (control) – 
3 μl DNA 
0.8 μl Buffer 3 
4.2 μl Water 
Single digest -          
3 μl DNA 
0.8 μl Buffer 3  
0.5 μl enzyme BspEI 
3.7 μl Water 
Expected band (bp)  
– ~6.2kb 
Double digest – 
3 μl DNA 
0.8 μl Buffer 3 
0.5 μl enzyme BspEI 
0.5 μl enzyme AseI 
3.2 μl Water 
Expected bands (bp)  
– ~1kb, ~5.2kb 
Table 2.4 Enzymes used to digest Pax7-mCherry constructs, with expected 
band sizes (All restriction enzymes and buffers were from New England Biolabs 
Ltd, UK). 
 
2.4.3.4. QIAfilter MidiPrep of plasmids for transfection 
To isolate plasmid DNA for transfection, glycerol stock was scraped with the tip of a pipette, 
spread on LB agar plates containing 100 μg/ml antibiotics [(kanamycin; Invitrogen, UK) or 
(Ampicillin; Sigma-Aldrich, UK)] and incubated in an incubator (37°C) overnight 
(approximately 18 hours). Single colonies were picked up and added to 3 ml of LB medium 
containing antibiotics in 10 ml sterile falcon tubes and placed in a rotating incubator (37°C) 
for 8 hours. 200 μl of the mixture was transferred to 50 ml LB and then placed back to 
incubator (37°C) overnight (16 hours). The Pax7-mCherry plasmid was subsequently purified 
using QIAfilter Midiprep kit (Qiagen, UK), following the manufacturer’s instruction. 
Bacterial cells were harvested by centrifugation at 6000×g at 4°C for 15 minutes. Supernatant 
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was removed and the bacterial pellet was re-suspended in 4 ml of Buffer P1. 4 ml of Buffer 
P2 was added into bacterial suspension and the mixture was inverted vigorously and 
incubated at room temperature for no more than 5 minutes to lyse the cells. QIAfilter Midi 
Cartridges were prepared during incubation with the caps screwed onto the outlet nozzle of 
the cartridges. 4 ml of chilled Buffer 3 was added to the lysate and mixed immediately and 
thoroughly by vigorously inverting 4 to 6 times. The mixtures were poured into cartridge 
directly and incubated at room temperature for 10 minutes. During this period, QIAGEN-tip 
100 columns were equilibrated with 4 ml of Buffer QBT, allowing the column to empty by 
gravity flow. Cell lysates were then filtered into the equilibrated QIAGEN-tip columns by 
gently inserting the plungers into the cartridges and cleared lysates were allowed to enter the 
resin by gravity flow. The QIAGEN-tip columns were washed with 10 ml of Buffer QC twice 
and DNA was eluted with 5 ml of Buffer QF and collected in clean tubes. DNA was 
precipitated by addition of 3.5 ml of room temperature isopropanol (0.7 volumes) and the 
mixture was centrifuged at 15,000×g at 4°C for 30 minutes. Supernatant was decanted 
carefully and DNA pellets were washed with 2 ml of room temperature 70% ethanol. Samples 
were centrifuged further at 15,000×g for 10 minutes and the supernatant was decanted 
carefully. The DAN pellets were air-dried for 5-10 minutes (until the pellets were transparent) 
and then re-dissolved in a suitable volume of dH2O (normally 400 μl; depends on the size of 
DNA pellet) at 4°C overnight, before stored at -20°C. DNA concentration was established 
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using Camspec M501 Single Beam Scanning UV/Visible Spectrophotometer (Spectronic 
Camspec Ltd, UK). The Plasmids used in this thesis were listed in table 2.5. 
Plasmid Antibiotic selection marker 
Neomycin resistant  
(G418 selection) 
Cav1-eGFP + 
Cav3-eGFP + 
pCR3.1-eGFP-minidystrophin + 
peGFP-N1 + 
pmCherry N1 + 
Pax7-mcherry + 
pSHAG-Cav3sh _ 
pSHAG-cav7 (Cav1sh plasmid) _ 
pSHAG-dsGFPsh 
Kanamycin 
_ 
pLKO.1-Pax7-sh Ampicillin _ 
Table 2.5 The plasmids used in this thesis and their selection markers for 
plasmid amplification in bacterial culture.  
Cav1-eGFP expression plasmid is a gift from Dr. Joshua Rappoport (University 
of Birmingham). Cav3-eGFP along with eGFP plasmids were acquired from Dr. 
A. Krüttgen (RWTH Aachen University School of Medicine). eGFP-
minidystrophin constrcut was obtained from Dr. Jacques P. Tremblay (Université 
Laval et Membre de l'Axe Neurosciences). pmCherry plasmid was a gift from 
Professor John Heath (University of Birmingham). Cav1sh expression construct 
was obtained from Dr. Jane Sottile (University of Rochester). Pax7sh expression 
plasmid was a gift from Professor Andrew Lassar (Harvard Medical School). 
 
2.5. Introduction of expression and shRNA plasmids into mammalian cells 
2.5.1. Optimized LipofectamineTM2000 Transfection protocol (24-well plate): 
3×105 of myoblasts were plated in a 24-well plate (Nunc Plasticware, UK) and cultured for 18 
hours to reach 80% - 100% confluence before transfection. 0.8 μg of interest plasmid DNA 
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was added into 50 μl of DMEM with 1% Glutamine only (serum free medium, SFM) and 
mixed gently. 2 μl of LipofectamineTM2000 (Invitrogen, UK) was diluted in 50 μl of SFM, 
gently mixed and then incubated at room temperature for 5 minutes. After 5 minutes, the 
liposome solution was added into DNA/SFM mixture with gentle mixing and the 
DNA/liposome mixture was incubated at room temperature for another 20 minutes to allow 
formation of DNA-LipofectamineTM2000 complex. Lipofectamine TM2000 is used at a strict 
ratio to DNA (liposome: DNA = 2.5:1) and plate area (1.6 μl liposome/cm2). 
For shRNA constructs, pmCherry plasmid was cotransfected as a selection marker. The ratio 
of pmCherry plasmid and shRNA plasmid was 1:7 (0.1 μg of pmCherry plasmid and 0.7 μg of 
shRNA plasmid). 5 minutes before addition of the DNA-liposome complex onto the cells, the 
culture medium was aspirated from the plate and cells were washed with SFM. 100 μl of 
DNA-liposome mixture was added into each well. After 16 hours (overnight) of incubation, 
100 μl of fresh culture medium containing 20% FCS and 2% P/S was added into each well. 
Cells were cultured for at least 24 hours before they were selected with G418 for stable clones 
(See section 2.5.3). Table 2.6 shows the volume of LipofectamineTM2000 and the amount of 
DNA applied to each plate size and cell density used in this thesis.  
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Table 2.6 Amount of DNA and transfection reagent (LipofactamineTM2000) 
required for different culture condition (Adapted from the thesis of Dr. Deborah 
Merrick, P54, Table 2.2, 2006). 
 
2.5.2. Transfection with Lipofectamine® LTX and PLUS™ Reagents (24-well plate): 
The minidystrophin-eGFP expression plasmids and the Oct4 reporter plasmid were 
respectively introduced into myoblasts and iPS cells with Lipofectamine®LTX PLUSTM 
reagents (Invitrogen, UK). 3×105 of myoblasts were plated in a 24-well plate. Cells were 
transfected with minidystrophin-eGFP expression plasmid when they reach 80-100% 
confluence. 1.5 μg of purified plasmid DNA was diluted with 100 μl of SFM along with 1.5 μl 
of PLUSTM (1 μl PLUSTM /μg DNA).  
The iPS cells in a 25-cm2 flask were subcultured (section 2.1.4 for iPS cell subculture) and 
plated into the wells of a feeder cell free/gelatin-coated 24-well plate. The pOEIN construct 
(Oct4 reporter plasmid; gift from Dr. Masahiro Sato of Kagoshima University, Japan; Figure 
2.4 A) was linearised with NotI (NEB, UK) before transfection. 0.5 μg of purified plasmid 
Culture vessel Culture area Plating Density  (Cells/cm2) 
DNA(diluted 
from SFM) 
LipofectamineTM2000 
(diluted in SFM) 
96 well plate 0.33 cm2/well 1.5x105  0.2 μg (25 μl) 0.5 μl (25 μl) 
Chamber slide 0.8 cm2/well 1.5x105  0.5 μg (33 μl) 1.25 μl (33 μl) 
48 well plate 1.1 cm2/well 1.5x105 0.7 μg (50 μl)  1.75 μl ( 50 μl) 
24 well plate 1.9 cm2/well 1.5x105  0.8 μg (100 μl) 2 μl (100 μl) 
6 well plate 9.6 cm2/well 1.5x105  4 μg (250 μl) 10 μl (250 μl) 
3.5 cm dish  8.8 cm2/well 1.5x105 3.7 μg ( 500 μl) 9.3 μl ( 500 μl) 
6 cm dish 21.5 cm2/well 1.5x105  9 μg ( 500 μl) 22.5 μl ( 500 μl) 
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DNA was diluted with 50 μl of SEM along with 0.5μl of PLUSTM (1 μl PLUSTM /μg DNA). 
 
 
Figure 2.4 Selection of iPS cells carrying Oct4 reporter plasmid.  
(A) The map of Oct4 reporter plasmid pOEIN, a kind gift from Dr. Masahiro 
Sato of Kagoshima University, Japan. (B) iPS cells bearing the pOEIN reporter 
plasmid gave green fluorescence as an indication of pluripotent status.  
The DNA- PLUSTM mixture was mixed well and stay at room temperature for 5 minutes. 
Lipofectamine®LTX in the ratio of 2.5 μl /μg DNA was then added into the DNA-PLUSTM 
mixture; they were mixed and stay at room temperature for 20 minutes for DNA-liposome 
complex formation. Cells were washed with SFM during DNA-liposome complex formation. 
After 20 minutes of incubation, the DNA-liposome complex was added dropwise onto cells 
A 
B 
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and the cells were incubated at 37°C  for at least 16 hours. The medium was replaced with 
fresh medium and the cells were cultured further for at least 24 hours before selection of 
stable clones (section 2.5.3). 
 
2.5.3. Stable transfectant selection after transfection  
Two days after transfection of the expression plasmids or shRNAi vehicles (see table 2.5), 
myoblasts which stably express the plasmid were selected with 800 μg/ml of G418 (Geneticin; 
Invitrogen, UK). For shRNA expression vehicles, which have no neomycin resistant gene, 
pmCherry expression plasmid was co-transfected for G418 selection. The iPS cells carrying 
the pOEIN (Figure 2.4 B) were selected with 400 μg/ml of G418. Medium was changed every 
three days for the myoblast transfectants and every two days for the iPS transfectants until 
colonies derived from the transfectants appeared. Those non-transfected cells died after G418 
treatment; cells detached from the culture plates and were washed away. Colonies were 
picked and transfered into the 25-cm2 culture flasks to expand the cell line. Expressions of the 
epigenes were confirmed by immunoblotting. The stable transfectants were frozen down and 
kept in liquid nitrogen. The myoblast transfectants were later used for protein extraction 
(section 2.8.1) or mechanical tests (section 2.11).  
 
 
 83 
2.6. Cell fixation and staining 
2.6.1. Fixing cells with 4% paraformaldehyde: 
Cells were fixed in 4% paraformaldehyde prior to fluorescent immunostaining (section 2.6.3). 
To prepare 4% paraformaldehyde solution, 4 grams (g) of paraformaldehyde (PFA; Sigma-
Aldich, UK) was weighed out and added to 100 ml of sterile PBS. A face-mask was worn 
whilst weighing out the paraformaldehyde to prevent inhalation. The solution was heated and 
gently shaken in a hybridization oven/shaker (Stuart Scientific, UK) at constant temperature 
(below 65°C) until the powder dissolved. Before fixation, the culture medium was removed 
and cells were washed with PBS at room temperature for 5 minutes on a Gyro-Rocker® 
shaker (STR9 Bibby; Stuart, UK). Approximately 0.2 ml of 4% paraformaldehyde was added 
to each well and the 48-well plate was placed on a shaker at room temperature for 15 minutes. 
Following this, each well was rinsed in PBS with 30 mM glycine (Fisher Scientific Ltd, UK) 
twice. 
 
2.6.2. Leishman's stain: 
Cells plated in a 48-well plate were fixed with 4% PFA (refer to section 2.6.1 for fixation). 
Approximately 0.2 ml of Leishman's stain [0.15% Leishman's stain (Leishman’s stain, Eosin-
polychrome methylene blue; Sigma-Aldrich, UK) in methanol] was added to each well and 
the plate was placed on a Gyro-Rocker® shaker for 5 minutes. After 5 minutes, 0.2 ml of 
 84 
dH2O was added to each well for dye fixation and the plate was placed on the shaker for 
another 5 minutes. The mixture was removed and the plate was put under running tap water. 
This should be done carefully without letting water hit the cell surface directly to prevent the 
cells from damage. The plate was dried before examination under an inverted microscope.  
 
2.6.3. Fluorescent immunostaining: 
The immunostaining method used in this thesis is based on the method published previously 
(Merrick et al., 2009). Adhered cells were first fixed with 4% PFA in PBS (see section 2.6.1.) 
for 10-15 minutes and then rinsed in PBS with 30 mM glycine twice. Fixed cells were 
permeabilized with 0.25% Triton-X-100 (Sigma-Aldrich, UK) in PBS for 5 minutes and 
rinsed with PBS twice. Cells were blocked with 5% BSA (sigma-Aldrich, UK) in PBS for at 
least 30 minutes and then incubated with primary antibody at 4°C overnight. The second day, 
samples were washed for 10 minutes three times in PBST [PBS + 150 mM NaCl (Fisher 
Scientific, UK) + 0.05% Tween20® (Sigma-Aldrich, UK)] and were incubated with 
secondary antibody at room temperature for 1 hour. Samples labelled with biotinylated 
secondary antibodies were then washed with PBST for 10 minutes three times and probed 
with Streptavidin-Texas Red (1:1,000; PerkinElmer, UK) for 30 minutes at room temperature 
if applicable and protected from light. DAPI (Sigma-Aldrich, UK) (10 μg/ml) was added into 
the sample to label the nuclei for 3 minutes. Cells were rinsed in PBST for 10 minutes three 
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times. A final rinse in PBS was applied to remove excess salt. Slides were mounted in 
Dakocytomation Fluorescence Mounting Medium (Dako UK Ltd, UK). Samples were 
examined with Nikon ECLIPSE Ti inverted microscope (Nikon UK Limited, UK). The 
antibodies and titres used are listed in table 2.7. 
 
Primary Antibody (Titre) Secondary Antibody (Titre) Tertiary Antibody 
(Titre) 
Mouse anti-calsequestrin 
antibody (1:20); gift from Dr. 
Francesco Michelangeli of 
University of Birmingham 
Mouse monoclonal anti-IGF2 
antibody; Upstate Biotechnology, 
USA (1:500) 
MANDRA1  - MOUSE ANTI- 
Dystrophin Clone No.7A10; 
CIND (1:4) 
anti-MF-20, mouse anti-pan 
myosin antibody; DSHB, USA  
(1:500) 
Biotinylated Anti-mouse IgG 
(whole antibody from goat); 
Amersham Pharmacia Biotech, 
UK (1:1,000) 
Biotinylated Anti-mouse IgG 
(whole antibody from goat); 
Amersham, UK (1:1,000) 
Streptavidin-Texas 
Red; PerkinElmer, 
UK (1:1,000) 
Mouse monoclonal anti-caveolin 
3 antibody; Becton Dickinson, 
UK  (1:500) 
Alexa Fluor® 488 F(ab')2 
fragment of goat anti-mouse IgG 
(H+L); Invitrogen, UK (1:500) 
N/A 
Biotinylated anti-rabbit Ig 
antibody; Amersham Pharmacia 
Biotech, UK (1:1,000) 
Streptavidin-Texas 
Red; PerkinElmer, 
UK (1:1,000) 
Rabbit polyclonal anti caveolin-1 
antibody;  BD Biosciences, UK  
(1:1,000) 
Alexa Fluor® 488 F(ab')2 
fragment of goat anti-rabbit IgG 
(H+L); Invitrogrn, UK (1:1000) 
N/A 
Rhodamine Phalloidin; Sigma-
Aldrich, UK  (2 μg/ml) 
N/A N/A 
Monoclonal Anti-α-Tubulin 
antibody produced in mouse; 
Sigma- Aldrich, UK (1:2,000) 
Biotinylated Anti-mouse IgG 
(whole antibody from goat); 
Amersham, UK (1:1,000) 
Streptavidin-Texas 
Red; PerkinElmer, 
UK (1:1,000) 
Table 2.7 The antibodies and titres used for the fluorescent immunostaining.  
Titres of antibodies used are shown in parenthens. (N/A: not applicable) 
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2.7. Immunohistochemisry (IHC) method 
2.7.1. Embedding Embryos in Paraffin  
Paraffin-embedded embryos and adult skeletal muscle blocks were fixed and embedded by Dr. 
Dean Larner, during his doctoral research in Dr. Janet Smith’s lab (Larner, 2012) following 
the protocol described below; all sectioning was performed by myself (Hung-Chih Chen). 
Embryos were dissected and placed in 4% PFA solution on a Gyro-Rocker® shaker at 4°C 
(cold room) for the optimal period of time (3-24 hrs, depending on embryonic stage shown in 
table 2.8). E11.5-E16.5 embryos were washed twice in sterile PBS for 10 minutes at room 
temperature. After wash with PBS, the embryos were dehydrated in serial washes of ethanol 
(40%, 70%, 95% and 100% respectively; made up in tap water) for a length of time that 
corresponded to the embryonic stage of the embryo (Refer to table 2.8). Embryos were then 
switched from plastic universal tubes to 20 ml glass bottles and ethanol was cleaned with 
xylene (Fisher Scientific, UK) (refer to table 2.8). For E17.5 embryos, an additional step of 
decalcification was carried out prior to dehydration. Decalcification was carried out by 
washing embryos in 0.5 M of EDTA solution (pH7.5) for 3 days at 4°C (solution was replaced 
daily), followed by washing in dH2O overnight. After decalcification, E17.5 embryos were 
dehydrated in accordance with table 2.8. Adult muscle samples were processed as for E17.5 
embryos except that they did not undergo decalcification.   
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STEP SOLUTION E11.5 E12.5 E13.5 E14.5 E15.5 E16.5 E17.5 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
4% PFA (4˚C) 
 
40% EtoH  
 
70% EtOH 
 
95% EtOH  
 
100% EtOH  
 
Xylene  
3 hrs 
 
30 mins 
 
30 mins 
 
30 mins 
 
3 x 30 mins* 
 
3 x 30mins 
5 hrs 
 
30 mins 
 
30 mins 
 
30 mins 
 
3 x 30 mins* 
 
3 x 30 mins 
20 hrs 
 
1 hr 
 
1 hr 
 
1 hr 
 
3 x1 hr* 
 
3x1 hr 
20 hrs 
 
1 hr 
 
1 hr 
 
1 hr 
 
3 x1 hr* 
 
3x1 hr 
20 hrs 
 
1.5 hrs 
 
1.5 hrs 
 
1.5 hrs 
 
3x 1.5hrs* 
 
3x 1.5 hrs 
24 hrs 
 
1.5 hrs 
 
1.5 hrs 
 
1.5 hrs 
 
3x 1.5hrs* 
 
3x 1.5 hrs 
24 hrs 
--------- 
1 day 
 
1 day 
 
1 day 
 
2 days 
 
3 days 
Table 2.8 Fixation, dehydration and clearing incubation times for E10.5-E17.5 
staged embryos in 4% paraformaldehyde, ethanol and xylene respectively.  
All of the above steps were carried out at room temperature, excluding step 1, which 
was carried out at 4°C. EtOH = Ethanol (all dilutions were prepared in tap water; * = 
final wash was overnight at 4°C; ---- = decalcification step for E17.5 embryos. (Taken 
from the thesis of Dr. Deborah Merrick, 2006) 
 
Following clearing with xylene, xylene was removed from the embryo and disposed of as 
non-halogenated waste solvent (special waste). Molten wax (60°C paramat; Fisher Scientific, 
UK) placed in a 60°C oven (Carbolite Incubator; Carbolite, UK) was poured into the glass 
bottles with embryos inside. The bottles were placed in an oven (Stuart Scientific, UK; 
Hybridisation oven/shaker S120H). E11.5-E13.5 embryos had 2-3 changes of wax over a 24-
hour interval and E14.5-E17.5 embryos had 3 changes over an interval of 24-48 hours. 
Embryos were thereafter removed from the wax using heated forceps. Forceps were heated to 
prevent wax from solidifying too quickly that could cause attachment of the forceps to the 
embryos, resulting in tissue damage. Embryos were orientated as required in 22 mm × 22 mm 
square peel-away disposable embedding molds (Fisher Scientific, UK), labelled, and then 
immersed in molten wax. Blocks were left to cool for 6-8 hours and then placed at 4°C until 
 88 
required for sectioning using a microtome (section 2.7.2).  
 
2.7.2. Microtome Sectioning of Paraffin Blocks 
A water bath [Grants Instruments (Cam) Ltd, UK] was set at 30°C (no more than 50°C) and 
an incubator was set to 37°C prior to sectioning. Paraffin blocks were removed from 4°C 
storage and excess wax was carefully removed from around the embryo with a razor blade. 
The block was clamped into the Reichert-Jung 1150/Autocut microtome (Leica Microsystems 
Ltd, UK) and aligned parallel to the blade. Sections were carefully cut at 5 μm thick and 
placed on top of water in the 30°C water bath. Sections were then collected on to superfrost 
slides (VWR International, UK). Excess water between sections and slide was carefully 
cleaned with tissue. Slides were placed in the 37°C oven overnight to ensure sections became 
firmly attached to the slide surface (particularly important when using the pressure cooker 
immunohistochemical labelling technique).  
 
2.7.3. Immunohistochemistry (IHC) (TSA protocol for paraffin embedded sections): 
Paraffin embedded sections on the slides (see section 2.7.2 microtome sectioning) were 
washed consecutively with xylene in 2 separate glass containers for 10 minutes and 5 minutes 
respectively to remove paraffin wax. These wax-removed sections were then rehydrated in 
ethanol with sequence of 100% ethanol for 2 minutes twice, 95% ethanol for 2 minutes, 70% 
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for 2 minutes, 50% for 2 minutes and 30% for 2 minutes. Slides were washed in PBS for 10 
minutes before antigen retrieval. The protein bonds created via PFA fixation were broken 
down (antigen retrieval) using a pressure cooker (Meyer Prestige Ltd., UK). Slides were 
placed in boiling antigen retrieval buffer [10 mM Sodium Citrate (Fisher Scientific, UK), 
pH6]. The lid was locked and the solution was brought to pressure before incubation of 
sectioned sample/slides for 1.5 minutes under pressure (check pressure achieved by pressure 
cooker), followed by cooling the pressure cooker under cold running water for approximately 
3 minutes. Sections were transferred to a glass container and washed in fresh PBS for 10 
minutes. After the PBS wash, individual sections were isolated by drawing around them with 
wax barrier pen (Vector Laboratories Ltd., UK), allowing multiple sections to be stained with 
different reagents on the same slide. The endogenous hydrogen peroxidase was blocked by 
first treating the sections with 3% Hydrogen Peroxide (H2O2) (Sigma-Aldrich, UK) in tap 
water (50 ml total; 5 ml of 30% H2O2 stock made up to 50 ml with tap water) for 5 minutes 
and then with 0.5% Hydrogen Peroxide in methanol (50 ml total; 833 μl of 30% H2O2 stock 
made up to 50 ml with methanol) for 1 hour. Sections were washed in PBST (0.05% 
Tween®20 in PBS; 1 ml Tween®20 in 2 litre PBS) for 10 minutes trice and then blocked with 
TNB [Tris-NaCl blocking buffer; 50 mM Tris base pH7.5, 75 mM NaCl , 0.25% Blocking 
reagent (TSA kit)] for 30 minutes at room temperature. TNB was tipped off and the sections 
were incubated with primary antibody overnight at 4° C in humidity chamber (lidded tray 
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with filter paper soaked in PBS).  
The next day primary antibody was removed and the slides washed with PBST for 10 minutes. 
After three PBST wash, biotinylated secondary antibody was applied to the sections for 1 
hour at room temperature. Nonspecific binding was washed away with PBST for 10 minutes 
trice. To amplify the signal, TSA (Tyramide Signal Amplification) amplification method was 
used. Sections were incubated with Streptavidin-horseradish peroxidase (SA-HRP; TSA kit) 
diluted 1/500 in TNB for 30 min at room temperature and then washed with PBST three times, 
10 minutes each time. Biotinyl tyramide (Amplication reagent; TSA kit), diluted 1:50 with 
diluent in kit, was added to each section for 12 minutes. The slides were washed in PBST for 
10 minutes trice and incubated with SA-HRP diluted 1/500 in TNB for 30 minutes at room 
temperature followed by further PBST washes for 10 minutes trice. To visualise the labelled 
antigen, DAB (3, 3'-diaminobenzidine; Dako, UK) was applied to the sections using a Pasteur 
pipette for 5 minutes. 1 μl of H2O2 was added to 1 ml DAB (1 tablet of DAKO
®DAB 
chromogen dissolved in 10 ml of PBS) right prior to use. DAB is a carcinogen; therefore two 
pairs of gloves were worn during the process with great care. Slides were then washed in tap 
water twice (5 minutes for each wash). The first wash was in a plastic container and the 2nd 
wash was in a glass container on shaker. The used water and equipments from the 1st wash 
were cleaned with bleach (sodium hypochlorite) to de-activate DAB washed away from the 
slides. The water from the 2nd wash was disposed of down the sink with copious amount of 
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water. Slides were then placed in Haematoxylin for 1.5 to 2 minutes and then transferred to 
clean containers with Scott’s water for 5 minutes. Slides were dipped in acid alcohol and 
washed immediately in Scott’s water for 5 minutes. Slides were placed under running water 
for 5 minutes and followed by dehydration in a series of ethanol with deceased concentration; 
30% for 2 minutes, 50% for 2 minutes, 70% for 2 minutes, 90% for 2 minutes, 95% for 2 
minutes and twice in 100%, each for 2 minutes. The slides were later washed twice with 
xylene for 5 and 10 minutes respectively. After wash, Slides were mounted in DePex 
mounting medium (VWR international, UK) and covered with cover slips. Slides were left in 
a fume hood overnight to dry and then analysed/viewed under a microscope. The antibodies 
used are listed in table 2.9. 
Primary Antibody (Titre) Secondary Antibody (Titre) 
Mouse monoclonal anti-Caveolin 3 
antibody; Becton Dickinson, UK (1:500) 
Biotinylated anti-mouse IgG antibody; 
Amersham Pharmacia Biotech, UK 
(1:1,000) 
Mouse monoclonal anti-skeletal myosin 
(fast) clone MY-32; Sigma-Aldrich, UK 
(1:500) 
Biotinylated anti-mouse IgG antibody; 
Amersham Pharmacia Biotech, UK 
(1:1,000) 
Rabbit polyclonal anti Caveolin-1 
antibody; BD Biosciences, UK (1:1,000) 
Biotinylated anti-rabbit Ig antibody; 
Amersham Pharmacia Biotech, UK 
(1:1,000) 
Table 2.9 The primary, secondary antibodies used for immunohistochemistry.  
Titres of antibodies used are shown in parentheses. 
 
2.8. Protein assay 
2.8.1. Protein extraction: 
Protein extraction from cell lines: 
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Protein was extracted from cells plated in 10-cm dishes with 8.5×105 cells/dish density at 24, 
48 and 96 hours after cultured with osteoblast-conditioned medium or differentiation medium 
respectively (see section 2.2.2). The old medium was removed and cells were washed twice 
with PBS. After washing, 100 μl of lysis buffer containing 15 μl of protease inhibitor solution 
(Roche Diagnostic Ltd, UK) (the Radio Immuno Precipitation Assay or RIPA buffer) [50 mM 
Tris (Fisher scientific, UK), 150 mM NaCl, 1% IGEPAL® CA-630 (Sigma-Aldrich, UK), 
0.5% deoxycolic acid (Sigma-Aldrich, UK), sterile H2O to 100 ml; 1 protease inhibitor 
tablet/1.5 ml dH2O added to 8.5 ml buffer for working solution](refer to APPENDIX 2 for 
recipe) was added into the plate and cells were removed by cell scraper (SARSTEDT Ltd., 
UK) and collected in Eppendorf tubes on ice. The cell mixture was then subjected to a soni-
pre150 machine (Sonicator; Sanyo, UK) for 3-minute sonication with 10 amplitude/dunce one 
to two times. The mixture was centrifuged at 13,000 rpm at 4°C for 2 minutes (Mikro20 
Heltich, Zentrifugen). The supernatant was collected into Eppendorf tubes in small aliquots 
and stored at -20°C for further use. 
 
Protein extraction from embryos and adult limb muscles:  
All the embryonic protein extracts and adult tissue extracts were prepared by Dr. Dean Larner 
(Larner, 2012). 
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Embryonic stage E17.5 [C57BL10, mdx, cav3-/- and mdxcav3+/- (double mutant het; DMhet)] 
pregnant mice were culled and uterus removed. Embryos were dissected and ground using a 
mortar and pestle. RIPA buffer sufficient to just fully immerse the embryo (3 ml) was added 
and the embryos were homogenized. These samples were then aliquoted into 5 ml bijoux 
tubes. For adult muscle samples, triceps and quadriceps were removed from 4 week and 9 
week mice (C57BL10, mdx, and cav3-/-). The muscles were just fully immersed with RIPA 
buffer (1 ml) and homogenized. The homogenate was drawn into syringe using an 18 gauge 
needle (1.2×40 mm; Terumo, UK) and extruded into labelled Eppendorf tubes (1.5 ml). To 
remove any residual tissue the mixture was then spun at 14,000 rpm at 4°C for 20 minutes and 
the supernatant aliquoted into labelled Eppendorf tubes for storage at -20 °C before use.  
 
2.8.2. Determining Protein Yield: 
Unknown samples were diluted and compared to a set of bovine serum albumin standards 
(BSA; Pierce, UK). BSA standards were diluted with sterile ddH2O to obtain concentrations 
of 0, 1, 2, 5, 10, 15 and 25 μg/ml. 100 μl of each standard was plated into a 96-well plate 
(Nunc plasticware, UK) in duplicate. Unknown samples were diluted with sterile ddH2O in 
1:100 and 1:400 ratios and 100 μl of each sample was plated into the 96-well plate along side 
the standards. Equal volume of Coomassie® Protein assay reagent (Pierce, UK) was added 
into each well and mixed well with protein samples. The plate was allowed to stand for 20 
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minutes at room temperature. The 96-well plate was read at λ=595 nm on Emax precision 
microplate reader (Molecular Devices Ltd, UK) to obtain the standard curve for estimating the 
sample concentrations. The samples were stored in small aliquots (40 μl/aliquot).  
 
2.9. Protein-protein interaction assay 
2.9.1. Immunoprecipitation (IP) assay: 
Immunoprecipitation assay was performed following Dr. Lisanti’s protocol with subtle 
modifications of the IP buffer (0.5% CHAPS was replaced with 1% IGEPAL® CA-630) 
(Sotgia et al., 2000). Lysate samples used were limb muscle tissues from adult (4 week and 9 
week) wt, cav3-/- and mdx mice (see section 2.8.1 for protein preparation from limb muscle 
tissues). 100 μg of respective tissue lysates were diluted with 800 μl of IP buffer [50 mM 
Hepes (Sigma-Aldrich, UK), pH 7.5, 1 mM EDTA, 1 mM dithiothreitol (DTT; Sigma-Aldrich, 
UK), 1% IGEPAL® CA-630 (Sigma-Aldrich, UK), protease inhibitors]. 20 μl of Protein A 
Sepharose CL-4B beads slurry (see section 2.9.2 for Protein A Sepharose CL-4B beads slurry 
preparation) was added to preclean the lysates, avoiding non-specific binding of proteins to 
the beads. 4 μl of rabbit polyclonal antibody directly against Cav-1 (1 μg; BD biosciences, 
UK) were added into the precleared lysates and the lysates were incubated at 4°C for 2 hours. 
30 μl of Protein A Sepharose CL-4B beads slurry was then applied to each sample to 
immunoprecipitate Cav-1 and the associating complex at 4°C overnight. The bead-protein 
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complexes were spun down at 2500 rpm for 1 minute and the lysates were collected for future 
use. The bead-protein complexes were washed with IP buffer for three times. After extensive 
washing, equal amount (30 μl) of IP buffer containing sodium dodecyl sulphate (SDS) loading 
buffer was added into each sample and the mixture was heat denatured at 100°C for 5 minutes. 
After denaturation, samples were spun down at 13000 rpm and 15 μl of each sample were 
separated by SDS-polyacrylaminde eletrophoresis gels (SDS-PAGE) with 12% acrylamide gel. 
Separated proteins were transferred onto the nitrocellulose membrane. Blots were then probed 
with antibodies directed against Cav-1, Cav-3, IGF-2 and Src, phospho-Src and b-
dystroglycan. Refer to section 2.10 for detailed description of immunoblotting. 
 
2.9.2. Protein A Sepharose CL-4B beads slurry preparation: 
0.25 g of Protein A Sepharose CL-4B powder (Amersham, UK) was suspended in distilled 
water by gentle swirling. To wash away water soluble stabilization agents (i.e. alkaline used in 
production of Sepharose CL-4B), approximately 50 ml of distilled water was added to the 
beads suspension and the swollen beads were spun down at 2500 rpm (or less than 500×g), 
decanting off the supernatant. The wash step was repeated three times, using fresh distilled 
water each time. The swollen beads were kept in 20% ethanol (thus the Protein A Sepharose 
CL-4B slurry) at 4°C to prevent the beads from being re-dried. 
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2.9.3. GFP-trap assay 
Stable transfectants of non-dystrophic (C2C12-Cav1eGFP and C2C12-eGFP) and dystrophin-
deficient (dfd13-Cav1eGFP and dfd13-eGFP) myoblasts were cultured in DM for fourteen 
days to form myotubes (see section 2.5.3 for stable clone selection). Protein was harvested 
and the concentration was determined as described above in section 2.8. 30 μl of GFP-Trap® 
beads slurry (ChromoTek GmbH, Germany) was washed with 500 μl of dilution buffer (10 
mM Tris-Cl pH7.5, 150 mM NaCl, 0.5 mM EDTA) trice and spun at 2,500 rpm for 2 minutes 
at 4°C. 300 μg of protein samples were aliquoted into GFP-Trap® beads. IP buffer (50 mM 
Hepes, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 1% IGEPAL® CA-630, protease inhibitors) 
was added to the beads-protein mixture up to 1 ml and the mixture was incubated at 4°C 
overnight. Complexes were spun at 2,500 rpm for 2 minutes at 4°C and supernatant was 
collected. Complexes were washed twice with 500 μl of IP buffer and collected by 
centrifugation at 2,500 rpm for 2 minutes at 4°C. 30μl of RIPA buffer with 1×SDS loading 
buffer was aliquoted into the complexes. This mixture was first boiled at 100°C for 10 
minutes and placed on ice prior to immunoblotting.  
 
2.10. Immunoblotting (Western Blotting) 
Protein samples were separated on SDS-PAGE. SDS is present in both the loading buffer and 
gels used in this method and acts as a reducing agent to unfold the secondary structure of 
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proteins. SDS works by coating proteins with negative charge in proportion to the protein 
length such that proteins were separated by molecular weight (MW) (Towbin et al., 1979). 
The percentage of acrylamide in the resolving gel depends on the sizes of the proteins to be 
separated (Table 2.10).  
Percentage (%) 
Acrylaminde 
Range of protein 
separation (kDa) 
5 57-212 
7.5 36-94 
10 16-68 
12 13-50 
15 12-43 
Table 2.10 The percentage of polyacrylamide used in SDS-PAGE gels to 
separate different sized proteins. (Taken from Amersham Pharmacia Biotech 
UK Ltd HybondTMECLTM Nitrocellulose Membrane reference manual) 
 
2.10.1.  Electrophoresis: 
BioRad Mini-Protein II gel apparatus (Bio-Rad Laboratories Ltd, UK) was employed for 
vertical electrophoresis. Glass plates were cleaned and assembled into the gel holder with 
same size spacers. The gel holder was clipped to the gel-casting tray and the mixture of 
acrylaminde was poured in between the glass plates for poly-acrylaminde gel preparation. Gel 
percentage used depends on size of protein(s) of interest (Table 2.10). Once proper separation 
was achieved, proteins were transferred from gel to the nitrocellulose membrane (Amersham, 
UK) and the membrane was cut in half if needed. Membrane containing proteins with 
molecular weight lower than 30 kDa was probed for molecules such as Cav-3, Cav-1 and 
active IGF-2; membrane containing proteins with molecular weight above 40 kDa was probed 
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for molecules such as Erk, phospo-Erk, Akt, phospho-Akt and Pax7. 
The molecular weights of Cav-3 and Cav-1 are 17.5 kDa and 22 kDa respectively; therefore a 
12% resolving gel was chosen to separate the protein samples. One 12% resolving gel was 
made by gently and thoroughly mixing 1.6 ml of dH2O, 2.0 ml of 30% acrylamide (Protogel; 
Geneflow Ltd, UK), 1.3 ml of 1.5 M Tris-HCl (pH8.8; Tris base, Fisher scientific, UK), 50 μl 
of 10% SDS (Fisher Scientific, UK), 50 μl of Ammonium Persulfate (APS; Sigma-Aldrich, 
UK), and 2 μl of N,N,N',N'-Tetramethylethylenediamine (TEMED; Sigma-Aldrich, UK). 
Acylaminde polimerization is initiated and accelerated respectively by APS and TEMED so 
that APS and TEMED were added right before the mixture was poured in between the glass 
plates. The mixture was poured in between two glass plates until the mixture reached 3/4 of 
the way up the plates. A small amount of isopropanol was added to level the gel surface and 
the gel was set for approximately 30 minutes (or until solid) at room temperature. A 5% 
stacking gel was prepared by mixing 1.4 ml of dH2O, 0.33 ml of 30% acrylamide, 0.25 ml of 
1.0 M Tris-HCl (pH6.8), 20 μl of 10% SDS, 20 μl of APS and 8.5 μl of TEMED. This mixture 
was poured on top of the resolving gel and the gel comb then slid in between the two glass 
plates, avoiding bubbles and before the stacking gel had set. The Gel was allowed to set for 
approximately 30 minutes (or until solid) at room temperature. 
Protein samples were prepared whilst gel was set to solidify. 20 μg of total protein extract 
from cell samples and 15 μg of total protein extract from embryonic samples (see section 
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2.8.2 for protein yield determination) were mixed with 2.5 μl of 6×SDS Sample Buffer (see 
appendix 2 for 6×SDS Sample Buffer recipe) to reach a final volume of 15 μl. Sample 
mixture was boiled at 100°C for 5 minutes and then placed on ice. The mixture was 
centrifuged at 13,000 rpm for 1 minute and kept on ice for loading.  
Combs were removed after gels solidified completely. The gel holder was un-clipped from 
gel-casting tray and was placed into the electrophoresis tank (BioRad Laboratories Ltd, UK). 
Chambers inner and outer were filled with SDS running buffer [3 g of Tris, 14.42 g of glycine, 
1 g of SDS and dH2O to 1 Litre]. Samples and 4 μl prestained protein marker (New England 
Biolabs Ltd, UK) were loaded into individual wells. Gel was run at 70 V (constant voltage) 
first and the voltage was changed to 110V once the dye was stacked and started to enter the 
resolving gel. The gel was run on ice until the marker was separated properly or when the dye 
front reaches the end of the gel. 
 
2.10.2. Transfer Blotting: 
Running apparatus was dismantled and glass plates were removed from gel holder. The gel 
was removed from glass plates and the stacking gel was cut away by scalpel. One piece of 
HybondTMECLTM Nitrocellulose membrane (Amersham Life Science, UK) cut to the same 
size as the gel was soaked in dH2O for 1 minute to activate the membrane, and then placed 
into transfer buffer [0.03 g of Tris, 14.4 g of glycine, 200 ml of Methanol and dH2O to 1 litre] 
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until used. The Membrane was cut on the upright corner allowing subsequent orientation and 
placed on top of the gel with copious transfer buffer to prevent bubbles. The Gel and 
membrane were then sandwiched between four pieces of filter paper and two pieces of sponge 
pads (two pieces of filter paper and one piece of sponge pad each side). The sandwich was 
placed into a mini transfer blotting cassette (BioRad Laboratories Ltd, UK) with the gel side 
being positioned to the black-side of the transfer cassette case (-ve/negative charge) and the 
membrane side next to the clear/transparent side (+ve/positive charge). The cassette was 
clipped shut and placed into the blotting apparatus with the black side facing the black (-ve) 
electrode. Transfer buffer was added to the tank and the tank was connected to the power 
supply. Transfer was run at 100 V (constant current 220 mA) at 4°C (cold room) for 75 
minutes.  
 
2.10.3.  Hybridization, Detection and Analysis: 
The transfer equipment was dismantled and the gel was discarded. The membrane was 
incubated in blocking buffer [50 ml of TBS (see appendix 2 for TBS recipe), 2.5 g of non-fat 
milk (5% w/V; Marvel, UK) and 50 μl of Tween®20] at room temperature for 1 hour. The 
primary antibody (see table 2.10) was diluted in blocking buffer and overlaid to the membrane 
before being sealed into a plastic bag. The membrane was incubated overnight at 4°C with 
vigorous agitation on an orbital shaker (IKA® KS 130 shakers; GmbH & Co. KG, Germany). 
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The following day, the membrane was washed trice (10 minutes each time) in wash buffer 
(TBST; TBS with 0.1% Tween®20) and then probed with biotinylated secondary antibody 
(diluted in blocking buffer) appropriate to the primary antibody (table 2.10). The membrane 
was incubated at room temperature for 1 hour with vigorous agitation and after washing with 
TBS trice (10 minutes each time) was probed with streptavidin-conjugated DyLight(TM) 800 
(Fisher Scientific Ltd, UK) for 30 minutes at room temperature in the dark to amplify the 
signal. The membrane was then washed with TBS trice (10 minutes each time) to remove the 
detergent and the signal was detected using an Odyssey® infrared imaging system (LI-COR 
Biotechnology, UK). As the levels of tubulin vary in dystrophic embryos, we used coomassie 
blue staining of the nitrocellulose membranes as loading control (Figure 2.5).  
 
Figure 2.5 Protein levels of α-tubulin vary in dystrophic embryos.  
Whole protein extracts were collected from decapitated E17.5 embryos of wt, mdx, 
cav-3-/- and DMhet. Proteins were harvested by grinding the fresh embryos in 
RIPA buffer. (Refer to section 2.8.1 for detail) (A) 15 μg of each protein sample 
was loaded for immunoblotting of Cav-1, Cav-3 and Pax7 and α-tubulin. (B) 
Levels of α-tubulin protein increase in mdx and DMhet but decrease in cav-3-/- 
compared with wt (n = 2). Cav-1: caveolin-1; Cav-3: caveolin-3; cav-3-/-: Cav-3 
knockout; DMhet: mdx with cav-3 heterozygous knockout. 
 
A B 
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The primary and secondary antibodies used and their titre are listed in table 2.11. 
Primary Antibody (Titre) Secondary Antibody (Titre) Tertiary Antibody (Titre) 
(applied when biotinylated 
2nd Ab was used) 
Mouse monoclonal anti-β- actin 
antibody (1:20,000) 
Biotinated Anti-mouse IgG antibody 
(1:20,000) 
Mouse anti-β-dystroglycan antibody 
[MANDAG1 (7A11)] (1:1,000) 
Anti-p-ERK (E-4) mouse monoclonal 
antibody (1:1000) 
Mouse anti-mannose 6-phosphate / 
IGF II receptor, cation-independent 
(86F7) (1:1,000) 
Mouse monoclonal anti-Pax7 
antibody; DSHB, USA  (1:500) 
Biotinylated anti-mouse IgG antibody 
(1:1,000) 
 
Mouse monoclonal anti-IGF2 antibody 
(1:500) 
Biotinated Anti-mouse IgG antibody 
(1:100) 
Biotinylated anti-mouse IgG antibody 
(1:500) (for cell samples) 
Mouse monoclonal anti- caveolin 3 
antibody (1:500) 
Odyssey anti-mouse IRDye® 680 
(1:1,000) (for embryonic samples) 
Anti-Src (L4A1) Mouse monoclonal 
antibody (1:500) 
Monoclonal Anti-α-Tubulin antibody 
produced in mouse (1:10,000) 
Odyssey anti-mouse IRDye® 680 
(1:1,000) 
 
Rabbit anti-mouse Akt antibody 
(recognize Akt1, Akt2 and Akt3) 
(1:500) 
Rabbit anti-mouse phospho-Akt 
(Ser473) antibody (recognize Akt1, 
Akt2, Akt3) (1:1,000) 
Rabbit anti-caspase 3 antibody 
(1:2,000) 
Anti-ERK1(K-23) rabbit polyclonal 
antibody (1:1000) 
Phospho-mTOR (ser2448) rabbit 
monoclonal antibody (1:1,000) 
mTOR (7C10) rabbit monoclonal 
antibody (1:1,000) 
Rabbit anti-Phospho-Src Family 
(Tyr416) antibody (1:500) 
Biotinylated anti-rabbit Ig antibody 
(1:1,000) 
 
Odyssey anti-rabbit IRDye® 680 
(1:500) (for cell samples) 
Rabbit polyclonal anti Cav-1 antibody 
(1:5,000) 
Biotinylated anti-rabbit Ig antibody 
(1:1,000) (for embryonic samples) 
Goat anti-Kip2 p57 (M-20) (1:500) Anti-Sheep/goat Ig biotinylated 
(1:1,000) 
DyLight(TM) 800 
Conjugates-Streptavidin 
(1:20,000) 
Table 2.11 Primary, secondary and tertiary antibodies used for 
immunoblotting analysis.  Titres of antibodies used are shown in parentheses.  
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2.11. Determining the mechanical property of myoblasts and myotubes using atomic force 
microscopy  
The mechanical properties of dystrophin-deficient and non-dystrophic myoblasts/myotubes 
were determined using a NanoWizard II atomic force microscope (AFM; JPK, Germany) at 
18°C in collaboration with Dr. James Bowen (School of Chemical Engineering, the University 
of Birmingham). Additional lighting from a LED light source (Schott, UK) was applied from 
the bottom of the microscope for the purpose of finding the target cells easily through the 
poly(styrene) Petri dishes. The measurements required the use of a CellHesion module (JPK, 
Germany), affording an increased vertical scanning distance of up to 100 μm. Data acquisition 
was performed using rectangular Si cantilevers (type CONT-L, NanoWorld AG, Switzerland) 
which exhibited sphericonical tips with 2 μm nominal radii of curvature. As the cantilever 
approaches the cell surface and contacts it, tip-sample interactions lead to a vertical deflection 
of the cantilever (figure 2.6 A).  
   
A C 
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Figure 2.6 Illustration of how the atomic force microscopy (AFM) works.  
(A) The illustration of how the probe of AFM scans across the material surface. (B) A 
representative picture of the scanned force map and the corresponding force-
displacement curve. (C) A representative picture of the cell height. Scheme (A) was 
taken from the JPK website. 
 
The height of the contact point was recorded, representing one pixel in the image, which was 
converted into a map of surface topography. A maximum compressive load of 10 nN 
(Nanonewtons) was applied to the surface during data acquisition, which corresponded to a 
small strain during the indentation of a cell. The deflection (x) was converted to force (F) 
using Hooke’s law; 
F = −kx  
Here k is the cantilever spring constant which was in the range 0.1-0.2 N/m, and was 
calibrated by Dr. James Bowen according to the method reported previously (Bowen, 2010).  
The force maps were scanned with a resolution of 60×60 pixels (Figure 2.6 B). From each cell, 
B 
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9 pixels were selected and those force-displacement curves were analysed using a Hertzian 
model to obtain a mean Young's modulus for each cell. The mechanical properties of wild 
type and dystrophin-deficient myoblast cell lines were tested three times with 10 cells 
examined each time. The mechanical properties are reported in kilopascal (kPa). The 
mechanical property test of myolasts/myotubes was performed with the help of Dr. James 
Bowen (School of Chemical Engineering, University of Birmingham). 
 
AM2 acknowledgement 
The atomic force microscope used in this research was obtained, through Birmingham 
Science City: Innovative Uses for Advanced Materials in the Modern World (West Midlands 
Centre for Advanced Materials Project 2), with support from Advantage West Midlands 
(AWM) and part funded by the European Regional Development Fund (ERDF) awarded to 
School of Chemical Engineering, the University of Birmingham. 
 
2.12. Sequence alignment 
The alignment of caveolin amino acid sequences was performed using the alignment tools of 
Biology Workbench developed by the San Diego Supercomputer Center (SDSC), Department 
of Bioengineering at University of California, San Diego. The amino acid sequences of mouse 
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caveolin-1, 2 and 3 were obtained from the National Center for Biotechnology Information 
(NCBI) website; the accession numbers are NP_031642, NP_058596 and NP_031643 
respectively. The mouse dystrophin amino acid sequence (accession number: NP_031894) 
was also obtained from NCBI but only the actin binding domain of dystrophin (amino acids 
14-240) was used for alignment via NCBI Basic Local Alignment search tool (BLAST). The 
resulting actin binding sequence which has homologous counterpart in caveolin was then used 
for final alignment by alignment tool from SDSC Biology Workbench. 
 
2.13. Statistics analysis  
All western experiments were at least three repeats of different protein samples obtained at 
different times (unless mentioned), except the embryonic samples (n is indicated in each 
figure legend). For fusion index and apoptosis index analysis of myoblasts, each data point 
was triplicate with two repeats (total six samples for each data point). Standard error was 
obtained using analysis of variance (ANOVA) using Microsoft excel.  
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Chapter 3. The osteoblast MC3T3-E1 cell line promotes differentiation of dystrophin-
deficient myoblasts  
3.1. Introduction: 
Muscle fibre size variation is found in the skeletal muscles of DMD mouse model mdx mice 
compared to the non-dystrophic mice, especially an increase in the number of small size fibres 
in adult mdx mice and lower fibre density in embryonic mdx mice (Merrick et al., 2009; 
Tanabe et al., 1986; Torres and Duchen, 1987). These small fibres found in mdx suggest 
impairment of muscle fibre differentiation and maturation as a significant component of the 
progressive pathology in mdx and DMD. In a preliminary study, we found fusion impairment 
of skeletal myoblasts derived from 4 week-old mdx mice (Figure 3.1).  
 
 
Figure 3.1 Fusion impairment of mdx derived skeletal myoblasts.  
Primary skeletal myoblasts were isolated from 4 week-old mdx and wt mice. 
The fusion capacity of the myoblasts was investigated in proportion to the total 
number of myoblasts in cultures (%). (-): no fusion; (+, ++, +++) different 
degrees of fusion. This is unpublished data of Dr. Janet Smith. Skeletal 
myoblasts derived from 4 week-old mdx mice showed impairment of fusion. 
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It has been reported that DMD myoblasts isolated from twelve DMD patients with age of 3-11 
produced myotubes which are shorter, thinner and have fewer myonuclei compared to those 
from age-matched controls when these myoblasts were treated with low mitogen medium for 
21 days (Delaporte et al., 1984). However, a report suggests that dystrophin-deficient 
myoblasts exhibit no impairment of differentiation. Frances Chandler’s group (Blau et al., 
1983) suggested that myoblasts isolated from six DMD patients between the age of 1-13 
showed differentiation ability comparable to those isolated from age-matched controls 
through the analysis of myotube morphology and the level of acetylcholine receptors on the 
myotube surface. When quantitated by staining for pan-MyHC, myoblasts isolated from mdx 
mice of 2, 6 and 12 months old showed a similar differentiation efficiency to non-dystrophic 
controls (Schuierer et al., 2005). The Chandler’s and Hughe’s groups adapted protocol 
differred from the Fardeau’s group by culturing the muscle stem cells respectively on collagen 
and matrigel (Blau et al., 1983; Delaporte et al., 1984; Schuierer et al., 2005). PD50A 
myoblasts, a clonally mdx-derived (5 week-old) skeletal myoblast cell line, has been shown in 
vivo to be able to fuse with myofibers and rehabitat the satellite cell positions when they are 
transplanted into mdx mice (Smith and Schofield, 1994; Smith and Schofield, 1997). In this 
report I examined in vitro whether the dystrophin-deficient (PD50A) differentiating myoblasts 
have fusion impairment. 
Elevated apoptosis and proliferation have been reported in both primary and clonally derived 
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myoblasts isolated from dystrophic (mdx and cav3-/-) adult/juvenile mice and embryos 
compared to those from age-matched controls (Merrick et al., 2009; Smith et al., 1995; 
Woods et al., 2000). It has also been reported that myoblast differentiation is accompanied by 
apoptosis (Wang and Walsh, 1996). Several reports show that IGF-1 and IGF-2 can promote 
myoblast differentiation (Engert et al., 1996; Florini et al., 1991; Kaliman et al., 1998). 
Inhibition of AKT or ERK pathway that downstream IGF-1 and IGF-2 signalling reduces 
myoblast differentiation and proliferation respectively (Coolican et al., 1997). IGF-2 is also a 
survival factor for dystrophin-deficient myoblasts (Smith et al., 1995). IGF-2 is genetically 
linked to a cell cycle inhibitor p57kip2 (Cyclin-dependent kinase inhibitor 1c or CDKN1c; 
homologue of p21CIP1) in a cluster of imprinted genes in human chromosome 11p15.5 and 
down-regulates p57kip2 (Caspary et al., 1999; Grandjean et al., 2000; Matsuoka et al., 1996). 
It thus has alternate signalling pathway acting via p57kip2, which is not activated by IGF-1, 
and which is active in skeletal muscle cells. In addition, LIF can promote skeletal muscle 
regeneration in vivo (Kurek et al., 1997). To establish the relationship between differentiation 
and apoptosis in dystrophin-deficient myoblasts, I examined the effects of IGF-1, IGF-2 and 
LIF on myoblast differentiation.  
It has been reported that Cav-1 is present predominantly in proliferating myoblasts, whereas 
Cav-3 is present in differentiating myoblasts and myotubes (Volonte et al., 2005). In DMD 
and mdx, there is elevated level of Cav-3 (Merrick et al., 2009; Repetto et al., 1999; Vaghy et 
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al., 1998). In the present report, I examined whether there are differential expressions of Cav-
1 and Cav-3 between differentiating dystrophin-deficient and non-dystrophic myoblasts and 
whether these have a functionally significant effect on differentiation.  
 
3.2. Results: 
To establish whether the PD50A (dystrophin-deficient) myoblasts has impaired differentiation, 
I counted the number of myotubes and myonuclei of PD50A myoblasts treated with low 
mitogen medium for seven days. The number of myotubes were normalised to the surface 
area covered by differentiating myoblasts. The number of myonuclei is presented as the 
number of nuclei in myotubes per cm2 of surface area. 
 
3.2.1.Differentiation capacity of dystrophin-deficient myoblasts is reduced  
The number of myonuclei (number of nuclei in myotubes/cm2) of C2C12 myoblasts under 
low mitogen condition (differentiation medium or DM; DMEM with 2% horse serum) is 
about four fold higher than that in PD50A myoblasts under the same condition. The number 
of myonuclei is 2727 ± 235 in differentiating C2C12 myoblasts vs. 672 ± 110 in 
differentiating PD50A myoblasts (Figure 3.2 A, B and C; p= 6.09×10-9). There are fewer 
myotubes (less than a third) formed from PD50A (193 ± 29 myotubes/cm2) myoblasts than 
C2C12 myoblasts (603 ± 33 myotubes/cm2) (Figure 3.2 A, B and D; p= 1.26×10-6).  
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Figure 3.2 The differentiation capacity of dystrophin-deficient myoblasts (PD50A) 
is impaired under low mitogen condition compared to non-dystrophic myoblasts 
(C2C12). 
(A) C2C12 (wt) and (B) dystrophin-deficient/dystrophic (PD50A) myoblast cell lines 
were subjected to DMEM medium with 2% horse serum (DM) for 7 days. Cells were 
fixed in 4% paraformaldehyde (PFA) and stained with Leishmain’s stain to label the 
nuclei. Representative multinucleated myotubes are indicated by red arrows. (C) 
Myonuclei is defined as the number of nuclei in myotubes per area surface (cm2). (D) 
Myotube number is normalised to surface area. ANOVA; ＊ ＊ p ＜ 0.05 ; Data 
presented are the average of triplicate. Scale bar = 100 μm. 
C D 
A B 
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In addition, Leishman’s stain shows that the width and length of myotubes formed from 
PD50A myoblasts appear to be less than those formed from C2C12 myoblasts (Figure 3.2 A 
and B). From these data, it appears that the differentiation capacity of PD50A dystrophin-
deficient myoblasts is impaired in culture compared to the non-dystrophic myoblast line 
C2C12. 
 
3.2.2.  MC3T3-E1 osteoblasts induce differentiation of both C2C12 and PD50A 
myoblasts 
Because the dystrophic myoblasts induced by the standard (mitogen withdrawal) method 
differentiate poorly (section 3.2.1; Figure 3.2), I tried to find a method that can promote 
myoblast differentiation better than the low mitogen treatment, especially for the dystrophin-
deficient myoblasts. Previous study in our lab (unpublished data of Leah Foley and Dr. Janet 
Smith) suggests that osteoblasts MC3T3-E1 have the potential for inducing myoblast 
differentiation when they were co-cultured with non-dystrophic and dystrophin-deficient 
myoblasts. To establish this method, MC3T3-E1 cells were plated together with C2C12 or 
PD50A cells for 4 days. The resulting myotubes were fixed and stained with Leishman’s stain, 
which labels the nuclei; the differentiation capability of these cells was determined by scoring 
multinucleated myotubes and was represented as the number of myonuclei and the number of 
myotubes normalised with surface area (cm2).  
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Figure 3.3 Coculture with osteoblasts promotes the differentiation of myoblasts. 
Myoblasts were fixed with 4% PFA and then stained with Leishman’s stain on day 4 
to investigate differentiation capability. (A) C2C12 and (B) PD50A myoblasts were 
treated with DM for 4 days; myotubes are indicated by red arrows. (C) Coculture with 
MC3T3-E1 osteoblasts increases the myonuclei of C2C12 cells though less effective 
than DM induction. Coculture with osteoblasts increases the myonuclei of PD50A 
myoblasts. (D) Coculture with osteoblasts increases the number of myotubes of 
C2C12 and PD50A myoblasts. ANOVA; ﹟ p＜ 0.05 ; ﹟﹟,＊＊ p＜ 0.01 ; ＊ 
C2C12 vs. PD50A; ﹟ compared with GM) Data presented are the average of two 
repeats with triplicate for each; n = 6. Scale bar = 100 μm. 
A B 
C 
D 
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In the early stages of differentiation (cultured in DM for 4 days), differentiating PD50A 
myoblasts had significantly fewer myonuclei (number of nuclei in myotubes/cm2) (1117 ± 80) 
compared to the differentiating C2C12 myoblasts (2527 ± 223) (Figure 3.3 C; p= 4.98×10-2). 
Similarly, the total number of myotubes formed from PD50A myoblasts treated with DM 
(DMEM with 2% horse serum) (391 ± 57) is about 42% of that formed from C2C12 
myoblasts (917 ± 150) (Figure 3.3 D; p= 4.89×10-3). Coculture with osteoblasts increases 
differentiation efficiency for PD50A compared to the DM treatment; the number of myonulcei 
(1656 ± 253; p= 4.99×10-2) increases by 45% and the total number of myotubes (602 ± 53; p= 
1.45×10-2) increases by 50% for PD50A (Figure 3.3 C and D). For C2C12 myoblasts, 
coculture with osteoblasts also induces differentiation of C2C12 myoblasts but it is less 
efficient as DM such that the number of myonuclei (1239 ± 89; p= 1.50×10-4) reduces by 50% 
and total number of myotubes (514 ± 59; p= 2.08×10-2) reduces by 44% compared to those 
treated with DM (Figure 3.3 C and D). These data suggest that coculture with osteoblasts can 
induce the differentiation of both PD50A and C2C12 myoblasts and that coculture with 
osteoblasts induces differentiation of PD50A myoblasts most effectively. 
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Figure 3.4 Factors secreted from osteoblasts promote the differentiation of C2C12 
myoblasts. 
Myoblasts were fixed with 4% PFA and then stained with Leishman’s stain on day 4 
to investigate differentiation capability. Osteoblasts and C2C12 secrete factors that 
promote PD50A differentiation while PD50A secrete factors that inhibit myoblast 
differentiation. The differentiation capability of myoblasts is presented as (A) number 
of myonuclei and (B) number of myotubes. All conditioned medium treatments were 
performed in the presence of 2% HS plus 5% FCS. C2C12 and PD50A myoblasts 
treated with DM+5 (2% HS+ 5% FCS) serve as controls for determining the effects of 
conditioned medium. Differentiation ability of myoblasts were examined under 
osteoblast-conditioned medium (OCM), conditioned medium from C2C12-osteoblast 
coculture (CCM) and conditioned medium from PD50A-osteoblast coculture (PDCM) 
for 4 days. ANOVA; ﹟ p＜0.05 ; ﹟﹟,＊＊ p＜0.01 ; ＊ C2C12 vs. PD50A; ﹟ 
compared to the DM+5 treatment. Data presented are the average of two repeats with 
triplicate for each; n = 6.  
A 
B 
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Osteoblast-myoblast contact is required for induction of differentiation for PD50A myoblasts 
To test whether this osteoblast induction effect came from osteoblast-myoblast contact or 
from secreted factors produced by osteoblasts, PD50A and C2C12 were cultured in the 
presence of conditioned medium from osteoblasts [OCM; 50% osteoblast-conditioned 
medium with 50% differentiation medium (DM)]. This 50% conditioned medium protocol 
which has been established previously maintains the myoblast culture without compromising 
their ability to differentiate under appropriate induction (Smith and Schofield, 1994). As the 
conditioned medium collected from osteoblasts culture contained 10% FCS, medium with 2% 
HS and 5% FCS (DM+5) were used as control. After cultured for 4 days, the number of both 
myonuclei (2203 ± 299; p= 2.40×10-3) and myotubes (818 ± 181; p= 4.17×10-2) produced by 
C2C12 is 2 fold more in OCM treatment than in DM+5 control (myonuclei: 987 ± 141; 
myotubes: 412 ± 60) (Figure 3.4 A). However, it has no effect on the number of myonuclei 
and myotubes in differentiating PD50A myoblasts compared to the DM+5 control (Figure 3.4 
A). These data suggest that osteoblast-myoblast contact is required for induction of 
differentiation by osteoblasts in PD50A and that factors secreted from osteoblasts are capable 
of promoting the differentiation of C2C12 myoblasts. However, the effects of FCS on 
myoblast differentiation can not be excluded (refer to section 3.2.3; Figure 3.6). 
To further examine whether osteoblast-myoblast coculture secretes factors that have an effect 
on myoblast differentiation, I collected conditioned medium from C2C12-osteoblast coculture 
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(CCM) and PD50A-osteoblast coculture (PDCM) respectively. Myoblasts (both C2C12 and 
PD50A) were treated with either CCM or PDCM for 4 days before the myotubes were fixed 
and stained with Leishman’s stain. 
PD50A myoblasts treated with CCM display 2 fold more myonuclei (2533 ± 296) and 
myotubes (985 ± 95) compared to those treated with DM+5 (Figure 3.4 A and B; p = 1.18×10-
3 for myonuclei; p= 6.69×10-3 for myotubes). Similarly, C2C12 myoblasts treated with CCM 
exhibit differentiation capacity (myonuclei 1895 ± 330; number of myotubes 851 ± 150) 2 
fold more than those treated with DM+5 (Figure 3.4 A and B). Conversely, PDCM treatment 
has no effects on the number of myonuclei and myotubes for PD50A and C2C12 myoblasts 
compared to the DM+5 controls (Figure 3.4 A and B). These data suggest that C2C12-
osteoblast coculture produces soluble differentiation promoting factors which PD50A-
osteoblast coculture do not. The data also suggest that there is disruption of signalling in 
dystrophin-deficient myoblasts.  
 
3.2.3. Fetal calf serum (FCS) promotes differentiation of PD50A myoblasts but suppresses 
differentiation of C2C12 myoblasts  
In section 3.2.2, myoblasts and osteoblasts coculture was supplementd with 10% FCS and 
myoblasts cultured in conditioned medium was also supplemented with 5% FSC. To study the 
effect of FCS on myoblast differentiation, I examined the fusion index of myoblasts 
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supplemented with 0, 0.5, 5 and 10% FCS. The fusion index is scored by immunostaining the 
myotubes with anti-pan-myosin (MF20) antibody after ten days of culture and defined as the 
ratio of nuclei in myotubes versus total nuclei.  
I first scored the fusion index of myoblasts cocultured with osteoblasts (Figure 3.5). C2C12 
myoblasts show higher fusion index than PD50A myoblasts under growth permissive (GM) or 
low-mitogen (DM) differentiation conditions (Figure 3.5 A, B and C), demonstrating that 
dystrophin-deficient myoblasts (PD50A) have lower differentiation efficiency compared to 
the wt myoblasts (C2C12). For PD50A myoblasts, coculture with osteoblasts induces 8 fold 
more myotube formation compared to GM control (Fusion indices are 12.62 ± 0.90% and 
1.41 ± 0.51% respectively) (Figure 3.5 B and C; p= 1.36×10-2). Fusion index for PD50A 
myoblasts under OCM is comparable to that of PD50A cocultured with osteoblasts and is 
about 2 fold that of PD50A under DM+5 (6.11 ± 0.81%) (Figure 3.5 B and C; p= 2.94×10-3). 
Coculture of C2C12 myoblasts with osteoblasts leads to 4.26 fold more induction of 
differentiation compared to those treated with GM (Fusion indices are 14.36 ± 1.07% and 
3.37 ± 0.58% respectively) (Figure 3.5 A and C; p= 8.40×10-4). C2C12 myoblasts treated with 
OCM (12.91 ± 0.69%) show fusion index comparable to that of coculture (Figure 3.5 A and 
C). Together, data here indicate that in later stages of differentiation (10 days after 
differentiation induction), osteoblasts can effectively induce differentiation of both 
dystrophin-deficient and non-dystrophic myoblasts.   
 119 
 
 
B 
A 
 120 
 
 
 
Figure 3.5 Osteoblasts secrete factors to promote differentiation of C2C12 and PD50A 
myoblasts. 
Myoblasts (1.5×104) plated in 48-well plates were treated with GM, DM and OCM or 
cocultured with MC3T3-E1 osteoblasts. Because myosin heavy chain (labeled by MF-
20) expresses in differentiated myotubes, myoblasts were cultured for 10 days to obtain 
myotubes for MF-20 labelling. The myotubes were fixed with 4% PFA and stained with 
anti-pan-myosin (MF-20) antibody. (A) C2C12 myotubes are positive for MF-20. (B) 
PD50A myoblasts in coculture and OCM form more myotubes than in GM and DM; 
revealed by MF-20 staining. Ten different regions of each treatment were selected 
randomly and more than one hundred and fifty cells were counted. Data presented here 
are triplicates for each treatment. (C) The differentiation induction potential of 
osteoblasts for C2C12 and PD50A myoblasts is presented as fusion index. The fusion 
index is defined in percentage as the ratio of nuclei in myotubes versus total nuclei. 
(ANOVA; ＊,﹟p <0.05; ﹟﹟p <0.01; ﹟compared to the control; ＊compared to the 
C2C12; n = 3). GM: growth medium (with 10% FCS); DM+5: differentiation medium 
with 5% FCS; OCM: osteoblast-conditioned medium 
C 
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Figure 3.6 Fetal calf serum (FCS) promotes differentiation of PD50A myoblasts but 
suppresses differentiation of C2C12 myoblasts. 
Myoblasts (1.5×104) plated in 48-well plates were treated with DM supplemented with 0, 
0.5, 5 and 10% fetal calf serum (FCS) to examine the effect of FCS on myoblast 
differentiation. Myoblasts were cultured for 4 days to test the effect of FCS on early stage 
of myoblast differentiation. The myotubes were fixed with 4% PFA and stained with anti-
pan-myosin (MF-20) antibody. Ten different regions of each treatment were selected 
randomly and more than two hundred and fifty cells were counted. The differentiation 
efficiency for C2C12 and PD50A myoblasts is presented as fusion index. The fusion index 
is defined in percentage as the ratio of nuclei in myotubes versus total nuclei. FCS 
promotes fusion of PD50A myoblasts but suppresses fusion of C2C12 myoblasts (ANOVA;
﹟p <0.05; ＊＊,﹟﹟p <0.01; ﹟compared to the control; ＊compared to C2C12; n = 5). 
DM: differentiation medium; DMEM with 2% horse serum 
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I then examined the effect of FCS on myoblasts differentiation by scoring the fusion index of 
myoblasts supplemented with 0, 0.5, 5 and 10% FCS. FCS has a positive effect on the 
differentiation of dystrophin-deficient PD50A myoblasts. The fusion indices of PD50A 
myoblasts supplemented with 5 (fusion index: 7.28 ± 0.6%; p=4.46×10-5) and 10% (fusion 
index: 7.76 ± 0.44%; p=2.37×10-6) FCS increase by 2.6 fold compared to those without FCS 
supplement (Figure 3.6). Conversely, FCS has a negative effect on the differentiation of 
C2C12 myoblasts. Supplementing 0.5% FCS in C2C12 culture (fusion index: 5.69 ± 0.63%) 
suppresses the fusion index by 40% compared to those without FCS supplement (fusion index: 
9.32 ± 0.28%) (Figure 3.6; p= 3.8×10-4). The fusion indices of C2C12 myoblasts 
supplemented with 5 (fusion index: 4.58 ± 0.44%; p=8.2×10-6) and 10% (fusion index: 3.56 ± 
0.15%; p=4.2×10-8) FCS decrease respectively by 51% and 62% compared to those without 
FCS supplement (Figure 3.6). These data can help explain why differentiation efficiency of 
PD50A myoblasts is higher in coculture with osteoblasts than in OCM whereas that of C2C12 
myoblasts is higher in OCM than in coculture with osteoblasts (section 3.2.2). 
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Figure 3.7 Myoblasts in OCM have total cell number fewer than in GM but greater than 
in DM.  
1.5×104 of myoblasts were plated 4 hours before they were shifted to GM, DM and OCM. 
Total cell number was determined in 24-hour intervals by haemocytometer for 4 days 
(refer to section 2.2). (A) C2C12 myoblasts in OCM have greater total cell number 
compared to C2C12 myoblasts in DM on day 4. (B) PD50A myoblasts in OCM have 
greater total cell number compared to the PD50A myoblasts in DM from day 3. Each 
column represents an average of two repeats; each repeat has triplicates. (ANOVA; ＊
compared to DM; ＊p<0.05; ＊＊p＜0.01; n = 6).  
GM: growth medium (with 10% FCS); DM: differentiation medium (with 2% HS); 
OCM: osteoblast-conditioned medium. The cells under 50% OCM used DM (DMEM 
with 2% horse serum) as the rest 50%. 
B 
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3.2.4.MC3T3-E1 osteoblasts reduce apoptosis of both wt (C2C12) and dystrophin-deficient 
(PD50A) myoblasts via secreted factors 
In addition to the differentiation promotion effect (refer to section 3.2.2), the effect of 
osteoblast-conditioned medium on the total cell number of myoblasts was also determined 
(Figure 3.7). The total number of C2C12 myoblasts in OCM increases with time (Figure 3.7 
A). From day 2 to day 4, the total number of C2C12 myoblasts treated with OCM is greater 
than those treated with low-mitogen differentiation medium (DM) (Figure 3.7 A). The total 
cell number of PD50A myoblasts increases with time when they were treated with either DM 
or OCM (Figure 3.7 B). From day 3 to day 4, total cell number of PD50A treated with OCM 
lies between those treated with GM and DM (Figure 3.7 B). One thing noteworthy is that total 
cell number of PD50A myoblasts is higher than that of C2C12 myoblasts under the conditions 
examined (treated with GM, DM or OCM) from day 3 to day 4 (Figure 3.7; compare A and B). 
As total cell number is the balance between cell survival and proliferation, greater total 
number of cells observed in dystrophin-deficient myoblasts treated with OCM compared to 
non-dystrophic myoblasts could be attributed to effects of OCM on either cell proliferation 
rate or cell survival which is further investigated in the following section.  
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Oestoblast-conditioned medium reduces the apoptosis of myoblasts 
To establish whether osteoblast-conditioned medium (OCM) has effect on myoblast survival, 
I scored the apoptotic index of myoblasts treated with OCM at 24-hour intervals for 4 days. 
The nuclei of myoblasts were labelled with DAPI and the apoptotic nuclei (apoptotic body) 
can be identified as condensed chromatin (Figure 3.8 A and B, arrows). Both wt (C2C12) and 
dystrophin-deficient (PD50A) myoblasts exhibit an increased apoptotic index under low 
mitogen condition (DM) (Figure 3.8 B and C). The apoptotic indices of C2C12 and PD50A 
treated with DM lie respectively between 1.88 ± 0.24% to 5.44 ± 0.88% and 1.74 ± 0.34% to 
9.95 ± 0.85% (Figure 3.8 B and C). In contrast, C2C12 myoblasts treated with OCM show 
reduced apoptotic index compared to those treated with DM; the apoptotic index of the 
C2C12 treated with OCM is between 0.88 ± 0.1% and 2.4 ± 0.23% (Figure 3.8 B). Similarly, 
PD50A myoblasts treated with OCM exhibit reduced apoptotic index compared to those 
treated with DM, with the apoptotic index between 0.44 ± 0.08% and 3.0 ± 0.36% (Figure 3.8 
C). These data suggest that the increase in total myoblast number induced by OCM (Figure 
3.7) may partly be attributed to its effect on the reduction of apoptosis in both C2C12 and 
PD50A myoblasts.  
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Figure 3.8 Osteoblast-conditioned medium reduces the apoptotic index of PD50A 
myoblasts.  
1.5×104 of myoblasts were plated 4 hours before shifted to the following conditions. The 
Cells were labelled with 10 μg/ml of DAPI for 3 minutes to label DNA; apoptotic body is 
recognised as condensed DNA. The number of apoptotic bodies was scored at 24-hour 
intervals for 4 days. Apoptotic index is defined as the number of apoptotic bodies divided 
by total cell number. (A) Representative images of C2C12 and PD50A myoblasts in DM 
on day 4. The apoptotic body is indicated by arrows. (B) OCM reduces apoptosis of 
C2C12 cells compared to DM. (C) PD50A myoblasts in OCM have reduced apoptotic 
index compared to PD50A myoblasts in DM. Each point represents an average of two 
repeats; each contains triplicates (ANOVA; ＊p＜0.05 ;＊＊ p＜0.01 ; ＊compared with 
DM treatment; n = 6).  
DM: differentiation medium (DMEM with 2% HS); OCM: osteoblast conditioned 
medium (with 5% FCS).  
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Figure 3.9 The ratio of active/inactive caspase 3 decreases in differentiating PD50A 
myoblasts under osteoblast-conditioned medium (OCM) and increases in those under 
differentiation medium (DM). 
Cells were washed twice with PBS and then serum starved for 30 minutes before they 
were shifted to OCM or DM. Medium was changed every 2 days. (A) Whole cell extracts 
were harvested and immunoblotted with caspase 3 specific antibody to detect the ratio of 
active/cleaved and inactive/full length caspase 3 which reveals the progression of 
apoptosis. (B) Ratio of active/inactive caspase 3 decreases in C2C12 treated with DM 
while increases in PD50A treated with DM. Ratio of active/inactive caspase 3 decreases 
in PD50A in OCM. (ANOVA; ＊, ﹟ p＜0.05 ; ﹟﹟ p＜0.01 ; ＊ compared to C2C12 
myoblasts; ﹟compared to nondifferentiated control; n=3). Each column in (B) represents 
an average of three repeats. OCM: osteoblast-conditioned medium (with 5% FCS); DM: 
differentiation medium (with 2% HS) 
B 
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Osteoblast-condition medium (OCM) treatment reduced caspase 3 activity of differentiating 
dystrophin-deficient myoblasts 
Caspase 3 is the key effector of the apoptosis pathway. The ratio of cleaved (active)/full 
length (inactive) caspase 3 proteins is an important indicator of apoptosis mediated through 
the caspase cascade. Although the protein levels of active and inactive caspase 3 of C2C12 
myoblasts treated with OCM decrease with time, the ratio of active/inactive caspase 3 is 
comparable to that of non-differentiated control (Figure 3.9 A and B). Differentiating PD50A 
myoblasts induced with OCM have 36% reduction of the ratio of active/inactive caspase 3 
compared to those induced with DM on the fourth day of induction for differentiation (Figure 
3.9 A and B; p= 4.22×10-2). The reduced caspase 3 activity in PD50A myoblasts treated with 
OCM suggests the anti-apoptosis effect of OCM shown in Figure 3.8. Conversely, C2C12 
myoblasts induced to differentiate by DM have a decreased ratio of active/inactive caspase 3; 
the ratio of active/inactive caspase 3 decreases by 34% at 96 hours compared to the non-
differentiated control (Figure 3.9 A and B; p= 1.41×10-2). These data suggest an inverse 
relationship between myoblast differentiation and apoptosis. It further suggests that the 
increased apoptosis seen in PD50A myoblasts is a consequence of defects in differentiation 
caused by lack of dystrophin. 
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Figure 3.10 Protein levels of Pax7 increase in differentiating PD50A myoblasts induced 
with osteoblast-conditioned medium (OCM).  
Wt (C2C12) and dystrophin-deficient (PD50A) myoblasts were washed twice with PBS 
and serum starved for 30 minutes. Cells were then shifted to osteoblast-conditioned 
medium (OCM) or low mitogen medium (DM) for four days. Medium was changed every 
2 days. The proteins were harvested at 24-hour intervals. (A) Representative western 
blotting of Pax7. Coomassie blue stain of the nitrocellulose membrane was used as the 
loading control due to lack of a good internal protein as loading control. (B) Densitometry 
of Pax7 protein level shows that Pax7 protein increases in differentiating PD50A myoblasts 
compared to C2C12 cells cultured in OCM. (ANOVA; ＊p＜0.05 ; ＊＊p＜0.01 ; ＊＊＊p
＜0.001; ＊ compared to nondifferentiated control; n = 3).  
A 
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The level of Pax7 protein correlates with reduced apoptosis of myoblasts induced by 
osteoblast-conditioned medium  
It has been reported that Pax7 is required for the survival of satellite cells in postnatal mice 
(Relaix et al., 2006). Previous reports showed that there is a decrease in the level of 
transcription factor Pax7 protein and an attrition of Pax7-positive cells in mouse embryos of 
mdx (mouse model of DMD) and cav3-/- (mouse model of limb girdle muscular dystrophy 
type 1C) (Merrick et al., 2009). This down-regulation of Pax7 protein level correlates with the 
increased level of apoptosis in myoblasts isolated from mdx and cav3-/- embryos (Merrick et 
al., 2009). However, a detailed relationship between Pax7 protein level and apoptosis is not 
established in differentiating myoblasts. I examined the expression patterns of Pax7 in 
differentiating myoblasts (both C2C12 and PD50A) induced with low mitogen medium (DM) 
or osteoblast-conditioned medium (OCM). I found that Pax7 protein levels in differentiating 
C2C12 and PD50A myoblasts decrease with time when myoblasts were induced with DM but 
not OCM (Figure 3.10 A and B). Surprisingly, there is an elevation of the level of Pax7 
protein in both differentiating C2C12 and PD50A myoblasts induced with OCM; the levels 
increase with time, particularly in differentiating PD50A myoblasts at 96 hours which show 3 
fold more Pax7 compared to nondifferentiated controls (p= 4.83×10-2) (Figure 3.10 A and B). 
These data suggest that levels of Pax7 in differentiating myoblasts correlate with the reduced 
apoptosis seen in C2C12 and PD50A myoblasts treated with OCM (Figure 3.8). 
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3.2.5. Insulin-like growth factors promote proliferation and reduce apoptosis of dystrophin-
deficient myoblasts: 
I have shown that osteoblast-conditioned medium (OCM) can promote the differentiation 
(section 3.2.2) and reduce the apoptosis of myoblasts (section 3.2.4). One candidate for the 
effects on differentiation and apoptosis is the presence of growth factors in the conditioned 
medium. It has been shown that physiological concentrations of IGF-2 have a survival effect 
for dystrophin-deficient myoblasts (Smith et al., 1995; Smith et al., 2000). Supraphysiological 
concentration of IGF-1 can promote cell survival of IGF-2-deficient myoblasts in low 
mitogen medium and proliferation of L6E9 myoblasts in the absence of serum (Engert et al., 
1996; Lawlor and Rotwein, 2000). IGF-1 exerts its mitogenic effect through insulin-like 
growth factor receptor type 1 (IGF-1R) while the mitogenic effect of IGF-2 is mediated by 
IGF-1R and insulin receptor (IR) (Morrione et al., 1997). However, Supraphysiological 
concentration of IGF-1 activate IGF-1R, IR and insulin-like growth factor receptor type2 
(IGF-2R) (Ballard et al., 1986). I have shown that conditioned media from osteoblasts (OCM) 
and C2C12-osteoblast coculture (CCM) promote differentiation of PD50A myoblasts, 
suggesting that growth factors have an effect on the induction of myoblast differentiation. To 
understand the effects of IGF-1, IGF-2 and LIF on differentiating myoblasts, I cultured 
PD50A and C2C12 myoblasts in DM supplemented with IGF-2 (20 ng/ml; physiological 
concentration), IGF-1 (100 ng/ml; supraphysiological concentration) or LIF (1000 units/ml).  
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Figure 3.11 Growth factors increase mitotic index of differentiating myoblasts.  
C2C12 and PD50A myoblasts were cultured in DM supplemented with 100 ng/ml of 
IGF1 (supraphysiological concentration), 20 ng/ml of IGF2 (physiological 
concentration) or 1000 units/ml of LIF. Medium was changed every 2 days. The 
number of mitotic bodies was scored on the fourth day. Cells were fixed with 4% PFA 
and then labelled with 10 μg/ml of DAPI to score the mitotic index. The mitotic index 
is defined as the number of mitotic bodies divided by total cell number. (A) 
Representative image of mitotic body of PD50A in DM is indicated by arrows. (B) 
Growth factors (IGF-1, IGF-2 or LIF) increase the mitotic index of C2C12 and PD50A 
myoblasts. Each column represents an average of two repeats; each repeat contains 
triplicates (ANOVA; ﹟and ＊, p＜0.05 ; ﹟﹟and ＊＊ p＜0.01 ; ﹟ compared to DM 
control; ＊ compared to C2C12 cells; n = 6). IGF1: insulin-like growth factor 1; IGF2: 
insulin-like growth factor 2; LIF: leukaemia inhibitory factor.  
A 
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I first examined the mitogenic effect of growth factors on differentiating myoblasts (Figure 
3.11). The mitotic nuclei were labelled with DAPI and scored (Figure 3.11 A). IGF-1 
increases the mitotic index of C2C12 myoblasts by 9 fold compared to the DM control 
(Figure 3.11 B; p= 2.74×10-2). IGF-2 and LIF also induce proliferation of C2C12 myoblasts 
by 14 and 17 fold respectively compared to the DM control (Figure 3.11 B; p= 1.68×10-3 for 
IGF-2 and p= 1.31×10-3 for LIF). Growth factors (IGF-1, IGF-2 or LIF) do not have a 
significant effect on proliferation of PD50A myoblasts (Figure 3.11 B). One noteworthy thing 
is that growth factors have a greater mitogenic effect on PD50A myoblasts than on C2C12 
myoblasts (Figure 3.11 B). These data suggest that IGF-1, IGF-2 or LIF can induce 
proliferation of both C2C12 and PD50A myoblasts. A greater effect of growth factors on the 
proliferation of PD50A myoblasts than C2C12 myoblasts suggests that either there may be 
upregulation of receptors in PD50A myoblasts or signalling cascades induced by these growth 
factors are perturbed in PD50A myoblasts (e.g. feedback loop of IGF-2/mTOR signalling; 
section 3.2.8).  
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Figure 3.12 IGF-2 and LIF, but not IGF-1, reduce the apoptotic index of differentiating 
dystrophin-deficient myoblasts.  
C2C12 and PD50A myoblasts were cultured in DM supplemented with 100 ng/ml of 
IGF1, 20 ng/ml of IGF2 or 1000 units/ml of LIF for four days. Medium was changed 
every two days. The number of apoptotic bodies was scored on the fourth day. Cells were 
fixed with 4% PFA and then labelled with 10 μg/ml of DAPI to examine the apoptotic 
body. Apoptotic index is defined as the number of apoptotic bodies divided by total cell 
number. (A) Representative images of apoptotic bodies of C2C12 and PD50A myoblasts 
in DM. Representative apoptotic bodies are indicated by arrows. (B) IGF-2 and LIF 
reduces the apoptosis of differentiating PD50A myoblasts. Each column represents an 
average of two repeats; each repeat contains triplicates (ANOVA; ﹟and ＊ p＜0.05 ; ﹟
﹟and ＊＊ p＜0.01 ; ﹟ compared to DM control; ＊ compared to C2C12 cells; n = 6). 
IGF1: insulin-like growth factor 1; IGF2: insulin-like growth factor 2; LIF: leukaemia 
inhibitory factor.  
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The effect of IGF-1, IGF-2 and LIF on myoblast apoptosis 
Treatment of C2C12 with supraphysiological concentration of IGF-1 (100 ng/ml) exert no 
effects on the apoptotic index of differentiating C2C12 myoblasts compared to those cultured 
in low mitogen medium (DM) (Figure 3.12 B). The differentiating C2C12 myoblasts 
supplemented with IGF-2 have apoptotic index comparable to those cultured in DM (Figure 
3.12 B). However, LIF induces apoptosis of differentiating C2C12 myoblasts about 1.5 fold 
(p= 4.92×10-2) that of non-dystrophic myoblasts cultured in DM (Figure 3.12 B). These 
different effects of growth factors on C2C12 myoblasts suggest that different signalling 
pathways are induced in response to these growth factors or that the same pathway but with 
different components is activated. IGF-1 has no effects on the apoptotic index of 
differentiating PD50A myoblasts (Figure 3.12 B). Conversely, IGF-2 and LIF reduce 
apoptosis of differentiating PD50A myoblasts by 54% (p= 6.1×10-5) and 74% (p= 2.2×10-6) 
respectively compared to dystrophin-deficient myoblasts cultured in DM (Figure 3.12 B). 
These data suggest that both IGF-2 and LIF can reduce apoptosis of differentiating 
dystrophin-deficient myoblasts. These data also suggest that LIF is the only second survival 
factor identified other than IGF-2 for myoblasts (Smith et al., 1995; Smith et al., 2000). 
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Figure 3.13 Growth factors promote myotube formation in dystrophic context.  
C2C12 and PD50A myoblasts in DM were supplemented with 100 ng/ml of IGF-1, 20 
ng/ml of IGF-2 or 1000 units/ml of LIF for four days. Medium was changed every 2 days. 
Cells were fixed with 4% PFA and then stained with Leishman’s stain to score the fusion 
index on the fourth day. The number of (A) myonuclei and (B) myotubes produced by the 
myoblasts supplemented with growth factors were scored. Myonuclei is defined as the 
number of nuclei in myotubes normalised with the surface area (cm2). Differentiation 
ability of myoblasts was examined in the following growth factor conditions. In single 
growth factor condition, only IGF-2 promotes differentiation of PD50A myoblasts. 
Combinations of any two growth factors promote myotube formation of PD50A myoblasts. 
Administration of all three growth factors suppresses differentiation of PD50A myoblasts. 
Each column represents an average of two repeat; each has triplicates. (ANOVA; ＊, ﹟p＜
0.05 ;＊＊, ﹟﹟p＜0.01 ; ＊compared to C2C12 myoblasts; ﹟compared to DM treatment; 
n = 6). Data are also analysed with.IGF-1: insulin-like growth factor 1; IGF2: insulin-like 
growth factor 2; LIF: leukaemia inhibitory factor. 
B 
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3.2.6. Insulin-like growth factors (IGF-1 and IGF-2) promote differentiation of dystrophin-
deficient myoblasts cultured in low mitogen medium 
IGF-1 and IGF-2 have been reported to induce myoblast differentiation (Florini et al., 1991; 
Kaliman et al., 1998). In vivo LIF-/- mouse have impaired skeletal muscle regeneration after 
injury, suggesting that LIF can promote skeletal muscle regeneration (Kurek et al., 1997). 
However, primary human myoblasts in culture showed impairment of myotube formation in 
response to LIF (10 ng/ml) (Wang et al., 2008). To study the effects of these growth factors on 
myoblast differentiation, I cultured myoblasts (C2C12 and PD50A) in low mitogen medium 
(DM) supplemented with IGF-1, IGF-2 and/or LIF (alone or in combinations) for four days 
and scored the number of myonuclei and myotubes (Figure 3.13). The number of myonuclei 
(1823 ± 247) and myotubes (544 ± 17) produced by C2C12 myoblasts supplemented with 
IGF-2 is not significantly different from those treated with DM (Figure 3.13 A and B). IGF-1 
reduces the number of myonuclei of C2C12 myoblasts by 60% (p= 3.0×10-4) and LIF reduces 
the number of myonuclei by 66% (p= 1.5×10-4) compared to the DM control (Figure 3.13 A). 
LIF suppresses the myotube formation of C2C12 myoblasts by 32% compared to DM control 
(Figure 3.13 B; p= 1.5×10-4). These data are consistent with the report that LIF suppresses the 
differentiation of myoblasts (Wang et al., 2008).  
In contrast, there is neither increase nor decrease in the number of myonuclei and myotubes of 
PD50A myoblasts supplemented with IGF-1 and LIF compared to DM control (Figure 3.13 A 
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and B). However, IGF-2 promotes differentiation of PD50A myoblasts by increasing the 
number of myonuclei by 38% (p= 3.15×10-2) and the number of myotubes by 64% (p= 
1.15×10-2) compared to DM control (Figure 3.13 A and B). This suggests that IGF-2 may be a 
myogenic factor for dystrophin-deficient myoblasts. Different responses of C2C12 and 
PD50A myoblasts to IGF-2 or LIF suggest that the signalling pathways induced by IGF-2 or 
LIF are perturbed in dystrophin-deficient myoblasts. 
The number of myonuclei and the number of myotubes of C2C12 myoblasts supplemented 
with a combination of IGF-2/LIF reduce respectively by 55% (p= 1.4×10-4) and 28% (p= 
5.11×10-3) compared to the DM control (Figure 3.13 A and B). The number of myonuclei of 
C2C12 supplemented with a combination of IGF-1/LIF reduces by 64% (p= 3.9×10-4) 
compared to DM control (Figure 3.13 A). Conversely, combinations of growth factors induce 
differentiation of PD50A myoblasts (Figure 3.13). The number of myonuclei and the number 
of myotubes of PD50A cells supplemented with a combination of IGF-1/LIF increase by more 
than 2 fold compared to DM control (Figure 3.13 A and B; p= 2.12×10-3 for myonuclei; p= 
6.92×10-5 for myotubes). The number of myonuclei increases by 1.8 fold in PD50A myoblasts 
supplemented with a combination of IGF-1/IGF-2 compared to DM control (Figure 3.13 A; 
p= 1.38×10-3). Similarly, the number of myonuclei and the number of myotubes for PD50A 
myoblasts supplemented with a combination of IGF-2/LIF increase by 1.7 fold compared to 
DM control (Figure 3.13 A and B; p= 7.08×10-3 for myonuclei; p= 6.77×10-3 for myotubes). 
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These data suggest that there exist synergistic effects for IGF-1/IGF-2, IGF-1/LIF or IGF-
2/LIF, which can be used to supplement differentiation medium (DM) and promote the 
differentiation of PD50A myoblasts. One thing noteworthy is that a combination of IGF-1, 
IGF-2 and LIF together strongly suppresses the differentiation of C2C12 myoblasts compared 
to low mitogen medium; the number of myonuclei decreases by 77% (p= 2.7×10-5) and the 
number of myotubes decreases by 56% (p= 1.1×10-5) (Figure 3.13 A and B). These data 
suggest that a combination of IGF-1/IGF-2, IGF-1/LIF or IGF-2/LIF has a synergistic effect 
on dystrophin-deficient myoblast differentiation and that there may be crosstalks among 
signalling via IGF-1, IGF-2 and LIF pathways.  
 
3.2.7. Elevated levels of Cav-1 and Cav-3 proteins in PD50A myoblasts correlate with the 
lower differentiation induction: 
It has been reported that Cav-3 protein is detected in myotubes whereas Cav-1 protein is 
detected in myoblasts and its level decreases in the first day of differentiation in 
differentiating C2C12 myoblasts using immunoblotting (Volonte et al., 2005). To establish the 
expression pattern of Cav-1 and Cav-3 proteins in the differentiating dystrophin-deficient 
myoblasts induced with osteoblast-conditioned medium (OCM), I cultured C2C12 and 
PD50A myoblasts in the presence of DM or OCM for four days and examined the expression 
pattern of Cav-1 and Cav-3.  
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Figure 3.14 Protein levels of Cav-1 isoforms are higher in dystrophic myoblasts under 
osteoblast-conditioned medium (OCM) and differentiation medium (DM).  
Non-dystrophic (C2C12) and dystrophin-deficient (PD50A) cells were washed twice with 
PBS and then serum starved for 30 minutes. Myoblasts were shifted to OCM or DM for 4 
days. Medium was changed every 2 days. (A) Whole cell extracts were harvested at 24-
hour intervals for immunoblotting. (B) PD50A myoblasts have more Cav-1α than C2C12 
myoblasts. (C) PD50A myoblasts have more Cav-1β than C2C12 myoblasts. (D) Ratio of 
Cav-1β/Cav-1α is similar in C2C12 and PD50A myoblasts. Each column represents an 
average of three repeats from different samples. (ANOVA; ＊, ﹟p＜0.05 ; ＊＊p＜0.01 ; 
＊＊＊p<0.001; ﹟compared to C2C12 myoblasts; ＊compared to non-differentiated 
control; n = 3).  
OCM: osteoblast-conditioned medium; DM: differentiation medium 
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There are two isoforms of Cav-1 termed alpha (Cav-1α; 24 kDa) and beta (Cav-1β; 21 kDa), 
which are derived from distinct transcription initiation sites (Kogo and Fujimoto, 2000; 
Scherer et al., 1995). I examined the protein levels of Cav-1α and β in differentiating 
dystrophin-deficient and non-dystrophic myoblasts cultured in OCM or DM. Protein levels of 
both Cav-1α and β are consistently higher in PD50A compared to C2C12 myoblasts under 
these conditions (Figure 3.14 A, B and C). 
The levels of both Cav-1α and β decrease in the first 24 hours and then increase from 48-96 
hours in C2C12 myoblasts cultured in OCM or DM (Figure 3.14 A, B and C), suggesting a 
role for Cav-1 isoforms in the process of myoblast differentiation. Although the level of Cav-
1α protein remains high for 96 hours in PD50A myoblasts cultured in DM or OCM, the level 
of Cav-1β protein decreases at the first 24 hours before then increasing between 48-96 hours 
in PD50A compared to the nondifferentiated control (Figure 3.14 A, B and C). The ratio of 
Cav-1α/β in both differentiating PD50A and C2C12 myoblasts cultured in OCM or DM 
shows no significant difference compared to the nondifferentiated controls (Figure 3.14 D). 
These data suggest that modulating the protein level of Cav-1 plays a role in myoblast 
differentiation and that OCM and DM induced differentiation is mediated via distinct 
signalling pathways.   
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The regulation of Cav-1 and Cav-3 is perturbed in differentiating dystrophin-deficient 
myoblasts  
To study the relationship between Cav-1 and Cav-3 in differentiating dystrophin-deficient 
myoblasts, I examined the expression pattern of Cav-3 and Cav-1 proteins in differentiating 
C2C12 and PD50A myoblasts treated with low mitogen medium (DM) or osteoblast-
conditioned medium (OCM). In the present report, I show in myoblast culture that 
dystrophin-deficient myoblasts have higher level of Cav-1 protein compared to non-
dystrophic myoblasts (Figure 3.15 A and B; also Figure 3.14). Surprisingly I found that Cav-1 
protein levels decrease in the first 24 hours of induction and Cav-1 levels increase between 
24-96 hours in differentiating C2C12 myoblasts cultured in OCM or DM (Figure 3.15 A and 
B). This is consistent with the report which shows that Cav-1 protein levels decrease on the 
first day of muscle regeneration and increase from day 3 to day 10 (Volonte et al., 2005). 
Cav-1 protein levels also decrease in the first 24 hours and increases from 48-96 hours in 
differentiating PD50A myoblasts treated with DM (Figure 3.15 A and B). For differentiating 
PD50A myoblasts cultured in OCM, Cav-1 protein levels increase substantially along with 
time; the Cav-1 protein levels at 96 hours of OCM treatment are higher compared to 
nondifferentiated control (Figure 3.15 A and B). These data suggest that Cav-1 plays a role in 
the differentiation process and that signalling cascades response to DM and OCM 
differentiation induction are perturbed in dystrophin-deficient myoblasts. 
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Figure 3.15 Protein levels of Caveolin-1 and Caveolin-3 are higher in PD50A cells than 
in C2C12 cells under osteoblast-conditioned medium (OCM) and differentiation 
medium (DM).  
Myoblasts were washed twice with PBS and serum starved for 30 minutes. Myoblasts 
were then shifted to OCM or DM. Medium was changed every 2 days. Whole cell 
extracts were collected for western blotting at 24-hour intervals. (A) Representative 
immunoblotting of Cav-1 and Cav-3. Coomassie blue stain of nitrocellulose membrane is 
used as loading control. (B) PD50A myoblasts have higher Cav-1 protein levels than 
C2C12 in DM or OCM.  (C) Cav-3 protein levels are higher in PD50A than in C2C12 
myoblasts; both in OCM or DM. (D) The ratio of Cav-3/Cav-1 is higher in PD50A than 
C2C12 myoblasts under OCM or DM treatments. (ANOVA; ＊, ﹟p＜0.05 ; ＊＊,﹟﹟p
＜ 0.01 ; ＊ ＊ ＊ p<0.001; ﹟ compared to C2C12 myoblasts; ＊  compared to 
nondifferentiated control; n = 3).  
Cav-1: caveolin-1; Cav-3: caveolin-3; OCM: osteoblast-conditioned medium; DM: 
differentiation medium 
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Compared to nondifferentiated myoblasts with time, PD50A myoblasts have higher level of 
Cav-3 protein compared to C2C12 (Figure 3.15 A and C); consistent with the up-regulation of 
Cav-3 expression in mdx mice (Merrick et al., 2009; Vaghy et al., 1998). I was unable to 
detect Cav-3 protein in nondifferentiated C2C12 myoblasts by immunoblotting with our 
present techniques but I showed expression of Cav-3 protein in nondifferentiated C2C12 
myoblasts by immunofluorescent method in chapter 5 (Figure 5.3). Cav-3 protein expression 
increases by 96 hours after C2C12 myoblasts were induced for differentiation in DM (Figure 
3.15 A and C). This is consistent with previous report that Cav-3 protein is expressed in 
differentiated myotubes (Volonte et al., 2003). The protein level of Cav-3 in differentiating 
PD50A myoblasts treated with both OCM and DM decreases in the first 24-48 hours of 
switching to differentiation and then increases from 48 to 96 hours (Figure 3.15 A and C). 
These data suggest that higher levels of Cav-3 protein in differentiating PD50A myoblasts 
may correlate with the lower differentiation efficiency observed in the dystrophin-deficient 
myoblasts cultured in DM (refer to section 3.2.1).  
The ratio of Cav-3/Cav-1 for C2C12 myoblasts increases during differentiation induction; this 
is evidence of a decrease of Cav-1 protein level and an increase of Cav-3 protein level in 
differentiating C2C12 myoblasts treated with DM or OCM (Figure 3.15 D). However, the 
ratio of Cav-3/Cav-1 in differentiating PD50A myoblasts cultured in OCM or DM is not 
significantly different (Figure 3.15 D). These data suggest that the expression of Cav-1 and 
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Cav-3 in differentiating dystrophin-deficient myoblasts is perturbed compared to the 
differentiating C2C12 myoblasts. The perturbed expression of Cav-1 and Cav-3 in 
differentiating dystrophin-deficient myoblasts may contribute to their impaired differentiation. 
 
3.2.8.  IGF-2 signalling pathways are perturbed in dystrophin-deficient myoblasts: 
I have shown that dystrophin-deficient (PD50A) myoblasts have impaired differentiation 
profiles compared to C2C12 myoblasts (refer to section 3.2.1) and that differentiating PD50A 
myoblasts display elevated apoptosis and proliferation compared to C2C12 myoblasts (refer 
to section 3.2.5). IGF-2 has been shown to serve as an autocrine factor for C2 myoblasts and 
its level is elevated in mdx (Florini et al., 1991; Marotta et al., 2009; Merrick and Smith, 
unpublished). Previous reports and unpublished data (Sarbjit Nijjar and Janet Smith) show 
that IGF-2 conveys signals through AKT/mTOR and ERK (Extracellular signal-regulated 
kinases) pathways to regulate myoblast differentiation (Erbay et al., 2003). The cell cycle 
inhibitor p57kip2 (or CDKN1c) is negatively regulated by IGF-2 (Grandjean et al., 2000). To 
understand whether the IGF-2/AKT/mTOR and ERK signalling is perturbed in dystrophin-
deficient myoblasts, I examined proteins involved in IGF-2, AKT and ERK signal 
transduction in differentiating C2C12 and PD50A myoblasts cultured in OCM or DM (Figure 
3.16 and 3.16). IGF-2 is expressed as pro-IGF-2 (23-26 kDa) which is post-translationally 
cleaved and glycosylated to form the active IGF-2 (14-18 kDa) (Duguay et al., 1998).  
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Figure 3.16 The levels of IGF-2 and p57kip2 decrease in differentiating C2C12 and 
PD50A myoblasts induced by differentiation medium (DM). 
Dystrophin-deficient (PD50A) and wt (C2C12) myoblasts were washed twice with PBS 
and then serum starved for 30 minutes. Medium was changed every 2 days. (A) Whole 
cell extracts were collected for immunoblotting at 24-hour intervals. Coomassie blue 
stain of the nitrocellulose membrane serves as the loading control. (B) PD50A myoblasts 
have higher protein levels of mature IGF-2 in DM and OCM at 96 hours compared to 
C2C12 myoblasts. The mature/active IGF-2 is of 14.3 kDa. (C) PD50A myoblasts have 
higher protein level of p57kip2 in OCM and DM at 96 hours compared to C2C12. Each 
column represents an average of at least three repeats from different samples. (ANOVA; 
＊, ﹟p＜0.05 ; ＊＊, ﹟﹟p<0.01; ＊＊＊p<0.001; ＊compared to non-differentiated 
control; ﹟compared to C2C12 myoblasts  n≧3).  
IGF-2: Insulin-like growth factor-2 
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In both differentiating C2C12 and PD50A myoblasts treated with OCM, active IGF-2 
decreases from the first 24 hours and then increases between 48-96 hours (Figure 3.16 A and 
B). The levels of active IGF-2 decrease in differentiating C2C12 and PD50A myoblasts 
cultured in low mitogen medium (DM) compared to their nondifferentiated controls (Figure 
3.16 A and B). Although there is no significant difference in the p57kip2 protein levels in 
differentiating C2C12 myoblasts treated with OCM compared to the nondifferentiated control, 
the levels of p57kip2 decrease in differentiating C2C12 myoblasts cultured in DM (Figure 3.16 
A and C). Differentiating PD50A myoblasts cultured in OCM at 96 hours have higher levels 
of p57kip2 protein compared to differentiating C2C12 myoblasts under these conditions 
(Figure 3.16 A and C). These data are consistent with the higher mitotic index in 
differentiating PD50A myoblasts compared to differentiating C2C12 myoblasts in response to 
IGF-2 treatment (Figure 3.11). 
 
AKT/mTOR signalling pathway is activated in differentiating myoblasts treated with 
osteoblast-conditioned medium (OCM) 
I then examined the downstream pathways of IGF-2 signalling. The levels of AKT and 
phosphorylated AKT (pAKT) proteins decrease in both differentiating C2C12 and PD50A 
myoblasts cultured in DM compared to their nondifferentiated controls (Figure 3.17 A). 
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Figure 3.17 AKT/mTOR signalling pathway is perturbed in differentiating PD50A 
myoblasts cultured in osteoblast-conditioned medium (OCM) and differentiation 
medium (DM). 
C2C12 (wt) and PD50A (dystrophin-deficient) myoblasts were washed twice with PBS 
and then serum starved for 30 minutes. Cells were shifted to OCM or DM for four days. 
Medium was changed every 2 days. (A) Whole cell extracts were collected for 
immunoblotting at 24-hour intervals. Coomassie blue stain of nitrocellulose membrane 
serves as the loading control. (B) PD50A myoblasts have higher pAKT/AKT ratio than 
C2C12 myoblasts in OCM or DM conditions. (C) C2C12 myoblasts have higher ratio of 
pmTOR/mTOR in OCM while PD50A myoblasts have higher pmTOR/mTOR ratio in 
DM. Each column represents an average of three repeats from different samples. 
(ANOVA; ＊, ﹟p＜0.05; ＊＊, ﹟﹟p＜0.01; ﹟compared to C2C12 myoblasts;＊
compared to non-differentiated control; n=3).  
pAKT: phospho-AKT; mTOR: mammalian target of rapamycin 
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The levels of both AKT and pAKT are higher in differentiating PD50A myoblasts cultured in 
DM compared to differentiating C2C12 myoblasts under this condition (Figure 3.17 A). In 
contrast, protein levels of pAKT and AKT increase in both differentiating C2C12 and PD50A 
myoblasts treated with OCM for 96 hours (Figure 3.17 A). The levels of both AKT and pAKT 
proteins are higher in differentiating C2C12 myoblasts cultured in OCM compared to 
differentiating PD50A myoblasts under this condition (Figure 3.17 A). This suggests that AKT 
signalling is more active in myoblasts under OCM than under DM. Activity of AKT signalling 
can be examined through the pAKT/AKT ratio in cells. The ratio of pAKT/AKT is higher in 
differentiating PD50A myoblasts treated with OCM or DM compared to differentiating 
C2C12 myoblasts under these conditions (Figure 3.17 A and B). However, this is not 
statistically significant. These data suggest that higher activity of AKT signalling in 
differentiating myoblasts under OCM than under DM may correlate with the effect of OCM 
on induction of myoblast differentiation; both wt and dystrophin-deficient (refer to Figure 3.4).  
The downstream target of AKT signalling pathway, mTOR, has been reported to respond to 
IGF-2 induction and form a feedback loop to up-regulate IGF-2 (Erbay et al., 2003). I 
examined the protein levels of phospho-mTOR (pmTOR) and mTOR in differentiating wt and 
dystrophin-deficient myoblasts. Differentiating PD50A myoblasts cultured in OCM or DM 
have higher levels of both mTOR and pmTOR proteins compared to differentiating C2C12 
myoblasts under these conditions (Figure 3.17 A). In both differentiating C2C12 and PD50A 
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myoblasts under OCM for 96 hours, the protein levels of mTOR and pmTOR increase 
compared to nondifferentiated controls (Figure 3.17 A). In contrast, the protein levels of 
mTOR and pmTOR decrease in differentiating C2C12 and PD50A myoblasts treated with DM 
(Figure 3.17 A). Expression of pmTOR and mTOR is consistent with the change of pAKT in 
myoblasts cultured with OCM or DM (Figure 3.17 A). The observation that more pmTOR and 
mTOR proteins in differentiating PD50A myoblasts treated with OCM or DM compared to 
differentiating C2C12 myoblasts under these conditions correlates with the higher total cell 
numebr of PD50A myoblasts compared to C2C12 myoblasts (Figure 3.7). I examined the 
ratio of pmTOR/mTOR in differentiating myoblasts which can serve as an indicator for 
mTOR signalling activity. While differentiating PD50A myoblasts cultured in DM have 
higher pmTOR/mTOR ratio compared to differentiating C2C12 myoblasts treated with DM, 
differentiating PD50A myoblasts treated with OCM have lower pmTOR/mTOR ratio 
compared to differentiating C2C12 myoblasts cultured in OCM (Figure 3.17 A and C). These 
data suggest that OCM and DM induce myoblast differentiation through distinct signalling 
cascades.  
 
ERK signalling pathway in differentiating myoblasts is not affected by osteoblast-conditioned 
medium (OCM) or low mitogen medium (DM)  
In unpublished microarray and immunoblotting data (Sarbjit Nijjar and Dr. Janet Smith), we 
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found that treating myoblasts with IGF-2 can induce the ERK signalling. Therefore I 
examined this downstream target of IGF-2 in differentiating wt and dystrophin-deficient 
myoblasts treated with osteoblast-conditioned medium (OCM) or low mitogen medium (DM). 
Protein levels of total ERK1/2 (ERK1 molecular weight of 44 kDa and ERK2 molecular 
weight of 42 kDa) showed no difference in differentiating PD50A myoblasts induced by 
either OCM and DM (Figure 3.18 A). Although the level of total ERK1/2 in differentiating 
PD50A myoblasts is slightly higher compared to differentiating C2C12 myoblasts, there is no 
statistical significance (Figure 3.18 A). The levels of both phosphorylated ERK1 (pERK1) 
and phosphorylated ERK2 (pERK2) proteins are higher in differentiating PD50A myoblasts 
cells treated with OCM or DM compared to C2C12 myoblasts cultured in OCM or DM 
(Figure 3.18 A). The levels of both pERK1 and pERK2 proteins increase in differentiating 
PD50A myoblasts cultured in OCM or DM (Figure 3.18 A); in contrast, the levels of pERK1 
and pERK2 proteins decrease in differentiating C2C12 myoblasts under these conditions 
(Figure 3.18 A). The ratio of pERK2/ERK2 is higher in differentiating PD50A myoblasts 
cultured in either OCM or DM compared to differentiating C2C12 myoblasts under these 
conditions (Figure 3.18 B). Similarly, the ratio of pERK1/ERK1 is also higher in 
differentiating PD50A myoblasts than in C2C12 myoblasts under OCM or DM conditions 
(Figure 3.18 C). These data suggest that IGF2/ERK signalling is up-regulated in 
differentiating dystrophin-deficient myoblasts.          
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Figure 3.18 Ratio of phospho-ERK (pERK)/ERK is higher in PD50A myoblasts under 
osteoblast-conditioned medium (OCM) and differentiation medium (DM) compared 
with C2C12 myoblasts.  
Dystrophin-deficient (PD50A) and wt (C2C12) myoblasts were washed twice with PBS 
and then serum starved for 30 minutes. Cells were treated with OCM or DM for 4 days. 
Medium was changed every 2 days. (A) Whole cell extracts were collected for 
immunoblotting at 24-hour intervals. Coomassie blue stain of the nitrocellulose 
membrane serves as the loading control. The ERK proteins detected were of 42 (ERK2) 
and 44 (ERK1) kDa respectively. (B) Ratio of pERK2/ERK2 (pERK42/ERK42) is higher 
in PD50A compared to C2C12 myoblasts. (C) Ratio of pERK1/ERK1 (pERK44/ERK44) 
is higher in PD50A compared to C2C12 myoblasts. Each column represents an average of 
three repeats from different samples. (ANOVA; ＊ p ＜ 0.05; ＊ compared to 
nondifferentiated control; n = 3).  
pEKR: phospho-ERK; ERK: Extracellular signal-regulated kinases 
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3.3. Discussion: 
3.3.1. Dystrophin-deficient myoblasts have impaired differentiation 
In this report I established impairment of differentiation in the clonally derived dystrophin-
deficient myoblasts (PD50A) on the basis of morphology and the expression of a muscle 
specific marker (myosin heavy chain; MyHC) (Figure 3.1 and 3.5). Differentiation 
impairment in dystrophin-deficient myoblasts observed in my study is consistent with 
previous reports that also determine the differentiation ability by the morphological change 
(Blau et al., 1983; Delaporte et al., 1984). However, Hughes’ group (Schuierer et al., 2005) 
reported that there is no significant difference in the differentiation between control and 
dystrophin-deficient myoblasts from mice of more than 2 months old. This inconsistency 
between my result and the Hughes’ group (Schuierer et al., 2005) may be due to different 
methods applied in these two experiments. I differentiated isolated clonal muscle stem cells 
from 5 week-old mice while they activated the satellite cells in cultured single muscle fibre 
from mice of more than 2 months old. In addition, they plated muscle stem cells on Matrigel 
substrate which may affect the adhesion properties of the muscle stem cells (Schuierer et al., 
2005). This also implies that the differentiation impairment of dystrophin-deficient myoblasts 
reported may be attributed to the lack of dystrophin, as dystrophin is a bridge to link the 
extracellular matrix and the intracellular cytoskeleton (Ervasti and Campbell, 1993). However, 
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whether Matrigel can overcome the signal defect in dystrophin-deficient myoblasts requires 
further investigation.  
 
3.3.2. Osteoblasts promote differentiation of dystrophin-deficient myoblasts via cell-cell 
contact but promote differentiation of wt myoblasts via secreted factors 
I established that MC3T3-E1 osteoblasts can induce differentiation of both wt (C2C12) and 
dystrophin-deficient (PD50A) myoblasts and this promotion likely comes from the factor(s) 
secreted from osteoblasts. This provides a useful method to differentiate the dystrophin-
deficient myoblasts, which are otherwise difficult to induce to differentiate under 
conventional differentiation induction (i.e. low mitogen stimulation). In contrast, C2C12 
myoblasts cultured in OCM have higher efficiency of differentiation compared to those 
cocultured with osteoblasts (Figure 3.3 and 3.4), suggesting there may be an inhibitory effect 
from cell-cell contact. As C2C12 myoblasts were cocultured with osteoblasts supplemented 
with 10% foetal calf serum (FCS); factors from FCS may also have contributed to the 
inhibition of differentiation in C2C12 myoblasts (Figure 3.6). PD50A myoblasts cultured in 
OCM show lower efficiency of differentiation induction compared to C2C12 myoblasts under 
this condition (Figure 3.4). In cocultures with osteoblasts, PD50A myoblasts show greater 
differentiation ability compared to low mitogen treatment (Figure 3.3). This suggests that 
continuing secreted factors from osteoblasts or cell-cell contact/effectors is needed to 
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maintain the differentiation of PD50A cells. Overexpression of integrin α7β1 in mdx mice has 
been shown to protect the mdx skeletal muscles from sarcolemmal damages; this further 
supports the importance of cell-cell contact for differentiation of PD50A myoblasts which 
lack dystrophin (Liu et al., 2012). In addition, C2C12 myoblasts overexpressing integrin α7β1 
have increased proliferation and resistance to apoptosis (Liu et al., 2008). The idea that 
coculture system continuously provides secreted myogenic factors is supported by 
observation that conditioned medium from osteoblasts-C2C12 myoblast coculture (CCM) 
induces better differentiation of PD50A myoblasts compared to those treated with osteoblast-
conditioned medium (Figure 3.4). This is further supported by the observation that FCS 
promotes differentiation of PD50A myoblasts (Figure 3.6). 
 
3.3.3. Treatment of dystrophin-deficient myoblasts with combinations of IGF-2/IGF-1, IGF-
1/LIF or IGF-2/LIF promotes their differentiation  
I show that IGF-2 alone can promote the differentiation of dystrophin-deficient myoblasts in 
low mitogen medium (Figure 3.13) and that combinations of IGF-1/IGF-2, IGF-1/LIF or IGF-
2/LIF act synergistically to promote differentiation of dystrophin-deficient myoblasts to a 
greater extent than the single growth factors (Figure 3.13), suggesting a synergistic effect of 
these factors on differentiation induction in dystrophin-deficient myoblasts. IGF-2 has been 
reported to induce the spontaneous differentiation of C2 myoblasts (approximately 80% 
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confluence) cultured in low mitogen medium by autocrine mechanisms (Florini et al., 1991; 
Merrick et al., 2007). IGF-2 secreted from C2 myoblasts can further up-regulate the 
expression of IGF-2 through mTOR pathway in C2 myoblasts, establishing a feedback loop 
(Erbay et al., 2003). Elevated levels of IGF-1 can lead to muscle hypertrophy through the 
mTOR/p70S6K pathway; this effect is pronounced in young mice with growing muscles and 
diseased mice (e.g. mdx) with regenerating muscles, suggesting the effect of IGF-1 on 
myoblast differentiation may be cell density dependent (Shavlakadze et al., 2010; Song et al., 
2005). Previous reports show that osteoblasts in culture secrete both IGF-1 and IGF-2 
(McCarthy et al., 1992; Nakasaki et al., 2008). Here I observed elevated levels of IGF-2 
protein in differentiating C2C12 and PD50A myoblasts treated with osteoblast-conditioned 
medium (OCM) (Figure 3.16). In addition, the downstream signalling pathway of IGFs, the 
AKT/mTOR signalling, is also activated in response to OCM stimulation. This suggests that 
in our dystrophin-deficient myoblast-osteoblasts coculture, osteoblasts may secrete IGF-2 
which activates the IGF-2/mTOR signalling pathway in the dystrophin-deficient myoblasts. 
Secreted IGF-2 induces production of IGF2 in dystrophin-deficient myoblasts and promotes 
differentiation of these myoblasts. However, osteoblasts may also secreted myogenic factors 
other than IGF-2, such as IGF-1 and LIF.  
C2C12 myoblasts cultured in low mitogen medium (DM) supplemented with IGF-1, IGF-2 or 
a combination of IGF-1 and IGF-2 differentiate less efficiently compared to the DM control 
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(Figure 3.13). This may be attributed to the proliferative effect of IGF-1 and IGF-2 since IGF-
1 and IGF-2 can increase the mitotic index of differentiating C2C12 myoblasts cultured in 
DM (Figure 3.11). Treating rats with IGF-2 after muscle damage suggests a role of IGF-2 
during muscle regeneration in that IGF-2 administration delays the early regeneration (from 
day 1 to day 4) but enhances the late regeneration, showing larger size of regenerated muscle 
fibres on day 7 (Kirk et al., 2003). Similar biphasic effects on myoblast differentiation was 
also found in rat skeletal myoblasts L6E9 treated with IGF-1 which induced the 
phosphorylation of ERK1/2 in the first 24 hours and subsequently inhibited ERK1/2 
phosphorylation after 24 hours onward (Adi et al., 2002).  
Our unpublished data (Sarbjit Nijjar and Dr. Janet Smith) that LIF (leukaemia inhibitory 
factor) mRNA level is elevated in mdx and DMD is consistent with previous reports (Kurek et 
al., 1996b; Reardon et al., 2000). In vitro, LIF has been reported to induce proliferation and 
survival of myoblasts cultured in DMEM supplemented with 5% foetal calf serum (Alter et 
al., 2008; Spangenburg and Booth, 2002; White et al., 2001). In the present report, I 
demonstrate that LIF increases the mitotic index of both differentiating wt and dystrophin-
deficient myoblasts cultured in DMEM supplemented with 2% horse serum (DM) (Figure 
3.11). I also show LIF reduces apoptosis in differentiating dystrophin-deficient myoblasts 
cultured in DM (Figure 3.12). From the present report, I show that other factors are required 
for LIF to boost the promotion effects on muscle regeneration, since under low mitogen 
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condition, LIF failed to induce differentiation of C2C12 myoblasts. In addition, the opposite 
responses to LIF in non-dystrophic and dystrophin-deficient myoblasts indicate the signalling 
pathways induced by LIF may be perturbed in the dystrophin-deficient myoblasts.   
 
3.3.4. IGF-2 is a survival factor for differentiating dystrophin-deficient myoblasts  
In the present study, I established that IGF-2 can reduce apoptosis in differentiating PD50A 
myoblasts cultured in low mitogen medium (Figure 3.12). It has been reported that IGF-2 is a 
survival factor that ameliorates dystrophic phenotype and reduces apoptosis of mdx muscles 
(in vitro and in vivo) (Smith et al., 1995; Smith et al., 2000; Stewart and Rotwein, 1996). It 
has been suggested that myoblast differentiation is accompanied by cell cycle withdrawal and 
apoptosis; following mitogen deprivation, C2C12 myoblasts that can not induce Cdk inhibitor 
p21CIP1 expression undergo apoptosis instead of terminal differentiation (Wang and Walsh, 
1996). This differentiation induced apoptosis involves the DNase γ which causes the 
nucleosomal DNA fragmentation (Shiokawa et al., 2002). In the present study, I show that 
osteoblast-condition medium (OCM) induces higher protein levels of p57KIP2 in both 
differentiating C2C12 and PD50A myoblasts compared to the conventional low mitogen 
induced differentiation (differentiation medium; DM) (Figure 3.16), suggesting that more 
myoblasts treated with OCM exit the cell cycle compared to DM. It has been reported that 
p57KIP2 protein increases in differentiating C2C12 myoblasts and acts to stabilize MyoD 
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(Reynaud et al., 1999). Although higher induction of p57KIP2 protein is observed in 
differentiating PD50A myoblasts treated with OCM for 96 hours compared to differentiating 
C2C12 myoblasts under this condition, the fusion index for PD50A myoblasts cultured in 
OCM is still lower than that for C2C12 myoblasts under similar condition (Figure 3.4). These 
data connect apoptosis and differentiation and also suggest a mode of action for IGF-2, 
distinct from IGF-1, which could depend on receptor availability, extent of differentiation 
contingent on signalling defects or on the lack of another CDK inhibitor such as p21CIP1.  
 
3.3.5. Apoptosis correlates with myoblasts differentiation 
The observation that PD50A myoblasts under growth permissive (GM) and differentiating 
(DM and OCM) conditions have higher total number of cells compared to C2C12 myoblasts 
under these conditions (Figure 3.7) is consistent with the high rate of proliferation found in 
the primary myoblasts isolated from mdx embryos (Merrick et al., 2009). Higher apoptosis in 
differentiating myoblasts induced by DM (Figure 3.8) supports the hypothesis that myoblasts 
which fail to be induced to differentiate undergo apoptosis (Wang and Walsh, 1996). The 
observation that OCM treatment reduces apoptosis and promotes myoblast differentiation 
(Figure 3.4, 3.5 and 3.8) further supports the coupling of apoptosis and differentiation of 
myoblasts. Investigation of the protein level of caspase 3, which is an effector of apoptosis 
(Kuribayashi et al., 2006), shows that there is higher ratio of cleaved/uncleaved caspase 3 (i.e. 
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caspase 3 activity) in differentiating PD50A myoblasts induced by DM than in differentiating 
C2C12 myoblasts under the same condition (Figure 3.9). This is consistent with the higher 
apoptotic index in PD50A myoblasts in DM compared to C2C12 myoblasts in DM (Figure 
3.8). A lower ratio of cleaved/uncleaved caspase 3 in PD50A myoblasts under OCM 
compared to DM (Figure 3.9) suggests that OCM has a survival effect on dystrophin-deficient 
myoblasts which reduces apoptosis of differentiating PD50A myoblasts, providing a means to 
overcome differentiation block. This is supported by the effect of OCM on reducing the 
apoptosis of both dystrophin-deficient and wt myoblasts (Figure 3.8). The increased ratio of 
cleaved/uncleaved caspase 3 in differentiating C2C12 myoblasts cultured in OCM suggests a 
new role for caspase 3 during myoblast differentiation other than as an effector of apoptosis. It 
has been reported that caspases also play a role in myoblast differentiation through the non-
apoptosis mechanism (Larsen et al., 2010; Murray et al., 2008). Caspase 9 activates caspase 3 
which in turn activates caspase-activated DNase (CAD) to create DNA strand breaks; the 
change of DNA micro-environment leads to the activation of p21CIP promoter, producing 
p21CIP and promoting myoblast differentiation (Larsen et al., 2010; Murray et al., 2008). The 
survival effects of osteoblast-conditioned medium on differentiating myoblats and the 
coupling of apoptosis/differentiation of myoblasts need to be further investigated by methods 
such as TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labelling) assay to 
label the fragmented DNA and propidium iodide (PI) flow cytometric assay (Borycki et al., 
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1999b; Wang and Walsh, 1996). 
 
3.3.6. Elevated protein levels of Cav-1 and Cav-3 correlate with impairment of 
differentiation in dystrophin-deficient myoblasts  
It has been reported that over-expression or targeted down-regulation of Cav-3 impairs 
myoblast fusion (Galbiati et al., 1999; Volonte et al., 2003). In the present study, Cav-3 
protein level is down-regulated in differentiating PD50A myoblasts treated with both OCM 
and DM, suggesting the level of Cav-3 is crucial for the differentiation effect induced by 
OCM (Figure 3.15). The protein level of Cav-1 has previously been shown to decrease in 
myoblasts during the first day of differentiation induction and then to increase again (Volonte 
et al., 2005). Similarly, I found that Cav-1 is down-regulated in differentiating C2C12 
myoblasts induced by OCM or DM in the first 24 hours and is up-regulated between 48-96 
hours in the present study (Figure 3.15). The levels of Cav-1 protein are considerably higher 
in differentiating PD50A myoblasts treated with both OCM and DM compared to 
differentiating C2C12 myoblasts under the same conditions (Figure 3.14 and 3.15). This 
finding suggests that aberrant regulation in Cav-1 protein levels and ratio of Cav-1 to Cav-3 
may contribute to the lower differentiation of PD50A myoblasts compared to C2C12 
nyoblasts. However, I cannot exclude that mis-regulation of Cav-1 in differentiating PD50A 
myoblasts may also compensate for the lack of dystrophin (refer to chapter 6 for mechanical 
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properties and caveolins). In addition, it has been reported that in adipocytes, IGF1R 
signalling (insulin like growth factor receptor type 1) is mediated through caveolae (Huo et al., 
2003). Higher levels of Cav-1 protein in differentiating PD50A myoblasts compared to 
differentiating C2C12 myoblasts may explain the higher activity of IGF-2/AKT/mTOR and 
IGF-2/ERK signalling in differentiating dystrophin-deficient myoblasts compared to 
differentiating non-dystrophic myoblasts (Figure 3.15, 3.16 and 3.17). In addition, the 
elevated Cav-1 levels found in differentiating PD50A myoblasts compared to differentiating 
C2C12 myoblasts in the present study may contribute to the higher levels of apoptosis in 
these cells compared to differentiating non-dystrophic C2C12 myoblasts since Cav-1 has been 
shown to activate the PI3K/Akt/GSK3 signalling pathway which causes cells to sensitize to 
stress, such as TGF-α, H2O2 and arsenite, and leads to cell death (Ono et al., 2004; Shack et 
al., 2003).  
Both Cav-1α and Cav1-β express in the heart, notochord and somite of zebrafish during 
development (Fang et al., 2006). In zebrafish, knocking down either Cav-1α or Cav1-β leads 
to somite, neural and eye defects (Fang et al., 2006). Whereas Cav-1α expresses in the kidney, 
gut and lung endothelial cells in mice, Cav1-β expresses in the lung alveolar epithelial cells in 
mice (Kogo et al., 2004; Ramirez et al., 2002). In the present report, I examined the protein 
levels of Cav-1α and Cav-1β in differentiating myoblasts. Interestingly, the levels of Cav-1β 
protein increase during differentiation of both wt and dystrophin-deficient myoblasts induced 
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by OCM and DM; this has not been reported previuously (Figure 3.14). The observation that 
the levels of both isoforms change in differentiating C2C12 and PD50A myoblasts suggests 
regulation of both isoforms is important during myoblasts differentiation. These data also 
suggest that both Cav-1α and Cav-1β express in skeletal muscles. Summary of localisation of 
Cav-1 isoforms is listed in table 3.1.  
  Localisation Role in developments Reference 
Cav-1α 
Heart, pharyngeal vasculature, 
notochord, somites, skin, neuromast 
tissue, intestinal epithelial (zebrafish) 
Kidney, gut and lung endothelial cells 
(mouse) 
KO causes neural and tail 
tissues defect  
(Fang et al., 2006) 
(Kogo et al., 2004; 
Ramirez et al., 
2002) 
Cav-1β 
Heart, pharyngeal vasculature, 
notochord, somites, skin, neuromast 
tissue (zebrafish) 
Lung alveolar epithelial cells (mouse)  
KO causes neural tissue 
defect 
(Fang et al., 2006) 
(Kogo et al., 2004) 
Table 3.1 The localisation and roles of Cav-1 isoforms during embryogenesis 
 
3.3.7. Up-regulation of Pax7 protein level in differentiating dystrophin-deficient myoblasts 
induced by OCM coincides with reduced apoptosis  
Over-expression of Pax7 in myoblasts inhibits myogenesis and promotes cell cycle 
progression in myoblasts (Halevy et al., 2004; Olguin and Olwin, 2004; Zammit et al., 2006b). 
Persistent levels of Pax7 in PD50A myoblasts treated with low mitogen medium (DM) 
(Figure 3.10) may explain in part the reduced rate of differentiation seen in dystrophin-
deficient myoblasts. In addition, increased levels of Pax7 protein in both C2C12 and PD50A 
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myoblasts treated with OCM may well explain the reduced apoptosis of both C2C12 and 
PD50A myoblasts under OCM (Figure 3.8) since Pax7 has been reported to promote satellite 
cell survival (Relaix et al., 2006). Up-regulation of Pax7 in differentiating myoblasts (both 
dystrophin-deficient and non-dystrophic) treated with OCM also correlates with the increased 
total cell number (Figure 3.7) as Pax7 has been reported to regulate the self-renewal of 
postnatal satellite cells (Oustanina et al., 2004). 
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Chapter 4. Cav-1 and Cav-3 are elevated in dystrophic embryos and play a role in 
heart development  
4.1. Introduction: 
DMD patients suffer from cardiomyopathy which is also reported in mdx embryos (Merrick et 
al., 2009; Parker et al., 2005). Although limb girdle muscular dystrophy type 1C (LGMD-1C) 
do not have cardiomyopathy, the mouse model (Cav-3 knockout mice) develops 
cardiomyopathy (Aboumousa et al., 2008; Minetti et al., 1998; Woodman et al., 2002). In 
addition, mice lacking Cav-1 exhibit cardiomyopathy (Jasmin et al., 2011; Zhao et al., 2002). 
In chapter 3 and our previous report, we found elevated Cav-3 protein levels in both mdx 
embryos and dystrophin-deficient myoblasts compared to their non-dystrophic counterparts 
(Merrick et al., 2009; Figure 3.14). The level of Cav-3 protein is critical for the function of 
embryonic skeletal muscles. mdx mice with heterozygous Cav-3 (cav-3+/-) knockout 
(mdx/cav-3+/-; double mutant het or DMHet) have been shown to exacerbate the pathology of 
mdx mice, including attrition of Pax7-positive cells in skeletal muscles and reduction of 
intercostal fibre density (Merrick et al., 2009). These DMHet mice have a reduced level of 
Cav-3 protein than mdx (Merrick et al., 2009). In the present study I found increased levels of 
Cav-1 protein in cultured clonally derived PD50A myoblast line compared to C2C12 
myoblasts (Figure 3.14 and 3.15). To further understand the roles of Cav-1 and Cav-3 during 
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development, I conducted immunohistochemistry of embryonic sections to determine the 
localisation of Cav-1 and Cav-3 in dystrophic and non-dystrophic (C57BL10; wt) mouse 
embryos.  
 
4.2. Results: 
4.2.1. Levels of Cav-1 and Pax7 proteins are perturbed in E17.5 dystrophic embryos 
In a previous report, embryonic Cav-3 protein levels in mdx mice were found to be higher 
compared to wt mice and the levels of Pax7 protein are down-regulated in dystrophin-
deficient mouse embryos (Merrick et al., 2009). In chapter 3, I showed that protein levels of 
Pax7, Cav-1 and Cav-3 are perturbed in differentiating PD50A myoblasts (clonally derived 
myoblasts isolated from 5-week old mdx mice) (Figure 3.10, 3.14 and 3.15). To establish the 
relationship between Cav-1 and Cav-3 in dystrophin-deficient mouse embryos, I examined the 
levels of Cav-1 and Cav-3 proteins in E17.5 embryonic protein extracts (Figure 4.1). 
Increased levels of Cav-3 protein in dystrophin-deficient mice (mdx; mouse model of DMD) 
compared to wt embryos are consistent with Merrick et al. (2009) (Figure 4.1 A and B).  
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Figure 4.1 Pax7 and Caveolin-1 protein levels are perturbed in E17.5 dystrophic 
embryos.  
Whole protein extracts were collected from decapitated E17.5 embryos of wt, mdx, 
DMhet and cav-3-/-. Proteins were harvested by grinding the fresh embryos in RIPA 
buffer. (Refer to section 2.8.1 for detail) (A) 15 μg of each protein sample was loaded for 
immunoblotting of Cav-1, Cav-3 and Pax7. (B) Cav-3 protein levels are elevated in E17.5 
mdx compared to wt embryos (wt). (C) Levels of Pax7 protein are reduced in E17.5 mdx, 
cav-3-/- and DMhet compared to wt. (D) Cav-1 protein levels connect with Cav-3 protein 
levels in E17.5 mdx, cav-3-/- and DMhet embryos. (E) Cav-1/Cav-3 ratio increases in 
E17.5 dystrophic embryos. Coomassie blue stain of nitrocellulose membranes was used 
as loading control. (ANOVA; ＊＊ p<0.01; ＊＊＊ P<0.001; n = 4).  
Cav-1: caveolin-1; Cav-3: caveolin-3; cav-3-/-: Cav-3 knockout; DMhet: mdx with cav-
3 heterozygous knockout. 
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In E17.5 DMhet, protein levels of Cav-3 reduce by 30% compared to wt mouse embryos 
(Figure 4.1 A and B; p= 8.2×10-6). Decreased levels of Pax7 protein in E17.5 mdx and Cav-3 
null (cav-3-/-; mouse model of LGMD-1C) mouse embryos compared to wt embryos are 
consistent with previous report (Figure 4.1 A and C) (Merrick et al., 2009). In E17.5 DMhet, 
levels of Pax7 protein decrease by 37% compared to wt embryos (Figure 4.1 A and C; p= 
1.3×10-4).  
In chapter 3, I used immunoblotting to demonstrate that Cav-1 protein levels are elevated in 
differentiating PD50A myoblasts (Figure 3.14 and 3.15). To further establish the levels of 
Cav-1 protein in dystrophic mouse embryos, I examined the levels of Cav-1 protein in E17.5 
mouse embryos. The levels of Cav-1 protein increase by 3-fold in mdx (p= 3.4×10-4) and 2-
fold (p= 2.0×10-5) in DMhet embryos compared to the wt embryos (Figure 4.1 A and D). In 
contrast, the levels of Cav-1 protein in cav-3-/- is only half (p= 2.1×10-3) of that in wt embryos 
(Figure 4.1 A and D). This suggests that the levels of Cav-1 correlate with the levels of Cav-3 
in dystrophic context (Figure 4.1 E). 
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4.2.2. Cav-1 and Cav-3 localise in skeletal and cardiac muscles and there is a positive 
correlation between the staining intensities of Cav-1 and Cav-3 
In section 4.2.1, I established that there are elevated levels of Cav-1 and Cav-3 proteins in 
E17.5 mdx and DMhet mouse embryos (Figure 4.1). To further establish the relationship 
between Cav-3 and Cav-1 in embryos, I examined the localisation of Cav-3 and Cav-1 in 
E17.5 wt, mdx, cav-3-/- and DMhet (mdxcav-3+/-) mouse embryos via immunohistochemistry. 
I first established the localisation of Cav-3 protein in E17.5 mouse embryos.  
Cav-3 localises to the epaxial (back), diaphragm, intercostal and cardiac muscles of wt mouse 
embryos (Figure 4.2 A, B, C and D). In nondystrophic mouse embryos, the staining intensity 
of Cav-3 is stronger in respiratory muscles (diaphragm and intercostals) compared to epaxial 
and cardiac muscles (Figure 4.2 A, B, C and D). Cav-3 is expressed in the epaxial, diaphragm, 
intercostal and cardiac muscles of mdx (Figure 4.2 E, F, G and H). The staining intensity of 
Cav-3 is higher in the skeletal and cardiac muscles of mdx compared to wt embryos (compare 
Figure 4.2 E, F, G and H with Figure 4.2 A, B, C and D). The E17.5 mdx embryos also show 
heterogeneity of Cav-3 staining in the muscles, with more intense staining of Cav-3 in the 
epaxial and diaphragm muscles (Figure 4.2 E, F, G and H). 
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Figure 4.2 E17.5 mdx embryos have higher staining intensity of Caveolin-3 compared 
to nondytrophic mouse embryos. 
E17.5 wt, mdx, cav-3-/- and DMhet embryos were fixed and embedded in paraffin wax 
(prepared by Dr. Dean Larner). The embryo wax blocks were microtome dissected in 5 
μm and stained with anti-Cav-3 antibody to determine the expression pattern of Cav-3. 
In epaxial (back) muscles, (E) mdx has higher staining intensity of Cav-3 than (A) wt; 
the staining intensity of Cav-3 in (M) DMhet  is between that in (E) mdx and (A) wt; (I) 
cav-3-/-  has no Cav-3. In diaphragm, (F) mdx has higher staining intensity of Cav-3 
than (B) wt; the staining intensity of Cav-3 in  (N) DMhet is comparable to that in (F) 
mdx; (J) cav-3-/-  has no Cav-3. In intercostal muscles, the staining intensity of Cav-3 is 
higher in (G) mdx than in (C) wt; the staining intensity of Cav-3 in (O) DMhet  is 
comparable to that in (C) wt; (O) cav-3-/-  has no Cav-3. In cardiac muscles, (H) mdx 
has higher staining intensity of Cav-3 than (D) wt; (P) DMhet has staining intensity of 
Cav-3 comparable to that in (D) wt; (L) cav-3-/- has no Cav-3. Images are representative 
Cav-3 immunohistochemistry of two mouse embryos. (Q) The regions examined is 
labeled in the representative section of E17 embryo (taken from e-Mouse Atlas project).  
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In E17.5 DMhet epaxial muscles, the staining intensity of Cav-3 is between that in E17.5 mdx 
and wt embryos (Figure 4.2 A, E and M). In the E17.5 DMhet diaphragm, the staining 
intensity of Cav-3 is comparable to that of mdx (Figure 4.2 F and N). The intercostal and 
cardiac muscles of the E17.5 DMhet have comparable intensity of Cav-3 staining to that in 
the wt embryos (Figure 4.2 O and P; compare with Figure 4.2 C and D). As expected, the cav-
3-/- embryos have no staining of Cav-3 (Figure 4.2 I, J, K and L). Similar to the wt and mdx 
embryos, the DMhet embryos also exhibit heterogeneity in Cav-3 staining; the DMhet 
diaphragm muscles have more intense Cav-3 staining than the other muscles examined 
(Figure 4.2 M, N, O and P). The heterogeneity of Cav-3 staining may correlate with the fibre 
type distribution which is addressed in chapter 6 (Figure 6. 19). The greater staining intensity 
of Cav-3 in the skeletal and cardiac muscles of E17.5 mdx and DMhet embryos compared to 
the wt embryos is consistent with the previous report that mdx has elevated levels of Cav-3 
protein compared to wt embryos and that DMhet has Cav-3 protein levels less than mdx in 
embryos (Merrick et al., 2009). The localisation of Cav-3 in skeletal and cardiac muscles is 
also consistent with reports that Cav-3 is predominantly in the muscles (Song et al., 1996; 
Way and Parton, 1995). 
 
 180 
 
Figure 4.3 E17.5 mdx embryos have higher staining intensity of Caveolin-1 in skeletal 
muscles than that in non-dystrophic mouse embryos. 
E17.5 wt, mdx, cav-3-/- and DMhet embryos were fixed and embedded in paraffin wax 
(prepared by Dr. Dean Larner). Embryo wax blocks were microtome dissected in 5 μm 
and the localisation of Cav-1 in muscles was determined by immunohistochemistry 
staining with anti-Cav-1 antibody. In epaxial (back) muscles, compared to (A) wt embryos, 
(D) mdx  has higher staining intensity of Cav-1 while (G) cav-3-/- has lower staining 
intensity of Cav-1; the staining intensity of Cav-1 in (J) DMhet is in between (D) mdx and 
(A) wt embryos. In diaphragm, the staining intensity of Cav-1 in (E) mdx  is comparable 
to that in (B) the wt embryos; Cav-1 localises on the edge of (H) cav-3-/- diaphragm; (K) 
DMhet  has lower staining intensity of Cav-1 than (A) the wt embryos. In cardiac muscles 
(F) mdx has more intense staining of Cav-1 than (C) the wt embryos; (I) cav-3-/- and (L) 
DMhet have lower staining intensity of Cav-1 compared to the (A) wt embryos. Images 
are representative Cav-1 immunohistochemistry of two embryos.  
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Caveolin-1 localises in the skeletal and cardiac muscles of E17.5 mouse embryos 
In chapter 3, I observed elevated protein levels of Cav-1 in dystrophin-deficient myoblasts 
which also have elevated levels of Cav-3 protein (Figure 3.14 and 3.15). I also established 
that there are elevated levels of Cav-1 protein in E17.5 mdx and DMhet embryos which have 
elevated levels of Cav-3 (Figure 4.1). There is no report on the immunohistochemistry of 
Cav-1 in mouse skeletal muscles. To establish whether there is staining of Cav-1 in skeletal 
and cardiac muscles of mdx and DMhet mouse embryos where the staining of Cav-3 is intense, 
I examined the localization of Cav-1 in E17.5 wt, mdx, DMhet and cav-3-/- mouse embryos.  
Cav-1 localises in the epaxial (back), diaphragm and cardiac muscles in E17.5 wt embryos 
(Figure 4.3 A, B and C) with the strongest staining in the diaphragm (Figure 4.3 B). In the wt 
heart, Cav-1 localises in trabeculae (Figure 4.3 C). A larger number of the epaxial (back) 
muscles in mdx are positive for Cav-1 compared to the wt embryos (Figure 4.3 A and D). In 
mdx, Cav-1 protein concentrates around the sarcolemma of muscle fibres in diaphragm 
(Figure 4.3 B). Different from the wt heart, Cav-1 proteins localise around the edge of heart 
trabeculae in mdx embryos (Figure 4.3 F). A larger number of E17.5 DMhet epaxial muscles 
are positive for Cav-1 compared to wt embryos (Figure 4.3 A and J). The proportion of Cav-1 
positive fibres in the E17.5 DMhet diaphragm muscles is comparable to those in the wt mouse 
embryos (Figure 4.3 B and K). Cav-1 localises to the sarcolemma of cardiac muscles in E17.5 
DMhet embryos (Figure 4.3 L). Except for the diaphragm muscles where the intensity of Cav-
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1 staining is the stongest in mdx and the weakest in DMhet, skeletal and cardiac muscles of 
mdx have the strongest intensity of Cav-1 staining and those of the wt embryos have the 
weakest intensity of Cav-1 staining (Figure 4.3 A-F and J-L). These data demonstrate that 
E17.5 dystrophin-deficient (mdx and DMhet) mouse embryos have elevated levels of Cav-1 
and Cav-3 (also refer to Figure 4.1). In E17.5 cav-3-/- embryos, Cav-1 proteins localise mainly 
on the edge of the epaxial, diaphragm and heart trabeculae (Figure 4.3 G, H and I). The 
staining intensity of Cav-1 proteins in the epaxial muscles, diaphragm and cardiac muscles of 
E17.5 cav-3-/- embryos is low compared to those in the wt, mdx and DMhet mouse embryos 
(Figure 4.3 G, H and I). These data suggest that the levels of Cav-1 in skeletal and cardiac 
muscles are affected by the levels of Cav-3 and dystrophin. 
 
4.2.3. The localisation and staining intensity of Cav-1 in other organs are affected in E17.5 
DMhet and cav-3-/- embryos 
Previous reports on immunoblotting of mouse tissues and established cell lines suggest that 
Cav-1 is in lung and adipose tissues (Scherer et al., 1997; Song et al., 1996). It has also been 
reported that Cav-1 is in the kidney, the gut and vascular endothelium of the lung in normal 
mouse embryos at E14.5-E15.5 (Kogo et al., 2004; Ramirez et al., 2002). To examine the 
specificity of the Cav-1 antibody used, I examined the localisation of Cav-1 in lung, kidney, 
liver and intestines of E17.5 wt, mdx, cav-3-/- and DMhet mouse embryos (Figure 4.4). 
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Figure 4.4 The staining pattern of Caveolin-1 are altered in E17.5 mdx, DMhet and  
cav3-/- mouse embryos compared to E17.5 wt mouse embryos. 
E17.5 wt, mdx, cav-3-/- and DMhet mouse embryos were fixed and embedded in paraffin 
wax (prepared by Dr. Dean Larner). Embryo wax blocks were microtome dissected in 5 
μm and localization of caveolin-1 (Cav-1) in internal organs was determined by 
immunohistochemistry staining with anti-Cav-1 antibody. In the lungs of (A) non-
dystrophic and (E) mdx embryos, Cav-1 localises in the epithelium lining of aveolae; (I) 
cav-3-/- and (M) DMhet embryos have no detectable Cav-1 staining in the lungs. Cav-1 
localises to the smooth muscle layer of small intestines in (B) wt, (F) mdx, (J) cav-3-/- and 
(N) DMhet embryos. Cav-1 localises to the parenchyma of livers in (C) wt, (G) mdx and 
(O) DMhet embryos. (K) cav-3-/- has no detectable Cav-1 staining in the liver. Cav-1 
localises to the tubular structures of kidneys in (D) wt and (H) mdx embryos; (L) cav-3-/- 
and (P) DMhet have lower staining intensity of Cav-1 in the kidneys compared to (D) wt 
embryos. Images are representative Cav-1 staining of two embryos.  
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Consistent with previous report, Cav-1 localises to the lung, gut, and kidney of wt mouse 
embryos (Kogo et al., 2004; Ramirez et al., 2002; Figure 4.4 A, B and D). I also establish that 
Cav-1 localises to the liver of wt mouse embryos (Figure 4.4 C). Cav-1 localises in the 
vascular endothelium and the epithelium lining of alveolae of the lungs in both E17.5 wt and 
mdx (Figure 4.4 A and E). Surprisingly I found no Cav-1 in the lungs of the E17.5 DMhet 
mouse embryos (Figure 4.4 M). In E17.5 wt, mdx and DMhet intestines, Cav-1 localises in the 
smooth muscle layer (Figure 4.4 B, F and N). The staining intensity of Cav-1 in intestines is 
higher in mdx compared to those in the wt and DMhet mouse embryos (Figure 4.4 B, F and 
N). The intensity of Cav-1 staining is comparable in intestine smooth muscles of E17.5 wt and 
DMhet mouse embryos (Figure 4.4 B and N). Cav-1 localises to the parenchyma of liver in 
E17.5 wt and mdx mouse embryos, with stronger staining intensity in mdx (Figure 4.4 C and 
G). The staining of Cav-1 in liver parenchyma is sporadic in both mdx and wt mouse embryos 
whereas it is distributed diffusely in the DMhet mouse embryos (Figure 4.4 C, G and O). Cav-
1 localises in the tubular structures of kidneys in E17.5 wt and mdx, especially in the 
condensed epithelial mesenchyme (Figure 4.4 D and H). The staining intensity of Cav-1 in the 
E17.5 DMhet kidney is much lower compared to the wt and mdx mouse embryos (Figure 4.4 
D, H and P). Cav-1 also localises in the smooth muscle layer of E17.5 cav-3-/- intestines and 
the staining intensity of Cav-1 in the intestines of E17.5 cav-3-/- mouse embryos is lower 
compared to the wt, mdx and DMhet mouse embryos (Figure 4.4 B, F, J and N). Cav-1 is not 
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detected in the lung, liver and kidney of E17.5 cav-3-/- mouse embryos (Figure 4.4 I, K and L). 
Overall, Cav-1 is up-regulated in the lung, intestine, liver and kidney of E17.5 mdx embryos 
which also have elevated levels of Cav-3. DMhet, which has Cav-3 level in between mdx and 
wt embryos and is dystrophin-deficient, has reduced Cav-1 levels and disrupted localisation in 
the lung, intestine, liver and kidney. These data suggest that the levels of Cav-1 in these 
organs are also affected by dystrophin.  
 
4.2.4. Expression of Cav-1 during the heart development is affected by dystrophin and Cav-3 
Our previous report showed that cardiomyopathy of mdx begins during cardiogenesis 
(Merrick et al., 2009).  
 
 
Figure 4.5 Illustration of the development of the mouse heart.  
Heart development begins at E7.5 as the cardiac crescent (a and b). The cardiac 
crescent develops into the linear hear tube at E8.25 (c and d). At E10.5 the linear 
heart tube folds into loop (e and f). The looping heart remodels to form the heart with 
left/right ventricles and atriums at E12.5 (g and h). (Taken from Harvey, 2002) 
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The development of mouse heart begins at E7.5 as the cardiac crescent, followed by linear 
heart tube at E8.25, looping heart at E10.5 and remodelled heart with left/right ventricles and 
atriums at E12.5 (Harvey, 2002) (Figure 4.5). In section 4.2.2, I found more intense staining 
of Cav-1 in the heart of mdx compared to the heart of the wt mouse embryos at E17.5 (Figure 
4.3 C, F, I and L). It has been reported that Cav-1 protein localises in endothelium of heart in 
E14.5 wt mouse (Ramirez et al., 2002). To better understand the localisation of Cav-1 during 
heart development, I examined the staining patterns of Cav-1 in the hearts of wt, mdx, DMhet 
and cav-3-/- embryos from E11.5 to E17.5 (Figure 4.6). In the heart of wt embryos, Cav-1 
localises to the atrium as early as at E11.5 (Figure 4.6 A). Surprisingly at E11.5, the DMhet 
embryo has looping heart and mdx embryo has linear heart tube, suggesting a one-day and 
three-day delays in the heart development respectively (Figure 4.6 B and D). Cav-1 localises 
to a small region in the atrium of E11.5 mdx heart and in the heart loop of E11.5 DMeht 
embryos (Figure 4.6 B and D). The staining intensity of Cav-1 in the atrium of the wt 
embryos increases at E13.5 and then decrease from E15.5 to E17.5 (Figure 4.6 E, I and M). 
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Figure 4.6 Cav-1 localises in the atrium of developing hearts 
Wt, mdx, cav-3-/- and DMhet embryos of E11.5-E17.5 were fixed and embedded in 
paraffin wax (prepared by Dr. Dean Larner). Embryo wax blocks were microtome 
dissected in 5 μm and localisation of Cav-1 in hearts was determined by 
immunohistochemistry stain with anti-Cav-1 antibody. At E11.5, Cav-1 protein is 
detected in the atrium of hearts in (A) wt, (B) mdx, (C) cav-3-/-  and (D) DMhet 
embryos. The intensities of Cav-1 staining in the atrium at E13.5 are comparable in (E) 
wt, (F) mdx and (G) cav3-/-; staining intensity is lower in (H) DMhet compared to (E) 
wt embryos. At E15.5, the staining intensity of Cav-1 in (J) mdx atrium are higher than 
(I) wt embryos; the intensity of Cav-1 staining is comparable in (I) wt and (L) DMhet 
atria; the staining intensity of Cav-1 is higher in (K) cav3-/- atrium compared to (I) wt 
atrium. At E17.5, the staining intensities of Cav-1 are comparable in the atria of (M) 
wt, and (N) mdx embryos; the intensity of Cav-1 staining in (O) cav3-/- atrium is lower 
compared to that in (M) wt atrium; the staining intensity of Cav-1 in (P) DMhet atrium 
is comparable to that in (O) cav3-/- atrium. Images are representative Cav-1 
immunohistochemistry of two embryos.  
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Cav-1 localises to the wall and trabeculae in both mdx atrium and DMhet atrum between 
E13.5-E17.5 (Figure 4.6 F, J and N; H, L and P). Similar to the non-dystrophic atrium, the 
staining intensity of Cav-1 in mdx atrium and DM het atrium in E13.5 mdx atrium increases 
between E13.5-E15.5 and then decreases between E15.5-E17.5 (Figure 4.6 F, J and N; H, L 
and P). In the atrium at E15.5, the intensity of Cav-1 staining is higher in mdx compared to 
the non-dystrophic and DMhet embryos (Figure 4.6 I, J and L).  
Cav-1 localises in the ventricle and atrium of the E11.5 cav-3-/- heart; the staining intensity is 
higher in the ventricle than in the atrium (Figure 4.6 C). In the atrium of the cav-3-/- embryos, 
Cav-1 localises to the wall of cav3-/- atrium trabeculae between E13.5-E17.5 (Figure 4.6 G, K 
and O). The intensity of Cav-1 staining increases between E13.5 to E15.5 and decreases at 
E17.5 (Figure 4.6 G, K and O). There is more intense staining of Cav-1 in the cav3-/- atrium at 
E15.5 and less in the cav3-/- atrium at E17.5 compared to the non-dystrophic atrium at the 
same stages (Figure 4.6 I, K, M and O). There is hypercellularity of the atrium in mdx and 
cav3-/- embryos compared to non-dystrophic embryos at E15.5 (Figure 4.6 I, J and K). These 
data suggest that both Cav-1 and Cav-3 may play a role in the heart development. 
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Figure 4.7 Structure of the atrial trabeculae is perturbed in mdx, DMhet and cav-3-/- 
embryos during development. 
Wt, mdx, cav-3-/- and DMhet embryos of E11.5-E17.5 were fixed and embedded in 
paraffin wax (prepared by Dr. Dean Larner). Embryo wax blocks were microtome 
dissected in 5 μm and immunohistochemically stained with anti-Cav-1 antibody. The 
structure of atrial trabeculae was then examined. Cav-1 localises in the wt atrial 
trabeculae at (A) E11.5, (E) E13.5, (I) E15.5 and (M) E17.5. Compared to the wt atrial 
trabeculae, the mdx atrial trabeculae are longer at (B) E11.5, (F) 13.5, (J) E15.5 and (N) 
E17.5. The cav-3-/- atrial trabeculae are short and fat at (C) E11.5, (G) E13.5 and (O) 
E17.5 but was long and thin at (K) E15.5 compared to the wt embryos at the same stages. 
The DMhet atrial trabeculae are thin and long at (D) E11.5, (H) E13.5, (L) E15.5 and (P) 
E17.5 compared to the wt embryos at the same stages. Images are representative Cav-1 
immunohistochemistry of two embryos.  
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Cav-1 localises in atrial trabeculae 
Our previous report has established that the atrial trabeculae in E17.5 mdx are long and 
hooked and those in E17.5 cav-3-/- are short and stubby (Merrick et al., 2009). To further 
establish the localisation of Cav-1 in the heart and the relationship of Cav-1 and 
cardiomyopathy in muscular dystrophy, I examined the Cav-1 staining in the atrium of hearts 
from wt, mdx, DMhet and cav-3-/- embryos. Cav-1 localises in the atrial trabeculae of wt, mdx, 
DMhet and cav-3-/- hearts at E11.5, E13.5, E15.5 and E17.7 (Figure 4.7). The atrial trabeculae 
of mdx (Figure 4.7 B, F, J and N) are longer than those of the wt mouse embryos (Figure 4.7 
A, E, I and M) at E11.5, E13.5, E15.5 and E17.5. Similarly, the atrial trabeculae of DMhet are 
also thinner and longer compared to the wt atrial trabeculae at E11.5, E13.5, E15.5 and E17.5 
(Figure 4.7 D, H, L and P; compare with Figure 4.7 A, E, I and M). Compared to the wt atrial 
trabeculae, the atrial trabeculae of both mdx (Figure 4.7 B, F, J and N; compare to Figure 4.7 
A, E, I and M) and DMhet embryos (Figure 4.7 D, H, L and P; compare to Figure 4.7 A, E, I 
and M) are hooked at all stages examined. The atrial trabeculae of the cav-3-/- embryos are 
short and fat at E11.5, E13.5 and E17.5 compared to the wt atrial trabeculae at the same stages 
(Figure 4.7 C, G, and O; compare to Figure 4.7 A, E and M). However, the atrial trabeculae of 
E15.5 cav3-/- embryos are long and thin compared to the atrial trabeculae of E15.5 wt 
embryos (Figure 4.7 K; compare to Figure 4.7 I). These data suggest that both Cav-1 and Cav-
3 may play a role in the progress of cardiomyopathy in the dystrophic embryos. . 
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Figure 4.8 Localisation of Cav-1 in atrial trabeculae changes during heart development 
Wt, mdx, cav-3-/- and DMhet embryos of E11.5-E17.5 were fixed and embedded in 
paraffin wax (prepared by Dr. Dean Larner). Embryo wax blocks were microtome 
dissected in 5 μm; Cav-1 in atrial trabeculae was immunohistochemically labeled with 
anti-Cav-1 antibody. Cav-1 localises in constraint regions in the wt atrial trabeculae at (A) 
E11.5, (E) E13.5, (I) E15.5but diffuses at (M) E17.5. In mdx atrial trabeculae, Cav-1 
widely spreads from (B) E11.5 to (F) 13.5 and concentrates at the edge from (J) E15.5 to 
(N) E17.5. In the cav-3-/- atrial trabeculae, Cav-1 is not found at (C) E11.5. In cav-3-/- 
embryos, Cav-1 is widespread punctate staining in (G) E13.5 atrial trabeculae, and 
localises at the edge of the atrial trabeculae at (K) E15.5 and (O) E17.5. Cav-1 in the 
DMhet atrial trabeculae spreads widely at (D) E11.5, is punctate staining at (H) E13.5and 
(L) E15.5 and diffuses at (P) E17.5. Images are representative Cav-1 
immunohistochemistry of two embryos. 
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Determining the localisation of Cav-1 in atrial trabeculae in higher magnitude 
I examined further the localisation of Cav-1 in atrial trabeculae in higher magnitude (Figure 
4.8). In the non-dystrophic atrial trabeculae, Cav-1 distributes widely at E11.5 and E15.5 and 
represents as punctate staining at E13.5 (Figure 4.8 A, E and I). In the E17.5 wt atrium, Cav-1 
staining is diffused and within the trabeculae (Figure 4.8 M). Cav-1 staining is widespread 
within the mdx atrial trabeculae at E11.5 (Figure 4.8 B). Cav-1 staining is dispersed within the 
mdx trabeculae at E13.5 and then concentrates to the edge of the muscles in mdx trabeculae 
from E15.5 to E17.5 (Figure 4.8 F, J and N). The localisation of Cav-1 in the DMhet atrial 
trabeculae is similar to that in mdx at all stages examined (Figure 4.8 B, F, J and N; Figure 4.8 
D, H, L and P). In the DMhet embryos, Cav-1 is dispersed within the atrial trabeculae at 
E11.5, localises on the edge of the atrial trabeculae at E13.5 and E15.5, and diffuses within 
the atrial trabeculae at E17.5 (Figure 4.8 D, H, L and P).  
At E11.5, Cav-1 staining is not detected in the atrial trabeculae of cav-3-/- hearts (Figure 4.8 
C). At E13.5, Cav-1 staining distributes dispersedly in the cav-3-/- atrial trabeculae (Figure 4.8 
G). At E15.5 and E17.5, Cav-1 staining is confined to the edge of the cav-3-/- atrial trabeculae 
(Figure 4.8 K and O). Difference in the localisation of Cav-1 in the heart trabeculae of mdx, 
cav-3-/- and DMhet embryos compared to the wt embryos correlates with the perturbed atrial 
trabeculae structure observed in the present study (Figure 4.7) and our previous report 
(Merrick et al., 2009). These data suggest that Cav-1 together with Cav-3 may contribute to 
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the cardiomyopathy reported in muscular dystrophy and the mouse models (Merrick et al., 
2009; Woodman et al., 2002). The presence of Cav-1 protein at as early as the heart tube stage 
(E13.5 of DMhet) suggests it may participate in the heart development though this would 
need to be confirmed in nondystrophic mouse embryos at earlier stages.  
 
Cav-1 localisation in the developing heart ventricles 
I also examined the localisation and staining intensity of Cav-1 in the heart ventricles during 
development (Figure 4.9). At E13.5, the staining intensity of Cav-1 is greater in mdx 
ventricles compared to the wt ventricles at the same stage (Figure 4.9 A and B). Ventricles of 
E13.5 DMhet have intensity of Cav-1 staining comparable to that in the wt ventricles at the 
same stage (Figure 4.9 A and D). Cav-1 staining spreads widely in the trabeculae of the non-
dystrophic, mdx and DMhet heart ventricles at E13.5 (Figure 4.9 A, B and D). At E15.5, the 
staining intensity of Cav-1 in the ventricles of the wt, mdx and DMhet hearts decreases 
compared to the wt, mdx and DMhet ventricles at E13.5 (Figure 4.9 E, F and H). At E17.5, 
Cav-1 localises to the edge of the trabeculae in the wt and mdx ventricles (Figure 4.9 I and J). 
The intensity of Cav-1 staining in the wt and mdx ventricles is comparable at this stage 
(Figure 4.9 I and J). The staining intensity of Cav-1 is lower in the ventricles of E17.5 DMhet 
compared to the E17.5 wt ventricles (Figure 4.9 I and L). 
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Figure 4.9 Localisation of Cav-1 changes in ventricles during heart development. 
The non-dystrophic, mdx, cav-3-/- and DMhet embryos of E13.5-E17.5 were fixed and 
embedded in paraffin wax (prepared by Dr. Dean Larner). Embryo wax blocks were 
microtome dissected in 5 μm. Cav-1 in the heart ventricles was immunohistochemically 
labeled with anti-Cav-1 antibody. At 13.5, the staining intensity of Cav-1 is higher in the 
(B) mdx ventricles compared to the (A) wt heart ventricles; the staining intensity of Cav-1 
in the (C) cav-3-/- ventricles is weaker than the wt control; the (D) DMhet heart ventricles 
have intensity of Cav-1 staining comparable to that of the (A) wt ventricles. The staining 
intensity of Cav-1 decreases in ventricles of the E15.5 (E) wt, (F) mdx, (G) cav3-/- and (H) 
DMhet hearts compared to the ventricles of (A) wt, (B) mdx, (C) cav3-/-  and (D) DMhet  
hearts at E13.5. At 17.5, the intensity of Cav-1 staining is comparable in the (I) wt and (J) 
mdx ventricles; (K) cav3-/- and (L) DMhet ventricles have lower intensity of Cav-1 
staining compared to the (I) wt ventricles.  
Images are representative Cav-1 immunohistochemistry of two embryos. 
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Cav-1 localises in the outer region of the cav-3-/- ventricle at E13.5 (Figure 4.9 C) and the 
intensity of Cav-1 staining in the cav-3-/- ventricle decreases at E15.5 and E17.5 (Figure 4.8 G 
and K). There is hypercellularity in ventricles of mdx and cav3-/- at all stages examined 
(Figure 4.9 B, C, F, G, J and K). Furthermore, the long hooked ventricle trabeculae in mdx and 
DMhet hearts as well as the short and stubby trabeculae in the cav-3-/- ventricles at E13.5 and 
E15.5 are consistent with our previous report (Merrick et al., 2009). Here I further established 
that at E17.5, the ventricular trabeculae of mdx and DMhet hearts are long hooked while those 
of the cav-3-/- hearts are short and stubby (Figure 4.9 J, K and L). These data suggest that Cav-
1 plays a role in the development of heart ventricles. These data also suggest that the 
localisation and the staining intensity of Cav-1 in the heart ventricles are affected by Cav-3.  
 
4.3. Discussion  
4.3.1. E17.5 mdx embryos have elevated levels of Caveolin-1 and Caveolin-3 proteins 
Previous reports suggested that levels of Cav-1 protein in skeletal and cardiac muscles are not 
altered when Cav-3 is knocked down; however, they did not provide reliable loading controls 
in these reports (Galbiati et al., 2001a; Volonte et al., 2008). In the present study, I established 
a positive correlation between the protein levels of Cav-3 and Cav-1 in that elevated Cav-3 
protein levels in mdx are accompanied by the increased protein levels of Cav-1 (Figure 4.1). 
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With the absence of or reduced levels of Cav-3 protein, Cav-1 levels are concomitantly down-
regulated (Figure 4.1). The effect of Cav-3 on the protein levels of Cav-1 is supported by an 
immunohistochemistry analysis of Cav-1 localisation in E17.5 embryos, which reveal 
elevated intensity of Cav-1 staining in mdx and decreased intensity of Cav-1 staining in 
DMhet and cav-3-/- (Figure 4.2 and 4.3).  
 
4.3.2. Cav-1 protein levels correlate with Cav-3 protein levels in E17.5 mouse embryos 
Previous report showed that Cav-1 is expressed in the lung, kidney and gut of E15 mouse 
embryos (Ramirez et al., 2002). Here I established the localisation of Cav-1 in heart, lung, gut, 
kidney and liver in E17.5 wt and dystrophin-deficient mdx mouse embryos (Figure 4.3 and 
4.4). Using immunohistochemistry I established the localisation of Cav-1 to the epithelium 
lining of lung, the smooth muscle layer of gut, the parenchyma of liver and the tubular 
structure of kidney of both E17.5 wt and mdx mouse embryos (Figure 4.4). The staining 
intensity of Cav-1 is elevated in heart, lung, gut, kidney and liver of E17.5 dystrophin-
deficient mdx embryos, which have elevated levels of Cav-3 protein (Figure 4.1 and 4.2). 
With no or reduced Cav-3 staining (E17.5 cav-3-/- or DMhet), there is concomitant reduction 
of Cav-1 staining intensity in heart, lung, gut and kidney (Figure 4.1 and 4.4). This suggests 
that levels of Cav-3 protein affect the levels of Cav-1 protein in organisms. Cav-3 has long 
been reported to be the predominant caveolin in striated (skeletal and cardiac) and smooth 
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muscles (Scherer et al., 1997; Song et al., 1996). It has been reported that Cav-3 also 
expresses in the lung, kidney and liver of 3 to 4-week old mice using immunohistochemistry 
and in the brain and kidney of 10 to 12-week old rats by RT-PCR (Galbiati et al., 2000; Park 
et al., 2012). Therefore, the expression of Cav-3 may be low in tissues other than muscles, 
making detection of Cav-3 protein in other tissues difficult. The maintenance of a balance 
between protein levels of Cav-1 and Cav-3 could be important for the homeostasis of signal 
transduction within tissues such that down-regulation of one type of caveolin leads to the 
reduction of the other type.  
 
4.3.3. Perturbed protein levels of Cav-1 and Cav-3 may contribute to cardiomyopathy in 
dystrophic mouse models   
The patients of Duchenne muscular dystrophy (DMD) suffer from cardiomyopathy (Parker et 
al., 2005). The mouse model mdx which has elevated levels of Cav-3 also displays 
cardiomyopathy (Merrick et al., 2009). It has been reported that Cav-1 null mice display 
dilation and hypertrophy of ventricles and atria as well as the failure of heart function (Cohen 
et al., 2003; Jasmin et al., 2011; Zhao et al., 2002) (Table 4.1). Cardiomyopathy has also been 
reported in cav-3-/- mice, including left ventricle hypertrophy, chamber dilation and reduced 
heart function (Woodman et al., 2002) (Table 4.1). Furthermore, the cav-1/cav-3 double 
knocked out mice have cardiac hypertrophy and cardiac myocyte disorganisation, suggesting 
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that both Cav-1 and Cav-3 proteins are important for the function and development of hearts 
(Park et al., 2002) (Table 4.1). In the present study I established that protein levels of Cav-1 
are elevated along with Cav-3 up-regulation in mdx heart (Figure 4.2 and 4.3). Other 
pathologies of caveolin knocked-out mice are summarised in table 4.1.  
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 Pathologies in adults Reference Pathologies in embryos Reference 
Cav1 KO 
• Dilated cardiomyopathy and ventricle 
hypertrophy 
- Dilated and thin-walled atrium 
- Pulmonary hypertension 
- Lung/body weight ratio and liver body 
weight ratio increase 
• Hyperproliferation of angioblastic cells  
- Thickening of alveolar septa 
- Vascular dysfunction 
- Loss of Cav2 
- Exercise intolerance 
• Lean (resistant to diet-induced obesity) 
• Microvascular hyperpermeability 
(Zhao et al., 2002) 
(Cohen et al., 2003) 
 
 
 
(Drab et al., 2001) 
 
 
 
 
(Razani et al., 2002) 
(Schubert et al., 2002) 
 Notocord defect  
- neuromast defect (zebra fish)  
 
(Nixon et al., 2007) 
Cav2 KO 
- Pulmonary dysfunction 
- Tubular and mitochondria aggregates   
- Hyperproliferation of satellite cells and  
incomplete regeneration  
(Schubert et al., 2007)   
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 Pathologies in adults Reference Pathologies in embryos Reference 
Cav3 KO 
• Whole body adiposity increase – insulin 
resistance 
-Decreased level of insulin receptor (IR) and 
hyperphosphorylation of IR 
• Dilation and wall thickness of left ventricles 
(Capozza et al., 2005b) 
 
 
(Woodman et al., 2002) 
 Muscle  
-  Hypertrophy 
-  Fibre density increase 
-  Myonuclei displacement 
 Muscle stem cell 
-  Hyperproliferation (E15.5) 
-  Increased apoptosis (E15.5) 
-  Pax7+ cell loss 
 Heart  
-  Left ventricular wall thickening 
-  Long and hooked atrium  
  trabeculae 
(Merrick et al., 2009) 
 
 
 
 
 
 
 
(Merrick et al., 2009) 
and the present report 
Cav1/Cav3 KO 
- Cardiac hypertrophy 
- Cardiac myocyte disorganization 
- Lack Cav2 
(Park et al., 2002)   
mdx/cav-3+/- 
(DMhet) 
   Muscle 
- Decreased muscle fibre density of  
intercostal muscles 
- Increased Fast MyHC positive 
fibres 
 Muscle stem cells 
(Merrick et al., 2009) 
 
 
 
(Merrick et al., 2009) 
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 Pathologies in adults Reference Pathologies in embryos Reference 
- Attrition of Pax7-positive cells 
 Heart  
- Delayed heart development by 1 
day 
- long and hooked atrial and 
ventricular trabeculae 
- hypercellularity of ventricles 
 
The present report  
Table 4.1 The summary of the pathologies of mice with caveolin knocked out.  
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In the present study, I found abnormal trabeculae in atria and ventricles and hypercellularity in 
ventricles (Figure 4.7 and 4.9; table 4.1). Trabeculae in both mdx and DMhet mice hearts at 
E13.5 are long and hooked; this phenotype persists to E17.5 (Figure 4.7 and 4.9; table 4.1). 
Trabeculae in cav-3-/- mice from E13.5 to 17.5 are short and stubby (Figure 4.7 and 4.9; table 
4.1). Moreover, different localisations of Cav-1 in atrial and ventricular trabeculae of wt and 
dystrophic (mdx, cav-3-/- and DMhet) mouse embryos correlate with the cardiomyopathy 
observed in dystrophic embryos (Figure 4.8 and 4.9). It is likely that both Cav-1 and Cav-3 
proteins take part in the progression of cardiomyopathy in mdx. 
 
4.3.4. Heart development in mdx embryos is delayed 
In the present study, I observed a linear heart tube in E11.5 mdx which represents a three-day 
delay during heart development (Figure 4.6). However, immunohistochemical staining of 
Cav-1 for wt mice at earlier stages is required to confirm the delayed heart development of 
dystrophin-deficient mice. This suggests that dystrophin, Cav-1 and Cav-3 are important in 
heart patterning as mdx mice are dystrophin-deficient and have elevated levels of Cav-3 and 
Cav-1 proteins (Figure 4.1).  
Involvement of dystrophin in the development of cardiomyopathy is further supported by 
mdx/cav-3+/- (DMhet) embryos with reduced levels of Cav-3 protein than mdx (Figure 4.1). 
DMhet mouse embryos exhibit looping hearts at E11.5 which is two-day more mature than 
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the E11.5 mdx heart but one-day less mature than the documented E11.5 wt heart (Figure 4.6). 
There is no delay of heart development for E11.5 cav-3-/- heart (Figure 4.6). Since there is still 
Cav-1 staining in the heart of E11.5 cav-3-/- mouse embryo (Figure 4.6), it is likely that 
development of heart in the cav-3-/- mouse is maintained by the presence of Cav-1 proteins. 
This suggests that Cav-3 play a role in the delay of heart development in these mice.    
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Chapter 5. The protein levels of Cav-1, Cav-3 and Pax7 and the IGF-2 signalling are 
perturbed in mdx mouse and dystrophin-deficient myoblasts  
5.1. Introduction: 
Primary myoblasts from mdx embryos and juvenile mdx exhibit aberrant behaviours, 
including elevated proliferation rate and increased apoptosis (Merrick et al., 2009; Smith et 
al., 1995; Smith and Schofield, 1994). These mis-regulated stem cell behaviours may account 
in part for the pathology of mdx mouse as these occur earlier in myogenesis. In chapter 3, I 
showed that impaired differentiation of dystrophin-deficient myoblasts is related to the 
perturbation of the levels of transcription factor Pax7, the levels of Cav-1 and Cav-3 and the 
levels of growth factor IGF-2 and related signalling pathways (p57kip2, AKT/mTOR and ERK) 
(section 3.2.7 and 3.2.8). IGF-2 is expressed and glycosylated as prepro-IGF-2 (67 kDa), 
which after subsequent post-translational cleavage produces pro-IGF-2 (23-26 kDa) and 
mature/active IGF-2 (14-18 kDa) (Duguay et al., 1998). To further understand the expression 
patterns of these key genes in vivo, I conducted immunoblotting of protein extracts from 
dystrophin-deficient and wt mouse embryos. I also conducted immnuoprecipitation of extracts 
from juvenile and adult skeletal muscle tissues to demonstrate the relationship that Cav-3 
level affects the level of Cav-1.  
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5.2. Results: 
5.2.1. IGF-2 and its downstream signalling pathways are perturbed in E17.5 dystrophic 
embryos   
In chapter 3, I found that the levels of IGF-2 protein and its downstream signalling pathways 
are perturbed in differentiating PD50A myoblasts (section 3.2.8). It has also been established 
in chapter 3 (Figure 3.12) and in previous work that IGF-2 is a survival factor for cultured 
PD50A myoblasts (Smith et al., 1995). In a previous report using transgenic mice which 
overexpress IGF-2, we showed that IGF-2 is required for the differentiation of fast skeletal 
muscle fibres during fibre type specification (E15.5-P1) (Merrick et al., 2007). We have also 
reported previously that the number of fast skeletal muscle fibres increases in E17.5 mdx 
embryos compared to wt (Merrick et al., 2009). To establish whether IGF-2 signalling 
pathways are also perturbed in E17.5 dystrophic embryos, I examined the expression of IGF-2 
protein and its downstream targets (Figure 5.1). I was unable to detect the active IGF-2 
peptide in the E17.5 mouse embryos with our present immunoblotting technology. However, I 
was able to detect the levels of prepro- and pro-IGF-2 in the E17.5 mouse embryos. Levels of 
prepro-IGF-2 (67 kDa) in E17.5 mdx and DMhet mouse embryos increase respectively by 
20% (p= 8.27×10-3) and 24% (p= 1.4×10-4) compared to wt embryos (Figure 5.1 A and B). In 
contrasts, the level of prepro-IGF-2 (67 kDa) in the E17.5 cav-3-/- mouse embryos is only 
around 90% (p= 8.46×10-3) of that in the wt embryos (Figure 5.1 A and B). 
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Figure 5.1 IGF-2 signalling in mdx is mediated from AKT/mTOR pathway. 
Whole protein extracts were collected for decapitated E17.5 embryos of wt, mdx, 
DMhet and cav-3-/-. Proteins were harvested by grinding the fresh embryos in RIPA 
buffer. (Refer to section 2.8.1 for detail) (A) 15 μg of each protein sample was loaded 
for immunoblotting of IGF-2, pmTOR, pAKT/AKT and pERK/ERK. Prepro-IGF-2 
(67 kDa) and pro-IGF-2 (23-26 kDa) were detected here. (B) At E17.5, mdx and 
DMhet embryos have higher pro-IGF-2 protein levels while the cav-3-/- embryos have 
lower pro-IGF-2 compared to the wt embryos. (C) p57kip2 protein levels decrease in 
mdx, cav-3-/- and DMhet embryos compared to wt mouse embryos at E17.5. (D) At 
E17.5, AKT signaling is perturbed in the dystrophic embryos. (E) Levels of pmTOR 
protein increase in mdx and DMhet embryos while levels of mTOR protein decrease in 
the cav-3-/- embryos. (F) Erk signaling is perturbed in the E17.5 dystrophic embryos. 
(ANOVA; ＊: p <0.05; ＊＊p<0.01; ＊＊＊P<0.001; compared to wt embryos; n≧4).  
Igf2: insulin-like growth factor 2; CDKN1c (p57kip2): Cyclin-dependent kinase 
inhibitor 1c; pmTOR: phospho-mTOR; Erk: Extracellular signal-regulated kinases; 
pErk: phospho-Erk; cav-3-/-: Cav-3 knockout; DMhet: mdx with Cav-3 heterozygous 
knockout. 
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Protein levels of pro-IGF-2 (23-26 kDa) remain constant in E17.5 mdx, DMhet and cav-3-/- 
embryos but are 13-18% lower compared to wt embryos (Figure 5.1 A and B; p= 7.89×10-5, 
6.36×10-3 and 3.64×10-5 respectively), suggesting that different isoforms may have distinct 
functions in embryos. The perturbed IGF-2 expression in E17.5 mdx adds to our 
immunohistochemistry data, which show abnormal expression/localisation of IGF-2 in mdx 
compared to the wt control (unpublished data of Dr. Deborah Merrick and Dr. Janet Smith), 
by showing that ratios between prepro-IGF-2 and pro-IGF-2 increase in E17.5 mdx.  
p57kip2 (Cdk inhibitor; CDKN1c) is negatively regulated by IGF-2 (Grandjean et al., 2000; 
Matsuoka et al., 1995; Matsuoka et al., 1996). In differentiating PD50A myoblasts, I found 
the levels of p57kip2 protein are perturbed (Figure 3.16). To study whether the levels of p57kip2 
protein are affected by IGF-2 in the dystrophic embryos, I examined the expression of p57kip2 
protein in the E17.5 wt, mdx, DMhet and cav-3-/- embryos (Figure 5.1 A and C). Levels of 
p57kip2 protein are down-regulated in E17.5 mdx by 20% (p= 2.78×10-4), in cav-3-/- by 18% 
(p= 3.79×10-4) and in DMhet by 35% (p= 2.63×10-4) compared to the wt embryos (Figure 5.1 
A and C). Decreased protein levels of p57kip2 in the E17.5 mdx and DMhet embryos are 
consistent with the up-regulation of IGF-2 in these dystrophic embryos (Figure 5.1 A, B and 
C). These data suggest that IGF-2/p57kip2 pathway may be essential to normal embryonic 
myogenesis and that its misregulation may contribute to the dystrophic pathology.  
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IGF-2 signalling is mediated via AKT/mTOR pathway in mdx  
I have established that IGF-2/AKT/mTOR signalling pathway is perturbed in the 
differentiating PD50A myoblasts (Figure 3.17). To establish whether the AKT/mTOR 
signalling is perturbed in dystrophic embryos, I examined levels of AKT, phosphorylated 
AKT (pAKT) and phosphorylated mTOR (pmTOR) proteins in the E17.5 wt, mdx, DMhet 
and cav-3-/- embryos (Figure 5.1 A, D and E). At E17.5, protein levels of total AKT increase 
by 30% in mdx (p= 3.29×10-3) and by by 50% in DMhet embryos (where Cav-3 is reduced; 
p= 8.33×10-3) compared to the wt embryos (Figure 5.1 A). In E17.5 cav-3-/- embryos, the 
levels of total AKT decrease by 53% (p= 6.41×10-8) compared to the wt embryos (Figrue 5.1 
A), suggesting that there is a feedback loop for Cav-3 and AKT pathway. The levels of active 
AKT (pAKT) increase by 26% in E17.5 mdx (p=3.7×10-2) and by 20% in E17.5 DMhet 
(p=1.13×10-4) compared to wt (Figure 5.1A). At E17.5, the levels of pAKT decrease by 44% 
in cav-3-/- embryos (p=1.93×10-8) compared to wt (Figure 5.1 A). However, the ratio of 
pAKT/AKT is comparable in the E17.5 mdx, DMhet, cav-3-/- and non-dystrophic embryos 
(Figure 5.1 A and D), suggesting that this pathway may not substantially contribute the 
pathology of muscular dystrophy.  
Phospho-mTOR (pmTOR) protein, a target of AKT signalling but also a positive regulator of 
Igf-2 expression, increases in both E17.5 mdx and E17.5 DMhet embryos, by 1.6 fold (p= 
2.59×10-3) and 2.8 fold (p= 1.42×10-3) respectively compared to wt embryos (Figure 5.1 A 
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and E). Increased activity in mTOR is consistent with the elevated levels of IGF-2 protein in 
the E17.5 mdx and DMhet embryos (Figure 5.1 A, B, D and E). In E17.5 cav-3-/-, the level of 
pmTOR decrease by 43% (p= 1.77×10-2) compared to the wt embryos (Figure 5.1 A and E). 
Decreased activity of AKT/mTOR correlates with the decrease in IGF-2 protein levels in 
E17.5 cav-3-/- (Figure A, B, D and E). These data suggest that IGF-2/mTOR signalling 
pathways are perturbed in the E17.5 dystrophic embryos. 
 
Erk signalling pathway is perturbed in the dystrophic mouse embryos 
In chapter 3, I showed that ERK signalling pathways are perturbed during in differentiating 
PD50A myoblasts (Figure 3.18). To establish whether the ERK signalling is also perturbed in 
dystrophic embryos, I examined protein expression of ERK42 and ERK44 in E17.5 
dystrophic embryos. The ratios of pERK42/ERK42 and pERK44/ERK44 in mdx decrease by 
28% (p= 2.31×10-3) and 36% (p= 1.1×10-4) respectively compared to the wt embryos (Figure 
5.1 A and F). In E17.5 DMhet, the ratio of pERK42/ERK42 increases by 33% (p= 1.32×10-2) 
compared to wt embryos while the ratio of pERK44/ERK44 is not significantly different from 
that in wt embryos (Figure 5.1 A and F). In the E17.5 cav-3-/- embryos, the ratios of 
pERK42/ERK42 and pERK44/ERK44 are comparable to those in wt embryos (Figure 5.1 A 
and F). These data suggest that Cav-3 suppresses the ERK signalling pathways in E17.5 mdx 
embryos.  
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Figure 5.2 Caveolin-1 interacts with caveolin-3 in adult skeletal muscles.  
100 μg of skeletal muscle tissue extracts from wt, cav-3-/- and mdx mice were used for 
immunoprecipitation. The Cav-1 protein complex in extract was pulled down with 
anti-caveolin-1 antibody and Protein A Sepharose CL-4B beads. There are muscle 
tissue extracts from 4 weeks (A) and 9 weeks (B) old mice. 10 μg of each extract were 
loaded as input control and rabbit Igs were applied as the negative control for IP. 
Pulled-down complexes were aliquoted into two; one of which was treated with 8 M 
urea and 5 mM DTT at 37 ° C for 30 minutes to break down the complexes. 
Components of pulled-down complex were detected with anti-Cav-3 antibody. (A) 
More Cav-3 proteins bind to the Cav-1 protein complexes in 4-week mdx skeletal 
muscles. (B) In 9-week mdx skeletal muscles, Cav-1 protein complexes have more 
Cav-3 within.  
 
A 
B 
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5.2.2. Cav-1 and Cav-3 form hetero-oligomers in the skeletal muscles of both wt and mdx 
mice 
In chapter 3 and 4, I established that there were elevated levels of Cav-3 in PD50A myoblasts 
and mdx embryos using immunoblotting (Figure 3.15 and 4.1). I also established that levels of 
Cav-1 (together with Cav-3) are up-regulated in PD50A myoblasts and mdx embryos (Figure 
3.14 and 4.1). Through immunohistochemistry, I found that staining of both caveolins is more 
intense in mdx and DMhet embryos compared to wt embryos (Figure 4.2 and 4.3). It has been 
reported that Cav-1 interacts with Cav-3 in atrial cardiac myocytes and in fibroblasts 
overexpressing Cav-3 using a Triton insolubility assay and immunoprecipitation (IP) 
(Capozza et al., 2005a; Volonte et al., 2008). There is pathological crisis between 4 weeks 
(late juvenile) to 9 weeks (adult) of skeletal muscles in mdx mice; characterised by increases 
in the number of hypertrophic fibres and the number of split fibres (Tanabe et al., 1986). To 
establish whether Cav-1 and Cav-3 form heteroligomers in dystrophin-deficient skeletal 
muscles, I used adult muscle tissue samples from 4- and 9-week old mice (non-dystrophic, 
cav-3-/- and mdx) (Figure 5.2). Cav-3 proteins are pulled down with Cav-1 in the wt and mdx 
skeletal muscles from both 4- and 9-week old mice (Figure 5.2 A and B), suggesting the 
potential of Cav-1 and Cav-3 to form hetero-oligomers. Both the levels of Cav-1 and Cav-3 
increase in mdx (Figure 5.2 A and B), and this is consistent with the immunoblotting results 
from E17.5 embryos (Figure 4.1).  
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Figure 5.3 The PD50A myoblasts and myotubes have higher coincident expression of 
Cav-1 and Cav-3 proteins compared to the C2C12 myoblasts and myotubes.  
Localisation of Cav-1 and Cav-3 was investigated in the myoblasts and myotubes (C2C12 
and PD50A). Myotubes were obtained by shifting the 80% confluent myoblasts to low 
mitogen medium for 14 days. (A) Cav-1 colocalises with Cav-3 in PD50A myoblasts. (B) 
Cav-1 colocalises with Cav-3 in perinuclear region of PD50A myotubes. (a)(e) Nuclei 
were labelled with 10 μg/ml of DAPI. (b)(f) Cav-1 proteins were labeled with Alexa Fluor 
488. (c)(g) Cav-3 proteins were labeled with Texas Red. Merged images are shown in (d) 
and (h). (A (c)) The fluorescent signals for Cav-3 are hardly visible in C2C12 myoblasts. 
Arrows in the insets of A (h) and B (f) suggests the colocalisation of Cav1 and Cav-3 in 
the PD50A myblast and myotube; the arrow in the inset of B (d) suggests the 
colocalisation of both caveolins in the C2C12 myotube. 
B 
A 
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Cav-1 and Cav-3 colocalise in the non-dystrophic and dystrophic myoblasts and myotubes 
I have shown in Figure 5.2 that there is a functional relationship between Cav-1 and Cav-3 in 
skeletal muscles. I then doubly labelled both caveolins in myoblasts and myotubes (both 
C2C12 and PD50A) (Figure 5.3). In undifferentiated myoblasts, Cav-1 protein localises 
predominantly in the plasma membrane of both PD50A and C2C12 myoblasts (Figure 5.3 A 
(b) and (f)). Staining of Cav-3 in the non-dystrophic and dystrophin-deficient myoblasts forms 
a pattern of distinct punctate dots which are also in the plasma membrane of myoblasts 
(Figure 5.3 A (c) and (g)). There are more cytosolic Cav-1 and Cav-3 in PD50A myoblasts 
compared to C2C12 controls (Figure 5.3 A (b), (c), (g) and (f)). Cav-1 colocalises with Cav-3 
in PD50A myoblasts; however, no obvious colocalisation of Cav-1 and Cav-3 is observed in 
C2C12 myoblasts (Figure 5.3 A (d) and (h)).  
Cav-1 proteins are presented as punctate structure along the sarcolemma of C2C12 myotubes 
while the majority of Cav-1 are cytosolic in PD50A myotubes (Figure 5.3 B (b) and (f)). Cav-
3 localises to the sarcolemma of C2C12 myotubes but it is predominately in perinuclear 
regions in PD50A myotubes (Figure 5.3 B (c) and (g)). In both C2C12 and PD50A myotubes, 
Cav-3 proteins colocalise with Cav-1 (Figure 5.3 B (d) and (h)). These data are consistent 
with the IP result shown in Figure 5.2 which shows more Cav-3 proteins associate with Cav-1 
in the mdx skeletal muscles.  
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Figure 5.4 IGF-2 colocalises with Cav-3 in C2C12 and PD50A myoblasts 
Localisation of IGF-2, Cav-1 and Cav-3 was examined in C2C12 and PD50A myoblasts. 
Myoblasts in growth permissive condition (DMEM with 10% FCS) were fixed with 4% 
PFA and then doubly immunolabelled with Cav-1/Cav-3 and IGF-2 specific antibodies. 
Nuclei were labeled with 10 μg/ml of DAPI (A, E, I and M). Cav-1 protein was labeled 
with Alexa Fluor 488. Cav-1 proteins localise around plasma membrane of PD50A (J) and 
C2C12 (B) myoblasts. Cav-3 protein was labeled with Alexa Fluor 488. Cav-3 proteins 
localise around the plasma membrane in C2C12 (F) and PD50A (N) myoblasts. More IGF-
2 localises perinuclearly in PD50A (K and O) than in C2C12 (C and G) myoblasts. IGF-2 
proteins were labeled with Texas Red. Merged images are shown in (D), (H), (L) and (P). 
Arrows in the inset represents colocalisation of IGF-2 with Cav-3 in C2C12 (H) and 
PD50A (P) myoblast.  
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5.2.3. IGF-2 associates with Cav-1 
Immunofluorescent double labelling of Cav-1 and Cav-3 in the myoblasts 
In chapter 3, I observed perturbed IGF-2 signalling in PD50A myoblasts (Figure 3.16). I also 
demonstrated that there were elevated levels of both Cav-1 and Cav-3 in PD50A myoblasts 
(Figure 3.15). To study whether the perturbed IGF-2 signalling is related to the elevated levels 
of Cav-1 and Cav-3, I doubly labelled the myoblasts (C2C12 and PD50A) with either Cav-
1/IGF-2 or Cav-3/IGF-2 (Figure 5.4). In C2C12 myoblasts, IGF-2 localises to the plasma 
membrane and more is perinuclear (Figure 5.4 C and G). IGF-2 colocalises with Cav-3 in 
C2C12 myoblasts (Figure 5.4 D and H). In PD50A myoblasts, IGF-2 predominantly localises 
to the perinuclear region (Figure 5.4 K and O). Similar to C2C12 myoblasts, IGF-2 
colocalises with Cav-3 in PD50A myoblasts (Figure 5.4 L and P). 
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Figure 5.5 IGF-2 colocalises with Cav-3 in PD50A myotubes 
C2C12 and PD50A myoblasts were cultured in low mitogen medium (DMEM with 2% horse 
serum) for fourteen days for myotube formation. Localisation of IGF-2, Cav-1 and Cav-3 was 
examined in the C2C12 and PD50A myotubes. Myotubes were fixed with 4% PFA and then 
doubly immunolabeled with either Cav-1/IGF-2 or Cav-3/IGF-2 specific antibodies. Nuclei 
were labeled with 10 μg/ml of DAPI (A, E, I and M). Cav-1 is labeled with Alexa Fluor 488. 
Cav-1 localises around the sarcolemma of PD50A (J) and C2C12 (B) myotubes. Cav-3 is 
labeled with Alexa Fluor 488. Cav-3 localises around the sarcolemma of C2C12 (F) and 
PD50A (N) myotubes. More IGF-2 localises perinuclearly in PD50A (K and O) than in C2C12 
(C and G) myotubes. IGF-2 was labeled with Texas Red. Merged images are shown in (D), (H), 
(L) and (P). Arrows in the insets represent the colocalization of (L) IGF-2 with Cav-1 and (P) 
IGF-2 with Cav-3 in PD50A myotubes. 
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IGF-2 colocalises with Cav-3 in myotubes 
In Figure 5.1, I established that IGF-2 signalling is perturbed in E17.5 dystrophic embryos 
(mdx and DMhet). I also established that there were elevated levels of Cav-1 and Cav-3 in 
E17.5 mdx embryos (Figure 4.1). To establish whether IGF-2 also colocalises with Cav-1 or 
Cav-3 in myotubes, I examined the localisation of IGF-2, Cav-1 and Cav-3 in C2C12 and 
PD50A myotubes (Figure 5.5). In C2C12 myotubes, IGF-2 staining is predominantly 
perinuclear (Figure 5.5 C and G). There is no obvious colocalisation of IGF-2 with neither 
Cav-1 nor Cav-3 in C2C12 myotubes (Figure 5.5 D and H). In PD50A myotubes, IGF-2 is 
also perinuclear (Figure 5.5 K and O). Although only a minority of IGF-2 colocalise with 
Cav-1 in PD50A myotubes (Figure 5.5 L; inset), the majority of IGF-2 colocalises with Cav-3 
in PD50A myotubes (Figure 5.5 P; inset). These data suggest that the localisation of IGF-2 to 
Cav-3 may contribute to the perturbed IGF-2 signalling found in PD50A myoblasts and mdx 
embryos (Figure 3.16 and 5.1). 
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Figure 5.6 More prepro-IGF-2 associates with Caveolin-1 and Caveolin-3 in the 
skeletal muscles of 4-week old mice 
100 μg of skeletal muscle tissue extracts from wild type (wt), cav-3-/- and mdx mice were 
used for immunoprecipitation. The Cav-1 protein complex in extract was pulled down 
with anti-caveolin-1 antibody and Protein A Sepharose CL-4B beads. There are muscle 
tissue extracts from 4 weeks (A) and 9 weeks (B) old mice (non-dystrophic, mdx and 
cav3-/-). 10 μg of each extract were loaded as input control and rabbit Igs were used as the 
negative control for IP. Components of the complex pulled down were detected by anti-
IGF-2 antibody. (A) Prepro-IGF-2 (46-50 kDa) associate with Cav-1 and Cav-3 in 
skeletal muscles from 4-week adult mice. (B) Fewer prepro-IGF-2 (46-50 kDa) associates 
with Cav-1 and Cav-3 in skeletal muscles from 9-week compared to 4-week adult mice. 
(n=3) The prepro-IGF-2 (46-50 kDa) is indicated by arrows.  IGF-2: insulin-like growth 
factor  
 
A 
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IGF-2 proteins coprecipitate with Cav-1 
To further investigate whether IGF-2 functionally interacts with Cav-1 and Cav-3 in skeletal 
muscles, I examined the association of IGF-2 with Cav-1 and Cav-3 by immunoprecipitation 
using anti-Cav-1 antibody (Figure 5.6). In the skeletal muscle tissues from both 4- and 9-week 
old mice (wt, mdx and cav-3-/-), prepro-IGF-2 peptides (46-50 kDa) associate with Cav-1 and 
Cav-3 (Figure 5.6 A and B). The prepro-IGF-2 (46-50kDa) was found in skeletal muscles of 
both 4-week and 9-week old mice (Figure 5.6 A and B). The bands for prepro-IGF-2 (46-
50kDa) pulled down together with Cav-1 and/or Cav-3 are more intense in 4-week old mdx 
and cav-3-/- mice compared to 4-week old wt mice (Figure 5.6 A and B). In addition, the band 
intensity for prepro-IGF-2 (46-50kDa) pulled down together with Cav-1 and/or Cav-3 is more 
intense in skeletal muscle tissues of 4-week old mice (wt, mdx and cav-3-/-) compared to 9-
week old mice (Figure 5.6 A and B). These data suggest that IGF-2 signalling may be 
mediated by Cav-1 and Cav-3 in skeletal muscles, especially via Cav-1. However, 2-
dimentional native gel analysis is required to confirm whether IGF-2, Cav-1 and Cav-3 form 
complexes.   
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Figure 5.7 pSrc and Src proteins associate with Caveolin-1 and Caveolin-3 in 
dystrophic skeletal muscles.  
100 μg of muscle tissue extracts from wt, cav-3-/- and mdx mice were used for 
immunoprecipitation. Cav-1 protein complex in extract was pulled down with anti-
caveolin-1 antibody (rabbit origin) and Protein A Sepharose CL-4B beads. There were 
muscle tissue extracts from 4 weeks (4w) (A) and 9 weeks (9w) (B) old mice (non-
dystrophic, mdx, and cav-3-/-). 10 μg of each extract were loaded as input control and 
rabbit Igs were applied to the extracts as the negative control for IP. (C) The amount of 
pSrc co-immunoprecipitated with Cav-1 is more in both the 4w and 9w mdx muscles 
compared to the 9w and 4w wt muscles (D) The amount of Src co-immunoprecipitated 
with Cav-1 is more in both the 4w and 9w mdx muscles compared to the 4w and 9w wt 
muscles (E) Ratio of pSrc/Src decreases in 9w mdx skeletal muscle tissues. (ANOVA; ＊
compared to wt; ＊p<0.05; ＊＊p<0.01;  n = 4).   
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5.2.4. Src and phospho-Src (pSrc) proteins associate with Cav-1 and Cav-3  
Src has been reported to associate with Cav-1 and this interaction inhibits 
autophosphorylation of Src (Li et al., 1996a; Li et al., 1996b). In myotubes, Src can associate 
with Cav-3 (Smythe et al., 2003); however, whether Cav-1 associates with Src in the 
myotubes has not been reported. To establish whether Src or Phospho-Src (pSrc) associates 
with Cav-1 and Cav-3 in 4w and 9w skeletal muscles (wt, mdx and cav-3-/-), Cav-1 IP 
products were immunoblotted with pSrc and Src specific antibodies. The amount of Src and 
pSrc in the complex was examined to identify the correlation of Src/pSrc proteins with the 
levels of Cav-3. Both Src and pSrc proteins associate with Cav-1 and Cav-3 in skeletal muscle 
tissues of both 4- and 9-week old mice (wt, mdx and cav3-/-) (Figure 5.7 A and B). 
Although the amount of p-Src and Src proteins identified by Cav-1 pull-down is very low 
compared to Cav-3 in the pull-down, I was able to establish that more pSrc and Src proteins 
associated with Cav-1 and Cav-3 in both 4-week (1.6 fold for pSrc, p= 3.88×10-2; 1.8 fold for 
Src, p= 1.33×10-3) and 9-week (1.3 fold for pSrc, p= 2.74×10-3; 1.3 fold for Src, p= 1.14×10-3) 
old mdx skeletal muscles compared to wt skeletal muscles of the same ages (Figure 5.7 A, B, 
C and D). In 4-week old cav-3-/- skeletal muscles, association of pSrc and Src with Cav-1 is 
elevated by 1.1 (p= 3.88×10-2) and 1.3 (p= 3.18×10-2) fold respectively compared to wt 
skeletal muscles (Figure 5.7 A, C and D). The ratio of pSrc/Src remains constant between wt 
and dystrophic (cav-3-/- and mdx) skeletal muscles (Figure 5.7 E). These differences in pSrc 
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and Src that associate with Cav-1 and/or Cav-3 suggest that Src signalling is disturbed in the 
dystrophic skeletal muscles. Lower levels of pSrc and Src associate with Cav-1 in skeletal 
muscles of 9-week old cav-3-/- is consistent with previous report that muscle cells with TFT 
mutation of Cav-3, which results in LGMD-1C, lose membrane localisation of Src (Smythe et 
al., 2003).   
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Figure 5.8 pSrc and Src proteins associate with Caveolin-1eGFP in myotubes.  
C2C12-Cav-1eGFP and dfd13-Cav-1eGFP stable cells were cultured in DM for 14 day 
for myotube formation. Proteins were harvested and concentration was determined (Refer 
to section 2.8). 300 μg of extracts from myotubes were used for GFP-trap (Refer to 
section 2.9.3). Cav-1eGFP protein complex in extract was pulled down with GFP-Trap®A 
beads. (A) The pulled-down Cav-1eGFP complex was immunoblotted with pSrc, Src and 
β-dystroglycan specific antibodies. 20 μg of each extract was loaded as input control. (B) 
More Src proteins associate with Cav-1eGFP proteins in dfd13-Cav-1eGFP myotubes 
compared to C2C12-Cav-1eGFP myotubes. (C) More pSrc proteins associate with Cav-
1eGFP proteins in dfd13-Cav-1eGFP myotubes compared to C2C12-Cav-1eGFP 
myotubes. This experiment was performed only once due to the lack of protein extracts. 
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GFP-trap with whole cell extracts of the Cav-1eGFP overexpressing C2C12 myotubes  
GFP-trap assay is used to pull down the GFP-tagged proteins together with the partners 
associate with them (Metzger et al., 2012); thus is a useful tool to establish the interactions 
between GFP-tagged proteins (Cav-1eGFP in this study) and the target proteins we are 
interested in. To further test the specificity of the association of pSrc and Src with Cav-1, I 
isolated stable transfectants with Cav-1eGFP, both non-dystrophic (C2C12-Cav-1eGFP) and 
dystrophin-deficient (dfd13-Cav-1eGFP) (Refer to section 2.5.1 for transfection and 2.5.3 for 
stable transfectant selection).  The transfectants reaching more than 80% confluence were 
cultured in low mitoegen medium to induce the formation of myotubes, and the whole cell 
extracts were collected to perform GFP-trap (Refer to section 2.9.3 for method) (Figure 5.8). 
This GFP-trap assay was performed only once due to the limited amounts of whole cell 
extracts available. There is an increase association of pSrc and Src with Cav-1eGFP in dfd13-
Cav-1eGFP myotubes compared to C2C12-Cav-1eGFP myotubes (Figure 5.8 A); this is 
consistent with the results from skeletal muscle tissues of 4- and 9-week old mice (Figure 5.7). 
Although there is some non-specific binding of Src and pSrc proteins to the GFP-Trap® A 
beads, there is more association of Src and pSrc proteins with Cav-1eGFP (Figure 5.8 A, B 
and C). These data suggest that association of pSrc and Src to the Cav-1 is specific. 
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5.2.5. IGF-2 regulates Pax7, Caveolin-1 and Caveolin-3 in C2C12 myoblasts  
In Figure 5.1, I demonstrated that IGF-2 protein is significantly elevated in E17.5 mdx 
embryos. In chapter 4 (Figure 4.1), I showed that these embryos (E17.5 mdx) also have altered 
protein expression of Pax7, Cav-1 and Cav-3 compared to wt controls. To establish whether 
these proteins are functionally linked, I used shRNAi (short hairpin RNA interference) to 
knock down IGF-2 [RNAi-igf-2 and RNAi-gfp (target gfp; control)] and MIG to overexpress 
IGF-2 in C2C12 myoblasts [C2MIG and C2MG (control)] (Merrick et al., 2007) to examine 
the effect of IGF-2 on the protein levels of Pax7, Cav-1 and Cav-3. MIG is an IGF-2 
expression vehicle driven by mCK (muscle creatine kinase) promoter which is expressed 
during myoblast differentiation and MG is the control vehicle.  
We have previous reported that C2MIG myoblasts have higher levels of IGF2 RNA compared 
to the C2MG control and that IGF-2-RNAi effectively knocks down the IGF-2 RNA (Merrick 
et al., 2007). Here I established that C2MIG myoblasts have 2.5 fold more active IGF-2 
compared to C2MG myoblasts (Figure 5.9 A and B; p= 2.22×10-2; gfp-shRNAi controls). 
IGF-2-RNAi reduces the levels of active IGF-2 by 38% in C2MIG myoblasts compared to the 
control myoblasts (Figure 5.9 A and B; p= 7.16×10-2).  
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Figure 5.9 Down-regulation of IGF-2 affects the Cav-1, Cav-3 and Pax7 protein levels 
in myoblasts.  
IGF-2 in control (C2MG) and IGF-2-overexpressing (C2MIG) myoblasts were knocked 
down with igf2-shRNAi (or gfp-shRNAi as control). The myoblasts were cultured in GM 
(DMEM + 10% FCS). (A) Protein extracts were harvested and immunoblotted with 
antibodies recognizing IGF-2, Pax7, myogenin, Cav-1 and Cav-3. β-actin is used as a 
loading control. (B) Densitometry of prepro-IGF-2 (64 kDa) and mature IGF-2 (17.5 
kDa). (C) The levels of myogenin increases in C2MG and C2MIG myoblasts when IGF-2 
was knocked down. (D) Down-regulating of IGF-2 induces expression of Pax7 proteins.  
(E) IGF-2 over-expression reduces expression of Cav-1 proteins. (F) Elevated IGF-2 
protein levels lead to increase of Cav-3 proteins. (G) There is a negative correlation 
between the levels of Cav-1 and active IGF-2. (ANOVA; ＊<0.05; ＊＊<0.01 compared 
to gfpRNAi controls; n=3). Each column represents an average of three repeats from 
different samples. MIG: IGF-2 expression vehicle driven by muscle creatine kinase 
promoter; MG: control expression vehicle without IGF-2 gene; RNAi-igf2: short hairpin 
RNA expression vehicle targeting IGF2; RNAi-gfp: control short hairpin RNA expression 
vehicle targeting GFP  
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The level of myogenin increases in C2MIG myoblasts compared to C2MG myoblasts (Figure 
5.9 A and C); this is consistent with previous report that C2MIG myoblasts differentiate 
spontaneously at high cell density (Merrick et al., 2007). These data suggest that 
differentiation of C2C12 myoblasts is influenced by the levels of IGF-2 within the myoblasts. 
Knocking down IGF-2 in C2MG myoblasts leads to an increase of Pax7 protein level by 2.7 
fold compared to control myoblasts (Figure 5.9 A and D; p= 2.44×10-3). Similarly, the levels 
of Pax7 in C2MIG myoblasts increase by 2.2 fold when IGF-2 was knocked down compared 
to the control myoblasts (5.8 A and D; p= 6.35×10-3). Together these data show that Pax7 
protein levels are negatively regulated by IGF-2 in myoblasts and this relates to differentiation 
status (Figure 3.10).  
Overexpressing IGF-2 in myoblasts (C2MIG) leads to the decrease of Cav-1 compared to 
control myoblasts (C2MG); the levels of Cav-1 decrease by 57% (p= 1.96×10-2) in C2MIG 
control myoblasts and by 45% (p= 2.09×10-3) in C2MIG myoblasts with IGF-2 knock-down 
(Figure 5.9 A and E). The ratio of Cav-1/active IGF-2 shows that there is a negative 
correlation between level of IGF-2 and the level of Cav-1 in myoblasts (Figure 5.9 G) which 
correlates with differentiation status. The effect of IGF-2 on Cav-3 is opposite to that on Cav-
1 such that, over-expression of IGF-2 in myoblasts results in an up-regulation of Cav-3 
(Figure 5.9 A and F). Cav-3 increases by 1.74 fold (p= 4.4×10-3) in the C2MIG (gfp-shRNAi 
control) myoblasts (compared to the C2MG gfp-shRNAi control) whereas Cav-1 is down-
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regulated (Figure 5.9 A, E and F); thus causing a shift in Cav-1/Cav-3 ratio which correlates 
with differentiation status (Figure 3.15). These data suggest that IGF-2 positively regulates the 
levels of Cav-3. The ratio of Cav-3/active IGF-2 increases by 1.5 fold (p= 1.06×10-2) in 
C2MIG myoblasts with IGF2 knock-down compared to control myoblasts (Figure 5.9 G). 
Overall, these data suggest that IGF-2 has reverse effects on the levels of Cav-1 and Cav-3 
and that the ratio of Cav-1/3 may be important for the progression of myoblast differentiation.  
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Figure 5.10 Pax7-mCherry construct expression in C2C12 and dfd13 myoblasts.  
C2C12 and dfd13 myoblasts were transfected with Pax7-mCherry expression 
plasmid and stable transfectants were selected with 800 μg/ml of G418. pmCherry 
transfection was applied as the transfection control. mCherry proteins are cytosolic 
in both (A) non-dystrophic (C2C12-mCherry) and (C) dystrophic (dystrophin-
deficient; dfd13-mCherry) myoblast transfectants. Pax7-mCherry fusion proteins 
are nuclear in both (B) non-dystrophic (C2C12-Pax7mCherry) and (D) dystrophic 
(dfd13-Pax7mCherry) transfectants.  
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5.2.6. Altered Pax7 Levels affect levels of Cav-1 and Cav-3 in myoblasts 
In chapter 3 and 4, I demonstrated attenuated protein levels of Pax7 and elevated levels of 
Cav-1 and Cav-3 proteins in both PD50A myoblasts and E17.5 mdx embryos (Figure 3.10, 
3.15 and 4.1). To directly study the effect of Pax7 on Cav-1 and Cav-3 protein expression, I 
introduced a Pax7-mCherry expression construct (CMV promoter-drived) into myoblasts and 
knocked down endogenous Pax7 with short hairpin RNA interference (Pax7sh) (Refer to 
section 2.4 for Pax7-mCherry construct generation). Since PD50A myoblasts are resistant to 
G418 selection, the parental line of PD50A, dfd13, was used for these experiments to enable 
G418 selection of Pax-7mCherry-transfected mdx derived myoblasts. C2C12 and dfd13 
myoblasts were transfected with Pax7-mCherry or the control plasmid pmCherry and selected 
with G418 in order to obtain stable transfectants for Pax7-mCherry (Figure 5.10). Pax7-
mcherry proteins localise to the nuclei of both C2C12 and dfd13 myoblasts, consistent with 
the known localisation of Pax7 which is a transcription factor (Figure 5.10 B and D). Pax7-
mCherry fusion protein appears in the transfectants (both C2C12 and dfd13) 24 hours after 
transfection; however, expression of the fusion protein decreases thereafter such that few 
Pax7-mCherry positive cells were found for selection. Medium with 20% FCS was used to 
expand these Pax7-mCherry transfectants to usable quantities.  
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Figure 5.11 Levels of Pax7 protein in myoblasts affect the levels of Cav-1 and Cav-3 in 
myoblasts.  
Pax7-mCherry expression plasmid or Pax7 shRNAi expression vehicle was introduced 
into C2C12 and Dfd13 myoblasts. Stable transfectants were selected with G418. (A and B) 
Pax7-A protein levels are down-regulated by Pax7-mCherry. (A and C) Protein levels of 
Pax7-B are down-regulated by Pax7-mCherry. (A and D) Cav-1 protein levels are down-
regulated by Pax7-mCherry. (A and E) Cav-3 protein levels are affected by Pax7 protein 
levels in dystrophin-deficient myoblasts. (A and F) Protein levels of β-actin decrease in 
myoblasts with Pax7 knockdown. (ANOVA; ＊p＜0.05 ; ＊＊p＜0.01 ; ＊compared to 
transfection control; n=3). Each column represents an average of three repeats from 
different samples.  
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Two isoforms of Pax7 have been identified in the human rhabdomyosarcoma cell line Rh1; 
Pax7-A (molecular weight 57 kDa) and a shorter isoform Pax7-B (molecular weight 54 kDa) 
are derived from alternative splicing events (Vorobyov and Horst, 2004). Both Pax7-A and 
Pax7-B express in undifferentiated and differentiated C2C12 myoblasts; the level of both 
isoforms decrease in differentiated C2C12 (Charytonowicz et al., 2011). I examined both 
Pax7-A and Pax7-B isoforms (Figure 5.11 A). The Predicted molecular weight of Pax7-
mCherry fusion protein is about 83 kDa. However, there is nonspecific band with similar size 
such that I was unable to identify Pax7-mCherry fusion protein with immunoblotting (Figure 
5.11 A). Over-expression of Pax7-mCherry (isoform A) down-regulates Pax7-A protein levels 
by 63% (p= 9.08×10-5) in C2C12 myoblasts compared to control myoblasts (Figure 5.11 A 
and B). Protein levels of Pax7-A decrease by 47% (p= 3.06×10-2) in dfd13 wich overexpresses 
Pax7-mCherry compared to control myoblasts (Figure 5.11 A and B). Protein levels of Pax7-B 
decrease by 65% in C2C12 (p= 4.7×10-4) and dfd13 (p= 2.15×10-3) myoblasts with Pax7-
mCherry overexpression compared to their respective controls (Figure 5.11 A and C). Protein 
levels of beta-actin are down-regulated in C2C12 myoblasts with Pax7 knock-down and in 
dfd13 myoblasts with Pax7-mCherry overexpression, with the severest reduction observed in 
C2C12 myoblasts with Pax7 knock-down (Figure 5.11 A and F). 
In C2C12 myoblasts, Pax7-mCherry overexpression leads to a decrease in the protein level of 
Cav-1 by 85% compared to control (Figure 5.11 A and D; p= 2.73×10-6). Cav-1 protein levels 
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also decrease in C2C12 myoblasts with Pax7 knock-down by 57% compared to control 
(Figure 5.11 A and D; p= 5.53×10-4). dfd13 myoblasts with Pax7-mCherry over-expression 
have the levels of Cav-1 reduced by 32% (Figure 5.11 A and D; p= 4.31×10-3). It is worth 
noting that both up- and down-regulation of Pax7 in dfd13 myoblasts lead to reduction of 
Cav-1β isoform protein levels in dystrophin-deficient myoblasts (Figure 5.11 A; lower band in 
the panel of Cav-1 western blotting). This reduction of Cav-1 protein level in C2C12 
myoblasts with Pax7-mCherry overexpression is consistent with previous report that Pax7 
over-expression inhibits Cav-1 gene expression in C2C12 myoblasts (Soleimani et al., 2012).  
Over-expressing Pax7-mCherry or knocking down Pax7 in C2C12 myoblasts has no effect on 
the levels of Cav-3 protein compared to their respective controls (Figure 5.11 A and E). 
Conversely, Cav-3 protein levels in dfd13 myoblasts with Pax7-mCherry overexpression are 
only 22% of those in control myoblasts (Figure 5.11 A and E; p= 1.67×10-5). Knocking down 
Pax7 in dfd13 myoblasts increases Cav-3 protein levels by 2.3 fold compared to control 
myoblasts (Figure 5.11 A and E; p= 4.11×10-3). Data above suggest that Pax7 negatively 
regulates Cav-1 expression in C2C12 myoblasts while negatively regulates Cav-3 expression 
in dfd13 myoblasts. This down-regulation of Cav-3 by Pax7 in dfd13 myoblasts is likely to be 
an indirect regulation and this may be related to dystrophin-deficiency in dfd13 myoblasts, 
suggesting a role of dystrophin in signal transduction.  
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5.2.7. Caveolin-1 and Caveolin-3 regulate Pax7 protein levels in myoblasts 
To further study whether up- or down-regulation of Cav-1 and Cav-3 affects Pax7 protein 
levels, dystrophin-deficient (dfd13) and non-dystrophic (C2C12) myoblasts were introduced 
with the following expression vehicles; eGFP, Cav-1eGFP, Cav-3eGFP, dsgfpshRNAi, Cav-
1shRNAi and Cav-3shRNAi. Stable transfectants were selected with G418 for further 
experiments. Levels of Cav-1 and Cav-3 proteins are down-regulated respectively in Cav-
1shRNAi and Cav-3shRNAi transfected cells showing that RNAi knocks down Cav-1 and 
Cav-3 in myoblasts (Figure 5.12 A). Protein levels of Pax7 decrease by 46% in C2C12-
Cav1eGFP transfectants (p= 1.09×10-2) and by 55% in C2C12-Cav3eGFP transfectants (p= 
1.34×10-2) compared to C2C12-eGFP transfectants (Figure 5.12 B and D). Tthe levels of Pax7 
protein increase by 18% (p= 3.58×10-3) in dfd13-Cav1eGFP transfectants and by 1.3 fold in 
dfd13-Cav3eGFP transfectants (though not significant; p= 0.1) compared to dfd13eGFP 
control (Figure 5.12 B and D). Knocking down Cav-1 or Cav-3 in C2C12 myoblasts (C2C12-
Cav1KD and C2C12-Cav3KD respectively) has no effect on the levels of Pax7 compared to 
C2C12-dsgfpsh control (Figure 5.12 C and E). In contrast, knocking down Cav-1 or Cav-3 in 
dfd13 myoblasts leads to an increase of the levels of Pax7 protein compared to dfd13-dsgfpsh 
control; 39% in dfd13-Cav1KD myoblasts (p= 5.2×10-4) and 46% in dfd13-Cav3KD 
myoblasts (p= 6.61×10-3) (Figure 5.12 C and E).  
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Figure 5.12 Levels of Cav-1 and Cav-3 in myoblasts affect the levels of Pax7 proteins in 
myoblasts.  
C2C12 and Dfd13 myoblasts were transfected with the following expression vehicles; eGFP, 
Cav-1eGFP, Cav-3eGFP, Cav-1shRNAi or Cav-3shRNAi. Stable transfectants were selected 
with G418 for these experiments. Whole cell extracts were harvested and immunoblotted 
with Pax7, Cav-1 and Cav-3 specific antibodies. Coomassie blue stain of the nitrocellulose 
membrane is used as loading control. (A) Cav-1 and Cav-3 proteins in myoblasts are 
labelled with Alexa Fluor 488. (B and D) Overexpressing Cav-1 or Cav-3 reduces Pax7 in 
C2C12 myoblasts; however overexpression of Cav-3 increases level of Pax7 in dfd13 
myoblasts. (C and E) Down-regulation of Cav-1 or Cav-3 has no effect on levels of Pax7 
protein in C2C12 and dfd13 myoblasts. (B and F) Overexpressing Cav-3 down-regulates 
Cav-1 protein levels in C2C12 myoblasts but up-regulates Cav-1 protein levels in dfd13 
myoblasts. (C and G) Down-regulating Cav-3 has no effect on the protein level of Cav-1 in 
C2C12 and dfd13 myobasts. (B and H) Overexpressing Cav-1 has no effect on protein 
levels of Cav-1 in C2C12 and dfd13 myoblasts. (C and I) Down-regulating Cav-1 has no 
effect on protein levels of Cav-1 in C2C12 and dfd13 myoblasts. (ANOVA; ＊p＜0.05 ; ＊
＊p＜0.01 ; ＊compared to transfection control; n=3). Each column represents an average 
of three repeats from different samples. 
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The levels of Cav-1 protein decrease by 44% in C2C12 myoblasts with Cav-3 overexpression 
(C2C12-Cav3eGFP; p= 3.77×10-2) and by 40% in C2C12 myoblasts with Cav-3 knock-down 
(C2C12-Cav3KD; p= 4.89×10-3) compared to control myoblasts (Figure 5.12 B, C, F and G). 
Overexpression of Cav-3 leads to an increase by 50% (p=0.09) in dfd13 myoblasts while 
down-regulation of Cav-3 has no effect on the level of Cav-1 protein in dfd13 myoblasts 
compared to control myoblasts (Figure 5.12 B, C, F and G). The levels of Cav-3 in C2C12 or 
dfd13 myolasts which overexpress Cav-1 are comparable to their respective controls (Figure 
5.12 B, C, H and I). However, knocking down Cav-1 causes decreases in the levels of Cav-3 
protein by 24% in C2C12 myoblasts (p= 3.15×10-3) and by 34% in dfd13 myoblasts (p= 
4.39×10-2) comparable to those in their respective controls (Figure 5.12 B, C, H and I). These 
data suggest that in dfd13 myoblasts, which have elevated levels of Cav-1 and Cav-3 proteins 
(Figrue 3.15), Pax7 protein levels are up-regulated by Cav-3 as well as Cav-1. However, in 
C2C12 myoblasts, Cav-3 proteins negatively regulate the levels of Pax7 protein.   
 
5.3. Discussion: 
5.3.1. IGF-2 signalling pathways are perturbed in dystrophic mouse embryos 
I demonstrate up-regulated mTOR-IGF2 signalling in E17.5 mdx (Figure 5.1), suggesting a 
feedback loop between IGF-2 and mTOR in mdx embryos. This is consistent with the up-
regulation of IGF-2 reported in mdx (eight weeks old) and DMD (six to nine years old) from 
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DNA micro-array analysis (Chen et al., 2000b; Porter et al., 2002) and our unpublished data 
(unpublished data of Dr. Deborah Merric and Dr. Janet Smith). It has been reported that 
transgenic mice, which over-express IGF-2, down-regulates p57kip2 (Grandjean et al., 2000). I 
established that the E17.5 mdx and mdx/cav-3+/- (DMhet) mouse embryos which show 
elevated levels of IGF-2 have down-regulated levels of cyclin-dependent kinase inhibitor 
p57kip2 (Figure 5.1). In E17.5 cav-3-/- embryos where IGF-2 is down-regulated, the levels of 
p57kip2 protein also decrease, suggesting that regulation of p57kip2 protein levels is perturbed 
in E17.5 cav-3-/- embryos (Figure 5.1). Decreased level of p57kip2 may contribute to the high 
growth rate of myoblasts isolated from E17.5 cav-3-/- and mdx mouse embryos (Merrick et al., 
2009). Although the proliferation rate of myoblasts from DMhet has not been reported, these 
data predict to be similar to or greater than the elevated rates of those myoblasts from mdx and 
cav-3-/- mice due to the low levels of p57kip2 protein.  
It has been reported that activated AKT/mTOR signalling pathway can cause skeletal muscle 
hypertrophy (Bodine et al., 2001). Erk6 signalling is reported to be down-regulated in DMD 
patients of 6-9 years of age (Chen et al., 2000b). It has also been reported that 6-week old mdx 
mice diaphragm muscles have higher mTOR activity compared to the non-dystrophic mice 
(Eghtesad et al., 2011). I established elevated activity of AKT/mTOR signalling in E17.5 mdx 
and DMhet mouse embryos in the present study (Figure 5.1). I also established down-
regulated Erk1/2 signalling in E17.5 mdx (Figures 5.1). The perturbed Erk1/2 and 
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mTOR/IGF-2/p57kip2 signalling pathways in E17.5 mdx, cav-3-/- and DMhet mice may help to 
explain the elevated proliferation of primary muscle stem cells from dystrophic (mdx, DMhet 
and cav-3-/-) mouse embryos (Merrick et al., 2009). It also further supports, in the molecular 
level, the early (embryonic) onset of muscular dystrophy reported by our group earlier 
(Merrick et al., 2009).  
 
5.3.2. Cav-1 protein associates with Cav-3 protein in skeletal muscles of adult mice 
Cav-1 can form homodimers and heterodimers with Cav-2 (Sargiacomo et al., 1995; Scherer 
et al., 1997). An interaction between Cav-1 and Cav-3 has also been reported in cardiac 
myocytes (Capozza et al., 2005a; Volonte et al., 2008), but interaction between Cav-1 and 
Cav-3 has not previously been determined directly in skeletal muscle tissue. In the present 
study, I established colocalisation of endogenous Cav-1 proteins with Cav-3 proteins in 
myoblasts and myotubes (both dystrophin-deficient and non-dystrophic) using 
immunofluorescent double labelling of Cav-1 and Cav-3 proteins (Figure 5.3). I also observed 
association of Cav-1 and Cav-3 proteins from wt and mdx adult (4-week and 9-week) mouse 
skeletal muscle tissues using co-immunoprecipitation (Figure 5.2). Stronger bands of Cav-1 
and Cav-3 in the complex were observed in skeletal muscle tissues of 9-week than 4-week 
mdx (Figure 5.2), which have cycles of degeneration and regeneration between 4 weeks and 9 
weeks old (Tanabe et al., 1986). The observation that strong correlation is found in the 9-week 
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mdx skeletal muscles suggests that the Cav-1/Cav-3 ratio may contribute to the pathology of 
mdx.  
 
5.3.3. Association of IGF-2, Src and pSrc proteins with Cav-1/Cav-3 protein complex may 
contribute to the pathology of mdx 
In the present study, I found that phospho-Src (pSrc) proteins associate with the Cav-1 and 
Cav-3 proteins (Figure 5.7 and 5.8). Association of pSrc with the caveolin complex is stronger 
in the skeletal muscles of 4-week mdx relative to the 9-week mdx (Figure 5.7), suggesting a 
difference in the signalling pathways between the early and late progress of mdx pathology or 
a decrease in the Src/Cav-1/Cav-3 mediated signalling in the late progress of mdx pathology. 
The presence of pSrc in the cav3-/- adult skeletal muscle tissues suggests that the interaction 
between pSrc and the Cav-1/Cav-3 complex is through the interaction with Cav-1 (Figure 5.7). 
Binding of Src to Cav-1 and Cav-2 and the subsequent phosphorylation of tyrosine 14 of Cav-
1 and tyrosine 19 of Cav-2 has been reported (Lee et al., 2002; Lee et al., 2000; Li et al., 
1996b). Recruitment of Src to caveolae can positively regulate the signal transduction of 
insulin receptor and Na+/K+ ATPase (Liu et al., 2003; Yamamoto et al., 1998). Nevertheless, 
phospho-Cav-1 recruits the C-terminal Src kinase (Csk) which phosphorylates Src at Tyr527 
and inactivates Src associated with Cav-1, forming a negative feedback loop (Cao et al., 2002; 
Li et al., 1996a; Radel and Rizzo, 2005). Cav-3 proteins or peptide representative of the 
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scaffolding domain of Cav-3 can inhibit the activity of Src (Li et al., 1996a; Smythe et al., 
2003). In the present study I found more pSrc and Src proteins associate with the caveolin 
complex in mdx skeletal muscles which have elevated levels of Cav-1 and Cav-3; whereas 
association of pSrc and Src with the caveolin complex in skeletal muscles of cav3-/- mice is 
comparable to wt skeletal muscles (Figure 5.7). These data explain opposite roles of Cav-1 
and Cav-3 in regulating Src activity in skeletal muscle; Cav-3 recruitment of pSrc may help 
concentrate the signalling molecules to activate and/or maintain the signalling while Cav-1 in 
caveolae then inactivates the activity of pSrc, maintaining homeostasis of Src signal 
transduction (Figure 5.13). This suggests that Cav-1 and Cav-3 may act antagonistically in 
skeletal muscles.  
 
Figure 5.13 A negative feedback loop exists between Src and Cav-1 to regulate signal 
transduction. 
(Adapted from Cui et al., 2005; Boney et al., 2001; Lieskovska et al., 2006; Lu et al., 
2002; Lee et al., 2002; Radel and Rizzo, 2005)  
It has been reported that Src responds to IGF-1 which mediates proliferation of vascular 
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smooth muscle cells (SMC) and 3T3-L1 preadipocytes via the MAPK signalling pathway 
(Boney et al., 2001; Lieskovska et al., 2006). Src has also been reported to mediate the effect 
of IGF-1 on survival of oligodendrocytes through the PI3K/AKT signalling pathways (Cui et 
al., 2005). Down-regulation of Cav-1 in rat cardiomyoblasts and HUVECs (human umbilical 
vein endothelial cells) inhibits the AKT signalling pathway downstream of the IGF-1 receptor 
(IGF1R), suggesting a link between Cav-1, IGF-1 and Src (Salani et al., 2008). In myoblasts, 
differentiation signals from IGF-1 and IGF-2 have been shown to be mediated through IGF-
1R and downstream AKT signalling (Galvin et al., 2003). In addition, overexpression or 
underexpression of protein tyrosine phosphatase-α (PTPα), which dephosphorylates c-Src at 
tyrosine 527 and regulates c-Src activity, affects myoblast differentiation (Lu et al., 2002). 
Therefore, disturbed AKT/mTOR/IGF-2 and ERK1/2 signalling cascades in E17.5 mdx as 
well as cav-3-/- mouse embryos observed in the present study (Figure 5.1) may correlate with 
the perturbed association of the component within Cav-1/Cav-3 protein complex, including 
pSrc/Src proteins. In response to Cav-3 deficiency, protein extracts from hearts of cav3-/- 
mouse showed hyperactivation of the ERK1/2 cascade (Woodman et al., 2002). However, in 
the present study, I did not observe hyperactivated ERK1/2 cascade in the protein extracts 
from E17.5 cav3-/- embryos (Figure 5.1). This discrepancy may be attributed to the stages of 
the animals; they used 2-month and 4-month old mice while I used E17.5 mouse embryos 
(Woodman et al., 2002). In addition, they examined the heart only while I used decapitated 
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embryos containing both cardiac and skeletal musculature in addition to other tissues 
(Woodman et al., 2002).   
 
5.3.4. Pax7 expression in mdx is affected by Cav-1 and Cav-3  
The observation that modulation of Pax7 expression in myoblasts exerted influence on the 
protein levels of caveolins is intriguing (Figure 5.11). It has been reported that over-
expression of Pax7 represses the gene expression of Cav-1 but not Cav-3 in C2C12 myoblasts 
by direct binding to the promoter region of Cav-1 gene; binding of Pax7 to the promoter 
region of Cav-3 was not observed (Soleimani et al., 2012). My data provide further evidence 
that Cav-1 protein levels are down-regulated by Pax7 in C2C12 myoblasts (Figure 5.11). 
PD50A (dystrophin-deficient) myoblasts, however, have elevated levels of both Cav-1 and 
Cav-3 as well as Cav-3/Cav-1 ratio compared to wt myoblasts (Figure 3.14 and 3.15). The 
reduced level of Pax7 proteins in dystrophin-deficient mdx embryos may be attributed to the 
elevated levels of Cav-1 and Cav-3 in them (Figure 4.1). In dfd13 (dystrophin-deficient) 
myoblasts, overexpression of Cav-3 up-regulates the levels of Pax7 protein (Figure 5.12). 
However, overexpression of both Cav-1 and Cav-3 in C2C12 myoblasts down-regulates Pax7 
protein levels in theses cells, suggesting that the ratio of Cav-1/Cav-3 in myoblasts is crucial 
for regulation of Pax7 protein levels. In dystrophin-deficient myoblasts, Pax7 negatively 
regulates the level of Cav-3 protein (Figure 5.11). Furthermore, both knockdown and 
 247 
overexpression of Cav-3 leads to up-regulation of Pax7 protein levels in dystrophin-deficient 
myoblasts (Figure 5.12), suggesting that molecular mechanisms that modulate the 
homeostasis of Pax7/Cav-1/Cav-3 are disturbed in dystrophin-deficient myoblasts. These data 
also suggest that a new homeostasis of Pax7/Cav-1/Cav-3 levels is achieved in the 
dystrophin-deficient myoblasts where there are decreased level of Pax7 and elevated levels of 
Cav-1/Cav-3 compared to nondystrophic myoblasts.  
I demonstrate in this chapter that protein levels of Pax7 in myoblasts are negatively regulated 
by the level of IGF-2 in that down-regulating IGF-2 leads to the up-regulation of Pax7 in 
myoblasts (Figure 5.9). In addition, I also found elevated protein levels of IGF-2 in E17.5 
mdx embryos (Figure 5.1). These data suggest that up-regulation of IGF-2 protein levels 
correlates with the perturbed expression of Pax7/Cav-1/Cav-3 noted in E17.5 mdx (Figure 
4.1). As IGF-2 associate with Cav-1 and Cav-3 in dystrophin-deficient myoblasts and skeletal 
muscles (Figure 5.4, 5.5 and 5.6), it is possible that the effect of IGF-2 on level of Pax7 is 
mediated through Cav-1 and Cav-3. Reduced protein levels of Pax7 in mdx, cav-3-/- and 
DMhet (mdx/cav-3+/-) (Figure 4.1) together with attrition of pax-7(+) myoblasts in these 
embryos (Merrick et al., 2009) suggests the number of Pax7-positive cells responsible for 
muscle regeneration is impaired in these mutants.  
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Chapter 6. Functional analysis of Caveolin-1 and Caveolin-3 in relation to dystrophin 
deficiency 
6.1. Introduction:  
In chapter 3 and 4, I established elevated levels of Cav-1 and Cav-3 in dystrophin-deficient 
mdx embryos and PD50A myoblasts (Figure 3.14, 3.15 and 4.1). Triads are membrane 
structures of muscle fibres which consist of T-tubule accompanied by terminal cisternae of the 
sarcoplasmic reticulum (SR) and are marked by the presence of dihydropyridine receptor 
(DHPR) and ryanodine receptors (RyRs) (Franzini-Armstrong et al., 1987) (Figure 6.1).  
 
Figure 6.1 Organisation of triads in skeletal muscles  
Triads of the muscles consist of transverse tubules (T-tubule) each accompanied by 
two terminal cisternae of sarcoplamic reticulum (SR) on either side. Interaction 
between dihydropyridine receptors (DHPRs) on T-tubule membrane and ryanodine 
receptors (RyRs) on SR membrane creates channels for calcium (Ca2+). Cav-3 
proteins associate with RyRs on the SR membrane and are involved in the 
development of T-tubules (Galbiati et al., 2001a). Calsequestrin (CSQ) linked to RyR 
can help maintain Ca2+ in SR lumen (Lanner et al., 2010). 
Calsequestrin localises on the lumen face of sarcoplasmic reticulum (SR) membrane adjacent 
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to T-tubule (Figure 6.1). Cav-3 has been reported to participate in the development of T-
tubules in skeletal muscles and down-regulating Cav-3 impairs T-tubule formation (Figure 6.1) 
(Galbiati et al., 2001a; Parton et al., 1997). I examined the localisation of Cav-1 and Cav-3 in 
embryonic skeletal muscle fibres using immunohistochemistry and in myotubes using 
immunofluorescent double labelling to establish the relationship between Cav-1/Cav-3 and t-
tubules in dystrophin deficiency.   
Cav-3 can interact with β-dystroglycan (a component of the dystrophin-glycoprotein complex; 
DGC) which plays a role in mediating mechanical response and signalling transduction of 
muscles (Ervasti and Campbell, 1993; Glass, 2005; Sotgia et al., 2000). Redistribution of 
caveolins in response to mechanical stress (i.e. stretching and osmosis pressure) has been 
reported; Cav-3 is reported to enhance stretch-induced phosphorylation of Src in myoblasts 
(Gervasio et al., 2011; Sinha et al., 2011). To understand whether different levels of caveolins 
(Cav-1 and Cav-3) in dystrophin-deficient myotubes/myoblasts have effect on the mechanical 
properties, functional analysis of wt and dystrophin-deficient myotubes/myoblasts was 
performed with atomic force microscope. 
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Figure 6.2 Caveolin-3 proteins localise to the sarcolemma of embryonic skeletal 
muscles as punctate dots corresponding to the triads of muscles. 
(A) E15.5 and (B) E17.5 wild type, mdx, cav-3-/- and DMhet embryos were fixed and 
embedded in paraffin wax. Embryo wax sections were cut in 5 μm. I examined Cav-3 
protein localisation in the skeletal muscle fibers of epaxial (back) skeletal muscles using 
immunohistochemistry. (C) The red rectangle in the E17 embryo section represents the 
region examined (taken from e-Mouse Atlas Project website). The localisation of Cav-3 
protein in skeletal muscles of E15.5 [A (a) and inset] and E17.5 [B (a) and inset] wt 
embryos is in subsarcolemma region as punctate corresponding to triads. Cav-3 widely 
spreads along the sarcolemma of skeletal muscles in E15.5 A [(b) and inset] and E17.5 [B 
(b) and inset] mdx embryos. E15.5 [A (c)] and E17.5 [B (c)] cav-3-/- embryos have no 
staining for Cav-3. The Localisation of Cav-3 is in the subsarcolemma region of E15.5 
DMhet skeletal muscles as punctate corresponding to the triads [A (d) and inset]; Cav-3 is 
widespread in the sarcolemma of E17.5 DMhet skeletal muscles [B (d) and inset]. Images 
are representative immunohistochemistry labelling of Cav-3 proteins from two individual 
embryos. cav-3-/-: mouse with caveolin-3 knocked out; DMhet: mdx mouse with 
heterozygous caveolin-3 knockout. 
A) E15.5 B) E17.5 
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6.2. Results: 
6.2.1. Localisation of Cav-1 and Cav-3 in the sarcolemma regions of embryonic 
skeletal muscles are perturbed in dystrophin deficiency       
In chapter 5, I have established that Cav-1 and Cav-3 colocalise in dystrophin-deficient 
myoblasts and myotubes and that the localisation of Cav-1 and Cav-3 to the plasma 
membrane is heterogeneous (Figure 5.3). To functionally analyse the role of Cav-1 and Cav-3 
in the skeletal muscles, I examined the localisation of Cav-1 and Cav-3 proteins in the epaxial 
(back) skeletal muscle fibres of E15.5 and E17.5 wt, mdx, cav-3-/- and DMhet embryos using 
immunohistochemistry (Figure 6.2 and 6.3).  
The localisation of Cav-3 to sarcolemma is heterogeneous in the skeletal muscle fibres of 
E15.5 and E17.5 wt, mdx, cav-3-/- and DMhet embryos (Figure 6.2). In wt skeletal muscles 
from both E15.5 and E17.5 embryos, Cav-3 is localised to the subsarcolemma region and 
represented as punctate dots with regular distance which is similar to the triads of the 
sarcolemma (Figure 6.2 A (a) and B (a)). In E15.5 mdx and DMhet skeletal muscles, Cav-3 is 
also localised to the sarcolemma as punctate dots corresponding to the triads and the staining 
intensity is stronger compared to wt (Figure 6.2 A (b) and (d)).  
At E17.5, Cav-3 becomes widespread in the subsarcolemma of mdx and DMhet skeletal 
muscles (Figure 6.2 B (b) and (d)). As expected, no staining for Cav-3 is detected in the E15.5 
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and E17.5 cav3-/- skeletal muscles, demonstrating the specificity of anti-caveolin-3 antibody 
used here (Figure 6.2 A (c) and B (c)). These data suggest that Cav-3 is localised to the triads 
of skeletal muscles of E15.5 (wt, mdx and DMhet) and E17.5 wt mouse embryos. These data 
also demonstrate that the localisation of Cav-3 is perturbed in the skeletal muscles of E17.5 
mdx and DMhet mouse embryos. 
 
Localisation of Cav-1 in the subsarcolemma is perturbed in mdx, DMhet and cav-3-/- 
embryonic skeletal muscles  
Similarly to Cav-3, the localisation of Cav-1 in embryonic skeletal muscles is also 
heterogeneous such that some of the fibres in the skeletal muscle are positive for Cav-1 while 
others in the same skeletal muscle are not labelled for Cav-1 (Figure 6.3). Cav-1 is localised 
evenly to the sarcolemma of E15.5 wt skeletal muscles (Figure 6.3 A (a)). At E17.5 wt and 
mdx embryos, Cav-1 is localised to the sarcolemma of skeletal muscles and the plasma 
membrane of myoblasts as punctate staining (Figure 6.3 B (a) and (b)); this is consistent with 
the localisation of Cav-1 to the plasma membrane of cultured myoblasts (Figure 5.3) and 
additionally demonstrates that Cav-1 is also present in the sarcolemma of differentiated 
embryonic myotubes which has not previously been demonstrated. The staining for Cav-1 is 
weak in E15.5 mdx skeletal muscles compared to the nondystrophic control (Figure 6.3 A (b)).  
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Figure 6.3 Caveolin-1 localises to the sarcolemma in the skeletal muscles of E15.5 and 
E17.5 mdx, DMhet and cav-3-/- mouse embryos. 
(A) E15.5 and (B) E17.5 wild type, mdx, cav-3-/- and DMhet embryos were fixed and 
embedded in paraffin wax. Embryos were sectioned in 5 μm. I examined the localisation 
of Cav-1 proteins in the skeletal muscle fibers of epaxial (back) muscles using 
immunohistochemistry. (C) The red rectangle in the E17 embryo section represents the 
region examined (taken from e-Mouse Atlas Project website). [A (a) and inset] Cav-1 is 
localised to the sarcolemma of some of the E15.5 wt embryonic skeletal muscles; [B (a) 
and inset] Cav-1 localises to the sarcolemma of E17.5 wt embryonic skeletal muscles as 
punctate dots. [A (b) and inset] There is weak labelling for Cav-1 in the sarcolemma of 
E15.5 mdx embryonic skeletal muscles. [B (b) and inset] E17.5 mdx embryonic skeletal 
muscles have more Cav-1 labelling compred to E17.5 wt; Cav-1 localises to the 
sarcolemma region as punctate dots. Cav-1 localises to the subsarcolemma region as 
punctate dots in the embryonic skeletal muscles of both E15.5 cav-3-/- [A (c) and inset] 
and E15.5 DMhet [A (d) and inset]. [B (c) and inset] There is weak labelling for Cav-1 in 
the sarcolemma of E17.5 cav-3-/- embryonic skeletal muscles. [B (d) and inset] Cav-1 is 
widespread in the sarcolemma of E17.5 DMhet embryonic skeletal muscles. Images are 
representative immuno-histochemistry labelling of Cav-1 of two individual embryos. cav-
3-/-: mouse with caveolin-3 knocked out; DMhet: mdx mouse with heterozygous caveolin-
3 knockout. 
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A) E15.5 B) E17.5 
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In both E15.5 DMhet and cav-3-/- skeletal muscles, Cav-1 is localised to the subsarcolemma 
region and appears to be punctate dots (Figure 6.3 A (c) and (d)). There is weak labelling for 
Cav-1 to the sarcolemma of E17.5 cav-3-/- skeletal muscles (Figure 6.3 B (c)). In E17.5 
DMhet skeletal muscles, Cav-1 is widespread in the subsarcolemma (Figure 6.3 B (d)). 
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Figure 6.4 Mislocalisation of Cav-1 and Cav-3 in T-tubules 
C2C12 and PD50A myoblasts (80% confluence) were shifted to DM (DMEM+2% horse 
serum) for fourteen days to induce myotube formation. Location of Cav-1 and Cav-3 
relative to the T-tubules is determined by the colocalisation of Cav-1 or Cav-3 with 
calsequestrin. (B and J) Cav-1 in C2C12 and PD50A myotubes was labelled with Alexa 
Fluor 488. (F and N) Cav-3 in C2C12 and PD50A myotubes was labelled with Alexa Fluor 
488. (C, G, K and O) Calsequestrin in C2C12 and PD50A myotubes was labelled with 
Texas Red. (A, E, I and M) Nuclei of the myotubes were labelled with 10 μg/ml of DAPI 
for three minutes. The merged images were shown in (D), (H), (L) and (P). (D; inset) Cav-1 
but not (H; inset) Cav-3 colocalises with calsequetrin in C2C12 myotubes. (P; inset) Cav-3 
but not (L; inset) Cav-1 colocalises with calsequestrin in PD50A myotubes. Arrows in the 
inset represent (D) colocalisation of Cav-1 and calsequestrin in C2C12 myotubes and (P) 
colocalisation of Cav-3 and calsequestrin in PD50A myotubes. 
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6.2.2. Dystrophic myotubes have mislocalisation of Cav-1 and Cav-3 proteins in T-tubules 
Cav-3 has been reported to express in the developing T-tubules and is absent from the mature 
T-tubules in skeletal muscles (Galbiati et al., 2001a; Parton et al., 1997). I have established 
that both Cav-1 and Cav-3 are localised to the sub-sarcolemma of E17.5 wt embryonic 
skeletal muscles showing punctate staining corresponding to the triads of the skeletal muscles 
(Figure 6.2 and 6.3). I have also established that Cav-3 can associate with Cav-1 in 4-week 
and 9-week wt skeletal muscles (Figure 5.2). To establish the localisation of Cav-1 and Cav-3 
relative to the T-tubules, I doubly labelled either Cav-1 or Cav-3 with calsequestrin (a marker 
for T-tubules; Figure 6.1) in the wt (C2C12) and dystrophin-deficient (PD50A) myotubes 
(Figure 6.4). Localisation of calsequestrin is similar in both C2C12 and PD50A myotubes 
(Figure 6.4 C, G, K and O). 
In C2C12 myotubes, Cav-1 colocalises with calsequestrin (Figure 6.4 D and H). 
Colocalisation of Cav-1 and calsequestrin in C2C12 myotubes is mainly perinuclear (Figure 
6.4 D). In PD50A myotubes, both Cav-1 and Cav-3 staining is found perinulcear and in the 
cytoplasm (Figure 6.4 B and F; compare with J and N). In contrast to C2C12 myotubes, there 
is more Cav-3 than Cav-1 colocalises with calsequestrin in PD50A myotubes (Figure 6.4 L 
and P). Perturbed localisation of Cav-1 and Cav-3 relative to calsequestrin in dystrophin-
deficient myotubes may help to explain the impaired T-tubule function in mdx reported 
previously (Lovering et al., 2009).  
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Figure 6.5 β-dystroglycan interacts with caveolin-1 in wt and mdx muscles.  
100 μg of muscle tissue extracts from wild type (wt), cav-3-/- and mdx mice were used for 
immunoprecipitation (IP). Cav-1 and associated proteins were pulled down with anti-
caveolin-1 antibody and Protein A Sepharose CL-4B beads. The muscle tissue extracts 
were from (A) 4 weeks and (B) 9 weeks old mice. 10 μg of each extract was loaded as 
input control and rabbit Igs were applied as the negative control for IP. Components pulled 
down using anti-Cav-1 antibody were detected by anti-Cav-3 and anti-β-dystroglycan 
antibodies respectively. (A) The band for β-dystroglycan is stronger in skeletal muscles of 
4-week cav-3-/- mouse. (B) The band for β-dystroglycan is stronger in skeletal muscles of 9-
week mdx mouse. 
A 
B 
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6.2.3. β-dystroglycan associates with Cav-1/Cav-3 protein complex  
β-dystroglycan of the Dystrophin-dystroglycan complex (DGC) links the intracellular actin 
filament and extracellular matrix of muscle fibres (Ervasti and Campbell, 1993). It has 
previously been suggested that Cav-1 and Cav-3 respectively regulate the mechanical 
responses of epithelial cells and myoblasts (Gervasio et al., 2011; Sinha et al., 2011). In 
skeletal muscles and smooth muscles respectively, Cav-3 and Cav-1 have been reported to 
associate with β-dystroglycan (Jung et al., 1995; Sharma et al., 2010; Sotgia et al., 2000). In 
the present study, I established that there were elevated protein levels of both Cav-1 and Cav-
3 in dystrophin-deficient myoblasts and embryos (Figure 3.15 and 4.1). I also established that 
there were more cytosolic Cav-1 and Cav-3 in dystrophin-deficient myotubes which indicate 
these caveolins are targeted to degradation (Figure 6.4). To understand whether Cav-1 
interacts with β-dystroglycan in skeletal muscles, I examined the components pulled-down by 
anti-Cav-1 antibody from skeletal muscle tissue extracts of 4-week and 9-week wt, mdx and 
cav-3-/- mice (Figure 6.5).  
β-dystroglycan associates with Cav-1 in skeletal muscles from 4-week and 9-week wt, mdx 
and cav-3-/- mice (Figure 6.5 A and B). The intensity of the band for β-dystroglycan in the 
pull-down is in proportion to that for Cav-1 (Figure 6.5 A and B). The intensities of bands for 
β-dystroglycan and Cav-1 in the pull-down are higher in cav-3-/- than in mdx in the skeletal 
muscles of 4-week-old mice while those are lower in cav-3-/- than mdx in the skeletal muscles 
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of 9-week-old mice (Figure 6.5 A and B). These data suggest that Cav-1 may be responsible 
for the degradation of β-dystroglycan in dystrophin-deficient muscles as I demonstrate that 
there was more cytosolic Cav-1 in the dystrophin-deficient myotubes (Figure 6.4). . 
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Figure 6.6 Cav-3 but not Cav-1 protein colocalises with β-dystroglycan in myotubes  
C2C12 and PD50A myoblasts were cultured in DM (DMEM+2% horse serum) for 
fourteen days to induce myotube formation. (B and J) Cav-1 protein in myotubes was 
immunolabelled with Alexa Fluor 488. (F and N) Cav-3 protein in myotubes was 
immunolabelled with Alexa Fluor 488. (C, G, K and O) β-dystroglycan in myotubes 
was co-immunolabelled with Texas Red. Merged images are presented in (D), (H), (L) 
and (P). (A, E, I and M) The nuclei were labelled with 10 μg/ml of DAPI for three 
minutes. (D, H, L and P) In non-dystrophic and dystrophin-deficient myotubes, signals 
for Cav-3/β-dystroglycan colocalisation are stronger compared to those for Cav-1/β-
dystroglycan colocalisation.  
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Cav-3 colocalises with β-dystroglycan in myotubes 
I then examined the localisation of Cav-1, Cav-3 and β-dystroglycan proteins in myotubes 
through Immunofluorescent labelling of differentiated cultured myoblasts (Figure 6.6). There 
is both sarcolemmal and cytoplasmic labelling for β-dystroglycan in C2C12 myotubes (Figure 
6.6 C and G). This evenly spread-out localisation of β-dystroglycan in C2C12 myotubes 
suggests the presence of an intact DGC and synthesis. In dystrophin-deficient (PD50A) 
myotubes, β-dystroglycan proteins are cytoplasmic, suggesting that these are targeted for 
degradation (Figure 6.6 K and O). Cav-1 does not colocalise with β-dystroglycan in C2C12 
myotubes (Figure 6.6 D). Cav-3, on the other hand, colocalises with β-dystroglycan in C2C12 
myotubes (Figure 6.6 H). However, colocalisation of Cav-3 and β-dystroglycan is cytoplasmic 
(Figure 6.6 H). This suggests that interaction between Cav-3 and β-dystroglycan occurs in a 
cellular compartment distinct from that between dystrophin and β-dystroglycan. In PD50A 
myotubes, there is extensive colocalisation of Cav-1 with β-dystroglycan (Figure 6.6 L), 
suggesting that Cav-1 may play a role in the degradation of β-dystroglycan. Furthermore, 
more β-dystroglycan colocalises with Cav-3 around the nuclei of dystrophin-deficient 
myotubes (Figure 6.6 P). Perinuclear localisation of Cav-3 and β-dystroglycan in dystrophin-
deficient myotubes suggests that these may be newly synthesized or are targeted for 
degradation.  
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Figure 6.7 Cav-3 but not Cav-1 colocalises with actin in C2C12 and PD50A myoblasts 
Localisation of actin, Cav-1 and Cav-3 was examined in C2C12 and PD50A myoblasts. 
Myoblasts were fixed with 4% PFA and immunofluorescently doubly labelled with Cav-
1/phalloidin-rhodamine or Cav-3/phalloidin-rhodamine. Cav-1 in (B) C2C12 and (J) 
PD50A myoblasts was labelled with Alexa Fluor 488. Cav-3 in (F) C2C12 and (N) PD50A 
myoblasts was labeled with Alexa Fluor 488. Actin filaments in (C and G) C2C12 and (K 
and O) PD50A myoblasts were labelled with phalloidin-rhodamine. (A, E, I and M) Nuclei 
were labelled with 10 μg/ml of DAPI for three minutes. Merged images are shown in (D), 
(H), (L) and (P). Cav-1 does not colocalise with actin filament in both (D and inset) C2C12 
and (L and inset) PD50A myoblasts. Cav-3 colocalises with actin filament in both (H and 
inset) C2C12 and (P and inset) PD50A myoblasts. Arrows in insets represent colocalisation 
of Cav-3 with actin-filament. 
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6.2.4. Cav-1 and Cav-3 colocalise with the cytoskeleton architecture (actin filaments) 
in dystrophin-deficient myoblasts and myotubes  
Dystrophin-dystroglycan complex (DGC) plays an important role in transducing the force 
between actin filament and extracellular matrix (Ervasti and Campbell, 1993). Dystrophin 
binds to cytoskeleton architecture (stress fibres), filamentous actin (F-actin) and microtubules, 
to regulate the cortical stiffness of muscle cells (Ervasti and Campbell, 1993; Pasternak et al., 
1995; Prins et al., 2009). It has been reported that dystrophin deficiency causes 
disorganisation of costameric actin which connects the sarcomere of the muscles to the cell 
membrane (Rybakova et al., 2000). In the present study, I established that there are more 
cytoplasmic Cav-1 and Cav-3 in dystrophin-deficient myotubes (Figure 6.4 and 6.6). To study 
whether Cav-1 and Cav-3 interact with actin filaments in skeletal muscles, I examined the 
localisation of Cav-1, Cav-3 and actin in wt (C2C12)/dystrophin-deficient (PD50A) 
myoblasts and myotubes (Figure 6.7 and 6.8). Actin filament is labelled with phalloidin-
rhodamine. In C2C12 myoblasts, Cav-3 but not Cav-1 colocalises with actin filaments (Figure 
6.7 D and H). In PD50A myoblasts, Cav-1 does not colocalise with actin filaments (Figure 6.7 
L). Cav-3 colocalises with actin filaments in PD50A myoblasts (Figure 6.7 P). 
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Figure 6.8 Cav-3 and Cav-1 colocalise with actin in myotubes  
C2C12 and PD50A myoblasts were cultured in DM (DMEM+2% horse serum) for fourteen 
days to induce myotube formation. (B and J) Cav-1 in myotubes was immunolabelled with 
Alexa Fluor 488. (F and N) Cav-3 in myotubes was immunolabelled with Alexa Fluor 488. 
(C, G, K and O) Myotubes were co-immunolabelled with phalloidin-rhodamine that 
recognizes actin. (A, E, I and M) Nuclei were labelled with 10 μg/ml of DAPI for three 
minutes. Merged images are presented in (D), (H), (L) and (P). (D and H) Cav-1 and Cav-3 
colocalise with actin filament in C2C12 myotubes. (L and P) Cav-1 and Cav-3 colocalise 
with actin filament in PD50A myotubes. The patterns of Cav-1, Cav-3 and actin filaments 
in PD50A myotubes are disorganized compared to C2C12 myotubes (D, H, L and P). 
Arrows in insets represent (D and L) colocalisation of Cav-1 with actin filament and (H and 
P) colocalisation of Cav-3 with actin filaments. 
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Cav-1 and Cav-3 colocalise with actin filaments in myotubes 
The actin filaments found in dystrophin-deficient (PD50A) myotubes are short and irregularly 
orientated compared to non-dystrophic myotubes (Figure 6.8 C, G, K and O). This is 
consistent with previous report that the actin filament is distorted in mdx skeletal muscle 
fibres (Rybakova et al., 2000). In C2C12 myotubes, both Cav-1 and Cav-3 colocalise with 
actin filaments (Figure 6.8 D and H). Cav-1 and Cav-3 also colocalise with actin filaments in 
PD50A myotubes (Figure 6.8 L and P). Colocalisation of Cav-1/actin filaments and Cav-
3/actin filaments in PD50A myotubes is less extensive compared to C2C12 myotubes (Figure 
6.8 D, H, L and P). The patterns of Cav-1, Cav-3 and actin-filaments localisation are 
disorganised in PD50A myotubes compared to C2C12 myotubes (Figure 6.8 D, H, L and P). 
These data suggest that, Cav-1 and Cav-3 may participate in the mechanical stress response in 
myotubes in addition to playing roles in mediating DGC associated signal transduction (refer 
to section 6.2.5). 
It has been reported that Cav-1, Cav-3 and dystrophin bind to β-dystroglycan through WW 
domains (Jung et al., 1995; Sharma et al., 2010; Sotgia et al., 2000). Dystrophin can direct 
bind to actin filaments through the actin-binding domain within the spectrin-like repeats 11-17 
(Rybakova et al., 2006). To establish whether Cav-1 and Cav-3 interact with actin filament 
with similar actin-binding domain, I aligned the amino acid sequences of Cav-1, Cav-2 and 
Cav-3 with the actin-binding domain of dystrophin (Figure 6.9).  
 267 
 
 
 
Figure 6.9 Sequence alignments of mouse caveloin-1, caveolin-2, caveolin-3 and the 
partial actin binding domain (ABD) of dystrophin.  
The amino acid residues important for WW-domain are circled in red. The transmembrane 
domain is labelled in brown. The oligomerisation domain (scaffolding domain) is labelled 
in blue. The predicted actin binding domain (ABD) is labelled in green. Both Cav-1 and 
Cav-3 have ABD with 63% similarity to dystrophin ABD. Cav-2 does not have ABD 
homologous to dystrophin ADB. Refer to section 2.12 for sequence alignment procedure.  
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I identified actin binding sequences preceding the scaffolding (oligomerisation) domain of 
Cav-1 and Cav-3 which show 63% similarity to actin-binding domain in dystrophin (Figure 
6.9; highlighted in green). Such actin-binding sequences are absent in Cav-2 (Figure 6.9). 
Together with the immunofluorescent labelling results (Figure 6.7 and 6.8), these data show 
that Cav-1 and Cav-3 can interact with actin filaments and the interaction may be mediated by 
the actin-binding sequence identified here (Figure 6.9).  
 
Cav-1 and Cav-3 do not colocalise with microtubules in myotubes 
It has been reported that the organisation of microtubules in mdx skeletal muscles is perturbed 
(Khairallah et al., 2012; Prins et al., 2009). It has also been reported that stretch induced 
injury of mdx skeletal muscles is mediated by microtubule-dependent activation of NADPH 
oxidase-dependent production of ROS (reactive oxygen species) which cause Ca2+ influx 
(Khairallah et al., 2012). To examine whether Cav-1 and Cav-3 proteins interact with 
microtubules in myotubes, I doubly labelled Cav-1 or Cav-3 with α-Tubulin, a key constituent 
of microtubules (Figure 6.10). The microtubule in the PD50A myotubes is disorganised as the 
actin filament compared to C2C12 myotubes (Figure 6.10 C, G, K and O; Figure 6.8 C, G, K 
and O), suggesting that the mechanical properties may be compromised in PD50A myotubes. 
In C2C12 and PD50A myotubes, neither Cav-1 nor Cav-3 colocalises with tubulin (Figure 
6.10 D, H, L and P).  
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Figure 6.10 Cav-3 and Cav-1 do not colocalise with α-tubulin in myotubes  
C2C12 and PD50A myoblasts were cultured in DM (DMEM+2% horse serum) for 
fourteen days to induce myotube formation. (B and J) Cav-1 in non-dystrophic 
(C2C12) and dystrophin-deficient (PD50A) myotubes was immunolabelled with 
Alexa Fluor 488. (F and N) Cav-3 in myotubes was immunolabelled with Alexa 
Fluor 488. (C, G, K and O) The myotubes were co-immunolabelled with antibody 
against α-tubulin which is recognized by secondary antibody conjugated with Texas 
Red. (K and O) Microtubules are disorganized in PD50A myotubes. Merged images 
are presented in (D), (H), (L) and (P). (A, E, I and M) Nuclei were labelled with 10 
μg/ml of DAPI for three minutes. Cav-1 and Cav-3 do not colocalise with α-tubulin.  
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Figure 6.11 Sequence alignments of mouse caveolin-1, caveolin-2, caveolin-3 and the 
microtubule binding domain (MBD) of dystrophin. 
The amino acid residues important for WW-domain are circled in red. The transmembrane 
domain is labeled in brown. The oligomerisation domain (scaffolding domain) is labeled 
in blue. Cav-1, Cav-2 and Cav-3 have no microtubule binding domain homologous to that 
of dystrophin. Refer to section 2.12 for sequence alignment procedure. 
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The sequence alignment with the microtubule binding domain of dystrophin shows that Cav-1, 
Cav-2 and Cav-3 share no homologous microtubule binding domain with dystrophin (Figure 
6.11). It also suggests that dystrophin has a direct role in regulating the organisation of 
microtubules. 
 
6.2.5. The mechanical properties of myotubes are manipulated by minidystrophin△H2-
R19, Cav-1 and Cav-3 
mdx skeletal muscles have been reported to have impaired force output (Chan et al., 2007; 
Lynch et al., 2001). An earlier study using atomic force microscope (AFM) showed that 
myotubes formed from primary myoblasts of mdx mice (2-8 week) is less stiffer than non-
dystrophic control (Pasternak et al., 1995). In the present study, I demonstrated that the 
localization of Cav-1 and Cav-3 as well as the architecture of cytoskeleton are disorganized in 
dystrophin-deficient (PD50A) myotubes (Figure 6.8 and 6.10). To study the roles of Cav-1 
and Cav-3 in the mechanical properties of dystrophin-deficient myotubes, I examined the 
force modulus of wt (C2C12) and dystrophin-deficient (dfd13, parental cell line of PD50A 
myoblasts) myotubes by AFM in collaboration with Dr. James Bowen (School of Chemical 
Engineering, the University of Birmingham). 
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Figure 6.12 Minidystrophin-eGFP expression in C2C12 and dfd13 myoblasts.  
Human minidystrophin tagged with eGFP was introduced into C2C12 and dfd13 
myoblasts (Refer to section 2.5.2 for details of minidystrophin transfection). Stable clones 
were selected with G418 for further experiments. (A, E, I and M) Nuclei were labeled 
with DAPI (10 μg/ml). (B and J) The control transfectants express eGFP. (F and J) The 
stable transfectants express eGFP-tagged human minidystrophin△H2-R19. (C, G, K and O) 
Dystrophin or minidystrophin △ H2-R19 was labelled with MANDRA1 7A10 antibody 
specific for dystrophin (labeled with Texas Red). Merged images are presented in (D), (H), 
(L) and (P). minidys: minidystrophin△H2-R19 (Chapdelaine et al., 2000).  
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6.2.5.1. Knocking down Cav-3 improves formation of dystrophin-deficient 
(PD50A) myotubes  
To study the effect of Cav-1, Cav-3 and minidystrophin△H2-R19 on the force modulus of 
myotubes, I generated the stable myoblast transfectants with overexpression of Cav-1 or Cav-
3, with knockdown of Cav-1 or Cav-3 and with eGFP-tagged human minidystrophin△H2-R19 
(Figure 6.12; stable transfectants with overexpression of Cav-1 or Cav-3 and with knockdown 
of Cav-1 or Cav-3 have been described in chapter 5; Figure 5.12). Dystrophin expresses in 
C2C12-eGFP myoblasts but not in dystrophin-deficient dfd13-eGFP myoblasts (Figure 6.12 C 
and K). The expression of minidystrophin△H2-R19–eGFP in dystrophin-deficient and non-
dystrophic stable transfectants was confirmed using an antibody specific for dystrophin 
(Figure 6.12 F, G, J and K).  
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Figure 6.13 Morphology of C2C12 and dfd13 transfectants under differentiation 
condition for ten days. 
Stable transfectants were cultured under GM (DMEM+10% FCS) and then, when cells 
reached more than 80% confluence, were shifted to DM (DMEM+2% horse serum) to 
induce myotube formation. Images were taken at day ten of differentiation induction before 
these myotubes were subjected to mechanical testing using atomic force microscope. 
Myotubes obtained from (A) C2C12-eGFP, (E) dfd13-eGFP, (I) C2C12-gfpsh and (L) 
dfd13-gfpsh transfectants were used as controls. Myotubes derived from both (B) wt 
C2C12-Cav1eGFP and (F) dystrophin-deficient dfd13-Cav1eGFP, myoblasts which were 
overexpressing Cav-1 are larger compared to eGFP control tranfectants (A) C2C12-eGFP 
and (E) dfd13-eGFP. Myoblast transfectants form smaller myotubes compared to (A and E) 
controls when Cav-3 is over-expressed [(C) C2C12-Cav3eGFP and (G) dfd13-Cav3eGFP]. 
(D) C2C12-minidys-eGFP and (H) dfd13-minidys-eGFP transfectants form larger 
myotubes compared to controls (A and E). (J) C2C12-Cav1KD and (M) dfd13-Cav1KD 
transfectants form larger myotubes compared to (I) C2C12-gfpsh and (L) dfd13-gfpsh 
controls. Myoblasts form larger myotubes compared to (I and L) controls when Cav-3 in 
knocked down [(K) C2C12-Cav3KD and (N) dfd13-Cav3KD].  
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I then differentiated these stable transfectants to obtain myotubes (Figure 6.13). C2C12-Cav-
1eGFP and dfd13-Cav-1eGFP myoblasts form larger myotubes compared to their respective 
controls (C2C12-eGFP and dfd13-eGFP) (Figure 6.13 A, B, E and F). Conversely, 
overexpression of Cav-3 (C2C12-Cav-3eGFP and dfd13-Cav-3eGFP) form myotubes with 
lower efficiency compared to their respective controls (C2C12-eGFP and dfd13eGFP) (Figure 
6.13 A, C, E and G). C2C12-minidys-eGFP and dfd13-minidys-eGFP myoblasts form larger 
myotubes compared to their respective controls (C2C12-eGFP and dfd13-eGFP) (Figure 6.13 
A, D, E and H). When Cav-1 was down-regulated in C2C12 myoblasts, the C2C12-Cav1KD 
myoblasts produce myotubes with the most mature morphology among the transfectants 
examined (Figure 6.13 J). For dfd13-Cav1KD transfectants, they are also more prone to line 
up and form myotubes compared to dfd13-dsgfpsh controls (Figure 6.13 M). Down-regulation 
of Cav-3 in myoblasts (both wt and dystrophin-deficient) induces the formation of myotubes 
compared to their respective controls (C2C12-gfpsh and dfd13-gfpsh) (Figure 6.13 I, K, L and 
N). These data suggest that elevated levels of Cav-1 and Cav-3 in dystrophin-deficient 
myoblasts impair their ability to form myotubes.  
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Figure 6.14 Mini-dystrophin increases the mechanical properties of dystrophin-
deficient myotubes. 
Stable transfectants (more than 80% confluence) were cultured in 6-cm dishes in DM 
(DMEM+2% horse serum) to induce myotube formation. Myoblasts were cultured in DM 
for 12-14 days for myotube formation. Force modulus of the myotubes was measured by 
atomic force microscope (AFM). The experiment was repeated three times with 10 cells 
analysed each time (Refer to section 2.11). (A) Minidystrophin increases the stiffness of 
dystrophin-deficient myotubes but decreases the stiffness of wt myotubes. (B) Force 
modulus distribution of minidystrophin over-expressing myotubes. The red lines represent 
means of each cell line. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
A 
B 
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6.2.5.2. Mminidystrophin△H2-R19 proteins increase the mechanical force modulus 
of dystrophin-deficient myotubes.  
Dystrophin has been reported to play a role in mediating the force exerted to muscle fibres 
(Ervasti and Campbell, 1993). Therefore I examined the force modulus of myotubes which 
overexpress a shorter dystrophin-eGFP fusion protein, minidystrophin H2△ -R19 (Figure 6.14). 
C2C12-minidys-eGFP myotubes have reduced stiffness which is only half that of C2C12-
eGFP controls (force modulus for C2C12-minidys-eGFP and C2C12-eGFP myotubes are 2.78 
± 0.59 kPa and 5.72 ± 0.54 kPa respectively) (Figure 6.14 A; p= 4.1×10-4). C2C12-minidys-
eGFP myotubes have a force modulus between 0-5 kPa while C2C12-eGFP myotubes have a 
force modulus between 1-11 kPa (Figure 6.14 B). One thing noteworthy is that while testing 
the mechanical properties of C2C12-minidys-eGFP myotubes, I noticed that the myotubes 
were less stably attached to the petri dish than control, suggesting that overexpression of 
mini-dystrophin may be detrimental to the function of non-dystrophic myotubes. The average 
force modulus of dfd13-minidys-eGFP myotubes (4.54 ± 1.36 kPa) is not significantly 
different from the dfd13-eGFP controls (2.48 ± 0.23 kPa) although the mean force modulus is 
doubled in dfd13-minidys-eGFP myotubes (Figure 6.14 A). This is because the variation is 
much greater in dfd13-minidys-eGFP myotubes. However, distribution of force modulus 
shifts from 1-6 kPa for dfd13-eGFP myotubes to 1-9 kPa for dfd13-minidys-eGFP myotubes 
(Figure 6.14 B). These data suggest that minidystrophin increases stiffness of dystrophin-
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deficient myotubes but to what extent may depend on the expression efficiency. This may also 
be because some cultures were not given enough time to differentiate, supporting the impaired 
differentiation of dystrophin-deficient myoblasts (Figure 3.2). 
  
6.2.5.3. The levels of Cav-3 affect the stiffness of dystrophin-deficient myotubes 
It has been reported that Cav-3 proteins may participate in stress response of cells (Gervasio 
et al., 2011; Sinha et al., 2011). In section 6.2.4, I established that Cav-1 and Cav-3 colocalise 
with actin filaments in dystrophin-deficient myotubes (Figure 6.8). To study the effect of Cav-
3 on the mechanical properties of myotubes, I measured the force modulus of myotubes which 
over-express Cav-3 or have down-regulation of Cav-3 (Figure 6.15 and 6.16). Although the 
average force modulus of C2C12-Cav-3eGFP myotubes (7.40 ± 0.86 kPa) is not significantly 
different from that of C2C12-eGFP myotubes, the distribution of modulus shifts from 2-8 kPa 
(C2C12-eGFP) to 2-10 kPa (C2C12-Cav-3eGFP) (Figure 6.15 A and B). Some C2C12-Cav-
3eGFP myotubes were found to have stiffness up to 22 kPa (Figure 6.15 B). The average 
force modulus of dfd13-Cav-3eGFP myotubes (2.95 ± 0.38 kPa) is not significantly different 
from that of dfd13-eGFP myotubes (Figure 6.15 A). However, the modulus distribution shifts 
downwards in dfd13-eGFP myotubes to between 1-6 kPa compared to 0-8 kPa in dfd13-Cav-
3eGFP myotubes (Figure 6.15 B). These data suggest that overexpression of Cav-3 increases 
the stiffness of non-dystrophic myotubes but has no effect on dystrophin-deficient myotubes. 
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Figure 6.15 Over-expressing Cav-3 increases the stiffness of myotubes. 
Myoblasts plated in 6-cm dishes (more than 80% confluence) were cultured in DM 
(DMEM+2% horse serum) to induce the formation of myotubes. Myotubes were 
cultured in DM for 12-14 days. Force modulus of myotubes was obtained with atomic 
force microscope (AFM). The experiment was repeated three times with 10 cells 
analysed each time. (A) Cav-3 over-expression increases the stiffness of non-dystrophic 
myotubes. (B) Distribution of force modulus shifts to higher force modulus in both 
C2C12-Cav-3eGFP and dfd13-Cav-3eGFP compared to the controls. The red lines 
represent means of each cell line (ANOVA; ＊<0.05; ＊compared to controls; n=30).  
A 
B 
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Figure 6.16 Down-regulating Cav-3 increases the mechanical properties of myotubes.  
Myoblasts plated in 6-cm dishes (more than 80% confluence) were cultured in DM 
(DMEM+2% horse serum) to induce the formation of myotubes. Myotubes were cultured 
in DM for 12-14 days. Force modulus was acquired with atomic force microscope (AFM). 
The experiment was repeated three times with 10 cells analysed each time. (A) Cav-3 
down-regulation increases the stiffness of dystrophin-deficient myotubes. (B) Force 
modulus distribution of myotubes with down-regulated Cav-3. The red lines represent 
means of each cell line. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
A 
B 
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The force modulus increases in both non-dystrophic and dystrophin-deficient myotubes with 
down-regulation of Cav-3 compared to controls (Figure 6.16). The force modulus of C2C12-
Cav3KD myotubes (3.62 ± 0.44 kPa) is comparable to C2C12-dsgfpsh controls (2.75 ± 0.15) 
(Figure 6.16 A). I have shown in chapter 3 that there are elevated levels of Cav-3 in PD50A 
myoblasts which are clonally derived from dfd13 myoblasts (Figure 3.15). The force modulus 
of dfd13-Cav-3KD myotubes (6.44 ± 0.36 kPa) increases by 60% compared to dfd13-dsgfpsh 
controls (3.94 ± 0.29 kPa) (Figure 6.16 A; p= 1.03×10-6). Force modulus shifts upwards from 
1-4 kPa in C2C12-gfpsh myotubes to 0-10 kPa in C2C12-Cav3KD myotubes and (a modest 
increase) upwards from 1-6 kPa in dfd13-gfpsh myotubes to 2-9 kPa in dfd13-Cav3 KD 
myotubes (Figure 6.16 B). These data suggest that down-regulation of Cav-3 increases the 
stiffness of dystrophin-deficient myotubes. They also suggest that Cav-3 levels are critical for 
the maintenance of mechanical properties and that this effect is not necessarily dependent on 
dystrophin. 
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Figure 6.17 Overexpressing Cav-1 in myotubes increases the stiffness of dystrophin-
deficient myotubes but impairs the stiffness of non-dystrophic myotubes.  
Myoblasts plated in 6-cm dishes (more than 80% confluence) were cultured in DM 
(DMEM+2% horse serum) for 12-14 days to induce myotube formation. The force 
modulus of myotubes was acquired with atomic force microscope (AFM). The 
experiment was repeated three times with 10 cells analysed each time. (A) Cav-1 
overexpression has opposite effects on the stiffness of dystrophin-deficient and non-
dystrophic myotubes. (B) dfd13-Cav-1eGFP myotubes have more cells with higher 
modulus compared to C2C12-Cav-1eGFP myotubes. The red lines represent means of 
each cell line. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
A 
B 
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6.2.5.4. Cav-1 is important for the maintenance of mechanical properties of 
dystrophin-deficient myotubes 
Rapid disassembly of Cav-1 in caveolae has been reported in fibroblasts in response to stretch 
or osmotic stress (Gervasio et al., 2011; Sinha et al., 2011). In chapter 3, I have shown that 
there are elevated levels of Cav-1 in PD50A myoblasts (clonally derived from dfd13 
myoblasts) (Figure 3.14). To establish whether levels of Cav-1 in myotubes affect their 
mechanical properties, I examined the effect of Cav-1 on the force modulus of non-dystrophic 
(C2C12) and dystrophin-deficient (dfd13) myotubes (Figure 6.17). The force modulus of 
C2C12-Cav1-eGFP myotubes (3.60 ± 0.43 kPa) decreases by 37% compared to C2C12-eGFP 
myotubes (Figure 6.17 A; p= 2.68×10-3). Conversely, the force modulus of dfd13-Cav1-eGFP 
myotubes (5.25 ± 0.49 kPa) increases by 2 fold compared to dfd13-eGFP myotubes (Figure 
6.17 A; p = 2.86×10-6). These data strongly suggest that the elevation of Cav-1 found in 
dystrophin-deficient myotubes has a compensatory effect on myotube function and provide 
further evidence to support the idea that the differentiation process in dystrophin-deficient 
myoblasts is significantly compromised (Figure 3.14). The force modulus of C2C12-Cav-1-
eGFP and dfd13-Cav1-eGFP myotubes falls respectively in 0-8 kPa and 2-9 kPa (Figure 6.17 
B).  
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Figure 6.18 Down-regulation of Cav-1 has reverse effects on the mechanical properties 
of non-dystrophic and dystrophin-deficient myotubes.  
Myoblasts plated in 6-cm dishes (more than 80% confluence) were shifted to DM 
(DMEM+2% horse serum) to induce the formation of myotubes. Myotubes were in DM 
for 12-14 days. Force modulus of myotubes was acquired with the atomic force 
microscope (AFM). The experiment was repeated three times with 10 cells analysed each 
time. (A) Cav-1 down-regulation impairs the stiffness of dystrophin-deficient myotubes 
but promotes the stiffness of non-dystrophic myoblasts. (B) C2C12-Cav-1KD myotubes 
have more cells with higher force modulus than dfd13-Cav1KD myotubes. The red lines 
represent means of each cell line. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
B 
A 
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Knocking down Cav-1 in myotubes has opposite effects on the stiffness of non-dystrophic and 
dystrophin-deficient myotubes (Figure 6.18). The force modulus of C2C12-Cav-1KD 
myotubes (5.48 ± 0.55 kPa) increases compared to C2C12-dsgfpsh myotubes (Figure 6.18 A; 
p=8.56×10-6). In dfd13-Cav-1KD myotubes, however, the force modulus (1.89 ± 0.26 kPa) is 
significantly reduced compared to dfd13-dsgfpsh myotubes (Figure 6.18 A; p= 1.62×10-6). 
C2C12-Cav-1KD myotubes have force modulus within 1-12 kPa while dfd13-Cav-1KD 
myotubes have force modulus within 0-5 kPa (Figure 6.18 B). These data show that increased 
levels of Cav-1 may be compensatory in dystrophin-deficient myotubes. 
 
6.2.6. The number of Cav-3(+)My32(+) fibres increases at the expense of Cav-1(+)My32(+) 
fibres in E15.5 mdx intercostal muscles  
It has been reported that intercostal and diaphragm muscles of mdx (E13.5 and E17.5) have 
perturbed localisation of fast myosin heavy chain (FMyHC or My32) (Merrick et al., 2009). 
This may correlate with force deficit of adult mdx skeletal muscles in previous report (Lynch 
et al., 2001). In addition, a recent report suggests that up-regulation of FMyHC in 
gastrocnemius muscles after exercise correlates with increase expression of Cav-3 gene (Park 
et al., 2012). We have shown in previous report that there was no difference in the number of 
FMyHC-positive (My32-positive) fibres in the E15.5 mdx intercostal (Merrick et al., 2009).  
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Figure 6.19 More colocalisation of Cav-3 and Fast MyHC in E15.5 mdx intercostal 
muscles compared to E15.5 wt. 
Paraffin wax embedded E15.5 wt and mdx embryos were consecutively sectioned in 5 μm 
thick. Sections were immunohistochemically labelled for Cav-1, Cav-3 and fast myosin 
heavy chain. Two embryos were used for each strain and six intercostal regions from each 
section were examined. Myofibres positive for Cav-1, Cav-3 and/or My32 were scored. 
(A) Representative images of wt and mdx intercostal muscles labelled with Cav-1, Cav-3 
and My32. (B) mdx intercostal muscles have comparable number of Cav-1(+) and Cav-
3(+) fibres compared to wt. (C) mdx intercostal muscles have more Cav-3(+)My32(+) 
fibres and fewer Cav-1(+)My32(+) fibres compared to wt. My32: fast myosin heavy 
chain. (ANOVA; ＊compared with mdx; ＊P< 0.05; ＊＊＊P<0.001; n=12).  
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In chapter 4, I established that there were elevated levels of Cav-1 and Cav-3 in mdx embryos 
(Figure 4.1). To investigate the relationship among Cav-1, Cav-3 and FMyHC in E15.5 mdx 
embryos, I examined the localisation of Cav-1, Cav-3 and FMyHC proteins in intercostal 
muscles of E15.5 mdx embryos (Figure 6.19).  
 The number of Cav-3-positive fibres [Cav-3(+)] in mdx intercostal muscles is not 
significantly different from that in wt (38.83 ± 3.64 for wt and 43.75 ± 4.45 for mdx) (Figure 
6.19 A and B). As reported earlier (Merrick et al., 2009), the number of My32-positive 
[My32(+)] fibres is comparable in wt and mdx intercostal muscles (53.50 ± 3.78 for wt and 
54.08 ± 4.95 for mdx) (Figure 6.19 A and B). However, the intensity of My32 staining is 
weaker in mdx compared to wt (Figure 6.19 A). The number of Cav-1-positive [Cav-1(+)] 
fibres in mdx intercostal muscles is comparable to wt counterparts (Figure 6.19 A and B). In 
wt intercostal muscles, muscle fibres positive for both Cav-3 and My32 [Cav-3(+)My32(+); 
30.44 ± 1.44% relative to My32 positive fibres] outnumbered those positive for both Cav-1 
and My32 [Cav-1(+)My32(+); 7.30 ± 0.92% relative to My32-positive fibres] (Figure 6.19 C; 
p= 1.97×10-13). Proportion of Cav-3(+)My32(+) fibres in mdx intercostal muscles increases by 
55% (47.15 ± 3.10% relative to My32-positive fibres) compared to wt intercostal muscles 
(Figure 6.19 C; p= 3.09×10-5). In addition, proportion of Cav-1(+)My32(+) fibres in mdx 
intercostal decreases by 66% compared to wt intercostal muscles (2.46 ± 0.68% relative to 
My32-positive fibres) (Figure 6.19 C; p= 2.98×10-4). There is only few proportion of muscle 
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fibers positive for Cav-1/Cav-3/My32 [Cav-1(+)Cav-3(+)My32(+)] in wt and mdx intercostal 
muscles (5.35 ± 3.10% for wt and 1.42 ± 0.59% for mdx) (Figure 6.19 C). Colocalisation of 
Cav-3 and FMyHC in both wt and mdx muscles supports a previous report that shows 
correlation between Cav-3 and FMyHC proteins in gastrocnemius muscles after exercise 
(Park et al., 2012). These data suggest that altered localisation of Cav-3/My32 proteins and 
Cav-1/My32 proteins in mdx intercostal muscles relative to wt counterparts may contribute to 
the impairment of respiratory function in mdx (Huang et al., 2011). 
 
6.2.7. Modulation of Cav-1, Cav-3 and minidystrophin△H2-R19 also affects the mechanical 
properties of myoblasts  
In chapter 3, I established that there were elevated levels of Cav-1 and Cav-3 in dystrophin-
deficient myoblasts (Figure 3.15). I also established that dystrophin expresses in C2C12 
myoblasts (Figure 6.12). To study whether modulation of Cav-1, Cav-3 and human 
minidystrophin△H2-R19 affects the mechanical properties of myoblasts, I examined the force 
modulus of stable transfectants which overexpress human minidystrophin△H2-R19, Cav-1 or 
Cav-3 and knock down Cav-1 or Cav-3. 
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Figure 6.20 Mechanical properties of non-dystrophic and dystrophin-deficient 
myoblasts. 
9×104 of myoblasts were plated in 6-cm dishes for 4 days and the mechanical properties 
of myoblasts were analysed by atomic force microscope (AFM). The experiment was 
repeated three times with 10 cells each time. (A) Force modulus of dystrophin-deficient 
(dfd13) myoblasts is impaired compared to non-dystrophic myoblasts (C2C12). (B) 
Dystrophin-deficient myoblasts have a wider distribution of force modulus compared to 
non-dystrophic myoblasts. (C) The height of dystrophin-deficient myoblasts increases 
compared to non-dystrophic myoblasts. The red lines represent means of each cell line. 
(ANOVA; ﹟<0.05; ﹟C2C12 cells compared to dfd13 cells; n=30).  
A B 
C 
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6.2.7.1. Dystrophin-deficient myoblasts have compromised mechanical properties   
In Figure 6.14, I established that the force modulus of dystrophin-deficient myotubes is 
impaired. To establish whether the mechanical property of dystrophin-deficient (dfd13) 
myoblasts is also impaired, I examined the force modulus of dfd13 and non-dystrophic 
(C2C12) myoblasts. The force modulus of dfd13 myoblasts (3.99 ± 0.37 kPa) is lower than 
C2C12 myoblasts (5.04 ± 0.53 kPa); but this is not significantly different (Figure 6.20 A; p= 
6.58×10-2). dfd13 myoblasts have a wider range of modulus distribution which is between 1-8 
kPa (Figure 6.20 B). The modulus distribution of dfd13 myoblasts falls in between 3-7 kPa 
(Figure 6.20 B). Distribution of cell height (thickness of the myoblasts; or the distance from 
the attachment to the upmost cell surface) correlates with the distribution of modulus (Figure 
6.20 C). The heights of C2C12 myoblasts fall between 0-3 μm and the heights of the majority 
of dfd13 myoblasts fall between 2-3 μm. These data suggest that the mechanical properties in 
dystrophin-deficient myoblasts have altered.   
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Figure 6.21 Mini-dystrophin increases the force modulus of non-dystrophic myoblasts.  
9×104 of myoblasts were plated in 6-cm dishes for 4 days and the force modulus was 
measured by atomic force microscope (AFM). The experiment was repeated three times 
with 10 cells each time. Myoblasts transfected with eGFP expression vehicles were used 
as controls. (A) Minidystrophin (eGFP tagged) increases the force modulus of C2C12 
myoblasts. (B) Minidystrophin expressing cells have wider distribution of force 
modulus. (C) Cell height distribution of myoblasts. The red lines represent means of 
each cell line. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
B 
C 
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6.2.7.2. Minidystrophin△H2-R19 increases the force modulus of non-dystrophic myoblasts.  
In section 6.2.5.2, I established that minidystrophin△H2-R19 increases the force modulus of 
dystrophin-deficient myotubes (Figure 6.14). I also established that dystrophin expresses in 
C2C12 myoblasts using immunofluorescent labelling (Figure 6.12). To determine the effect of 
minidystrophin△H2-R19 on the mechanical properties of myoblasts, I examined the force 
modulus of myoblasts overexpressing minidystrophin△H2-R19 (Figure 6.21). The expression 
levels of minidystrophin△H2-R19–eGFP are low in C2C12-minidys-eGFP and dfd13-minidys-
eGFP myoblasts. In addition, overexpression of minidystrophin△H2-R19 does not cause 
spontaneous differentiation in both C2C12 and dfd13 myoblasts at the cell density examined. 
The force modulus of C2C12 myoblasts expressing minidystrophin△H2-R19–eGFP (C2C12-
minidys-eGFP; 4.79 ± 0.56 kPa) increases by 1.7 fold compared to C2C12-eGFP myoblasts 
(2.78 ± 0.25 kPa) (Figure 6.21 A; p= 1.41×10-3). The force modulus of dystrophin-deficient 
myoblasts which over-express minidystrophin△H2-R19–eGFP (dfd13-minidys-eGFP; 4.36 ± 
0.43 kPa) is comparable to dfd13-eGFP myoblasts (4.83 ± 0. 34 kPa) (Figure 6.21 A). 
C2C12-eGFP myoblasts have a modulus distribution ranging between 1-4 kPa while C2C12-
minidys-eGFP myoblasts exhibited a wider modulus distribution ranging between 1-12 kPa 
(Figure 6.21 B). Both dfd13-eGFP and dfd13-minidys-eGFP myoblasts have a modulus 
distribution of within the range between 2-6 kPa (Figure 6.21 B). The modulus distribution 
shifts downwards from myoblasts to myotubes in C2C12-minidys-eGFP and upwards in 
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dfd13-minidys-eGFP (Figrue 6.14 B and 6.21 B), supporting the role of dystrophin in the 
maintenance of mechanical properties in skeletal muscles (Ervasti and Campbell, 1993).  
Distribution of cell heights falls within the range of 4-9 μm for C2C12-eGFP myoblasts, 2-8 
μm for C2C12-minidys-eGFP myoblasts, 2-7 μm for dfd13-eGFP myoblasts and 2-10 μm for 
dfd13-minidys-eGFP myoblasts (Figure 6.21 C). The cell height distribution is in reverse to 
the modulus distribution; lower range of modulus distribution in myoblasts is accompanied 
with higher range distribution of heights. The altered cell height distribution may suggest that 
the cytoskeleton architecture is re-organised in the myobalsts.  
  
6.2.7.3. Fine-tuning of Cav-3 protein levels is required to maintain the mechanical 
properties of dystrophin-deficient myoblasts 
In section 6.2.5.3, I established that knocking down Cav-3 increases the force modulus of 
dystrophin-deficient myotubes (Figure 6.16). To study whether the levels of Cav-3 also affect 
the mechanical properties of myoblasts, I examined the force modulus of myoblasts with Cav-
3 overexpression or Cav-3 knockdown (Figure 6.22). The force modulus of C2C12-Cav-
3eGFP myoblasts (5.48 ± 0.43 kPa) is 2 fold that of C2C12-eGFP myoblasts (Figure 6.22 A; 
p= 8.74×10-7). The force modulus of dfd13-Cav3-eGFP myoblasts (2.46 ± 0.20 kPa) is only 
half that of dfd13-eGFP myoblasts (Figure 6.22 A; p= 1.19×10-7). 
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Figure 6.22 Over-expressing Cav-3 impairs the mechanical properties of dystrophin-
deficient myoblasts.  
9×104 of myoblasts were plated in 6-cm dishes for 4 days. The force modulus was 
obtained by atomic force microscope (AFM). The experiment was repeated three times 
with 10 cells analysed each time. (A) Cav-3 overexpression promotes the foce modulus 
of non-dystrophic (C2C12) myoblasts but compromises that of dystrophin-deficient 
(dfd13) myoblasts. (B) The modulus distribution shifts upwards from 1-4 kPa in C2C12-
eGFP to 3-8 kPa in C2C12-Cav-3eGFP. The modulus distribution shifts downwards 
from 2-6 in dfd13-eGFP to 0-4 in dfd13-Cav-3eGFP. (C) C2C12-Cav-3eGFP myoblasts 
have higher cell height compared to C2C12-eGFP myoblasts. The red lines reprent 
means of each cell lines. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
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The modulus distribution shifts upwards from 1-4 kPa in C2C12-eGFP to 3-11 kPa in C2C12-
Cav-3-eGFP myoblasts (Figure 6.22 B). For dystrophin-deficient myoblasts, the modulus 
distribution shifts downwards from 2-6 kPa in dfd13-eGFP myoblats to 0-4 kPa in dfd13-Cav-
3-eGPF myoblasts (Figure 6.22 B).The distribution of cell heights shifts from 4-9 μm in 
C2C12-eGFP myoblasts to 3-7 μm in C2C12-Cav-3-eGFP myoblasts (Figure 6.22 C). The 
cell height distribution is between 3-5 μm in dfd13-eGFP myoblasts and between 2-7 μm in 
dfd13-Cav-3-eGFP myoblasts (Figure 6.22 C). These data suggest that Cav-3 improves the 
force modulus of non-dystrophic myoblasts while impairs that of dystrophin-deficient 
myoblasts where there is significantly elevated levels of Cav-3 (Figure 3.15).  
To further determine the effect of Cav-3 on the mechanical properties of myoblasts, I 
examined the effect of knocking down Cav-3 on the force modulus in myoblasts (Figure 6.23). 
The force modulus of C2C12-Cav3KD myoblasts (1.73 ± 0.09 kPa) is only half that of 
C2C12-dsgfpsh myoblasts (3.44 ± 0.14 kPa) (Figure 6.23 A; p= 1.74×10-12). The force 
modulus of dfd13-Cav-3KD myoblasts (2.02 ± 0.11 kPa) is reduced by 50% compared to 
dfd13-dsgfpsh myoblasts (3.95 ± 0.33 kPa) (Figure 6.23 A; p= 5.45×10-7). The modulus 
distribution shifts downwards from 1-5 kPa in C2C12-dsgfpsh myoblasts to 1-2 kPa in 
C2C121-Cav-3KD myoblasts (Figure 6.23 B). For dystrophin-deficient myoblasts, the 
modulus distribution shifts downwards from 1-5 kPa in dfd13-dsgfpsh myoblasts to 1-3 kPa 
in dfd13-Cav3KD myoblasts (Figure 6.23 B). 
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Figure 6.23 Down-regulating Cav-3 reduces the force modulus of myoblasts.  
9×104 of myoblasts were plated in 6-cm dishes for 4 days. Force modulus was 
acquired with atomic force microscope (AFM). The experiment was repeated three 
times with 10 cells analysed each time. (A) Down-regulation of Cav-3 reduces the 
stiffness of both non-dystrophic and dystrophin-deficient myoblasts. (B) The force 
modulus shifts to lower range in Cav-3 knockdown myoblasts. (C) The distribution of 
cell heights in myoblasts with Cav-3 down-regulation. The red lines represent means 
of each cell line. (ANOVA; ＊＊<0.01; ＊compared to controls; n=30).  
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The distributions of cell heights for C2C12-dsgfpsh and C2C12-Cav3KD myoblasts are 
similar, ranging from 3-7 μm (Figure 6.23 C). Similarly, the distribution of cell heights in 
dfd13-dsgfpsh myoblasts is comparable to dfd13-Cav3KD myoblasts, ranging from 2-8 μm 
(Figure 6.23 C). These suggest that down-regulation of Cav-3 in myoblasts reduces the force 
modulus of both dystrophin-deficient and non-dystrophic myoblasts. Both overexpression and 
down-regulation of Cav-3 reduce the force modulus of dystrophin-deficient myoblasts (Figure 
6.22 and 6.23 A), suggesting that a fine-tuning of Cav-3 levels in dystrophin-deficient 
myoblasts is required for the maintenance of mechanical properties in these myoblasts.  
 
6.2.7.4. Cav-1 is important for the maintenance of mechanical property of dystrophin-
deficient myoblasts 
In section 6.2.5.4, I established that Cav-1 is important for the maintenance of force modulus 
in dystrophin-deficient myotubes (Figure 6.17 and 6.18). I have shown in chapter 3 that there 
are elevated levels of Cav-1 in dystrophin-deficient myoblasts (Figure 3.14). To determine the 
function of Cav-1 in dystrophin-deficient myoblasts, I examined the effect of Cav-1 
overexpression on the force modulus of non-dystrophic (C2C12) and dystrophin-deficient 
(dfd13) myoblasts (Figure 6.24).  
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Figure 6.24 Over-expression of Cav-1 exerts no effects on mechanical properties of 
myoblasts.  
9×104 of myoblasts were plated in 6-cm dishes for 4 days. Force modulus was acquired 
with atomic force microscope (AFM). The experiment was repeated three times with 10 
cells analysed each time. (A) Cav-1 over-expression has no effects on the force modulus 
of myoblasts. (B) More dystrophin-deficient myoblasts have higher force modulus 
compared to non-dystrophic myoblast. (C) Non-dystrophic myoblasts have wider 
distribution of cell heights compared to the dystrophin-deficient myoblasts. The red 
lines represent means of each cell line. (ANOVA; n=30). 
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The stiffness of either C2C12-Cav1-eGFP or dfd13-Cav1-eGFP myoblasts is not affected by 
the elevated levels of Cav-1 in these myoblasts (Figure 6.24 A). The force modulus for 
C2C12-Cav1-eGFP and dfd13-Cav1-eGFP myoblasts is 3.03 ± 0.35 kPa and 4.82 ± 0.49 kPa 
respectively (Figure 6.24 A). The modulus distribution for C2C12-eGFP and C2C12-Cav1-
eGFP myoblasts is within the range of 1-4 kPa (Figure 6.24 B). The modulus distribution of 
dfd13-Cav-1-eGFP and dfd13-eGFP myoblasts falls within 2-6 kPa (Figure 6.24 B). The cell 
height distribution is within 2-10 μm for C2C12-Cav-1-eGFP and 2-5 μm for dfd13-Cav1-
eGFP myoblasts (Figure 6.24 C).  
I then examined the effect of Cav-1 knockdown on force modulus of myoblasts (Figure 6.25). 
The force modulus of C2C12-Cav1KD myoblasts (3.91 ± 0.36 kPa) is not significantly 
different from that of C2C12-dsgfpsh myoblasts (Figure 6.25 A). The force modulus of dfd13-
Cav1KD (3.05 ± 0.26 kPa) is reduced by 23% compared to dfd13-dsgfpsh myoblasts (Figure 
6.25 A; p= 3.56×10-2). The force modulus of C2C12-Cav1KD myoblasts falls within 1-8 kPa 
while that of dfd13-Cav1KD myoblasts falls within 0-4 kPa (Figure 6.25 B). The cell height 
distribution falls within 3-12 μm in C2C12-Cav1KD myoblasts and within 2-9 μm in dfd13-
Cav1KD myoblasts (Figure 6.25 C). These data suggest that the elevated levels of Cav-1 
found in dystrophin-deficient myoblasts (Figure 3.14) are important for the maintenance of 
force modulus in these myoblasts. 
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Figure 6.25 Down-regulating Cav-1 reduces the stiffness of dystrophin-deficient 
myoblasts.  
9×104 of myoblasts were plated in 6-cm dishes for 4 days to examine the force modulus 
with an atomic force microscope (AFM). The experiment was repeated three times with 
10 cells analysed each time. (A) Cav-1 knockdown reduces the stiffness of dystrophin-
deficient myoblasts but increases that of non-dystrophic myoblasts. (B) C2C12-Cav1KD 
myoblasts have more cells with higher stiffness compared to dfd13-Cav-1KD myoblasts. 
(C) Non-dystrophic myoblasts are thicker than the dystrophin-deficient myoblasts. The 
red lines represent means of cell lines (ANOVA; ＊<0.05; ＊compared with controls; 
n=30).  
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Figure 6.26 Down-regulation of IGF-2 reduces the force modulus of myoblasts.  
9×104 of myoblasts (C2MG-RNAi-gfp, C2MG-RNAi-igf2, C2MIG-RNAi-gfp or C2MIG-
RNAi-igf2) were plated in 6-cm dishes in GM (DMEM+10%FCS) for 4 days. Force 
modulus of myoblasts was acquired with atomic force microscope (AFM). 10 cells were 
analysed and the experiment was repeated three times. (A) Stiffness of myoblasts reduces 
with IGF-2 down-regulation. (B) IGF-2 down-regulated myoblasts have smaller force 
modulus. (C) IGF-2 down-regulated myoblasts are thicker compared to controls. The red 
lines represent means of each cell line. MIG: IGF-2 expression vehicle driven by muscle 
creatine kinase promoter; MG: control expression vehicle without IGF-2 gene; RNAi-igf2: 
short hairpin RNA expression vehicle targeting IGF-2; RNAi-gfp: control short hairpin 
RNA expression vehicle targeting GFP. (ANOVA; ＊＊<0.01;  ＊compared to gfpRNAi 
controls; n=30 for force modulus; n≧24 for cell height).  
 307 
 
 
 
 
 
A 
C 
B 
 308 
6.2.8. Modulating IGF-2 in myoblasts affects their mechanical properties 
In section 5.2.5, I established that IGF-2 suppresses Cav-1 but promotes Cav-3 expression in 
myoblasts (Figure 5.9 A, E, F and G). I also established that there were elevated levels of 
IGF-2 in dystrophin-deficient myoblasts and E17.5 mdx embryos (Figure 3.16 and 5.1). In 
addition, I established that Cav-1 and Cav-3 levels are important for the maintenance of force 
modulus in dystrophin-deficient myoblasts (section 6.2.7.3 and 6.2.7.4; Figure 6.22-6.25). To 
determine whether IGF-2 manipulation affects the mechanical properties of myoblasts, I 
examined the force modulus of myoblasts which overexpress or down-regulate IGF-2 (Figure 
6.26). 
C2C12 myoblasts stably transfected with IGF-2 expression vehicle (C2MIG-gfpRNAi 
myoblasts) have higher levels of prepro-IGF-2 (64kDa) and active IGF-2 (17kDa) compared 
to the control cell line (C2MG-gfpRNAi) (Figure 5.9). The force modulus of C2MIG-
gfpRNAi myoblasts decreases by 45% (4245.82 ± 531.87 kPa) compared to the C2MG-
gfpRNAi myoblasts (9421.36 ± 580.10 kPa) (Figure 6.26 A; p= 9.76×10-9). C2MG (C2MG-
RNAi-igf2) and C2MIG (C2MIG-RNAi-igf2) myoblasts with IGF-2 knockdown have 
reduced force modulus compared to their respective controls (C2MG-RNAi-gfp and C2MIG-
RNAi-gfp) (Figure 6.26 A). The force modulus of C2MG-RNAi-igf2 myoblasts (1774.86 ± 
143.57 kPa) decreases by 82% compared to C2MG-RNAi-gfp myoblasts (Figure 6.26 A; p= 
7.49×10-19). Similarly, the force modulus of C2MIG-RNAi-igf2 myoblasts (2217.83 ± 198.61 
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kPa) decreases by 48% compared to C2MIG-RNAi-gfp myoblasts (Figure 6.26 A; p= 
5.95×10-4). The distribution of force modulus shifts from 6-14 kPa in C2MG-RNAi-gfp 
myoblasts to 1-3 kPa in C2MG-RNAi-igf2 myoblasts (Figure 6.26 B); it also shifts from 0-7 
kPa in C2MIG-RNAi-gfp myoblasts to 0-3 kPa in C2MIG-RNAi-igf2 myoblasts (Figure 6.26 
B). C2MG-RNAi-gfp myoblasts have thickness within 2-3 μm while C2MG-RNAi-igf2 
myoblasts have thickness within 3-12 μm (Figure 6.26 C). The distribution of cell thickness 
falls within 2-7 μm for C2MIG-RNAi-gfp myoblasts and within 3-15 μm for C2MIG-RNAi-
igf2 myoblasts (Figure 6.26 C). Shifts of the cell thickness suggest remodelling of the 
cytoskeleton within these myoblasts. These data suggest that IGF-2 may play a role on 
regulating the mechanical response of myoblasts. 
 
6.3. Discussion:  
6.3.1. Perturbed localisation of Cav-1 and Cav-3 relative to calsequestrin in dystrophin-
deficient myotubes may contribute to impaired development of T-tubules  
It has been reported that Cav-3 associates with developing T-tubule in the skeletal muscles 
and T-tubules are disorganised in the skeletal muscles of cav-3-/- mice (Galbiati et al., 2001a; 
Parton et al., 1997). In section 6.2.1, I established that Cav-3 and Cav-1 localise to the 
subsarcolemma of embryonic skeletal muscles and staining appears to be punctate 
corresponding to the triads of skeletal muscles (Figure 6.2 and 6.3). Such a distribution 
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suggests that Cav-1 and Cav-3 may localise in areas such as T-tubules. The perturbed 
localisation of Cav-1 and Cav-3 in mdx embryonic skeletal muscles suggest that there may be 
impairment of T-tubules in mdx. I further established the association among Cav-1, Cav-3 and 
T-tubule in the myotubes derived from non-dystrophic (C2C12) and dystrophin-deficient 
(PD50A) myoblasts in that the relative localisation of Cav-1 and Cav-3 to T-tubules is 
perturbed in dystrophin-deficient myotubes (section 6.2.2; Figure 6.4). Calsequestrin is in the 
lumen of sarcoplasmic reticulum and associates with the ryanodine receptor at triads 
(Franzini-Armstrong et al., 1987). Colocalisation of Cav-1 with calsequestrin in the in vitro 
generated C2C12 myotubes suggests that Cav-1 and Cav-3 play different roles during T-
tubule development. This localisation is consistent with a previous report that Cav-3 but not 
Cav-1 associates with T-tubules in differentiating mouse skeletal muscles (Parton et al., 1997). 
In addition, perturbed localisation of Cav-1 and Cav-3 relative to calsequestrin in the in vitro 
dystrophin-deficient myotubes (Figure 6.4) suggests that formation of T-tubules is perturbed 
in dystrophin-deficiency. These data also suggest that the clonally derived dystrophin-
deficient myobast line (PD50A) is a good model for mdx/DMD. 
 
6.3.2. Cav-1 and Cav-3 associate with β-dystroglycan and actin filaments- a role for 
mechanical response 
Dystrophin interacts with β-dystroglycan of the dystrophin-glycoprotein complex (DGC) 
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through the WW-like domain (Jung et al., 1995). It has been reported that Cav-1 associate 
with β-dystroglycan in 293T cells which overexpress both proteins; using GST-pull down 
assay (Sotgia et al., 2000). It has also been reported that Cav-1 associates with β-dystroglycan 
in smooth muscles using immunoprecipitation (Sharma et al., 2010). In section 6.2.3, I pulled 
down Cav-1, Cav-3 and β-dystroglycan in the wt and mdx skeletal muscles, suggesting that 
these proteins may interact with each other (Figure 6.5). I established an interaction between 
Cav-1 and β-dystroglycan in the skeletal muscle tissues of Cav-3 null mice (Figure 6.5). I also 
established that both Cav-1 and Cav-3 colocalise with β-dystroglycan in dystrophin-deficient 
myoblasts (Figure 6.6). In addition, I identified that both Cav-1 and Cav-3 have conserved 
WW-like domains through which they could interact with β-dystroglycan (Figure 6.9). These 
data suggest that both Cav-1 and Cav-3 can associate with β-dystroglycan in skeletal muscles 
and that elevated levels of Cav-1 and Cav-3 in dystrophin-deficient myoblasts/myotubes may 
in part compensate for the lack of dystrophin. 
Dystrophin in skeletal muscles is considered to support cells against the mechanical stress and 
to mediate signal transduction (Ervasti and Campbell, 1993; Glass, 2005; Pasternak et al., 
1995). In addition to dystrophin, reassembly of caveolins (both Cav-1 and Cav-3) also 
contributes to the response to stretching and osmosis pressure of cells (Gervasio et al., 2011; 
Sinha et al., 2011). Remodelling of actin filaments and microtubule has also been reported to 
mediate the cortical stiffness change of muscle cells and fibres (Collinsworth et al., 2002; 
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Hofmann et al., 1997; Khairallah et al., 2012). In this chapter, I observed that organisation of 
actin filaments and microtubules is impaired in dystrophin-deficient myotubes (Figure 6.8 and 
6.10). I also found a correlation of impaired cytoskeleton architecture and impaired stiffness 
in dystrophin-deficient myoblasts and myotubes (Figure 6.14 and 6.20). I predicted that there 
is an actin binding domain adjacent to the scaffolding domain of Cav-1 and Cav-3, which is 
supported by the colocalisation of Cav-1 and Cav-3 with actin filaments in myoblasts and 
myotubes (Figure 6.7, 6.8 and 6.9). These data suggest that Cav-1, Cav-3 and actin filaments 
may play a role in regulating the mechanical properties of skeletal muscles. Over-expression 
of Cav-3 in mouse disrupts the DGC in the skeletal muscles of this mouse (Galbiati et al., 
2000). In addition, although knocking down Cav-3 in mouse does not alter the expression 
level and sarcolemmal localisation of DGC components, the localisation of the DGC within 
the cholesterol-sphingolipid raft is compromised (Galbiati et al., 2001a). The current data 
suggest that fine-tune regulation of Cav-1 and Cav-3 levels is necessary to maintain the 
proper localisation and function of DGC.  
 
6.3.3. Cav-1 and Cav-3 are important for maintenance of the mechanical properties in 
dystrophin-deficient myotubes and myoblasts 
It has been reported that overexpressing Cav-3 in mouse results in the disruption of DGC in 
skeletal muscles (Galbiati et al., 2000). In section 6.2.5.3, I established that overexpression of 
 313 
Cav-3 increases the stiffness of both wt (C2C12) and dystrophin-deficient (dfd13) myotubes 
(Figure 6.15). I also demonstrated that down-regulation of Cav-3 increases the stiffness of 
both non-dystrophic and dystrophin-deficient myotubes (Figure 6.16). This suggests that Cav-
3 is important for the maintenance of force modulus in both C2C12 and dfd13 myotubes. 
Overexpression of Cav-1 decreases the stiffness of C2C12 myotubes while down-regulation 
of Cav-1 increases that of C2C12 myotubes (Figure 6.17 and 6.18). Conversely, Cav-1 
overexpression increases the stiffness of dfd13 myotubes while Cav-1 down-regulation 
decreases that of dfd13 myotubes (Figure 6.17 and 6.18). These data suggest that Cav-1 is 
important for dystrophin-deficient but not non-dystrophic myotubes to maintain their 
mechanical properties. Together these data suggest that a fine-tune regulation of Cav-1 and 
Cav-3 levels (and perhaps the ratio between Cav-1 and Cav-3) is required to maintain 
myotube function.   
In section 6.2.7.3, I established that down-regulation of Cav-3 impairs the stiffness of C2C12 
myoblasts while overexpression of Cav-3 promotes that of C2C12 myoblasts (Figure 6.22 and 
6.23). I also established that both down-regulation and overexpression of Cav-3 impair the 
stiffness of dfd13 myoblasts (Figure 6.22 and 6.23). These data suggest that elevated levels of 
Cav-3 in dystrophin-deficient myoblasts may contribute to the mechanical response but 
impair the differentiation of these myoblasts. Although overexpression of Cav-1 has no effects 
on the stiffness of C2C12 and dfd13 myoblasts, down-regulation of Cav-1 reduces that of 
 314 
dfd13 myoblasts, suggesting a contribution of the elevated Cav-1 in dystrophin-deficient 
myoblasts to the response of mechanical stress (Figure 6.24 and 6.25).  
 
6.3.4. Cav-3 correlates with the fast myosin heavy chain (FMyHC) expression in muscles  
In 10-12 weeks old rats after exercise, myosin heavy chain (MyHC) composition changes in 
gastrocnemius muscles such that there are increased expressions of MyHCIIx (fast myosin) in 
male and MyHCIIa (fast myosin) in female (Park et al., 2012). Along with the elevated levels 
of fast MyHC isoforms, expression of Cav-3 gene also increases (Park et al., 2012). This 
suggests that levels of Cav-3 may influence the levels of fast MyHC (FMyHC) isoforms. In 
mdx mouse embryos, there is substantial excess expression of FMyHC from E15.5 to E17.5 
(Merrick et al., 2009). In chapter 4 and our previous report, we showed that there were 
elevated levels of Cav-3 in E17.5 mdx embryos (Merrick et al., 2009; Figure 4.1). In section 
6.2.6, I further established that there is correlation between Cav-3 and FMyHC proteins in 
intercostal muscles of E15.5 mdx embryos; there are more Cav-3(+)/My32(+) (FMyHC) 
muscle fibres in embryonic intercostal muscles of E15.5 mdx compared to E15.5 wt embryos 
(Figure 6.19). Conversely, there are more Cav-1(+)/My32(+) muscle fibres in the intercostal 
muscles of E15.5 wt embryos compared to E15.5 mdx embryos (Figure 6.19). These data 
suggest that modulating Cav-1 and Cav-3 expression has an influence on the mechanical 
properties of skeletal muscles.  
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6.3.5. Down-regulation and overexpression of IGF-2 impair the mechanical properties of 
myoblasts 
It has been reported that IGF-2 mediates the transition of myosin heavy chain from slow to 
fast types (Merrick et al., 2007). It has also been reported that Cav-3 expression correlates 
with FMyHC expression in skeletal muscles after exercise (Park et al., 2012). In chapter 5 and 
our unpublished data (Sarbjit Nijjar and Dr. Janet Smith), I established that there was elevated 
IGF-2 expression in mdx (Figure 5.1). I also established that IGF-2 increases levels of Cav-3 
but reduces levels of Cav-1 in myoblasts (Figure 5.9), suggesting that IGF-2 levels may 
modulate signal transduction mediated by Cav-1 and Cav-3. In section 6.2.6, I established that 
expression of Cav-3 in embryonic muscle fibres correlates with the expression of FMyHC 
(Figure 6.19). It is likely that reduction of force modulus in IGF-2 manipulated myoblasts 
observed in section 6.2.8 (Figure 6.26) is partly mediated by the effects of IGF-2 on the 
expression of Cav-1, Cav-3 and MyHC. These data suggest that signal induction changes and 
mechanical force changes are interrelated. 
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Chapter 7. Conclusion and future perspectives 
7.1. Conclusions 
Dystrophin has been demonstrated to play roles in both signal transduction (Lapidos et al., 
2004) and force transmission between extracellular matrix and intracellular actin filaments to 
mediate mechanical response of muscle/myotube (Ervasti and Campbell, 1993). However, 
these two proposed functions for dystrophin have not previously been mechanistically linked. 
I establish that there are elevated levels of Cav-1 and Cav-3 in both dystrophin-deficient 
myoblasts (Figure 3.15) and mdx mouse embryos (Figure 4.1; Merrick et al., 2009) which had 
not previously been reported. The elevated levels of Cav-1 and Cav-3 may compensate for the 
role of dystrophin in modulating mechanical stress and signal transduction in dystrophin-
deficient myoblasts (refer to section 7.1.2). Previous reports have shown that the force output 
(measured by stretching the muscle fibres) of mdx skeletal muscle fibres is compromised 
(Chan et al., 2007; Lynch et al., 2001). Using AFM, I demonstrate that the force modulus is 
impaired in both dystrophin-deficient myoblasts and myotubes (Figure 6.14 and 6.20). In 
addition, I demonstrate that modifying the levels of Cav-1 and Cav-3 affects the force 
modulus of dystrophin-deficient myotubes (Figure 6.15-6.18) and myoblasts (Figure 6.22-
6.25). I also demonstrate that modulating Cav-1 and Cav-3 levels in both dystrophin-deficient 
and nondystrophic myoblasts affects the levels of Pax7 (Figure 5.12). These data support the 
roles of dystrophin in mechanical response and signalling transduction (Ervasti and Campbell, 
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1993; Glass, 2005) but also suggest that part of its roles in signalling and mechanical response 
may be compensated by elevated levels of Cav-1 and Cav-3 in dystrophin-deficient myoblasts 
and myotubes.  
Cav-1 expresses in the kidney, gut, lung and smooth and skeletal muscles in E14.5-15.5 
mouse embryos (Kogo et al., 2004; Ramirez et al., 2002). I further demonstrate that Cav-1 
expresses in the hearts of mouse embryos at as early as E11.5 (Figure 4.5), suggesting Cav-1 
may play a role in heart development. Localisation of Cav-1 and Cav-3 to the atrial and 
ventricle trabeculae (Figure 4.2, 4.6 and 4.8) suggests that both caveolins may contribute to 
the progression of cardiomyopathy in mdx (Merrick et al., 2009). Immunohistochemical 
staining (Figure 4.3) and immunoblotting (Figure 4.1) of E17.5 mouse embryonic samples 
suggest that the levels of Cav-1 are positively regulated by Cav-3. In addition, 
immunoprecipitation using adult skeletal muscles (Figure 5.2) and immunofluorescent 
labelling of myoblasts/myotubes (Figure 5.3) demonstrate that Cav-1 and Cav-3 can form 
hetero-oligomers in skeletal muscles.  
I demonstrate that the clonally derived dystrophin-deficient (PD50A) myoblast cell line has 
attenuated levels of Pax7 (Figure 3.10), elevated levels of Cav-1 and Cav-3 (Figure 3.15) as 
well as perturbed IGF-2/p57kip2 and mTOR signalling pathways (Figure 3.16 and 3.17); all of 
which are also found in mdx mouse embryos (Figure 4.1 and 5.1). In addition, I demonstrate 
that differentiation capacity of this cell line is impaired (Figure 3.2). I also demonstrate that 
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the force modulus of the dystrophin-deficient myoblasts/myotubes is impaired compared to 
the nondystrophic control (Figure 6.14 and 6.20) which may help explain the force deficit of 
mdx skeletal muscle fibres (Chan et al., 2007; Lynch et al., 2001). These data suggest the 
dystrophin-deficient PD50A cell line is a useful in vitro model for the study of DMD. 
Although the cell lines used in this thesis are muscle stem cells with self-renewal ability, I 
found that the differentiation capacity of both wt and dystrophin-deficient myoblasts is 
affected by passage number. Therefore, it will be helpful to isolate primary muscle stem cells 
for future experiment. In addition, as muscle regeneration may also be influenced by the 
signals from the micro-environment of regenerating site, using cell culture system could not 
reconstitute the micro-environment. In vivo analysis will be necessary to investigate whether 
the results from cell culture system are also discovered in animal models.  
 
7.1.1. A novel protocol for differentiation of dystrophin-deficient myoblasts by myoblast-
osteoblast coculture 
It has been reported that there was fusion impairment in primary myoblasts isolated from 
DMD patients (Delaporte et al., 1984). In chapter 3, I demonstrate that both the number of 
myotubes and the number of myonuclei decrease in the dystrophin-deficient PD50A cell line 
(Figure 3.2). I report a novel protocol to effectively differentiate the clonally derived 
dystrophin-deficient PD50A myoblasts (Refer to section 3.2.2). This coculture protocol is 
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performed in the presence of 10% FCS which can partly mimic the physiological situations 
myoblasts encounter during regeneration. To mimic more closely the physiological situations, 
the cells must be cultured under reduced oxygen. Based upon previous literature and my data 
in the present study, I propose a possible mechanism of how osteoblast-secreted factors 
promote the myoblast differentiation (Figure 7.1):  
 
Figure 7.1 Potential mechanism of how osteoblasts promote myogenesis 
(A) Osteoblasts produce IGFs to promote the differentiation of myoblasts. (B) IGF-2 
secreted from osteoblasts induces a feedforward signalling in the recipient myoblasts 
through mTOR pathway to produce more IGF-2.  
It has been shown that primary osteoblasts secrete IGF-1 and IGF-2 in culture (McCarthy et 
al., 1992). The secreted IGF-1 and IGF-2 induce both nondystrophic and dystrophin-deficient 
A 
B 
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myoblasts in coculture to undergo myogenesis (Figure 7.1 A). When myoblasts receive 
stimulation of IGFs from osteoblasts, especially IGF-2, this IGF-2 signalling is relayed via the 
mTOR signalling pathway; this leads to the production of more IGF-2 from the myoblasts 
forming a feedforward loop (Figure 7.1 B). The IGF-2/mTOR signalling is up-regulated in 
differentiating myoblasts (both C2C12 and PD50A) treated with OCM (Figure 3.16 and 3.17). 
In addition, the differentiation capacity of dystrophin-deficient myoblasts is higher in 
coculture compared to osteoblast-conditioned medium treatment (Figure 3.3 and 3.4). These 
data suggest that dystrophin may play a role in regulating IGF-2 signalling and that cell-cell 
contact is important for differentiation of dystrophin-deficient myoblasts.    
 
7.1.2. Dual roles of caveolin-1 and caveolin-3 in muscular dystrophy 
The relationship among Cav-3, Cav-1 and dystrophin is complex; my data presented here 
suggest that the elevated protein levels of Cav-1 and Cav-3 observed in mdx and in 
dystrophin-deficient myoblasts (Figure 3.15 and 4.1) do not simply compensate or 
compromise dystrophin deficiency. Instead, elevated levels of Cav-1 and Cav-3 may 
compensate dystrophin-deficiency in terms of mechanical properties of myotubes but 
compromise differentiation of dystrophin-deficient myoblasts. In addition, the amounts of 
IGF-2, Src and pSrc pulled down along with Cav-1 are greater in adult mdx skeletal muscles 
compared to nondystrophic controls (Figure 5.6 and 5.7). These data further support the role 
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of dystrophin in signalling transduction and in mechanical response. Based upon our data in 
the present study and previous literature, I propose a negative correlation between Cav-1/Cav-
3 and Pax7 in skeletal muscles (Figure 7.2).  
 
Figure 7.2 Schematical illustration of potential roles of Cav-1, Cav-3 and Pax7 in the 
absence of dystrophin. 
In wt muscles, the DGC associates with caveolae consisting of Cav-3 and Cav-1 proteins 
(Sharma et al., 2010; Sotgia et al., 2000; Figure 6.5) which may help to recruit signalling 
molecules (such as IGF-2, Src and pSrc) to the DGC (Figure 5.6-5.8). In mdx muscles, 
dystrophin deficiency causes an elevation of both Cav-3 (Merrick et al., 2009; Vaghy et al., 
1998; Figure 3.15 and 4.1) and Cav-1 (Figure 3.15 and 4.1) protein levels to compensate for 
part of the structural and signalling functions dystrophin plays in muscles by recruiting 
signalling molecules such as IGF-2, Src and pSrc (Figure 5.6 and 5.7) and by regulating 
cytoskeleton organisation (refer to section 7.1.3). In this dystrophin-deficient context, Cav-1 
and Cav-3 are likely to play dual roles (Figure 7.2). On one hand, the elevated levels of Cav-1 
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and Cav-3 in mdx inhibit myoblast differentiation and induce cycles of regeneration and 
hyperproliferation, which contribute to the dystrophic pathology of mdx (Merrick et al., 2009; 
Niebrqj-Dobosz et al., 1997; Tanabe et al., 1986). This could be attributed to the inhibitory 
roles of Cav-1 and Cav-3 for signalling molecules such as Src since the kinase activity of Src 
is inhibited by binding to Cav-1 (Li et al., 1996a). 
In addition, I have demonstrated that attenuated Pax7 protein levels cause elevated levels of 
Cav-3 in dystrophin-deficient myoblasts which then inhibit the expression of Pax7 (Figure 
5.11 and 5.12). This may lead to the development of pathology observed in mdx embryos, 
such as reduced number of Pax7(+) cells and increase apoptosis of myoblasts since Pax7 has 
been shown to suppress myoblast apoptosis (Merrick et al., 2009; Relaix et al., 2006). On the 
other hand, increased levels of Cav-1 and Cav-3 in dystrophin deficiency may compensate for 
the poor response to mechanical stress of dystrophin-deficient myoblats and myotubes (Figure 
7.2). It is clear from these data that fine-tuning the levels of Cav-1 and Cav-3 is essential for 
normal functioning of both myoblasts and myotubes since both overexpression and down-
regulation of Cav-1 or Cav-3 impair the mechanical properties of dystrophin-deficient 
myotubes (Figure 6.15-6.18) as well as their signal transduction (and cell cycle) response 
(Figure 5.1). 
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7.1.3. Perturbed localisation of Cav-1, Cav-3 proteins is related to the impaired organisation 
of actin filaments and microtubules in dystrophin-deficient myoblasts    
It has been reported that dynamic remodelling of actin filaments and microtubules is 
responsible for the directional migration of cells such as fibroblasts and astrocytes 
(Manneville et al., 2010; Watanabe et al., 2004). In fibroblasts, this regulation requires the 
activity of Rho family GTPases, Cdc-42 and Rac1, which through the effector IQGAP1 
recruits APC (adenomatous polyposis coli) to microtubule plus end, forming a network with 
the cortical actin filaments (Watanabe et al., 2004). In myoblasts, elongation and fusion 
during differentiation require the microtubule binding protein EB-3 to regulate microtubule 
dynamics (Manneville et al., 2007). In the present study, I established that the localisation of 
Cav-1 and Cav-3 to cytoskeleton (actin filaments and microtubules) is perturbed in 
dystrophin-deficient myoblasts and myotubes (Figure 6.7, 6.8 and 6.10). I also established 
that actin filaments and microtubules in dystrophin-deficient myoblasts and myotubes are 
disorganised (Figure 6.7, 6.8 and 6.10), suggesting dystrophin is required for proper 
organisation of microtubule and actin filaments in both myoblasts and myotubes. These data 
thus also, indirectly, suggest that loss of dystrophin may have a direct impact on the 
differentiation process (refer to section 7.1.2). The perturbed organisation of cytoskeleton 
architecture in dystrophin-deficient myotubes is also consistent with previous reports showing 
the presence of disorganised actin filaments and microtubules in mdx skeletal muscle fibres in 
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vivo (Prins et al., 2009; Rybakova et al., 2000).  
It has been reported that metastasis of malignant glioma is mediated by activated Src 
(phosphorylated Src or pSrc) which modulates actin dynamics (Angers-Loustau et al., 2004). 
pSrc-mediated arrangement of the actin cytoskeleton has also been reported to regulate the 
cell migration induced by growth factor, such as epithelial growth factor (EGF) (Chang et al., 
1995; Destaing et al., 2008). The activity of Src is inhibited by binding to Cav-1 (Grande-
Garcia et al., 2007). Activated Src regulates the cytoskeleton in dynamics by increasing the 
activity of Rho GTPase and inhibiting the activity of Rac and Cdc42 (Grande-Garcia et al., 
2007). In chapter 5, I found elevated levels of Cav-1 protein in adult dystrophin-deficient 
(mdx) skeletal muscles (2.3 fold increase in 4-week and 1.6 fold increase in 9-week mdx) 
(Figure 5.2). I also established increased association of pSrc and Src with Cav-1 in 
dystrophin-deficient skeletal muscles and myoblasts (Figure 5.7 and 5.8). These data suggest 
alteration of the signalling pathway involving Src and Cav-1; the Src signalling may be 
suppressed by elevated levels of Cav-1 in dystrophin-deficient myoblasts. These may help to 
explain the disorganised actin filaments in dystrophin-deficient myoblasts (Figrue 6.7). These 
data also suggest that migration of dystrophin-deficient myoblasts may be affected. As 
migration of myoblasts to the injured site is required for muscle regeneration, cell migration 
analysis on dystrophin-deficient compared to non-dystrophic myoblasts will further provide 
information on how muscle regeneration is affected by dystrophin-deficiency. 
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7.2. Future work 
I demonstrate that a clonally derived dystrophin-deficient PD50A myoblast cell line is a 
useful in vitro model to study the pathology and therapy of DMD. Transcription activator-like 
effector nucleases (TALENs) can be used to specifically remove the mutation sites on 
dystrophin (Ousterout et al., 2013) which can then be corrected by nonhomologus end-joining 
or homologous recombination directed by exogenous DNA fragments. The PD50A cell line is 
a useful model for this therapy as they have lacZ reporter and have been demonstrated to be 
able to integrate into the skeletal muscle of mdx mouse (Smith and Schofield, 1997). 
An unexpected and also a key finding in sections 3.2.7 and 4.2.1 (Figure 3.14 and 4.1) was an 
increase of both Cav-1α and β in dystrophin-deficient myoblasts and mdx mouse embryos. 
Since Cav-1α activity depends on phosphorylation of tyrosine 14 by Src and since the 
majority of Cav-1 data in the present report is total Cav-1, it will be useful to introduce Cav-
1α with mutations at tyrosine 14 into myoblasts because Cav-1β lacks the first 31 amino acids 
(includes Y14) that are present in Cav-1α (Scherer et al., 1995). Further investigation of 
differentiation capacity, the mechanical properties and the apoptosis of myoblasts with 
mutated Cav-1 proteins will give better understanding of the role of Cav-1α in myoblasts. To 
this end I have isolated stable myoblast transfectants (both non-dystrophic and dystrophin-
deficient) which respectively, overexpress or down-regulate Cav-1 (section 5.2.7). Analysis 
and characterisation of their properties, including correlations between Cav-3 and Pax7, will 
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help understand in more detail the role of elevated Cav-1 in dystrophin-deficient myoblasts 
and myotubes. 
A novel function of Cav-1 as a secreted factor has been reported in patients with prostate 
cancer and analysed with prostate cancer cell line (Tahir et al., 2001). The secretory role of 
Cav-1 was first suggested in pancreatic exocrine cells from which Cav-1 is secreted in a 
complex with lipid (Liu et al., 1999). When secreted from the prostate cancer cells, Cav-1 acts 
as a paracrine factor that promotes survival of cancer cells and contributes to metastasis of 
prostate cancer cells (Tahir et al., 2001; Tahir et al., 2008; Watanabe et al., 2009). It has also 
been reported that in skeletal muscles Cav-1 is not restricted to the sarcolemma; instead Cav-1 
is also found in the cytoplasm (Li et al., 2001). In the present study, I demonstrate that there 
are elevated levels of Cav-1 protein in dystrophin-deficient myoblasts and embryos (Figure 
3.15 and 4.1) and cytosolic localisation of Cav-1 and Cav-3 in dystrophin-deficient myoblasts 
and myotubes (Figure 5.3). Investigating whether Cav-1 could be secreted in mdx skeletal 
muscle and the role of the secreted Cav-1 (e.g. effect on the survival and migration of 
myoblasts) will be beneficial to the understanding of mdx pathogenesis.   
Somatic cell reprogramming makes it possible to generate patient-specific stem cells which 
may be useful for therapeutic application. To obtain myogenic lineages from iPS cells and 
isolate cells which can be utilized in stem cell transplantation for muscular dystrophy, I 
generated mouse iPS cells expressing a pluripotent reporter (Oct-4) (section 2.1.4, Figure 2.1; 
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section 2.5.2, Figure 2.4). Future work with this iPS cell line could include the forced 
commitment of these iPS cells to a muscle stem cell lineage by introducing Pax7 expression 
plasmid (the mCherry construct generated in this thesis work). By doing so the effect of Pax7 
over-expression will also be examined and this will add to the understanding of whether Pax7 
is a critical transcription factor for myogenic lineage determination. These iPS cells could be 
used to generate Pax7(+) cells which could be used as a source for therapeutic transplantation. 
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APPENDIX 1. Material suppliers
AB Applied Biosystems (Life Technologies Ltd, 3 
Fountain Drive, Inchinnan Business Park, 
Paisley, PA4 9RF, UK) 
Veriti® 96-Well Thermal Cycler  
Alta Bioscience Ltd (AltaBioscience, Building 
Y10, University of Birmingham, Edgbaston, 
Birmingham, B15 2TT, UK) 
Pax7-His/FLAG (Forward): 
5'CTACCTCGAGCATCACCATCCACCGGTACG
ATTATGATATTC 3' 
Pax7-His/FLAG (Reverse-insert C before AgeI site, 
ATC1554GGT): 
5'GAATATCATAATCGTACCGGTGGATGGTGA
TGCTCGAGGTAG 3’ 
Amersham Pharmacia Biotech UK Ltd 
(Amersham Place, Little Chalfont, 
Buckinghamshire, HP7 9NA, UK) 
Anti-Sheep/goat Ig biotinylated whole antibody 
from donkey (Cat No. RPN1025V; Lot No. 306822) 
Anti-Rabbit Ig biotinylated species specific F(ab)2 
fragment from Donkey (Cat No. RPN1064; Batch: 
46)  
Biotinylated Anti-mouse IgG (whole antibody from 
goat) (Cat No. RPN1177; Lot No. 322761) 
HybondTMECLTMNitrocellulose Membrane (Cat 
NO. RPN203D; Lot No. 1899/66/0407)  
Protein A Sepharose CL-4B beads (Cat No. 
17078001; Lot No. 10043746) 
Beckman Coulter (UK) Ltd ( Oakley Court, 
Kingsmead Business Park, London Road, High 
Wycombe HP11 1JU, UK) 
AvantiTM 30 centrifuge 
Becton Dickinson UK Ltd (The Danby Building, 
Edmund Halley Road, Oxford Science Park, 
Oxford, Oxfordshire OX4 4DQ) 
Purified mouse anti-Caveolin 3 monoclonal 
Antibody (Cat No. 610420; Lot No. 59391) 
Rabbit polyclonal anti-Caveolin 1 Antibody (Cat 
No. 610060)   
Becton Dickinson Labware (Becton Dickinson 
Company, Frankline Lakes, NJ, USA) 
15 ml falcon tubes BLUEMAX
TM Polypropylene 
Conical tube (Cat No. 35-2096) 
50 ml falcon tubes BLUEMAX
TM Polypropylene 
Conical tube (Cat No. 35-2070) 
Bio-Rad Laboratories Ltd (Bio-Rad House, 
Maxted Road, Hemel Hempstead, Hertfordshire, 
HP2 7DX, UK) 
Mini Protean II Electrophoresis Cell (Cat No. 165-
3301) 
Mini Trans-blot blotting Cell (Cat No. 170-3930) 
BIOLINE (Unit 16, The Edge Business Centre, 
Humber Road, London NW2 6EW, UK) 
Agarose molecular grade (Cat No. BIO41025; Lot 
No. AG5109K) 
Carbolite (Parsons Lane, Hope, Hope Valley, S33 
6RB, UK) 
Carbolite Incubator 
Cell Signalling (Distributed by New England 
BioLab in the UK) 
mTOR (7C10) rabbit monoclonal antibody (Cat No. 
2983P) 
Phospho-mTOR (ser2448) rabbit monoclonal 
antibody (Cat No. 5536P; Lot No. 1) 
Rabbit anti-caspase 3 antibody (Cat No. 9662S) 
Rabbit anti-mouse Akt antibody (recognize Akt1, 
Akt2 and Akt3) (Cat No. 9272) 
Rabbit anti-mouse phospho-Akt (Ser473) antibody 
(recognize Akt1, Akt2, Akt3) (Cat No. 9277) 
Rabbit anti-Phospho-Src Family (Tyr416) antibody 
(Cat No. 2101L) 
Src (L4A1) Mouse monoclonal antibody (Cat No. 
2110S) 
ChromoTek GmbH (Am Klopferspitz 19, 82152 
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Planegg-Martinsried, Germany) 
GFP-Trap®A (Cat No. gta-20) 
 Dako UK Ltd (Dako UK Ltd, Cambridge House, 
St. Thomas Place, Ely Cambridgeshire CB7 4EX)  
Dakocytomation Fluorescence Mounting Medium 
(Cat No. S3023; Lot No. 301514EFG 010104) 
DAB chromogen (Cat No. S3000; Lot No. 
10032888) 
Rabbit serum (normal) (Cat No. X0902; Lot No. 
087 (101)) 
Developmental Studies Hybridoma Bank (DSHB, 
Department of Biological Science, University of 
Iowa, 007 Biology Building East, Iowa City, 
IA52242, USA) 
Anti-MF20, Mouse Monoclonal 
Mouse anti-mannose 6-phosphate / IGF II receptor, 
cation-independent (86F7) 
Mouse monoclonal anti-Pax7 antibody 
Eppendorf (Eppendorf UK Ltd, Endurance 
House, Vision Park, Chivers Way, Histon, 
Cambridge CB24 9ZR, UK) 
Thermomixer 5436 
Fisher Scientific UK Ltd (Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG, UK) 
Boric Acid (Cat No. B380053; Batch: 0760056) 
Chromatography paper 460* 570 mm (Cat No. 
FB59515) 
Diaminoethanetetra-acetate acid disodium salt 
(EDTA) (Cat No. D070053; Batch: 0935537) 
DyLight(TM) 800 Conjugates-Streptavidin Thermo 
Scientific Pierce (Cat NO. PN21851; Lot NO. 
KG137713) 
Ethanol, Class 3, analytical reagent grade (Cat No. 
E/0650DF/17) 
Glycine (Cat No. G/P460/53) 
Haemocytometer (Cat No. 0630030; Lot No. 18801) 
Methanol (Cat No. M/4000/PK4; Batch No. 
0927206) 
Nitric acid S.G. 1.42 (70%) (Cat No. N/2300/PB17; 
Batch No. 0129758) 
Pelletised Paraffin Wax (Cat No. 9774006) 
Shandon* Peel-A-Way Disposable Embedding 
Molds (Cat No. 2219) 
Sodium Chloride (Cat No. 102415K; Batch No. 
K3113723 236) 
Tri-Sodium Citrate (Cat No. S332053; Batch: 
0552934) 
Sodium dodecyl sulphate (SDS; Cat No. S/5200/53; 
Batch No.0398855) 
2-propanol (iosopropanal; Cat No. P/7490/17; 
Batch No. 0380943) 
TRIS (hydroxylmethyl methylamine; Cat 
No.T/P630/53) 
Xylene (Cat No. 1330207) 
Geneflow Ltd (Fradley Business Centre, 
WoodEnd Lane, Fradley, Staffordshire, WS13 
8NF, UK) 
Protein and sequencing, Electrophoresis Grade (Cat 
No. EC-890; Lot No.02-07-16) Protogel, 30% 
Acrylaminde, 0.8% (w/V) Bis-Acrylaminde Stock 
Solution (37.5:1) 
GMBH & CO. KG (Janke & Kunkel-Str. 10, 
79219 Staufen, Germany / Deutschland) 
IKA®KS 130 basic orbital shaker  
Grants Instruments (Cambridge) Ltd, UK (29 
Station Road, Shepreth, Cambridgeshire, SG8 
6GB, UK) 
Water Bath 
Invitrogen Ltd (Inchinnan Business Park, 3 
Fountain Drive, Paisley, PA4 9RF, UK) 
Alexa Fluor® 488 F(ab')2 fragment of goat anti-
mouse IgG (H+L)(Cat No. A11017; Lot No. 
991633) 
Alexa Fluor® 488 F(ab')2 fragment of goat anti-
rabbit IgG (H+L)(Cat No. A11070; Lot No. 
1040038) 
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Dulbecco's Modified Eagle Medium (1×) without 
Glutamine (Cat No. 21969-035; Lot No. 670323) 
Dulbecco's MEN/Nutrient mix F-12 (Cat No. 
21331-046; Lot No. 652053) 
Ethdium Bromide Solution (Cat No. 15585011; Lot 
No. KH6901) 
Geneticin (G418 sulphate)(Cat No. 11811-031; Lot 
No. 3068712) 
GIBCO BRL 58 horizontal electrophoresis 
apparatus 
Kanamycine sulfate (Cat No. 11815-024; Lot No. 
3053853)   
KnockoutTM DMEM (Cat No. 10829; Lot No. 
701212) 
KNOCKOUTTM Serum Replacer (Cat No. 10828; 
Lot No. 637873) 
LipofectamineTM 2000 (Cat No. 11668-027; Lot No. 
867692) 
LipofectamineTM LTX & Plus Reagent (Cat No. 
A12621) 
Luria Agar (Cat No. 12945028; Lot No. 80235043)  
Luria Bruth Base (Cat No. 12795027; Lot No. 
80245231)) 
MEM Non-Essential Amino Acids 100× (Cat No. 
11140; Lot No. 709172) 
2-Mercaptoethanol (50MM) (Cat No. 31350010; 
Lot No. 26F0140) 
Jenkons (Scientific) Ltd (Cherrycourt Way, 
Stanbridge Road, Leighton Buzzard, 
Bedforshire, LU7 4UA, UK) 
Uvitec, UV light box 
JPK Instruments Limited (Unit 7223, 
Cambridge Research Park, Waterbeach, 
Cambridge CB25 9TL, UK) 
NanoWizard II atomic force microscope 
Kendro Laboratory Products Plc (Stortford Hall 
Park, Bishop's Sortford, Hertfordshire, CM23 
5GZ, UK) 
Labofuge 300 Heraeus centrifuge 
Heraeus Incubator (D-6450) 
Leica Microsystems Ltd, UK (Davy Avenue, 
Knowlhill, Milton Keynes, MK5 8LB, UK) 
Inverted microscope-Leica DMIRB 
Reichert-Jung 1150/Autocut microtome 
LI-COR Biotechnology - UK Ltd (St. John's 
Innovation Centre, Cowley Road, Cambridge, 
CB4 0WS, UK) 
Odyssey® infrared imaging system 
Odyssey anti-mouse IRDye® 680 (Cat No. 926-
32220; Lot No. B80908_011) 
Odyssey anti-rabbit IRDye® 680 (Cat No. 926-
32221; Lot No. B80814-01) 
Marval [Premier International Foods (UK) Ltd, 
Bridge Road, Long Sutton, Spalding, Lincs PE12 
9 EQ, UK] 
Non-fat milk 
Meyer Prestige Ltd. (Meyer Group Ltd., Wirral 
International Business Park, Riverview Road, 
Bromborough, Wirral, CH62 3RH, England) 
Smart Plus Pressure Cooker 
Millipore Ltd (Millipore Ltd, Suite 3 & 5, 
Building 6, Croxley Green Business Park, 
Watford, WD18 8YH, UK) 
ESGRO® (LIF) (Cat No. ESG1107; Lot No. 
ME9BN6983) 
Molecular Device Ltd (135 Wharfedale Road, 
Winnersh Triangle, Winersh, Wokingham, RG41 
5RB, UK) 
Emax microplate reader 
NanoWorld AG (Rue Jaquet-Droz 1, CH-2002 
Neuchâtel, Switzerland ) 
Rectangular Si cantilevers type CONT-L 
New Brunswick Scientific (Eppendorf UK Ltd, 
Endurance House, Vision Park, Chivers Way, 
Histon, Cambridge CB24 9ZR, UK) 
INNOVATM 433 refrigerated incubator shaker 
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New England BioLabs (UK) Ltd (75/77 Knowl 
Piece, Wilbury Way, Hitchin, Herts. SG4 0TY, 
UK) 
AgeI (Cat No. Ro552S; Lot No. 36) 
AseI (Cat No. R0526S; Lot No. 6) 
BspEI (Cat No. R0540S; Lot No. 4) 
EcoRI (Cat No. 101S; Lot No. 28) 
Gel loading Dye Blue 6x (Cat No. B7021S; Lot No. 
0010912) 
NEBuffer 1 (Cat No. B7001S; Lot No. 0503, 598) 
NEBuffer 3 (Cat No. B7003S; Lot No. 0902, 0303) 
NotI (Cat No. R0189S; Lot No. 50) 
Prestained Protein Marker, Broad Range (7-175 
kDa) (Cat No. P7708S; Lot NO. 0520807) 
T4 DNA ligase (Cat No. M0202S; Lot No. 75) 
10×Buffer for T4 DNA ligase (Cat No. B02025; 
Lot No. 0303A) 
Nikon UK Limited (380 Richmond Road, 
Kingston Upon Thames, Surrey, KT2 5PR, UK) 
Eclipse Ti inverted microscope 
Nunc Plasticware (Life Technologies Ltd., 3 
Fountain Drive, Ichinnan Business Park, Paisley, 
PA4 9RF, UK) 
CryoTubeTM vials (Cat No. 375353) 
Large culture flasks (175 cm2) (Cat No. 147589A) 
Medium culture flasks (75 cm2) (Cat No. 156462) 
Small culture flasks (25 cm2) (Cat No. 156367) 
30 mm polystyrene petri dish (Cat No. 150318; Lot 
No. 116031) 
60 mm polystyrene petri dish (Cat No. 150288; Lot 
No. 068689) 
10 cm polystyrene petri dish (Cat No. 150350; Lot 
No. 104912) 
24-well plates (Cat No. 143982A) 
48-well plates (Cat No. 150787) 
96-well plates (Cat No. 167008A) 
PALL Life Sciences (Europa House, Havant 
Street, Portsmouth, Hampshire, PO1 3PD, UK) 
Sterile Acrodisc® Syringe 32 mm Filters with 0.45 
μm Supor® Membrane (Cat No. 4654; Lot No. 
101084) 
Panasonic (Panasonic House, Willoughby Road, 
Bracknell, Berkshire RG12 8FP, UK) 
microwave 
PerkinElmer (PerkinElmer, Saxon Way Bar Hill, 
Cambridge, Cambridgeshire, CB23 8SL, UK) 
Streptavidin-Texas Red® (Cat No. NEL721001EA; 
Lot No. 552578) 
TSA™ Biotin System, for 50-150 Slides (Cat No. 
NEL700A00 1KL; Lot No. 596949) 
Pierce (Perbio Sciences UK Ltd, Century House, 
High Street, Tattenhall, Cheshire, CH3 9RJ, UK) 
Albumin Standard Samples (Cat No. 23209; Lot No. 
EB61479) 
Coomassie® Protein Assay Reagent (Cat No. 
1856209; Lot No. EC60857) 
Polysciences Inc. (Polysciences Europe GmbH, 
Handelsstrasse 3, D-69214 Eppelheim, Germany) 
Peel-A-Way® Embedding Mold (Square - S22) 
(Cat No. 18646A-1) 
Promega (Delta House, Southampton Science 
Park, Southampton SO16 7NS, UK) 
Pfu DNA polymerase (Cat No. M7741; Lot No. 
279515)  
QIAGEN (QIAGEN House, Fleming Way, 
Crawley, West Sussex, RH10 9NQ) 
dNTP Mix (10mM each) (Cat No. 201900; Lot No. 
124114769)  
QIAprep Spin Miniprep Kit (Cat No. 27104) 
QIAquick® Gel Extraction Kit (Cat No. 28704) 
QIAfilter Plasmid Midi Kit (Cat No. 12243) 
R & D systems (R&D Systems Europe Ltd, 19 
Barton Lane, Abingdon Science Park, Abingdon, 
OX14 3NB, UK) 
Recombinant Human IGF-I (Cat No. 291-G1-200) 
Recombinant Mouse IGF-II (Cat No. 792-MG-050; 
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Lot No. DFK1709031) 
Roche Diagnostic Ltd (Bell Lane, Lewes, East 
Sussex, BN7 1LG, UK) 
Protease Inhibitor Cocktail tablets (Cat No. 
1836153) 
Santa Cruz Biotechnology, Inc. (Bergheimer Str. 
89-2, 69115 Heidelberg, Germany) 
Anti-ERK1(K-23) rabbit polyclonal antibody (Cat 
No. sc-94; Lot No. 0609) 
Anti-p-ERK (E-4) mouse monoclonal antibody (Cat 
No. sc-7383; Lot No. 0910) 
Goat anti-Kip2 p57 (M-20) (Cat No. sc-1039; Lot 
No. B169, G226) 
Sanyo (1-300 Applewood Cres. Concord. Ont, 
L4K 5C7, UK) 
Soni-pre150 machine (Sonicator) 
SARSTEDT (SARSTEDT Ltd, 68 Boston Road, 
Beaumont Leys, Leicester LE4 1AW, UK) 
Cell scraper (Cat No. 83.1830;Lot no. 7253400) 
School of Bioscience Stores, Birmingham 
University, UK (University of Birmingham, 
Edgbaston, Birmingham, B15 2TT, UK) 
Foil, 450 Caterwrap (Cat No. FOI11CC/WRA1) 
5 ml bijoux tube 
SCHOTT UK Ltd. ( Drummond Road, ST16 
3EL Stafford, UK) 
LED light source 
Sigma-Aldrich (Sigma-Aldrich Company Ltd, 
Fancy Road, Poole, Dorest, BD12 4QH, UK) 
Ammonium Persulfate (APS; Cat No. A3678; Lot 
No.022K1258 ) 
Ampicillin (Cat No. A9518; Lot No. 062K0843) 
Bovine Serum Albumin (BSA) Fraction V (Cat No. 
A3059; Lot No. 086K0674)  
4’,6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) (Cat NO. D8417; Lot No. 123K4013) 
Dimethyl Sulfoxide (DMSO)(Cat No. D2650; Lot 
No. 53K2342) 
Dithiothreitol (DTT) (Cat No. D9779; Lot No. 
072K0916)  
Fetal Bovine Serum (FBS)-Heat inactivated (Cat 
No. F9665; Lot No. 91K3357) 
Gelatin (Cat No. G1890; Lot No. 27H0557) 
L-Glutamine 200 mM (Cat No. G7513; Lot No. 
103K2385) 
Glycerol (Cat No. G5516; Lot No. 0773DD) 
HEPES (Cat No. H4034; Lot No. 062K5438) 
Horse Serum (HS)-Heat inactivated (Cat No. 
H1138; Lot No. 061K8408) 
Hydrogen Peroxide Solution (Cat No. H1009; Lot 
No. S86968-419) 
IGEPAL® CA-630 (Octylphenyl-polyethylene 
glycol) (Cat No. I8896; Lot No. 048K0712) 
Insulin-like Growth Factor-II (IGF-II) human 
recombinant, expressed in Escherichia coli (≧97%; 
HPLC and SDS-PAGE), cell culture tested (Cat No. 
I-2526; Lot No. 082K0708) 
Leishman’s Stain (Eosin-polychrome methylene 
blue) (Cat No, L-6254; Lot No. 93H3690) 
2-Mercaptoethanol (Cat No. M7522-100ML; Lot 
No. 01496DK) 
Minimum Essential Medium Eagle (MEM)-Alpha 
Modification (1×) (Cat No. M4526; Lot No. 
127K2413) 
Mitomycin C (Cat No. M4728-2MG; Lot No. 
01M0665) 
Monoclonal Anti-α-Tubulin antibody produced in 
mouse (Cat No. T9026; Lot No. 096K4779) 
Monoclonal Anti-β-actin antibody produced in 
mouse (Cat No. A2228; Lot No. 129K4753) 
Mouse monoclonal anti-skeletal myosin (fast) clone 
MY-32 (Cat No. M4276; Lot No. 050M4805) 
Mitomycin C (Cat No. M4287-2MG; Lot No. 
o1M0665) 
t-octylpheoxypolyethoxyethanol (Triton X-100) 
(Cat No.T9284; Lot No.61K0126) 
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Paraformaldehyde (Cat No. 76240; Lot No. 
1065696 12104020) 
Penicillin/Streptomycin solution (100×), cell 
culture tested (Cat No. P0781) 
Phalloidin, Tetramethylrhodamine B isothiocyanate 
(Cat No. P1951) 
Polyethylene glycol MW 8,000 (Cat No. 81268; 
Lot No. 2034733) 
Polyethylene glycol sorbitan monolaurate 
(Tween®20) (Cat No. P7949; Lot No. 028K01853) 
Potassium Chloride KCl (Cat No. P9333; Lot No. 
7447407) 
Sodium phosphate Dibasic Na2HPO4 (Cat No. 
S7907; Lot No. 7558794) 
Sodium phosphate Monobasic NaH2PO4 (Cat No. 
S8282; Lot No. 7558807) 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED;Cat No. T9281; Lot No.38H0438 ) 
Trypsin (porcine trypsin in 0.2% EDTA‧4Na, 
0.9% Sodium Chloride (Cat No. T4174))  
Sony (Pipersway, Thatcham, Berkshire RG19 
4LZ, UK) 
Gel imaging camera, video graphic printer (UP-
860LE) 
Spectronic Camspec Ltd (Tudor House, Barley 
Hill Road, Garforth, Leeds LS25 1DX, UK) 
Camspec M501 Single Beam Scanning UV/Visible 
Spectrophotometer 
Stuart Scientific Co. Ltd (Holmethorpe 
Industrial Estate, Redhill, Surrey RH1 2NB, UK) 
Gyro-Rocker Shaker (STR9) 
Hybridization Oven/Shaker (SI 20H) 
Swann-Morton Ltd (Swann-Morton Limited, 
Owlerton Green, Sheffield, S6 2BJ, UK) 
Sterile Disposable Scalpel (Cat No.0508; Lot No. 
6750310) 
Terumo UK Ltd (3 Unily Grove, Off School 
Lane, Knowsley Industrials Park, Knowsley, 
Merseyside, L34 9GI, UK) 
18 gauge needles (1.2×40 mm) (Cat No. NN-1838R) 
Upstate Biotechnology, Inc (1100 Winter Street 
Suite 2300, Waltham, Massachusetts 02451, USA) 
Mouse monoclonal anti-IGF2 antibody (Cat No. 
05-166; Lot No. 21240) 
VECTOR LABORATORIES LTD. (VECTOR 
LABORATORIES LTD. 3 Accent Park, 
Bakewell Road, Orton Southgate, Peterborough, 
PE2 6XS, United Kingdom) 
ImmEdge Hydrophobic Barrier Pen (Cat No. H-
4000) 
VWR International, Formerly “BDH” (Merk 
Ltd, Hunter Boulevard, Magna Park, 
Lutterworth, Leics, LE17 4XN, UK) 
Coverglass- 24 mm × 50 mm (Cat No. 406-0188-82) 
Glass Coverslips-9mm2 (Cat No. 631-0169) 
DePex mounting medium (Cat No. 361252B; Lot 
No. HX896062)  
Hematoxylin solution modified acc. to Gill III (Cat 
No. 1.05174.0500) 
Magnesium Chloride 6-hydrate (Cat No. 101494V; 
Lot No. A407233311) 
Sodium Azide (Cat No.10369 2K; Lot No. 
K23188106693)  
Sodium Hypochlorite (Cat No. 301696S;Batch No. 
08K270507) 
Superfrost Plus Microscope Slides (Cat No. 
6310108 ; Lot No. 0201119)  
The Wolfson Centre for Inherited 
Neuromuscular Disease (CIND) 
Mouse anti-β-dystroglycan antibody (MANDAG1 
7A11) (Pereboev et al., 2001) 
Mouse anti-dystrophin antibody (MANDRA1 7A10) 
(Morris et al., 1998; Nguyen et al., 1992) 
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APPENDIX 2. Recipes 
Cell culture medium and buffer preparation: 
In-vitro cell culture: 
C2C12 cell culture medium  
DMEM + 10% FCS + 1% P/S + 1%L-Glutamine 
450 ml Dulbecco's Modified Eagles Medium 
(DMEM; Invitrogen Ltd, UK), 
50 ml Fetal Bovine Serum (FCS) Batch tested 
(Sigma-Aldrich, UK), 
5 ml L-Glutamine (Sigma-Aldrich, UK), 
5 ml Penicillin/Streptomycin (P/S; Sigma-Aldrich, 
UK) 
PD50A cell culture medium: 
DMEM-F12+ 10% FCS + 1% P/S + 1%L-Glutamine 
450 ml Dulbecco's Modified Eagles/Nutrient mix F-
12 Medium (DMEM-F12; Invitrogen Ltd, UK), 
50 ml Foetal Bovine Serum, 
5 ml L-Glutamine, 
5 ml Penicillin/Streptomycin 
MC3T3-E1 cell culture medium: 
alpha-MEM + 10% FCS + 1% P/S + 1% L-
Glutamine 
450 ml Minimum Essential Medium Alpha 
Modification (Alpha-MEM; Sigma Aldrich, UK),  
50 ml Foetal Bovine Serum, 
5 ml L-Glutamine,  
5 ml penicillin/Streptomycin 
Differentiation medium for coculture experiment: 
DMEM + 2% HS + 1% P/S + 1% L-Glutamine 
450 ml DMEM 
10 ml Horse serum (HS batched tested; Sigma-
Aldrich, UK), 
5 ml L-Glutamine,  
5 ml penicillin/Streptomycin  
iPS (induced pluripotent stem) cell culture 
medium  
KO-MEM+ KO-SR+ FCS + MEM NEAA+ 2-ME 
400 ml Knock-out Minimum Essential Medium (KO-
MEM; Invitrogen Ltd, UK),  
50 ml Knock-out Serum Replacer (KO-SR; 
Invitrogen Ltd, UK), 
50 ml Fetal Bovine Serum (FCS) Batch tested  
5 ml MEM Non-essential amino acid (MEM NEAA; 
Invitrogen Ltd, UK), 
3.5 μl 2-mercaptoethanol (2-ME; Sigma-Aldrich, 
UK), 
5 ml Penicillin/Streptomycin, 
The medium was filtered with 0.45 μm filter and 
stored at 4°C 
5 μl LIF (ESGRO®-LIF)/ 500 ml media was added 
before use and the medium can be stored at 4°C for 5 
days. 
0.1% Gelatin preparation: 
0.2 g of Gelatin (Sigma-Aldrich, UK) + 200 ml dH2O 
The solution needed to be autoclaved within 1 hour 
after the gelatin powder dissolved completely.  
10× PBS (phosphate buffered saline) 
8 g NaCl (Fisher Scientific, UK), 
0.2 g KCl (Sigma-Aldrich, UK), 
1.15 g Na2HPO4 (Sigma-Aldrich, UK), 
0.2 g NaH2PO4 (Sigma-Aldrich, UK), 
100 ml dH2O (PH7.4) 
Trypsin: 
Trypsin (porcine trypsin in 0.9% sodium chloride 
solution; Sigma-Aldrich, UK) in PBS 
Immunostaining:  
Fixation 
4 g Paraformaldehyde + 100 ml 1× sterile PBS 
Weight 4g Paraformadehyde (Sigma-Aldrich, UK) 
with care, wearing a facemask. Add the PFA to pre-
heated (60°C) PBS in a fumehood and allow 
dissolving in 65°C rocking oven, ensuring 
temperature did not go above 70 °C, as PFA is 
explosive at high temperatures. 
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PBST 
PBS + 150 mM NaCl  + 0.05% Tween20® 
500 ml PBS, 
1.46 g NaCl, 
0.25 ml Tween20® (Sigma-Aldrich, UK)  
Immunohistochemistry (IHC): 
Acidic-Alcohol  
400 ml 70% Ethanol (Fisher Scientific, UK) 
2 ml concentrated HCl (Fisher Scientific, UK) 
Antigen retrieval buffer 
4.7 g Sodium Citrate (Fisher Scientific, UK) and 1.6 
litre distilled water 
Adjusted to pH6 with Conc. HCl (Fisher Scientific, 
UK) 
DAB (3, 3'-diaminobenzidine) preparation: 
1 tablet of DAKO®DAB (DAKO, UK) chromogen 
10 ml of PBS  
The DBA solution was aliquoted to universal tubes 
with 1 ml per tube with great care. The solution was 
stored at -20°C. 
Wash Buffer (PBST) 
100 ml 10× PBS (see above), 
900 ml dH2O, 
1 ml Tween®20 
Scott’s water  
50 μl Sodium Hydroxide (Fisher Scientific, UK) 
400 ml tap water 
TNB (Tris-NaCl blocking buffer) 
0.61 g TRIS in 100 ml dH2O (pH7.5) 
0.44 g NaCl  
0.25g Blocking reagent (TSA kit) 
Protein Extraction and Blotting: 
Lysis Buffer (850 ul) and Protease Inhibitors (150 
ul)(Radio Immuno Precipitation Assay or RIPA 
Buffer) 
Lysis Buffer (store at 4C for 2-3 months) 
50 mM Tris (Fisher Scientific, UK), 
150 mM NaCl,  
1% IGEPAL® CA-630 (chemically indistinguishable 
from NP-40) (Sigma-Aldrich, UK), 
0.5% deoxycolic acid (Sigma-Aldrich, UK), 
Made up to 100 ml with sterile dH2O 
Protease Inhibitors (store at -20°C for 2-3 months) 
1 protease inhibitor tablet (Roche Diagnostic Ltd, UK) 
1.5 ml sterile dH2O 
6× SDS Sample Buffer 
For 10 ml: 
7ml 0.6 M Tris-HCl pH 6.8, 
3 ml glycerol, 
1 g SDS, 
0.93g DTT (Dithiothreitol) (Sigma-Aldrich, UK), 
1.2 mg bromophenol blue 
Running Buffer 
3 g Tris (Fisher Scientific Ltd, UK), 
14.42 g Glycine (Fisher Scientific Ltd, UK), 
1 g SDS (Fisher Scientific Ltd, UK) 
Made up to 1 litre with dH2O 
Transfer Buffer 
3.03 g Tris, 
14.4 g Glycine, 
200 ml Methanol (Fisher Scientific Ltd, UK), 
Made up to 1 litre with dH2O 
pH to 8.5 with Concentrated HCl (Fisher Scientific 
Ltd, UK) 
1.5 M Tris-HCl  
18.17 g Tris 
Made up to 100 ml with dH2O 
pH to 8.8 with concentrated HCl (Fisher Scientific 
Ltd, UK) 
1.0 M Tris-HCl 
12.1 g Tris  
Made up to 100 ml with dH2O 
pH to 6.8 with concentrated HCl (Fisher Scientific 
Ltd, UK) 
10% SDS 
10 g SDS made up to 100 ml with dH2O 
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10X TBS (Tris-buffered saline) 
24.2 g Tris,  
80 g NaCl  
Made up to 100 ml with dH2O 
pH to 7.6 with concentrated HCl 
Blocking Buffer 
15 ml 10× TBS (see above) 
135 ml dH2O, 
0.15 ml Tween®20,  
7.5 g non-fat dry milk (Marvel, UK) 
Wash Buffer (TBST) 
100 ml 10× TBS (see above), 
900 ml dH2O, 
1 ml Tween®20  
Primary Antibody Dilution Buffer 
2 ml 10× TBS, 
18 ml dH2O, 
20 ul Tween®20, 
1 g BSA (Sigma-Aldrich, UK) 
Bacteria culture and storage: 
LB (Luria-Bertani) medium  
12.5 g Luria Bruth Base powder (Invitrogen, UK) 
Made up to 500 ml with dH2O 
The medium was autoclaved and kept at 4°C 
LB agar plate 
9.25 g Luria Agar (Invitrogen, UK) 
Made up to 250 ml with dH2O 
The agar mixture was autoclaved. Appropriate 
antibiotics was added when the agar was lukewarm 
and then poured into petri dishes.  
TSS buffer (Transformation amd storage solution 
for chemical transformation) 
1.25 g Luria Bruth Base powder 
5 g Polyethylene glycol MW 8,000 (PEG) (Sigma-
Aldrich, UK) 
2.5 ml DMSO (Sigma-Aldrich, UK) 
0. 508 g MgCl2 (BDH) 
Add up to 50 ml with dH2O and adjust pH to ~6.5 
The solution was protected from light and autoclaved. 
The cooled solution was kept at 4°C for no more than 
2 weeks. 
Electrophoresis analysis for DNA: 
TBE (Tris/Borate/EDTA) buffer (5×) 
46.5 g Na2EDTA (Fisher Scientific Ltd, UK) 
275 g Boric acid (Fisher Scientific Ltd, UK) 
540 g Tris (Fisher Scientific Ltd, UK) 
Made up to 1 litre with dH2O 
The working concentration was 0.5× which was made 
by dilute the stock 10 times with dH2O. 
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Appendix 3. Raw data of Chapter 3 
Figure 3.2 
Fusion index in differentiation set-up experiment 
C2C12                                          PD50A  
myonuclei   # of myotube/cm2   myonuclei    # of myotube/cm2        Myonuclei: number of nuclei with the myotubes/cm2 
8.90E+2      5.15E+2               9.78E+2             1.64E+2                GM: DMEM + 10%FCS 
2.86E+3      5.98E+2               2.77E+2             1.31E+2                 DM: DMEM + 2% hosrse serum (HS) 
2.67E+3      5.86E+2               6.87E+2             1.32E+2                 DM+5: DMEM+2%HS+5%FCS 
3.45E+3      5.76E+2               6.64E+2             2.43E+2                 coculture: cocultured with osteoblasts 
3.01E+3      7.38E+2               5.58E+2             1.92E+2                 OCM: 50% osteoblast-conditioned medium+50% DM 
2.49E+3      6.06E+2               8.68E+2             2.94E+2                 CCM: 50% C2C12-osteoblast-conditioned medium+50%DM 
average   2.73E+3     6.03E+2               6.72E+2             1.93E+2                 PDCM: 50% PD50A-osteoblast-conditioned medium +50% DM 
STDEV   5.25E+2      7.36E+1              2.46E+2            6.49E+1 
St. error  2.35E+2      3.29E+1              1.10E+2            2.90E+1 
p value                                                     6.09E-06           1.2E-06 
myonuclei = # of nuclei in myotubes/cm2 ;surface area = cm2   
 
Figure 3.3 and 3.4 
myonuclei number of coculture experiment 
GM                    DM (2%HS)     DM+5                         cocutlrue              OCM                   CCM                    PDCM  
C2C12   PD50A    C2C12    PD50A    C2C12    PD50A    C2C12   PD50A   C2C12   PD50A   C2C12   PD50A   C2C12   PD50A 
2.64E+2  2.83E+2  2.63E+3   9.20E+2  1.48E+3  1.46E+3  1.42E+3  1.18E+3  1.68E+3 1.10E+3 1.51E+3  3.38E+3  6.19E+2 9.91E+2 
2.73E+2  3.46E+2  2.26E+3   9.59E+2  1.17E+3  1.43E+3  1.42E+3  1.24E+3  1.63E+3 1.16E+3 1.27E+3  2.72E+3  7.64E+2 1.05E+3 
2.41E+2  3.89E+2  2.00E+3   1.38E+3  9.94E+2  1.56E+3  9.68E+2  1.32E+3  1.78E+3 1.45E+3 1.07E+3  3.18E+3  6.50E+2 1.46E+3 
5.2E+1    2.4E+1    2.16E+3   1.21E+3  6.43E+2   7.70E+2 1.41E+3  2.56E+3  2.90E+3  7.76E+2 2.88E+3 2.09E+3  1.94E+3 6.95E+2 
3.64E+1  3.93E+1  2.76E+2   1.03E+3  9.70E+2   8.88E+2 1.10E+3  2.14E+3  3.17E+3  1.00E+3 2.02E+3 1.73E+3  1.69E+3 3.31E+2 
4.17E+1  2.91E+1  3.36E+2   1.19E+3  6.70E+2   7.42E+2 1.12E+3  1.50E+3  2.06E+3  1.47E+3 2.62E+3 2.10E+3  1.53E+3 3.56E+2 
Average1.51E+2 1.85E+2  2.53E+3  1.12E+3  9.87E+2  1.14E+3 1.24E+3  1.66E+3 2.20E+3 1.16E+3 1.89E+3 2.53E+3  1.20E+3 8.14E+2 
STDEV 1.19E+2 1.72E+2  4.98E+2  1.78E+2  3.15E+2  3.77E+2 1.99E+2  5.65E+2 6.68E+2  2.65E+2 7.38E+2 6.63E+2  5.87E+2 4.39E+2 
St. error5.32E+1 7.71E+1  2.23E+2 7.98E+1  1.41E+2  1.68E+2  8.91E+1  2.53E+2 2.99E+2  1.19E+2 3.30E+2 2.96E+2  2.63E+2 1.96E+2 
P C2 vs PD50A    7.01E-01                 6.64E-05                 4.68E-01                1.19E-01                5.19E-03               1.46E-01                 2.29E-01 
vs GM                                  4.9E-07  3.4E-06                                   4.4E-07   1.2E-04    
vs DM (2%HS+5%FCS)                                                                                                  2.4E-03  9.18E-01 2.3E-03  9.18E-01 4.57E-01 2.00E-01 
 
myotube number of coculture experiment 
GM                         DM (2%HS)      DM+5                        coculture              OCM                      CCM                    PDCM 
C2C12    PD50A    C2C12    PD50A   C2C12      PD50A    C2C12    PD50A  C2C12    PD50A   C2C12    PD50A  C2C12    PD50A 
9.56E+1 7.68E+1   7.41E+2  5.20E+2  6.13E+2  6.27E+2   6.51E+2   4.85E+2  4.38E+2  3.88E+2 6.49E+2 1.27E+3  2.71E+2  3.88E+2 
9.03E+1 9.98E+1   5.91E+2  4.45E+2  4.99E+2  6.07E+2   6.65E+2   5.21E+2  4.64E+2  3.85E+2 5.74E+2 1.01E+3  3.43E+2  4.05E+2 
8.64E+1 1.18E+2   5.73E+2  5.05E+2  4.25E+2  5.78E+2   4.47E+2   5.51E+2  5.31E+2  5.10E+2 4.93E+2 1.18E+3  2.98E+2  5.63E+2 
2.24E+1 1.04E+1   1.13E+3  2.28E+2  2.76E+2  2.91E+2   5.71E+2   7.94E+2  1.24E+3  2.88E+2 1.32E+3 8.15E+2  8.53E+2  2.75E+2 
1.34E+1 1.57E+1   1.06E+3  2.43E+2  3.96E+2  3.56E+2   3.86E+2   7.03E+2  1.35E+3  4.18E+2 9.02E+2 7.20E+2  7.50E+2  1.22E+2 
1.81E+1 9.69E+0   1.40E+3  4.07E+2  2.61E+2  2.82E+2   3.65E+2   5.58E+2  8.79E+2  6.27E+2 1.17E+3 2.10E+3  6.72E+2  1.18E+2 
Average5.44E+1 5.50E+1 9.17E+2 3.91E+2 4.12E+2  4.57E+2  5.14E+2   6.02E+2  8.18E+2  4.36E+2 8.51E+2 9.85E+2 5.31E+2  3.12E+2 
STDEV 4.01E+1 4.90E+1 3.34E+2 1.28E+2 1.34E+2  1.64E+2  1.32E+2  1.20E+2  4.04E+2   1.17E+2 3.36E+2 2.12E+2 2.56E+2  1.75E+2 
st error 1.79E+1 2.19E+1 1.50E+2 5.71E+1 5.99E+1  7.33E+1  5.92E+1   5.34E+1 1.81E+2   5.25E+1 1.50E+2 9.49E+1  1.15E+2 7.82E+1 
P C2 vs PD50A   9.81E-1                 4.89E-03                 7.12E-1                    2.55E-1                   5.07E-02               2.04E-01                 1.14E-1 
vs GM                                9.23E-5  1.3E-4                                     1.01E-5     1.1E-6    
vs DM (2%HS+5%FCS)                                                                                                 4.19E-02 8.05E-1  1.41E-2  6.69E-3   3.35E-1   1.70E-1 
 
Figure 3.5 
Fusion index of coculture (MF-20 staining)  
C2C12                                          GM                                           DM+5                                   coculture                                        OCM 
MF20(+)      total   Fusion index  MF20(+)   total  Fusion index MF20(+)     total  Fusion index  MF20(+)     total  Fusion index 
1.20E+01  3.79E+02  3.17E+00  8.70E+01  7.49E+02  1.16E+01  2.90E+01  1.81E+02  1.60E+01  3.10E+01  2.50E+02  1.24E+01 
8.00E+00  3.23E+02  2.48E+00  5.60E+01  6.33E+02  8.85E+00  3.60E+01  2.45E+02  1.47E+01  5.90E+01  4.13E+02  1.43E+01 
1.00E+01  2.24E+02  4.46E+00  3.10E+01  3.57E+02  8.68E+00  2.20E+01  1.78E+02  1.24E+01  4.70E+01  3.90E+02  1.21E+01 
Average                                   3.37E+00                                     9.72E+00                                      1.44E+01                                     1.29E+01 
STDEV                                     8.24E-01                                     1.35E+00                                      1.51E+00                                     9.82E-01 
st error                                     5.83E-01                                      9.51E-01                                      1.07E+00                                     6.94E-01 
p(vs GM)                                                                                       4.72E-03                                      8.4E-04                                        
p(vs DM)                                                                                                                                                                                                 5.33E-02 
p(vs. PD50A)                           6.37E-02                                       4.47E-02                                      2.82E-01                                     2.04E-01 
PD50A                                     GM                                          DM+5                                        coculture                                      OCM 
MF20(+)      total   Fusion index   MF20(+)  total  Fusion index  MF20(+)   total  Fusion index  MF20(+)  total    Fusion index 
1.00E+01  1.43E+03  7.01E-01   4.50E+01  7.22E+02  6.23E+00  5.10E+01  3.54E+02  1.44E+01  6.80E+01  5.49E+02  1.24E+01 
8.00E+00  7.08E+02  1.13E+00  1.40E+01  1.88E+02  7.45E+00  6.0E+01    5.78E+02  1.16E+01  5.70E+01  5.04E+02  1.13E+01 
1.00E+01  4.19E+02  2.39E+00  1.40E+01  3.01E+02  4.65E+00  8.00E+01  6.74E+02  1.19E+01  3.70E+01  3.20E+02  1.16E+01 
Average                                   1.41E+00                                     6.11E+00                                      1.26E+01                                     1.18E+01 
STDEV                                     7.15E-01                                     1.14E+00                                      1.27E+00                                      4.60E-01 
st error                                     5.06E-01                                      8.09E-01                                       8.96E-01                                      3.25E-01 
p(vs GM)                                                                                      7.88E-03                                        1.36E-02                                       
p(vs DM)                                                                                                                                                                                                  2.94E-03 
 
Figure 3.6 
The effect of FCS on myoblast differentiation  
C2C12 
          DM+0%FCS                                  DM+0.5%FCS                             DM+5%FCS                                DM+10%FCS 
          MF20(+)    total   Fusion index(%) MF20(+)     total  Fusion index(%) MF20(+)    total  Fusion index(%) MF20(+)    total  Fusion index(%)  
9.30E+01 9.77E+02 9.52E+00         3.00E+01 5.57E+02 5.39E+00       5.40E+01 1.21E+03    4.45E+00   4.00E+01 1.26E+03  3.17E+00 
9.30E+01 1.04E+03 8.97E+00         3.50E+01 8.43E+02 4.15E+00       6.90E+01 1.23E+03    5.60E+00   3.70E+01 1.03E+03  3.59E+00 
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1.04E+02 1.02E+03 1.02E+01         8.70E+01 1.14E+03 7.63E+00       4.80E+01 1.10E+03    4.36E+00   3.50E+01 1.00E+03  3.50E+00 
9.20E+01 1.00E+03 9.19E+00         5.90E+01 1.10E+03 5.37E+00       5.70E+01 1.09E+03    5.21E+00   4.10E+01 1.02E+03  4.03E+00 
9.50E+01 1.09E+03 8.72E+00         6.10E+01 1.03E+03 5.92E+00       3.50E+01 1.06E+03    3.29E+00   4.20E+01 1.20E+03  3.50E+00 
Average 9.54E+01 1.03E+03 9.32E+00       5.44E+01 9.34E+02 5.69E+00       5.26E+01 1.14E+03    4.58E+00   3.90E+01 1.10E+03  3.56E+00 
STDEV 4.93E+00  4.26E+01 5.69E-01        2.29E+01 2.39E+02 1.26E+00       1.25E+01 7.68E+01    8.88E-01   2.92E+00  1.20E+02  3.07E-01 
st error  2.46E+00  2.13E+01 2.85E-01        1.15E+01 1.20E+02  6.32E-01       6.23E+00 3.84E+01    4.44E-01   1.46E+00  6.01E+01  1.54E-01 
p (vs 0%FCS)                                                                            3.84E-04                                        8.25E-06                                   4.22E-08 
PD50A 
           DM+0%FCS                                DM+0.5%FCS                              DM+5%FCS                               DM+10%FCS 
          MF20(+)    total   Fusion index(%) MF20(+)     total  Fusion index(%) MF20(+)    total  Fusion index(%) MF20(+)    total  Fusion index(%)  
        3.30E+01 1.00E+03  3.29E+00      3.00E+01 9.41E+02   3.19E+00     6.00E+01 7.75E+02   7.74E+00     9.20E+01 1.09E+03   8.46E+00 
2.80E+01 9.42E+02  2.97E+00      2.00E+01 2.52E+02   7.94E+00     7.00E+01 9.09E+02   7.70E+00     4.80E+01 6.49E+02   7.40E+00 
2.10E+01 7.80E+02  2.69E+00      4.30E+01 5.93E+02   7.25E+00     4.80E+01 9.13E+02   5.26E+00     8.50E+01 1.02E+03   8.34E+00 
2.70E+01 9.94E+02  2.72E+00      3.30E+01 8.14E+02   4.05E+00     7.70E+01 1.06E+03   7.28E+00     6.30E+01 9.86E+02   6.39E+00 
2.30E+01 9.57E+02  2.40E+00      4.30E+01 9.24E+02   4.65E+00     9.00E+01 1.07E+03   8.44E+00     6.40E+01 7.79E+02   8.22E+00 
Average 2.64E+01 9.35E+02  2.81E+00      3.38E+01 7.05E+02   5.42E+00     6.90E+01 9.44E+02   7.28E+00     7.04E+01 9.04E+02   7.76E+00 
STDEV 4.67E+00  9.04E+01  3.33E-01      9.68E+00  2.89E+02   2.07E+00     1.60E+01 1.21E+02   1.21E+00     1.79E+01 1.83E+02   8.72E-01 
st error  2.33E+00  4.52E+01  1.67E-01      4.84E+00  1.44E+02   1.03E+00     8.02E+00 6.05E+01    6.04E-01     8.93E+00 9.17E+01   4.36E-01 
p (vs 0%FCS)                                                                              2.41E-02                                      4.46E-05                                      2.37E-06 
 
Figure 3.7 
total cell number change (1.5x104 cells plated) in 48 well plates 
C2C12+GM      C2C12+DM              C2C12+OCM             PD50A+GM                  PD50A+DM               PD50A+OCM 
confluency(%) cell #  confluency(%) cell #  confluency(%) cell #   confluency(%) cell #   confluency(%) cell #  confluency(%) cell # 
Day1    20        3.63E+4        20         2.69E+4          18         4.19E+4          10          3.38E+4            12          3.13E+4          15          3.56E+4 
22        4.19E+4        20         3.50E+4          18         3.88E+4          15          3.00E+4            15          2.88E+4          15           3.25E+4 
20        3.00E+4        20         3.00E+4          20         4.25E+4          10          3.00E+4            10          3.31E+4          15           3.50E+4 
15        1.94E+4        25         4.75E+4          15         5.25E+4          20          5.50E+4            25          5.56E+4          25           3.13E+4 
22        2.00E+4        25         4.94E+4          20         4.13E+4          20          3.44E+4            25          4.88E+4          25           4.63E+4 
20        3.25E+4        22         3.56E+4          15         4.56E+4          22          3.44E+4            25          4.38E+4          25           3.81E+4 
Average   19.83     3.00E+4        22.00      3.74E+4         17.67     4.38E+4         16.17      3.63E+4           18.67      4.02E+4      20.00     3.65E+4 
ST error    1.15      4.00E+3        1.10        4.10E+3          1.01      2.16E+3          2.37      4.21E+3            3.18       4.84E+4       2.45      2.40E+3 
p value (OCM vs. DM)                                                                   0.16                                                                                                    0.46 
Day2         50        6.63E+4            35        4.81E+4           25       6.25E+4           40         5.13E+4            40         4.68E+4         35       6.81E+4 
50       8.13E+4            40        4.38E+4           30        7.50E+4           45         7.38E+4            45         4.94E+4         40       7.00E+4 
50       1.00E+5            40        4.25E+4           30        5.88E+4           40         5.44E+4            40         4.44E+4         40       7.25E+4 
45       8.59E+4            55        4.94E+4           45        4.94E+4           50         7.50E+4            60         6.75E+4         50       5.44E+4 
50       8.91E+4            55        5.63E+4           50        6.75E+4           50         7.31E+4            60         7.88E+4         55       7.14E+4 
45       9.22E+4            50        4.88E+4           50        5.69E+4           50         8.44E+4            50         8.00E+4         45       5.63E+4 
Average    48.33   8.58E+4          45.83      4.81E+4          38.33     6.17E+4        45.83       6.86E+4         49.17        6.11E+4      44.17     6.54E+4 
ST error     1.15    5.12E+3           3.85       2.18E+3          5.03      3.98E+4          2.20       5.80E+43         4.10        7.29e+3        3.29      3.57E+3 
p value (OCM vs. DM)                                                                     0.012                                                                                                  0.58 
Day3         50       1.43E+5            60         6.94E+4            45       6.06E+4           55         1.87E+5            55         1.01E+5         55       1.58E+5 
50       1.38E+5            60        5.06E+5             45       6.75E+4           50         2.21E+5            50         8.56E+4         60       1.46E+5 
55       1.55E+5            60        6.69E+4             45       4.81E+4           45         1.88E+5            55         9.50E+4         50       1.49E+5 
65       1.29E+5            65        5.06E+4             70       1.31E+5           60         2.59E+5            60         1.32E+5         70       2.34E+5 
65       1.73E+4            70        6.56E+4             70       1.19E+5           60         2.41E+5            60         1.33E+5         65       1.84E+5 
60       1.38E+5            70        6.56E+4             70       1.38E+5           60         2.94E+5            60         1.05E+5         60       1.73E+5 
Average   57.5      1.46E+5        64.17       6.15E+4           57.5       9.40E+4           55         2.32E+5         56.67       1.08e+5          60      1.74E+5 
ST error    3.08     7.03E+3         2.20        3.80E+3           6.12       1.77E+4         2.83        1.87E+4          1.83        8.72E+4        3.16     1.46E+4 
p value (OCM vs. DM)                                                                  0.08                                                                                                 1.75E-03 
Day4         50        1.02E+5          55         5.56E+4            35          9.00E+4         55          3.71E+5            45         1.03E+5         45      2.87E+5 
50        9.88E+4          55         5.06E+4            35          9.38E+4         55          3.64E+5            50         7.69E+4         45      2.22E+5 
45        7.31E+4          60         5.50E+4            40          1.13E+5         55          3.81E+5            50         7.69E+4         45      1.89E+5 
75        1.20E+5          75         3.25E+4            70          1.34E+5         70          4.06E+5            65         1.39E+5         75      2.28E+5 
80        1.23E+5          75         3.06E+4            75          1.43E+5         70          5.19E+5            65         1.18E+5         70      2.18E+5 
80        1.05E+5          70         3.25E+4            75          1.39E+5         70          4.99E+5            65         1.03E+5         65      2.03E+5 
Average   63.33     1.03E+5          65         4.28E+4            55          1.19E+5        62.5        4.24E+5          56.67       1.03E+5       57.5     2.24E+5 
ST error   7.44       7.96E+4        4.24        5.42E+3           9.05        1.05E+4        3.67        3.05E+4            4.16       1.07E+4        6.28    1.51E+4 
p value (OCM vs. DM)                                                                   3.5E-05                                                                                             2.9E-05 
 
Figure 3.8  Apoptotic index  
C2C12                              PD50A                                                    C2C12                                PD50A 
GM       DM     OCM        GM       DM       OCM                        GM       DM      OCM        GM       DM       OCM 
Day1                           0.58       2.30      0.82         1.01       1.40       0.10            Day3     1.90        4.70      1.89          2.93        5.22      1.37 
0.63       2.46      1.08         0.99       3.02       0.58                          3.78        3.73      1.45          3.11        3.95      1.39 
0.44       2.07      0.78         0.85       2.00       0.44                          1.78        4.01      2.13          4.15        4.10       1.53 
0.68       2.01      1.08         1.17       0.70       0.49                          2.37        3.72      1.09          7.62        3.85       0.10 
0.83       1.39      0.51         0.89       1.53       0.59                          4.08        3.78      1.48          3.71        3.04       0.95 
0.70       1.06      1.03         1.19       1.79       0.50                          2.69        3.47      0.95          5.06        3.50       2.10 
Average                      0.64       1.88      0.88         1.02       1.74       0.45                          2.77        3.90      1.50          4.43        3.94       1.39 
STDEV                       0.13       0.54      0.22         0.14       0.77       0.18                           0.96        0.43      0.45          1.74        0.73       0.42 
st error                       0.06       0.24      0.10         0.06       0.34       0.08                           0.43        0.19      0.20          0.78        0.33       0.19 
p-value (vs. C2C12)                                        7.33E-04 7.22E-01 4.03E-03                                                               6.8E-02 9.11E-01  6.68E-01 
p-value (vs. DM)   2.9E-04             1.94E-03 4.69E-02                 2.47E-03                  2.47E-02             2.6E-06       5.4E-01               2.2E-05 
Day2                           1.08       5.15      1.73         1.39        3.62      0.42             Day4     6.25        5.60       1.83          8.09       8.36       4.09 
1.07       4.80      1.39         2.14        5.43      0.42                           6.75        3.13       2.00          9.65       8.75       3.37   
1.18       4.85      0.80         0.76        4.54      0.37                           9.65        5.84       2.49          6.63       12.58      2.82 
1.67       3.22      1.17         0.69        3.05      0.87                           6.39        5.30       2.05          5.68       11.81      1.97 
1.56       3.29      0.90         3.44        2.84      0.64                           5.75        3.92       3.03          8.22        8.04       3.44 
0.81       3.74      0.56         1.54        1.92      0.55                           4.76        8.82       3.00         12.34      10.17      2.20 
average                       1.23       4.17      1.09         1.66         3.56     0.55                          6.59        5.44       2.40          8.44         9.95       2.98  
STDEV                        0.33       0.86      0.43         1.02         1.26     0.19                         1.65        1.96       0.52          2.36         1.90        0.81 
st error                        0.15       0.38      0.19         0.46         0.56     0.08                          0.74        0.88       0.23          1.05         0.85       0.36 
p-value (vs. C2C12)                                           3.48E-01 3.5E-01 1.61E-02                                                              1.48E-01 2.33E-03 1.68E-01 
p-value (vs. DM)       1.4E-05              1.4E-05 1.67E-02                1.7E-04                    2.95E-01            4.39E-03    2.48E-01               8.7E-06 
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Figure 3.9     cleaved caspase 3/ uncleaved caspas 3 (normalized with coomassie blue) 
C2C12       OCM                                DM                            PD50A                  OCM                                  DM 
Nondifferentiated   24          48           96         24         48           96      nondifferentiated   24        48         96          24           48        96  (hrs) 
3.81       2.33       2.28         3.32      4.54      2.68        2.10          3.33               1.97      3.19       2.90        5.42        2.33       5.14 
3.17       3.10       3.04         3.47      3.22      2.39        2.44          3.21               2.38      2.67       2.43        2.48        3.20       3.25 
3.02       2.82       2.66         4.34      4.51      2.25        2.12          3.32               1.97      3.04       1.86        5.48        4.23       5.67 
Average        3.33       2.75       2.66         3.71      4.09      2.44        2.22          3.29               2.11      2.97       2.40        4.46        3.26       4.69 
STDEV         0.42       0.39       0.38         0.55       0.76      0.22         0.19          0.07              0.23       0.27       0.52        1.71        0.95      1.27 
st error         0.30       0.28       0.27          0.39      0.53      0.15         0.14          0.05              0.17       0.19       0.37        1.21        0.67       0.90 
p value (vs. C2)                                                                                              8.70E-01    7.1E-02  3.16E-01   4.0E-2 7.48E-01 2.21E-01 2.94E-02 
p value (vs. time 0)1.53E-01 1.09E-01 4.0E-01 2.05E-01 3.09E-02 1.41E-02            1.11E-03 1.16E-01  4.22E-02 3.03E-01 9.53E-01 1.3E-01 
 
Figure 3.11 Growth factor effects: Mitotic index  
C2C12                                              PD50A  
DM       IGF-1        IGF-2        LIF        DM            IGF-1      IGF-2       LIF 
9.43E-02   2.93E-01  2.35E-01  4.64E-01  5.36E-01  9.53E-01  4.81E-01  5.63E-01 
0.00E+00  3.18E-01  4.02E-01  1.90E-01  3.95E-01  3.82E-01  8.66E-01  8.69E-01 
0.00E+00  1.94E-01  2.68E-01  1.01E-01  1.92E-01  3.96E-01  1.71E-01  2.91E-01 
0.00E+00  1.99E-01  2.00E-01  3.55E-01  2.88E-01  4.48E-01  3.84E-01  1.45E+00 
0.00E+00  0.00E+00 1.20E-01  2.95E-01  1.96E-01  5.44E-01  3.98E-01  2.93E-01 
0.00E+00  0.00E+00 9.43E-02  1.83E-01  9.66E-02  4.43E-01  5.93E-01  3.97E-01 
Average 1.57E-02  1.67E-01  2.20E-01  2.64E-01  2.84E-01  5.28E-01  4.82E-01  6.44E-01 
STDEV  3.85E-02  1.39E-01  1.11E-01  1.33E-01  1.60E-01  2.16E-01  2.34E-01  4.52E-01 
st error  1.72E-02  6.20E-02  4.97E-02  5.93E-02  7.14E-02  9.66E-02  1.04E-01  2.02E-01 
p-value (vs. C2C12)                                                 2.51E-03  6.33E-03  3.22E-02  7.63E-02    
p-value (vs. DM)   2.74E-02  1.68E-03   1.31E-03                  5.04E-02  1.17E-01   9.52E-02 
 
Figure 3.12 Growth Factor effects: Apoptotic index 
C2C12                                         PD50A 
DM       IGF-1      IGF-2        LIF          DM       IGF-1      IGF-2      LIF 
5.75        6.15         8.23         14.38         9.29        5.32          2.69        3.38  
6.02        7.00         8.84         11.37         8.50        8.41          5.54        1.56  
5.78        4.76        10.74        10.88         7.41        9.91          2.65        2.62   
13.51      8.16        21.88        16.43         9.69        4.92          3.84        1.69 
9.05        4.79        21.90        7.47           6.26        8.01          2.59        2.05 
10.71     14.98       15.94        17.50         7.44        7.17          3.36        1.19     
average                       8.47       7.64         14.59        13.00         8.10       7.29           3.45        2.08 
STDEV                       3.21        3.82         6.28          3.79          1.30        1.90          1.14         0.80 
st error                       1.43        1.71         2.81          1.69          0.58        0.85           0.51        0.36 
p-value (vs. C2C12)                                                               7.97E-01  8.47E-01  1.62E-03  4.1E-06    
p-value (vs. DM)                   6.91E-01  5.95E-02   4.92E-02                4.11E-01   6.1E-05   2.2E-06 
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Figure 3.10 Pax7 level in myoblasts (compared to nondifferentiated C2C12) 
C2C12     OCM                                     DM                                        PD50A                  OCM                                      DM 
Nondifferentiated    24        48           96              24            48              96         nondifferentiated    24       48             96             24            48            96 (hrs) 
1                 8.97E-01    9.52E-01  1.76         3.95E-01  3.43E-01  2.87E-01        8.65E-01      6.97E-01   1.01         2.05         4.10E-01  3.77E-01  3.06E-01 
1                        1.21      1.44        1.19          3.74E-01  4.37E-01  3.40E-01             1.05        8.38E-01   1.05         4.99         6.95E-01  4.60E-01   3.47E-01 
        1                 7.56E-01     1.16        1.42          3.90E-01  3.56E-01  3.78E-01              1.19       5.06E-01   1.13          3.30         5.37E-01  4.32E-01  4.77E-01 
Average      1                 9.53E-01     1.18        2.14          3.56E-01  3.96E-01  3.59E-01             1.39       6.81E-01   1.07          3.44         5.47E-01  4.23E-01  3.76E-01 
STDEV       0                 2.30E-01   2.44E-01  9.72E-01  4.54E-02  5.78E-02  2.65E-02        4.75E-01    1.67E-01   6.00E-02  1.48         1.43E-01  4.25E-02  8.91E-02 
st error       0                 1.63E-01   1.72E-01  6.88E-01  3.21E-02  4.09E-02  1.87E-02        3.36E-01    1.18E-01   4.25E-02  1.05         1.01E-01  3.00E-02  6.30E-02 
p value (vs. time 0)       7.41E-01   2.67E-01  5.0E-01    1.63E-05  2.99E-05  1.46E-05                           4.49E-04   9.07E-02  5.55E-03  3.05E-05  9.21E-08  1.65E-04 
p value (vs. C2C12)                                                                                                                   7.38E-01    1.73E-01   4.68E-01  8.37E-02  9.18E-02  3.14E-01  5.13E-04 
 
Figure 3.13 Growth factor effects: myonuclei number 
DM                            IGF1                       IGF2                       LIF                       IGF1+IGF2            IGF1+LIF             IGF2+LIF                  IGF1+IGF2+LIF 
C2C12       PD50A    C2C12    PD50A   C2C12    PD50A   C2C12    PD50A     C2C12       PD50A    C2C12    PD50A   C2C12    PD50A      C2C12    PD50A 
2.07E+3     1.75E+3   1.24E+3 1.10E+3  2.02E+3  1.28E+3  1.03E+3  1.05E+3     2.10E+3   2.82E+2  1.03E+3  4.30E+3  7.83E+2  2.04E+3     6.01E+2   7.16E+2 
1.62E+3     1.16E+3   8.45E+2 1.24E+3  2.03E+3  1.39E+3  8.39E+2  8.71E+2     2.08E+3   1.97E+3  1.05E+3  2.76E+3  8.47E+2  2.08E+3     5.61E+2   7.27E+2 
2.63E+3     1.19E+3   9.81E+2 1.16E+3  1.93E+3  1.82E+3  1.00E+3  1.27E+3     2.24E+3   1.80E+3  9.96E+2  2.70E+3  8.75E+2  3.08E+3     5.21E+2   9.80E+2 
3.34E+3     7.54E+2   9.44E+2 8.58E+2  2.59E+3  2.01E+3  6.66E+2  8.40E+2     1.41E+3   2.54E+3  1.03E+3  2.27E+3  9.71E+2  1.58E+3     5.04E+2   7.99E+2 
2.01E+3     9.31E+2   8.52E+2 9.65E+2  1.11E+3  1.83E+3  5.84E+2  1.04E+3     1.24E+3   2.21E+3  1.07E+3  2.38E+3  8.28E+2  2.16E+3     4.66E+2   9.68E+2 
2.22E+3     1.46E+3   7.14E+2 6.65E+2  1.25E+3  1.69E+3  6.13E+2  9.46E+2     1.19E+3   1.65E+3  1.03E+3  2.14E+3  7.32E+2  1.64E+3     4.99W+2  1.09E+3 
Average   2.32E+3      1.21E+3  9.30E+2 9.99E+2  1.82E+3  1.67E+3 7.88E+2  1.00E+3     1.71E+3   2.17E+3  1.03E+3 2.76E+3  8.39E+2  2.10E+3    5.25E+2    8.80E+2 
STDEV    6.01E+2      3.57E+2  1.80E+2 2.14E+2  5.52E+3  2.81E+2 1.96E+2  1.55E+2     4.80E+2   4.49E+2  2.46E+1 7.92E+2  8.18E+1  5.40E+2    4.83E+1    1.54E+1 
st. error    2.69E+2     1.60E+2   8.03E+1 9.55E+1 2.47E+2  1.26E+2  8.78E+1  6.95E+1     2.15E+2  2.01E+2  1.10E+1  3.54E+2  3.66E+1  2.42E+2    2.16E+1    6.91E+1 
p (C2 vs. PD)              3.00E-03                 5.59E-01                5.57E-01                6.21E-02                    1.19E-01                  3.3E-04                  2.2E-04                       3.1E-04 
p ( vs. DM) N/A             N/A       3.0E-04 2.51E-01 1.70E-01 3.15E-02 1.5E-04  2.32E-01    8.23E-02 2.12E-03  3.9E-04  1.38E-03 1.4E-04  7.08E-03    2.7E-05    6.79E-02 
Myotube umber  
DM                               IGF1                        IGF2                          LIF                            IGF1+IGF2                 IGF1+LIF             IGF2+LIF                     IGF1+IGF2+LIF 
C2C12        PD50A     C2C12     PD50A    C2C12      PD50A     C2C12      PD50A      C2C12      PD50A     C2C12      PD50A      C2C12     PD50A      C2C12     PD50A 
4.66E+02  6.20E+02   5.11E+02 4.24E+02 5.75E+02  5.12E+02  4.27E+02  3.68E+02  5.98E+02  8.23E+02  4.16E+02  1.27E+03  3.21E+02  5.55E+02  2.22E+02  2.34E+02 
3.91E+02  4.00E+02   3.48E+02 4.51E+02 5.12E+02  4.67E+02  3.50E+02  3.12E+02  5.17E+02  5.88E+02  4.26E+02  8.31E+02  3.22E+02  5.81E+02  2.08E+02  2.41E+02 
4.48E+02  4.34E+02   4.02E+02 4.37E+02 5.80E+02  6.91E+02  4.29E+02  4.72E+02  5.69E+02  5.52E+02  4.09E+02  8.28E+02  3.49E+02  8.79E+02  1.98E+02  3.48E+02 
6.38E+02  2.35E+02   4.37E+02 3.74E+02 5.27E+02  8.73E+02  2.96E+02  3.42E+02  6.42E+02  1.08E+03  4.68E+02  9.75E+02  4.35E+02  6.62E+02  2.32E+02  3.46E+02 
5.06E+02  2.97E+02   3.89E+02 3.92E+02 4.93E+02  7.87E+02  2.60E+02  4.37E+02  5.59E+02  8.92E+02  4.88E+02  1.02E+03  3.82E+02  9.22E+02  2.14E+02  4.15E+02 
5.17E+02  4.94E+02   3.25E+02 2.67E+02 5.78E+02  7.41E+02  2.65E+02  3.94E+02  5.38E+02  6.91E+02  4.75E+02  9.44E+02  3.33E+02  6.24E+02  2.29E+02  4.68E+02 
Average 4.94E+02  4.13E+02   4.02E+02 3.91E+02 5.44E+02  6.79E+02 3.38E+02  3.88E+02  5.70E+02 7.71E+02  4.47E+02  9.78E+02  3.57E+02  7.04E+02 2.17E+02  3.42E+02 
STDEV  8.33E+01  1.17E+02   6.64E+01 6.71E+01 3.83E+01  1.59E+02 7.68E+01  5.97E+01  4.46E+01 2.01E+02  3.40E+01  1.62E+02  4.43E+01  1.57E+02 1.27E+01  9.28E+01 
st. error 3.73E+01  6.17E+01   2.97E+01 3.00E+01 1.71E+01  7.11E+01  3.44E+01 2.67E+01  1.99E+01 8.98E+01  1.52E+01  7.25E+01  1.98E+01  7.04E+01 5.67E+00   4.15E+01 
p (C2 vs. PD)          2.47E-01                     7.79E-01                    7.21E-02                    2.37E-01                    3.81E-02                      1.39E-05                     4.01E-04                    8.44E-03 
p ( vs. DM) N/A          N/A        5.97E-02  7.26E-01  2.12E-01   1.15E-02   6.91E-03  6.81E-01   7.67E-02  7.67E-02   2.27E-02    6.92E-05  5.11E-03   6.77E-03  1.1E-05      3.18E-01 
 
Figure 3.14 Cav1α and Cav-1β levels in myoblasts (nomalised with nondifferentiated C2C12) 
C2C12   OCM                                      DM                                                 PD50A             OCM                      DM 
Nondifferentiated  24            48                96            24            48               96      Nondifferentiated      24          48            96                  24           48             96 (hrs) 
Cav1α        1.00E+00       1.04E+00  1.07E+00  1.29E+00  1.02E+00  9.19E-01  1.11E+00      1.43E+00      1.30E+00  1.35E+00  2.15E+00  1.65E+00  1.53E+00  1.17E+00 
1.00E+00        9.74E-01   8.15E-01   1.11E+00  9.44E-01  1.13E+00  1.13E+00       5.23E-01      1.66E+00  2.45E+00  2.37E+00  1.86E+00   5.29E-01  1.35E+00 
1.00E+00        7.16E-01   8.50E-01   1.13E+00  7.41E-01   8.93E-01  1.22E+00      1.21E+00      1.33E+00  1.98E+00  1.36E+00  1.28E+00  1.29E+00   1.22E+00 
Average    1.00E+00       9.11E-01   9.13E-01   1.17E+00  9.02E-01   9.80E-01  1.15E+00      1.06E+00     1.43E+00  1.93E+00  1.96E+00  1.59E+00  1.12E+00  1.25E+00 
STDEV      0.00E+00      1.72E-01   1.41E-01    9.66E-02  1.45E-01   1.29E-01  5.83E-02       4.74E-01      2.01E-01   5.54E-01   5.31E-01   2.94E-01   5.24E-01   9.35E-02 
st error      0.00E+00       1.21E-01   9.96E-02    6.83E-02  1.03E-01  9.09E-02  4.12E-02       3.35E-01      1.42E-01   3.91E-01   3.76E-01   2.08E-01   3.70E-01   6.61E-02 
p value (vs.C2)                                                                                                                               8.5E-01        2.71E-02   3.72E-02   6.52E-02   2.17E-02   6.8E-01    2.02E-01 
p value (vs. time 0)         4.18E-01   3.46E-01   3.55E-02   3.09E-01   7.98E-01  1.1E-02                               2.75E-01   1.07E-01   9.24E-02   1.69E-01   8.85E-01  5.28E-01 
Cav1β        1.00E+00       8.36E-01  8.65E-01   9.06E-01   8.42E-01    8.19E-01   8.06E-01      1.05E+00       8.54E-01   1.71E+00  1.85E+00  8.75E-01   1.06E+00   1.05E+00 
1.00E+00       1.07E+00  9.34E-01   1.12E+00   6.98E-01   1.07E+00   8.03E-01     1.50E+00       1.05E+00   1.03E+00  1.35E+00  1.16E+00  1.29E+00   9.75E-01 
1.00E+00        7.37E-01  7.72E-01   9.68E-01   8.18E-01    7.67E-01   8.64E-01      1.59E+00       1.11E+00   1.34E+00  1.70E+00  1.12E+00  1.25E+00  1.68E+00 
 377 
Average    1.00E+00       8.81E-01  8.57E-01   9.99E-01   7.86E-01    8.86E-01   8.25E-01      1.38E+00      1.01E+00   1.36E+00  1.63E+00  1.05E+00 1.20E+00  1.24E+00 
STDEV      0.00E+00      1.71E-01  8.17E-02   1.11E-01   7.75E-02    1.63E-01   3.43E-02      2.91E-01       1.35E-01    3.39E-01   2.54E-01   1.54E-01  1.23E-01   3.88E-01 
st error      0.00E+00      1.21E-01  5.78E-02   7.83E-02   5.48E-02    1.15E-01   2.42E-02      2.06E-01       9.58E-02    2.40E-01   1.80E-01   1.09E-01   8.71E-02  2.74E-01 
p value (vs.C2)                                                                                                                               8.69E-02       3.75E-01    6.67E-02   1.65E-02   5.59E-02  5.77E-02   1.42E-01 
p value (vs.time 0)          2.93E-01  3.87E-02   9.83E-01   8.74E-03    2.94E-01   9.0E-04                              1.14E-01    9.46E-01   3.16E-01   1.59E-01  3.77E-01   5.34E-01 
Cav1β/α      1.73E+00   7.19E-01    7.21E-01   6.32E-01    7.38E-01   7.99E-01   6.54E-01       6.55E-01      6.77E-01    5.83E-01    5.94E-01   6.20E-01   6.19E-01    6.72E-01 
1.67E+00   1.08E+00   1.14E+00  1.21E+00   1.59E+00  1.41E+00   7.84E-01      7.66E-01      1.06E+00    1.21E+00   1.49E+00   7.74E-01  1.34E+00   4.77E-01 
1.41E+00   1.60E+00   1.28E+00  1.46E+00   1.55E+00  1.21E+00   1.20E+00     1.48E+00      1.18E+00    8.76E-01   9.54E-01   1.23E+00  9.54E-01   1.21E+00 
Average      1.60E+00   1.13E+00   1.04E+00  1.10E+00  1.29E+00  1.14E+00   8.80E-01      9.66E-01      9.70E-01     8.89E-01  1.01E+00   8.76E-01  9.71E-01    7.86E-01 
STDEV       1.73E-01    4.40E-01    2.89E-01   4.24E-01   4.81E-01   3.12E-01    2.86E-01     4.46E-01       2.61E-01    3.12E-01   4.51E-01   3.20E-01   3.62E-01    3.78E-01 
st error       1.22E-01    3.11E-01    2.04E-01   3.00E-01   3.40E-01   2.21E-01    2.03E-01     3.15E-01       1.85E-01    2.20E-01    3.19E-01   2.26E-01  2.56E-01    2.67E-01 
p value (vs.C2)                                                                                                                              8.24E-02      6.11E-01     5.58E-01   8.17E-01   2.79E-01   5.75E-01    7.48E-01 
p value (vs. time 0)       1.61E-01    4.55E-02   1.31E-01   3.54E-01   8.81E-02    2.01E-02                           9.90E-01     8.17E-01   9.04E-01   7.91E-01   9.88E-01    6.21E-01 
 
Figure 3.15 Average Cav-1 level in myoblasts (normalized with nondifferentiated C2C12) 
C2C12    OCM                                           DM                                        PD50A                       OCM                                      DM 
Nondifferentiated     24             48               96           24             48              96       Nondifferentiated       24           48             96              24             48             96 (hrs) 
1           7.87E-01   6.12E-01    8.01E-01  7.82E-01  6.28E-01   7.64E-01              1.71              1.75        1.36         3.24            2.44         1.88           2.64 
1           8.80E-01   8.18E-01    8.20E-01  8.13E-01  7.94E-01   8.41E-01              2.44         9.87E-01     1.14         1.38           1.09          1.45           4.98 
1           8.02E-01   8.39E-01    9.65E-01  8.63E-01  8.46E-01   1.10                      6.11              4.07        2.74         7.51           2.61         3.93            4.82    
1           8.59E-01   1.01            9.31E-01  9.02E-01  3.85E-01   1.34                      7.37              3.44        2.53         8.82           4.18         1.22            2.45 
Average            1           8.32E-01   8.19E-01   8.79E-01  8.40E-01  8.20E-01   1.01                      4.41              2.56        1.94         5.24           2.58         2.12           3.72 
STDEV             0           4.45E-02   1.62E-01   8.07E-02  5.30E-02  1.58E-01   2.63E-01              2.76              1.43     8.10E-01    3.51           1.27         1.24           1.36 
st error             0           2.57E-02   9.37E-02   4.66E-02  3.06E-02  9.15E-02   1.52E-01              1.59         8.28E-01  4.68E-01    2.02        7.31E-01  7.14E-01   7.87E-01 
p value (vs. C2)                                                                                                                            4.83E-02      5.28E-02  3.47E-02   4.75E-02  3.36E-01  5.92E-02  7.94E-03 
p value (vs. time 0)       2.80E-04   6.75E-02   2.43E-02  9.40E-04  6.35E-02   9.35E-01                              2.79E-01  1.37E-01  7.23E-01   2.73E-01 1.81E-01   6.70E-01 
 
Average Cav-3 level in myoblasts (normalized with nondifferentiated PD50A)  
C2C12   OCM                                     DM                                                  PD50A             OCM                                          DM   
Nondifferentiated    24          48                 96         24            48               96     Nondifferentiated      24             48            96              24              48        96(hrs) 
4.25E-03        1.52E-02  4.83E-02   8.08E-02  1.60E-02  9.11E-02   1.65E-01          1               4.78E-01    3.65E-01  3.00E-01  5.94E-01  7.24E-01   1.35E+00 
5.33E-02              0         4.46E-02   9.97E-02  4.27E-02  3.04E-03   9.59E-02          1               6.87E-01    4.09E-01  5.46E-01  7.64E-01  8.87E-01   5.39E-01 
0                     0         1.06E-01   2.89E-03      0             0             6.51E-02          1                4.53E-01   1.39E+00  3.74E-01  5.10E-01  3.81E-01   5.15E-01 
Average     1.92E-02         5.07E-03  6.63E-02   6.11E-02  1.96E-02  3.14E-02  1.09E-01         1                5.39E-01   7.22E-01   4.07E-01  6.22E-01  6.64E-01  8.02E-01 
STDEV      2.96E-02         8.77E-03  3.45E-02   5.13E-02  2.16E-02  5.17E-02  5.12E-02         0                1.28E-01    5.80E-01  1.27E-01  1.29E-01  2.59E-01  4.76E-01 
st error      2.09E-02         6.20E-03  2.44E-02   3.63E-02  1.53E-02  3.66E-02  3.62E-02          0               9.08E-02    4.10E-01  8.95E-02  9.13E-02  1.83E-01  3.37E-01 
p value (vs. C2)                                                                                                                           5.53E-07      1.98E-03    1.23E-01  1.18E-02  1.34E-03  1.42E-02  6.63E-02 
p value (vs. time 0)           4.73E-01  1.47E-01   2.87E-01  9.87E-01   7.41E-01  5.88E-02                          3.42E-03    4.53E-01  1.25E-03  7.15E-03  8.77E-02  5.11E-01 
 
Average Cav3/Cav1 
C2C12   OCM                                 DM                                            PD50A             OCM                                     DM 
Nondifferentiated    24         48          96           24              48          96     Nondifferentiated      24             48          96            24            48             96(hrs) 
0               0        0.21         1.11        0.39          0.72        1.40              2.79                3.27           1.22        1.54        1.98           1.07            3.03 
4.71E-02         0.28      0.39         0.65        0.53          0.10        1.31               4.70               4.01           3.52        1.94         3.06          1.42            3.63 
9.36E-02            0      4.45E-02    2.93       0.75      7.65E-03      0.85              2.20               3.61           2.77        1.70         3.59          1.87            2.68 
Average     4.69E-02     9.24E-02    0.22        1.56        0.56           0.49        1.19              3.23               3.63           2.50         1.73         2.87         1.45            3.11 
STDEV      4.68E-02          0.16       0.18        1.20        0.18           0.34         0.30              1.31              0.37           1.18         0.20          0.82         0.40           0.48 
st error      3.31E-02          0.11       0.12         0.85        0.13          0.24         0.21              0.92               0.26           0.83         0.14         0.58          0.28           0.34 
p value (vs. C2)                                                                                                                   1.35E-02       1.27E-02  2.91E-02  8.26E-01 9.02E-03  2.19E-02   4.05E-03 
p value (vs. time 0)       6.61E-01 1.8E-01  9.5E-02   9.51E-03 3.65E-01   2.75E-03                             6.39E-01  5.13E-01  1.2E-01   7.06E-01  8.72E-02   8.88E-01 
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Figure 3.16 IGF-2 levels in myoblasts (normalized with coomassie blue) 
C2C12    OCM                                        DM                                                     PD50A          OCM                                     DM 
Nondifferentiated   24              48            96           24               48           96      Nondifferentiated      24         48             96             24            48          96 (hrs) 
1         8.79E-01  7.37E-01  8.11E-01  8.26E-01  9.34E-01  5.46E-01      9.16E-01       5.69E-01  8.73E-01  2.03E+00 5.91E-01  8.70E-01  1.82E+00 
1         7.90E-01  8.81E-01  8.83E-01  8.60E-01  8.40E-01  8.53E-01          1.01           7.33E-01  7.11E-01     1.02       6.75E-01  7.70E-01  6.89E-01 
1         9.46E-01  9.78E-01  9.84E-01  7.58E-01  7.66E-01  6.65E-01          1.06           7.29E-01  9.96E-01     1.19       7.87E-01  7.13E-01  9.57E-01 
1         9.07E-01  9.66E-01  9.20E-01  8.62E-01  7.46E-01  7.42E-01      7.64E-01       6.22E-01  7.37E-01     1.23       7.69E-01  7.51E-01     1.16 
1         8.24E-01  8.41E-01  8.93E-01  6.54E-01  7.53E-01  5.06E-01      8.01E-01       5.18E-01  6.44E-01   8.09E-01  5.57E-01  6.59E-01  8.85E-01 
Average                      1         8.69E-01  8.80E-01  8.98E-01 7.92E-01  8.08E-01  6.62E-01      9.10E-01      6.34E-01  7.92E-01      1.26       6.76E-01  7.53E-01    1.16 
STDEV                       0         6.27E-02  9.86E-02  6.27E-02 8.77E-02  8.00E-02  1.42E-01      1.27E-01      9.56E-02  1.41E-01   4.64E-01  1.03E-01  7.80E-02  4.35E-01 
st error                       0         3.14E-02  4.93E-02  3.13E-02 4.39E-02  4.00E-02  7.11E-02       6.36E-02      4.78E-02  7.05E-02   2.32E-01  5.15E-02  3.90E-02  2.17E-01 
p value (vs. C2)                                                                                                                              1.51E-01      1.77E-03  2.84E-01   1.25E-01  9.07E-02  3.00E-01  6.36E-02 
p value (vs. time 0)              1.61E-02  2.66E-02   6.67E-03 7.30E-04  6.80E-04   7.20E-04                          4.72E-03   2.03E-01   1.46E-01  1.27E-02  4.63E-02  3.69E-01 
 
p57kip2 level in myoblasts (normalized with nondifferentiated C2C12) 
C2C12      OCM                                         DM                                                    PD50A             OCM                                   DM 
Nondifferentiated      24             48           96             24             48                96      Nondifferentiated    24         48             96             24           48          96 (hrs) 
1             1.10         1.14         1.86        5.99E-01  5.39E-01  5.14E-01          1.26           9.03E-01     1.10           1.67     7.20E-01  5.65E-01  4.74E-01 
1             1.68         1.20         1.48        4.90E-01  4.81E-01  6.12E-01          1.30                 1.28    9.29E-01      3.37     6.61E-01  5.68E-01  5.64E-01 
1             1.48         1.14         1.52        5.85E-01  4.85E-01  4.67E-01          1.15                 1.18       1.18           2.55     8.75E-01  7.35E-01  5.97E-01 
Average                        1             1.42         1.16         1.62        5.58E-01  5.02E-01  5.31E-01          1.24                 1.12       1.07           2.53    7.52E-01  6.23E-01  5.45E-01 
STDEV                         0          2.95E-01  3.61E-02  2.06E-01 5.94E-02  3.28E-02  7.41E-02      7.72E-02      1.96E-01  1.27E-01  8.46E-01  1.10E-01 9.76E-02  6.36E-02 
st error                         0          2.09E-01  2.55E-02  1.45E-01 4.20E-02  2.32E-02  5.24E-02      5.46E-02      1.38E-01  8.98E-02  5.98E-01  7.80E-02 6.90E-02  4.50E-02 
p value (vs. C2)                                                                                                                                 6.01E-03      2.18E-01  3.01E-01  1.45E-01  5.53E-02 1.12E-01  8.2E-01 
p value (vs. time 0)                  6.93E-02  1.59E-03  6.31E-03 2.09E-04  1.24E-05  3.95E-04                           3.96E-01  1.20E-01  5.77E-02  3.36E-03 1.03E-03   2.8E-04 
 
Figure 3.17 pAKT and AKT levels in myoblasts (normalized with coomassie blue) 
C2C12    OCM                                             DM                                               PD50A              OCM                                    DM 
Nondifferentiated   24              48                96          24              48             96       Nondifferentiated      24         48             96            24             48             96 
pAKT                     2.93E-02  4.06E-02  7.92E-02  1.10E-01  1.10E-02  9.92E-03   9.13E-03      3.55E-02         3.23E-02  4.39E-02  1.12E-01  1.98E-02  1.77E-02  1.25E-02 
2.61E-02  3.29E-02  5.23E-02  6.17E-02  1.26E-02  1.26E-02   1.19E-02       2.19E-02        1.55E-02  2.45E-02  4.28E-02  1.55E-02  1.47E-02  1.24E-02 
2.76E-02  2.29E-02  8.09E-02  9.41E-02  1.86E-02  1.57E-02   1.44E-02       5.36E-02        3.96E-02  5.83E-02  8.87E-02  2.44E-02  2.22E-02  1.87E-02 
1.85E-01  4.41E-02  5.45E-02  6.25E-02  1.07E-02  8.56E-03   7.57E-03       5.36E-02        3.56E-02  4.86E-02  7.47E-02  1.38E-02  1.00E-02  6.88E-03 
Average                  6.70E-02  3.51E-02  6.67E-02  8.22E-02  1.32E-02  1.17E-02  1.07E-02       4.11E-02        3.07E-02  4.39E-02  7.95E-02  1.84E-02  1.62E-02  1.26E-02 
STDEV                   7.87E-02  9.37E-03  1.54E-02  2.41E-02  3.66E-03  3.17E-03  3.03E-03       1.54E-02        1.06E-02  1.42E-02  2.88E-02  4.75E-03  5.14E-03  4.83E-03 
st error                   4.55E-02  5.41E-03  8.90E-03  1.39E-02  2.12E-03  1.83E-03  1.75E-03       8.90E-03        6.10E-03  8.22E-03  1.66E-02  2.74E-03  2.97E-03  2.79E-03 
p value (vs. C2)                                                                                                                                 5.42E-01         5.57E-01  7.20E-02  8.91E-01  1.38E-01  1.90E-01  5.37E-01 
p value (vs. time 0)                 4.52E-01  9.94E-01  7.26E-01  2.21E-01  2.10E-01  2.03E-01                               3.08E-01  8.05E-01  5.74E-02  3.01E-02  2.18E-02  1.23E-02 
AKT                       5.30E-02  6.58E-02  7.93E-02  9.77E-02  1.74E-02  1.66E-02   1.77E-02       5.40E-02         6.29E-02  1.32E-01  4.08E-02  3.70E-02  3.78E-02  2.19E-02 
4.72E-02  5.24E-02  8.14E-02  3.11E-02  2.28E-02  1.94E-02   1.76E-02       5.74E-02         5.56E-02  7.54E-02  5.25E-02  3.89E-02  2.88E-02  3.34E-02 
5.10E-02  3.27E-02  4.12E-02  1.15E-01  1.89E-02  2.02E-02   1.50E-02       6.25E-02         4.88E-02  2.93E-02  9.32E-02  2.01E-02  1.33E-02  1.77E-02 
4.44E-02  2.54E-02  1.03E-01  3.64E-02  2.08E-02  1.95E-02   9.09E-03       3.06E-02         2.27E-02  6.71E-02  4.18E-02  2.56E-02  2.43E-02  2.14E-02 
Average                 4.89E-02  4.41E-02  7.61E-02  7.01E-02  2.00E-02  1.89E-02  1.48E-02       5.11E-02         4.75E-02  5.09E-02  5.71E-02  3.04E-02  2.61E-02  2.36E-02 
STDEV                  3.82E-03  1.84E-02  2.55E-02  4.26E-02  2.34E-03  1.61E-03  4.03E-03       1.41E-02         1.75E-02  2.37E-02  2.47E-02  9.05E-03  1.02E-02  6.81E-03 
st error                  1.91E-03  9.22E-03  1.28E-02  2.13E-02  1.17E-03  8.05E-04  2.02E-03       7.06E-03         8.74E-03  1.19E-02  1.23E-02  4.53E-03  5.08E-03  3.40E-03 
p value (vs. C2)                                                                                                                                 7.72E-01         7.96E-01  9.99E-01  6.17E-01  6.74E-02  2.15E-01  6.89E-02 
p value (vs. time 0)                6.26E-01  7.97E-02  3.61E-01  1.3E-05    6.8E-06     1.8E-05                                 7.58E-01  3.08E-01   6.90E-01  4.82E-02  2.8E-02   1.26E-02 
pAKT/AKT            5.53E-01  6.28E-01  6.43E-01   6.31E-01  4.85E-01  5.11E-01  5.17E-01       6.17E-01        1.18E+00  6.85E-01  4.86E-01  8.06E-01  1.10E+00  7.00E-01 
5.53E-01  7.02E-01  6.67E-01   7.49E-01  6.68E-01  6.24E-01  6.73E-01        7.60E-01         9.84E-01  8.34E-01  8.15E-01  7.70E-01  9.15E-01  8.75E-01 
5.42E-01  7.66E-01  7.89E-01   8.18E-01  8.78E-01  8.07E-01  8.33E-01        8.57E-01         8.11E-01  8.69E-01  9.52E-01  9.55E-01  9.08E-01  7.84E-01 
Average                  5.49E-01  6.99E-01  7.00E-01   7.33E-01  6.77E-01  6.47E-01  6.75E-01       7.45E-01         9.93E-01  7.96E-01  7.51E-01  8.44E-01  8.65E-01  7.86E-01 
STDEV                   6.70E-03  6.92E-02  7.83E-02   9.45E-02  1.97E-01  1.50E-01  1.58E-01       1.21E-01         1.87E-01  9.75E-02  2.39E-01  9.82E-02  8.04E-02  8.74E-02 
st error                   4.73E-03  4.89E-02  5.54E-02   6.68E-02  1.39E-01  1.06E-01  1.12E-01       8.54E-02         1.32E-01  6.90E-02  1.69E-01  6.94E-02  5.69E-02  6.18E-02 
p value (vs. C2)                                                                                                                                   4.88E-02         6.26E-02  2.52E-01  9.08E-01  2.58E-01  3.8E-02   3.44E-01 
p value (vs. time 0)                 2.05E-02  2.97E-02   2.84E-02  3.25E-01  3.2E-01    2.43E-01                                1.26E-01  5.98E-01  9.71E-01  3.33E-01 7.16E-02  6.56E-01 
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pmTOR and mTOR levels in myoblasts (normalized with nondifferentiated C2C12) 
C2C12    OCM                                        DM                                                PD50A              OCM                                   DM 
Nondifferentiated   24         48              96              24             48              96       Nondifferentiated      24          48             96          24               48         96(hrs) 
pmTOR            3.30E-02   1.23E-02   1.46E-02  2.22E-02   9.36E-03   8.76E-03   8.32E-03        3.54E-02     1.95E-02  2.09E-02  5.06E-02  1.43E-02  1.03E-02  9.25E-03 
3.52E-02   1.41E-02   1.83E-02  3.31E-02   1.02E-02   1.04E-02   9.79E-03        3.67E-02     2.05E-02  2.47E-02  4.08E-02  1.70E-02  1.42E-02  1.20E-02 
4.00E-02   1.55E-02   1.58E-02  1.95E-02   8.46E-03   8.90E-03   8.95E-03        3.15E-02     3.29E-02  1.71E-02  2.56E-02  1.80E-02  1.62E-02  1.27E-02 
3.56E-02   1.74E-02   2.41E-02  3.12E-02   9.08E-03   8.45E-03   7.62E-03        2.25E-02     2.22E-02  2.68E-02  4.23E-02  1.66E-02  1.06E-02  8.40E-03 
Average            3.59E-02    1.98E-02  2.34E-02  3.80E-02  1.02E-02   8.83E-03   8.48E-03        2.62E-02     2.20E-02  2.63E-02  4.78E-02  1.52E-02 1.28E-02  1.15E-02 
STEDV             2.95E-03    8.40E-03  8.75E-03  2.10E-02  2.10E-03  1.14E-03   1.09E-03        1.25E-02     8.46E-03  8.04E-03  2.42E-02  4.12E-03  3.66E-03  4.00E-03 
st error             1.70E-03    4.85E-03  5.05E-03  1.21E-02  1.21E-03   6.58E-04   6.28E-04        7.22E-03     4.88E-03  4.64E-03  1.40E-02  2.38E-03  2.11E-03  2.31E-03 
p value (vs. C2)                                                                                                                                2.55E-01     3.41E-02  2.16E-01   7.46E-02  1.5E-04   4.68E-02  1.44E-01 
p value (vs. time 0)             2.5E-05    4.6E-04    4.14E-02  2.2E-06     2.2E-06     2.1E-06                              1.33E-01  5.56E-02   2.22E-01  3.85E-03 1.78E-03  8.1E-04 
mTOR            1.02E-02   1.26E-02    1.33E-02  1.51E-02   5.53E-03  8.93E-03   8.17E-03        1.65E-02      9.07E-03  9.16E-03   4.51E-02  8.14E-03  1.08E-02  1.01E-02 
1.04E-02   1.03E-02    1.03E-02  1.98E-02   5.85E-03  7.09E-03   7.33E-03        1.18E-02      1.21E-02  1.60E-02   1.37E-02  1.01E-02  1.02E-02  8.75E-03 
1.37E-02   1.18E-02    8.62E-03  9.64E-03   1.06E-02  7.30E-03   1.06E-02        7.66E-03      7.22E-03  8.32E-03   3.45E-02  1.37E-02  7.90E-03  9.22E-03 
1.17E-02   1.05E-02    7.91E-03  1.38E-02   7.57E-03  8.87E-03   1.08E-02        8.03E-03      7.98E-03  8.81E-03   3.69E-02  6.87E-03  8.17E-03  9.97E-03 
Average          1.15E-02   1.13E-02    1.00E-02  1.46E-02   7.38E-03  8.05E-03   9.22E-03       1.10E-02      9.09E-03  1.06E-02   3.26E-02  9.71E-03  9.25E-03  1.38E-02 
STEDV           1.62E-03   1.10E-03    2.42E-03  4.18E-03   2.31E-03  9.87E-04   1.74E-03       4.12E-03      2.14E-03  3.61E-03   1.34E-02  3.00E-03  1.43E-03  6.58E-03 
st error           2.46E-04   1.68E-04    3.68E-04  2.41E-03   1.33E-03  5.70E-04   1.00E-03       2.38E-03      1.24E-03  2.09E-03   7.73E-03  1.73E-03  8.25E-04  3.80E-03 
p value (vs. C2)                                                                                                                                  8.24E-01      1.17E-01   8.15E-01   4.27E-02  2.63E-01  2.15E-01  7.66E-01 
p value (vs. time 0)              8.31E-01   3.47E-01   2.21E-01  2.61E-02   1.06E-02   1.02E-01                             4.43E-01   8.79E-01  2.17E-02  6.32E-01  4.55E-01  5.03E-01 
pmTOR/mTOR3.45E+00  1.12E+00   1.37E+00  2.20E+00  9.26E-01   1.05E+00  1.03E+00       2.22E+00      1.55E+00  1.94E+00  1.87E+00 1.32E+00 1.61E+00  1.68E+00 
3.85E+00  8.34E-01   2.00E+00  1.41E+00  1.25E+00  1.07E+00  9.21E-01       1.25E+00       7.24E-01   7.64E-01  1.18E+00  9.27E-01  1.59E+00   1.46E+00 
3.42E+00  8.48E-01   9.48E-01  1.59E+00   1.20E+00  9.52E-01   7.07E-01       1.88E+00       8.43E-01   7.16E-01  1.15E+00  8.79E-01  1.13E+00   8.64E-01 
Average              3.57E+00  9.35E-01  1.44E+00  1.73E+00  1.12E+00  1.02E+00  8.86E-01      1.78E+00      1.04E+00  1.14E+00  1.40E+00  1.04E+00 1.44E+00  1.33E+00 
STEDV                2.37E-01  1.63E-01  5.27E-01   4.11E-01   1.74E-01   6.20E-02  1.64E-01       4.93E-01       4.45E-01    6.92E-01   4.10E-01  2.40E-01  2.69E-01   4.20E-01 
st error                1.68E-01  1.15E-01  3.73E-01   2.91E-01   1.23E-01   4.38E-02  1.16E-01       3.49E-01       3.15E-01    4.89E-01   2.90E-01  1.70E-01  1.90E-01   2.97E-01 
p value (vs. C2)                                                                                                                                  4.8E-03        7.25E-01     5.83E-01   3.79E-01  6.5E-01    5.79E-02   1.62E-01 
p value (vs. time 0)              9.15E-05  3.07E-03  2.56E-03    1.34E-04   5.56E-05  8.62E-05                             1.24E-01    2.59E-01    3.59E-01 7.89E-02  3.53E-01   2.93E-01 
 
Figure 3.18 pERK1/2 vs. ERK1/2 in myoblasts 
C2C12       OCM                                     DM                                             PD50A              OCM                                      DM 
Nondifferentiated   24            48            96             24             48            96      Nondifferentiated    24          48             96              24           48         96(hrs) 
pERK42/ERK42    8.08E-02  6.31E-02  4.38E-02   5.97E-02  7.19E-02  1.12E-01  8.53E-02       1.02E-01     1.54E-01  1.71E-01  9.34E-02  1.21E-01  1.56E-01  2.04E-01 
3.26E-02  2.83E-02   2.30E-02   3.07E-02  3.16E-02  3.25E-02  3.12E-02       2.21E-02     2.40E-02  2.07E-02  2.91E-02  2.61E-02  2.22E-02  2.78E-02 
1.30E-01  1.16E-01   1.03E-01   1.25E-01  1.14E-01  1.38E-01  1.29E-01       9.93E-02     9.40E-02  8.68E-02  1.01E-01  1.06E-01  1.00E-01  1.21E-01 
Average                  8.11E-02  6.92E-02   5.65E-02  7.17E-02  7.24E-02  9.41E-02  8.17E-02      7.44E-02     9.08E-02  9.29E-02  7.46E-02  8.46E-02  9.30E-02  1.18E-01 
STDEV                   4.86E-02  4.43E-02   4.14E-02  4.81E-02  4.10E-02  5.49E-02  4.88E-02      4.53E-02     6.52E-02  7.53E-02  3.96E-02  5.13E-02  6.74E-02  8.84E-02 
st error                   3.44E-02  3.13E-02   2.93E-02  3.40E-02  2.90E-02  3.88E-02  3.45E-02      3.21E-02     4.61E-02  5.33E-02  2.80E-02  3.62E-02  4.76E-02  6.25E-02 
p value (vs. C2)                                                                                                                                  8.71E-01     6.6E-01    5.05E-01  9.39E-01  7.63E-01  9.84E-01  5.71E-01 
p value (vs. time 0)                 7.71E-01   5.42E-01  8.24E-01  8.24E-01  7.74E-01  9.89E-01                          7.39E-01  7.35E-01   9.96E-01  8.09E-01  7.12E-01  4.31E-01 
pERE44/ERK44   6.11E-02  8.38E-02  4.92E-02  7.45E-02  1.28E-01  1.15E-01  8.11E-02         1.97E-01      3.73E-01  4.25E-01   2.28E-01  2.55E-01  3.40E-01  4.02E-01 
1.68E-02  3.25E-02  2.06E-02  2.85E-02  3.04E-01  2.46E-01  3.18E-02         3.00E-01      5.19E-01  3.73E-01   5.68E-01  4.68E-01  4.58E-01  3.53E-01 
5.74E-02  1.54E-01  8.24E-02  1.01E-01  1.73E-01  1.78E-01  1.37E-01         6.03E-02      7.38E-02  5.27E-02  5.78E-02  7.45E-02  5.53E-02  6.73E-02 
Average                  4.51E-02  9.01E-02  5.07E-02  6.80E-02  2.02E-01  1.80E-01  8.32E-02       1.86E-01      3.22E-01  2.83E-01  2.85E-01  2.66E-01  2.84E-01  2.74E-01 
STDEV                   2.46E-02  6.09E-02  3.09E-02  3.67E-02  9.15E-02  6.53E-02  5.25E-02       1.20E-01      2.27E-01  2.02E-01  2.60E-01  1.97E-01  2.07E-01  1.81E-01 
st error                   1.74E-02  4.31E-02  2.18E-02  2.60E-02  6.47E-02  4.62E-02  3.71E-02       8.50E-02      1.61E-01  1.43E-01  1.84E-01  1.39E-01  1.46E-01  1.28E-01 
p value (vs. C2)                                                                                                                                  1.18E-01      1.63E-01  1.19E-02  2.26E-01  6.35E-01  4.51E-01  1.54E-01 
p value (vs. time 0)                 3.01E-01  8.17E-01  4.19E-01  4.58E-02  2.88E-02  3.19E-01                             4.1E-01    5.1E-01    5.81E-01  5.79E-01  5.15E-01  5.19E-01 
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Appendix 4. Raw data of Chapter 4 and 5 
Figure 4.1 
Cav-3 level in E17.5 embryos (normalized with wt)            Cav-1 level in E17.5 embryos (normalized with wt) 
Wt       mdx            cav3-/-     DMhet                                                     Wt         mdx         cav3-/-        DMhet 
1       1.28              0          6.71E-01                                                     1           3.04       4.65E-01     1.43 
1       1.57              0          7.31E-01                                                     1           2.57       6.20E-01     2.02 
1       1.44              0          6.41E-01                                                     1           3.55       4.78E-01     1.83  
1       1.43              0          7.27E-01                                                     1           2.40       5.84E-01     2.24 
Average        1       1.46              0          7.14E-01                                 Average     1           2.97       5.47E-01     1.95 
STDEV         0       1.55E-01      0          4.39E-02                                 STDEV      0        7.00E-01  7.22E-02   3.82E-01 
st error         0       3.51E-04      0          2.54E-02                                  st error      0        4.04E-01  4.17E-02   2.20E-01 
p-value (vs. wt)     3.30E-04     N/A      8.17E-06                                  p-value (vs. wt)   3.41E-03  1.97E-05   2.10E-03 
 
Cav1/Cav3 in E17.5 embryos                              Pax7 level in E17.5 embryos (normalized with wt) 
Wt         mdx        DMhet                                                Wt        mdx           cav3-/-     DMhet 
1.91E+00  4.52E+00  4.07E+00                                              1    6.59E-01  7.73E-01  6.23E-01 
1.97E+00  3.22E+00  5.44E+00                                              1    7.09E-01  7.59E-01  5.37E-01 
1.84E+00  4.54E+00  5.25E+00                                              1    8.49E-01  8.12E-01  7.04E-01 
1.68E+00  2.82E+00  5.17E+00                                              1    7.67E-01  8.22E-01  7.11E-01  
Average  1.85E+00  3.77E+00  4.98E+00                       Average        1    7.41E-01  7.72E-01  6.39E-01 
STDEV   1.25E-01   8.88E-01   6.18E-01                        STDEV         0    6.49E-02  3.95E-02  6.88E-02 
st error   7.20E-02   5.13E-01   3.57E-01                        st error          0    3.75E-02  2.28E-02  3.97E-02 
p-value (vs. wt)        5.09E-03   5.96E-05                        p-value (vs. wt)  7.97E-04  9.38E-06  1.26E-04 
 
Figure 5.1 
IGF-2 levels in E17.5 embryos (normalized with wt) 
high MW  Wt          mdx         cav3-/-   DMhet             low MW Wt           mdx         cav3-/-     DMhet  
1        1.05         0.90         1.19                                   1             0.75        0.80         0.85 
1        1.37         0.95         1.30                                   1             0.87        0.97         0.87 
1        1.17         0.92         1.78                                   1             0.86        0.95         0.84 
1        1.26         0.79         1.32                                   1             0.82        0.89         0.81 
Average        1        1.21         0.89         1.40                                   1             0.93        1.00         0.91 
STDEV         0     1.38E-01  7.15E-02  2.62E-01                            1             0.89        0.94         0.90 
st. error        0     7.95E-02  4.13E-02  1.51E-01 Average             1             0.85        0.92         0.87 
p-value (vs. wt)   2.22E-02  2.17E-02  2.3E-02   STDEV              0        5.66E-02  6.70E-02  4.37E-02 
st error           0       2.53E-02  3.00E-02  1.96E-02 
 p-value (vs. wt)        2.00E-04  2.56E-02  5.70E-06 
 
p57kip2 level in E17.5 embryos (normalized with wt) 
Wt            mdx         cav3-/-    DMhet  
1          7.62E-01  8.87E-01  5.99E-01 
1          8.77E-01  8.12E-01  7.58E-01 
1          7.91E-01  8.30E-01  6.93E-01 
1          7.68E-01  7.68E-01  5.56E-01 
Average      1          8.00E-01  8.24E-01  6.51E-01 
STDEV       0          5.30E-02  4.92E-02  9.13E-02 
st error       0          3.06E-02  2.84E-02  5.27E-02 
p-value (vs. wt)      2.78E-04  3.79E-04  2.63E-04 
 
pmTOR level in E17.5 embryos (normalized with wt)    pAKT levels in E17.5 embryos (normalized with wt) 
Wt        mdx            cav3-/-    DMhet                                           Wt          mdx         cav3-/-    DMhet 
1         1.44          5.03E-01   2.93                                                 1            1.50       5.80E-01   1.17 
1         1.61          6.58E-01   1.89                                                 1            1.33       5.38E-01   1.15 
1         1.74          4.69E-01   3.43                                                 1            1.21       5.86E-01   1.25 
Average        1         1.65          5.69E-01   2.82                                                 1            1.02       5.54E-01   1.22 
STDEV         0         1.86          1.65E-01   5.74E-01                     Average      1            1.27       5.65E-01   1.20 
st error         0         1.32E-01  1.17E-01   4.06E-01                     STDEV       0         1.99E-01   2.24E-02  4.45E-02 
p-value (vs. wt)       2.59E-03  1.42E-03   1.77E-02                     st error       0          1.15E-01  1.29E-02  2.57E-02 
p-value (vs. wt)                        3.70E-02  1.93E-08  1.13E-04 
 
AKT level and pAKT/AKT ration in E17.5 embryos (normalized with wt) 
 AKT   Wt             mdx         cav3-/-   DMhet              pAKT/AKT      Wt           mdx          cav3-/-     Dmhet  
1              1.21     5.08E-01     1.40                                      1.31E+00  1.62E+00  1.49E+00  1.09E+00 
1              1.21     4.30E-01     1.25                                      1.27E+00  1.40E+00  1.60E+00  1.18E+00 
1              1.33     4.72E-01     1.87                                       5.78E-01  5.30E-01   7.18E-01    3.86E-01 
1              1.48     4.86E-01     1.54                                       6.11E-01  4.21E-01   6.95E-01    4.85E-01 
Average      1              1.31     4.74E-01     1.51                        Average 9.43E-01  9.94E-01  1.13E+00  7.86E-01 
STDEV        0        1.30E-01  3.31E-02  2.66E-01                     STDEV 4.03E-01  6.07E-01  4.86E-01   4.08E-01 
st error        0        7.52E-02  1.91E-02  1.53E-01                     st error 2.32E-01   3.50E-01  2.81E-01   2.36E-01 
p-value (vs. wt)     3.29E-03  6.41E-08  8.33E-03                     p-value (vs. wt)      8.94E-01  5.83E-01   6.03E-01 
 
pERK42/ERK42 and pERK44/ERK44 ratios in E17.5 embryos  
pErk42/Erk42 Wt           mdx         cav3-/-     DMhet   pErk44/Erk44 Wt            mdx       cav3-/-   DMhet 
2.47E-01  2.07E-01  2.26E-01  4.05E-01                       2.30E-01  1.78E-01  2.11E-01  2.87E-01 
3.13E-01  2.38E-01  2.38E-01  4.23E-01                       2.36E-01  1.56E-01  2.23E-01  3.00E-01 
4.33E-01  2.22E-01  2.36E-01  4.08E-01                       2.72E-01  1.63E-01  2.26E-01  2.56E-01 
2.83E-01  2.05E-01  2.53E-01  3.71E-01                       2.47E-01  1.60E-01  2.70E-01  2.73E-01 
Average     3.19E-01  2.18E-01  2.38E-01  4.02E-01   Average     2.46E-01  1.64E-01  2.33E-01  2.79E-01 
STDEV      8.08E-02  1.55E-02  1.12E-02  2.18E-02    STDEV     1.85E-02  9.67E-03  2.59E-02  1.88E-02 
st error      5.71E-02  1.09E-02  7.91E-03  1.54E-02    st error      1.31E-02  6.84E-03  1.83E-02  1.33E-02 
p-value (vs. wt)          4.92E-02  9.54E-02  9.52E-02    p-value (vs. wt)          2.20E-04  4.19E-01  4.98E-02 
 
Figure 5.7  
pSrc/Src in 4-week and 9-week adult skeletal muscle tissues  
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pSrc     4w                                   9w                                                             Src   4w                                               9w 
wt        cav3-/-        mdx             wt            cav3-/-       mdx         wt            cav3-/-       mdx           wt           cav3-/-         mdx 
1.00E+00  1.07E+00  1.78E+00  1.00E+00  1.04E+00  1.25E+00  1.00E+00  1.10E+00  1.73E+00  1.00E+00  9.94E-01  1.33E+00 
1.00E+00  1.09E+00  1.32E+00  1.00E+00  9.87E-01  1.23E+00   1.00E+00  1.09E+00  2.07E+00  1.00E+00  1.05E+00 1.18E+00 
1.00E+00  1.08E+00  1.93E+00  1.00E+00  8.35E-01  1.36E+00   1.00E+00  1.49E+00  1.44E+00  1.00E+00  8.04E-01  1.30E+00 
1.00E+00  1.25E+00  1.56E+00  1.00E+00  7.68E-01  1.45E+00   1.00E+00  1.40E+00  1.94E+00  1.00E+00  8.07E-01  1.44E+00 
Average1.00E+00  1.12E+00  1.65E+00  1.00E+00  9.07E-01 1.32E+00   1.00E+00  1.27E+00  1.80E+00  1.00E+00  9.13E-01 1.31E+00 
STDEV 0.00E+00  8.80E-02   2.65E-01  0.00E+00  1.27E-01  1.01E-01    0.00E+00  2.06E-01   2.74E-01  0.00E+00  1.26E-01  1.08E-01 
st error 0.00E+00  5.08E-02   1.53E-01  0.00E+00  7.32E-02  5.80E-02    0.00E+00  1.19E-01   1.58E-01  0.00E+00  7.29E-02  6.23E-02 
p(vs wt)                  3.18E-02    2.74E-03                    1.92E-01  6.86E-04                     3.88E-02   1.13E-03                    2.19E-01  1.44E-03 
pSrc/Src      4w                                           9w        
wt          cav3-/-       mdx           wt          cav3-/-        mdx 
9.57E-01   9.59E-01  9.53E-01   8.10E-01  8.46E-01  7.62E-01 
4.64E-01   5.68E-01  4.25E-01   7.48E-01  8.26E-01  5.95E-01 
1.00E+00  9.87E-01  1.00E+00  6.76E-01  7.08E-01  6.38E-01 
9.33E-01   9.33E-01  9.27E-01   8.64E-01  9.76E-01  8.91E-01 
Average8.39E-01   8.62E-01  8.27E-01  7.75E-01  8.39E-01  7.21E-01 
STDEV 2.52E-01   1.97E-01  2.70E-01  8.11E-02  1.10E-01  1.33E-01 
st error 1.46E-01   1.14E-01  1.56E-01  4.68E-02  6.34E-02  7.70E-02 
p value vs wt          8.94E-01  9.50E-01                   3.81E-01  5.21E-01 
 
Figure 5.9 
IGF-2 level in MG/MIG stable clones (normalized with β-actin) 
C2MG    C2MG        C2MIG    C2MIG                                    C2MG      C2MG        C2MIG      C2MIG 
Pro- IGF2            RNAi-gfp  RNAi-igf2  RNAi-gfp  RNAi-igf2   mature IGF2  RNAi-gfp  RNAi-igf2  RNAi-gfp   RNAi-igf2 
9.75E-01    1.03E+00    1.19E+00   1.16E+00                                1.25E-01    1.50E-01      3.13E-01    2.26E-01 
1.20E+00    7.92E-01    1.68E+00   1.29E+00                                1.60E-01    1.72E-01      4.65E-01    2.66E-01 
1.14E+00   1.56E+00    2.82E+00   1.83E+00                                 2.42E-01    2.35E-01     5.18E-01    3.16E-01 
Average              1.11E+00   1.13E+00    1.90E+00  1.43E+00       Average           1.76E-01    1.85E-01     4.32E-01    2.69E-01 
STDEV               1.19E-01    3.93E-01     8.38E-01   3.59E-01        STDEV            6.01E-02    4.40E-02     1.07E-01    4.55E-02 
St error               8.39E-02   2.78E-01      5.92E-01   2.54E-01        St error            4.25E-02   3.11E-02     7.53E-02    3.22E-02 
p value (vs control)              9.31E-01                        4.22E-01        p value (vs control)           8.36E-01                        7.16E-02 
 
Cav-1 and Cav-3 levels in MG/MIG stable clones (normalized with β-actin) 
C2MG     C2MG       C2MIG    C2MIG                          C2MG     C2MG        C2MIG    C2MIG- 
Cav1   RNAi-gfp  RNAi-igf2  RNAi-gfp  RNAi-igf2         Cav3  RNAi-gfp  RNAi-igf2  RNAi-gfp  RNAi-igf2 
7.41E-01    5.60E-01    3.20E-01   3.56E-01                         8.36E-02    1.14E-01    1.47E-01    1.35E-01 
1.13E+00   7.37E-01    4.99E-01   4.00E-01                         1.10E-01    1.07E-01    1.73E-01    1.83E-01 
1.09E+00   8.43E-01    3.08E-01   3.98E-01                         8.28E-02    1.30E-01    1.60E-01    1.53E-01 
5.03E-01    6.50E-01    3.70E-01   3.71E-01        Average   9.22E-02    1.17E-01    1.60E-01   1.57E-01 
Average          8.66E-01    6.98E-01    3.74E-01  3.81E-01        STDEV   1.55E-02    1.21E-02    1.31E-02   2.41E-02 
STDEV           2.99E-01   1.21E-01     8.70E-02  2.10E-02        St error   1.10E-02    8.56E-03    9.23E-03   1.71E-02 
St error          1.73E-01    6.97E-02    5.02E-02  1.21E-02  p value (vs control)          9.37E-02                      8.49E-01 
p value (vs control)          3.36E-01                     8.83E-01  
Cav1/low MW IGF-2                                                               Cav3/LowMW IGF-2 
C2MG-    C2MG-       C2MIG-    C2MIG-                     C2MG-    C2MG-       C2MIG-    C2MIG- 
RNAi-gfp  RNAi-igf2   RNAi-gfp  RNAi-igf2               RNAi-gfp   RNAi-igf2   RNAi-gfp  RNAi-igf2 
                        5.92E+00   4.34E+00   1.02E+00    1.65E+00                  6.62E-01     7.12E-01      4.70E-01    5.98E-01 
6.79E+00   4.29E+00   7.95E-01     1.50E+00                  5.21E-01     6.64E-01      3.44E-01    5.76E-01 
4.67E+00   3.59E+00   9.63E-01     1.26E+00                  4.54E-01     5.55E-01      3.34E-01    5.77E-01 
Average          5.79E+00   4.07E+00   9.27E-01    1.47E+00  Average 5.46E-01     6.44E-01      3.83E-01    5.84E-01 
STDEV           1.06E+00   4.17E-01   1.19E-01     1.93E-01    STDEV 1.06E-01     8.02E-02      7.59E-02   1.25E-02 
St error           7.52E-01   2.95E-01    8.38E-02    1.37E-01    St error 7.49E-02     5.67E-02      5.37E-02    8.85E-03 
p value (vs control)          5.93E-02                       1.45E-02 p value (vs control)     2.70E-01                         1.06E-02 
 
Pax7 level in MG/MIG stable clones (normalized with β-actin)          myogenin in MG/MIG stable clones (normalized with β-actin) 
C2MG      C2MG       C2MIG     C2MIG                             C2MG      C2MG       C2MIG     C2MIG 
RNAi-gfp  RNAi-igf2  RNAi-gfp  RNAi-igf2                        RNAi-gfp  RNAi-igf2  RNAi-gfp  RNAi-igf2 
4.03E-01   1.19E+00     4.24E-01    1.27E+00                          1.28E-01   1.36E-01     1.85E-01    1.44E-01 
2.93E-01   9.33E-01      4.37E-01    1.29E+00                          1.68E-01   1.44E-01     2.35E-01    1.66E-01 
5.13E-01   1.11E+00     7.95E-01    1.14E+00                          1.10E-01   9.69E-02     1.48E-01    9.56E-02 
Average          4.03E-01   1.08E+00    5.52E-01    1.23E+00                          1.40E-01   1.08E-01     1.73E-01    1.10E-01 
STDEV           1.10E-01   1.33E-01     2.11E-01    7.87E-02          Average   1.36E-01  1.21E-01     1.85E-01    1.29E-01 
St error          7.76E-02    9.38E-02    1.49E-01     5.56E-02           STDEV   2.46E-02  2.24E-02     3.64E-02    3.19E-02 
p value (vs control)          2.44E-03                        6.35E-03          St error   1.74E-02   1.58E-02     2.57E-02    1.84E-02 
p value (vs control)                  3.99E-01                        5.89E-02 
Figure 5.11 
Pax7 level in Pax7 transfectants 
Pax7A         C2C12                                                          dfd13 
mCherry  dsgfpsh Pax7mCherry Pax7sh  mCherry  dsgfpsh Pax7mCherry Pax7sh 
1               1            3.47E-01     4.71E-01       1               1         2.44E-01       8.11E-01 
1               1            3.15E-01     4.29E-01       1               1         6.99E-01       6.85E-01 
1               1            4.46E-01     4.28E-01       1               1         6.46E-01       8.95E-01 
Average        1               1            7.48E-01     3.68E-01       1               1         1.19E-01      1.24E-01 
STDEV         0               0            6.86E-02     2.44E-02       0               0         2.49E-01      1.06E-01 
st error         0               0             4.85E-02    1.73E-02       0               0         1.76E-01       7.50E-02 
p vlue (vs control)                       9.08E-05    2.45E-06                                    3.06E-02      2.95E-02 
 
Pax7B 
1                 1             2.79E-01      1.03              1               1          2.53E-01     4.03 
1                 1             4.75E-01   9.18E-01         1               1          5.37E-01     6.76 
1                 1             3.16E-01   1.98E-01         1               1          2.71E-01     2.62 
Average      1                 1             3.52E-01   7.15E-02         1               1          3.54E-01    4.47 
STDEV        0                0             1.07E-01   4.52E-01         0               0          1.59E-01    2.10 
st error        0                0             7.56E-02   3.20E-01         0               0          1.12E-01    1.49 
p vlue (vs control)                       4.70E-04   3.37E-01                                      2.15E-03    4.59E-02 
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Cav-3 level in Pax7 transfectants 
C2C12                                dfd13 
mCherry  dsgfpsh Pax7mCherry Pax7sh  mCherry  dsgfpsh Pax7mCherry Pax7sh 
1               1            7.22E-01      1.01             1               1          2.67E-01        2.56 
1               1            7.22E-01    8.19E-01       1               1          1.63E-01        2.52 
1               1              1.03          6.50E-01       1               1          2.46E-01        1.87 
Average          1               1            8.25E-01    8.26E-01       1               1          2.25E-01        2.32 
STDEV           0               0            1.79E-01    1.80E-01       0               0          5.49E-02        3.86E-01 
st error           0               0            1.27E-01    1.27E-01       0               0          3.88E-02        2.73E-01 
p vlue (vs control)                        1.66E-01     1.70E-01                                   1.67E-05        4.11E-03 
 
Cav-1 level in Pax7 transfectants 
C2C12                                dfd13 
mCherry  dsgfpsh Pax7mCherry Pax7sh  mCherry  dsgfpsh Pax7mCherry Pax7sh 
1                 1            1.10E-01    4.93E-01         1            1          6.37E-01       9.19E-01 
1                 1            1.59E-01    4.87E-01         1            1          6.19E-01       1.12 
1                 1            1.85E-01    3.21E-01         1            1          7.91E-01       9.47E-01 
Average        1                 1            1.52E-01    4.34E-01         1            1          6.82E-01      9.95E-01 
STDEV         0                 0            3.82E-02    9.77E-02         0            0          9.44E-02      1.07E-01 
st error         0                 0            2.70E-02    6.91E-02         0            0          6.67E-02      7.57E-02 
p vlue (vs control)                        2.73E-06    5.53E-04                                    4.31E-03     9.34E-01 
 
b-actin level in Pax7 transfectants 
C2C12                                dfd13 
mCherry  dsgfpsh Pax7mCherry Pax7sh  mCherry  dsgfpsh Pax7mCherry Pax7sh 
1               1          7.63E-01    9.49E-02          1              1           6.25E-01     4.83E-01 
1               1          1.02            6.18E-02          1              1           6.22E-01     6.96E-01 
1               1          8.74E-01    1.78E-01          1              1            7.27E-01    1.00 
Average          1               1          8.84E-01    1.12E-01          1              1           6.58E-01    7.28E-01 
STDEV           0               0          1.27E-01    5.99E-02          0              0           5.99E-02    2.62E-01 
st error           0               0          8.95E-02    4.24E-02           0             0            4.24E-02    1.85E-01 
p vlue (vs control)                      1.88E-01    1.37E-05                                        5.89E-04    1.46E-01 
 
Figure 5.12 
Pax7 level in Cav-1/Cav-3 transfectants 
C2C12                                                                                               dfd13 
eGFP     Cav1eGFP  Cav3eGFP  dsgfpsh  Cav1KD   Cav3KD  eGFP     Cav1eGFP  Cav3eGFP  dsgfpsh  Cav1KD   Cav3KD  
1          4.67E-01     3.42E-01           1        9.29E-01     1.65            1             1.24              5.14               1          1.42          1.46   
1          7.43E-01     7.11E-01           1        9.49E-01     1.06            1             1.16              1.21               1          1.32          1.61   
1          4.15E-01     3.08E-01           1        1.07             2.38            1             1.41              3.75               1          1.44          1.31    
Average        1          5.42E-01     4.54E-01           1        9.83E-01     1.70           1              1.18              3.37               1          1.39         1.46 
st error          0         1.25E-01     1.58E-01           0        5.46E-02  4.67E-01       0           3.56E-02        1.41                0       4.71E-02   1.08E-01 
p vlue (vs control)   1.09E-02     1.34E-02                     7.27E-01  1.41E-01                    3.58E-03    1.09E-01                     5.20E-04    6.61E-03 
 
Cav-1 level in Cav-1/Cav-3 transfectants 
C2C12                                                                                               dfd13 
eGFP     Cav1eGFP  Cav3eGFP  dsgfpsh  Cav1KD   Cav3KD  eGFP     Cav1eGFP  Cav3eGFP  dsgfpsh  Cav1KD   Cav3KD  
1           9.03E-01     5.33E-01          1         1.03          7.47E-01    1             8.82E-01        1.79             1          7.60E-01    6.05E-01   
1              1.33          3.23E-01          1         1.38          5.67E-01    1                1.27             1.69             1          8.02E-01    9.41E-01   
1              2.44          8.20E-01          1         2.74          5.20E-01    1             7.86E-01        1.05             1          6.43E-01    8.75E-01    
Average        1                2             5.59E-01          1         1.72          6.11E-01    1             9.80E-01        1.51            1          7.35E-01    8.07E-01 
st error          0          7.68E-01     1.77E-01          0        6.36E-01   8.45E-02     0            1.82E-01    2.82E-01         0          5.83E-02   1.26E-01 
p vlue (vs control)    5. 26E-01    3.77E-02                    2.39E-01   4.89E-03                    8.99E-01    9.13E-02                    5.11E-03    1.34E-01 
 
Cav-3 level in Cav-1/Cav-3 transfectants 
C2C12                                                                                               dfd13 
eGFP     Cav1eGFP  Cav3eGFP  dsgfpsh  Cav1KD   Cav3KD  eGFP     Cav1eGFP  Cav3eGFP  dsgfpsh  Cav1KD   Cav3KD  
1               1.12         9.75E-01         1        7.28E-01    6.47E-01      1           6.29E-01         1.43            1         4.64E-01     7.91E-01   
1               1.05         6.08E-01         1        7.22E-01    7.05E-01      1               1.03        9.40E-01          1        6.65E-01     6.61E-01   
1           9.15E-01     9.34E-01         1        8.37E-01    9.92E-01      1           8.12E-01         1.49             1         8.64E-01    5.66E-01    
Average        1               1.03        8.39E-01         1        7.63E-01    7.81E-01      1            8.24E-01         1.29             1        6.64E-01    6.73E-01 
st error         0           7.50E-02     1.42E-01         0        4.58E-02   1.31E-01      0           1.42E-01    2.14E-04           0        1.42E-01    8.01E-02 
p vlue (vs control)     6.63E-01    2.38E-01                   3.15E-03   1.10E-01                   2.03E-01     1.75E-01                    4.39E-02     7.45E-03 
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Appendix 5. Raw data of Chapter 6 
Mechanical test of MG/MIG stable clones                                              Modulus distribution of MG/MIG stable clones 
C2MG     C2MG       C2MIG     C2MIG                              C2MG     C2MG     C2MIG    C2MIG 
gfpRNAi   igf2RNAi   gfpRNAi   igf2RNAi                           gfpRNAi   igf2RNAi   gfpRNAi   igf2RNAi 
3.25E+03   1.54E+03   1.89E+03   3.50E+03                 0                                                       1             4 
4.62E+03   1.27E+03   8.72E+02   4.05E+02                 1                                  24                 2            10  
4.90E+03   1.51E+03   1.21E+03   1.92E+03                 2                2                  4                 7            11 
5.01E+03   2.63E+03   3.36E+03   8.37E+02                 3                8                  1               10             4 
3.34E+03   2.92E+03   2.73E+03   9.77E+02                 4                6                                     4 
7.90E+03   1.67E+03   4.72E+03   3.82E+03                 5                4                  1                 1             1 
2.77E+03   1.42E+03   3.17E+03   2.05E+03                 6                3                                     1 
5.45E+03   1.69E+03   2.82E+03   1.99E+03                 7                1                                     1 
2.65E+03   1.40E+03   3.29E+03   1.41E+03                 8                4 
2.11E+03   2.80E+03   3.95E+03   8.65E+02                 9                                                       1 
8.47E+03   1.43E+03   3.34E+03   1.52E+03                10               2 
3.59E+03   1.00E+03   3.14E+03   2.14E+03                11 
8.43E+03   1.12E+03   3.42E+03   1.86E+03                12                                                       2 
3.53E+03   1.43E+03   3.13E+03   2.25E+03              Total            30              30                 30           30 
6.37E+03   1.30E+03   2.38E+03   3.40E+03              
4.20E+03   1.43E+03   2.32E+03   2.02E+03                    Cell height distribution of MG/MIG stable clones   
3.26E+03   1.79E+03   3.16E+03   2.40E+03                                  C2MG    C2MG    C2MIG   C2MIG  
5.79E+03   1.74E+03   2.79E+03   1.98E+03           height (μm) gfpRNAi  igf2RNAi  gfpRNAi  igf2RNAi     
4.12E+03   1.04E+03   2.87E+03   2.16E+03                 2                   1                                 6 
3.04E+03   1.83E+03   2.08E+03   1.88E+03                 3                  11                1             10              1 
6.82E+03   1.42E+03   3.42E+03   2.47E+03                 4                  10                1             11              3 
8.21E+03   1.32E+03   4.38E+03   1.97E+03                 5                    5                2               7              8 
4.26E+03   1.32E+03   4.31E+03   1.60E+03                 6                    5                4               4              3 
8.22E+03   1.36E+03   6.03E+03   2.62E+03                 7                    2               10              4             11 
3.98E+03   1.56E+03   4.93E+03   2.61E+03                 8                                       4                              5 
1.09E+04   2.65E+03   1.28E+04   3.95E+03                 9 
6.43E+03   3.01E+03   7.29E+03   5.86E+03                 10                                     4                              3 
4.78E+03   1.91E+03   5.62E+03   1.81E+03                 11                                     1               2             2 
1.19E+04   1.13E+03   1.24E+04   2.02E+03                 12                  1                 1                              1 
5.40E+03   4.59E+03   9.56E+03   2.25E+03                 13                  1                                                 1 
Average (Pa) 5.50E+03   1.77E+03   4.25E+03   2.22E+03                 14 
STDEV          2.42E+03   7.73E+02   2.86E+03   1.07E+03                15                                                                      1 
st error          4.49E+02   1.44E+02   5.32E+02   1.99E+02                 16 
vs. control                         7.49E-19                       5.95E-04                 17                  1 
vs. MG                                                9.76E-09     7.11E-02             Total                37               28              44           39 
 
E15.5 wt intercostal 
My32(+)   Cav3(+)    Cav3(+)   % of My32(+)   Cav1(+)   Cav1(+)  % of My32(+)   Cav1(+)Cav3(+)   % of My32(+)                       
My32(+)                                               My32(+)                                                  My32(+) 
3.40E+01   1.20E+01  2.00E+01     3.53E+01       4.00E+00  1.20E+01      1.18E+01           4.00E+00         1.18E+01 
5.30E+01   1.80E+01  3.20E+01    3.40E+01        2.00E+00  9.00E+00      3.77E+00           2.00E+00         3.77E+00 
7.00E+01   2.00E+01  4.70E+01    2.86E+01        4.00E+00  1.40E+01      5.71E+00           2.00E+00         2.86E+00 
4.10E+01   1.20E+01  3.20E+01    2.93E+01        3.00E+00  1.00E+01      7.32E+00           2.00E+00         4.88E+00 
4.50E+01   1.10E+01  4.00E+01    2.44E+01        2.00E+00  1.00E+01      4.44E+00           2.00E+00         4.44E+00 
5.70E+01   1.50E+01  4.10E+01    2.63E+01        2.00E+00  1.30E+01      3.51E+00           3.00E+00         5.26E+00 
3.80E+01   1.00E+01  2.30E+01    2.63E+01        2.00E+00  1.00E+01      5.26E+00           2.00E+00         5.26E+00 
6.60E+01   2.20E+01  6.30E+01    3.33E+01        8.00E+00  2.50E+01      1.21E+01           5.00E+00         7.58E+00 
6.40E+01   2.40E+01  4.80E+01    3.75E+01        7.00E+00  2.50E+01      1.09E+01           4.00E+00         6.25E+00 
6.70E+01   1.80E+01  4.40E+01    2.69E+01        5.00E+00  1.30E+01      7.46E+00           3.00E+00         4.48E+00 
6.20E+01   2.00E+01  4.60E+01    3.23E+01        4.00E+00  2.00E+01      6.45E+00           2.00E+00         3.23E+00 
4.50E+01   1.40E+01  3.00E+01    3.11E+01        4.00E+00  1.30E+01      8.89E+00           2.00E+00         4.44E+00 
Average      5.35E+01  1.63E+01  3.88E+01    3.04E+01        3.92E+00  1.45E+01     7.30E+00           2.75E+00         5.35E+00 
STDEV       1.25E+01  4.64E+00  1.20E+01    4.11E+00        1.98E+00  5.68E+00     3.03E+00          1.06E+00          2.39E+00 
st error       3.78E+00  1.40E+00  3.63E+00    1.24E+00         5.96E-01  1.71E+00      9.15E-01           3.18E-01          7.20E-01 
p(vs mdx)    9.23E-01                     3.82E-01     3.09E-05                           9.53E-02       2.08E-04                                     2.15E-04 
15.5 mdx intercostal 
My32(+)    Cav3(+)  Cav3(+)   % of My32(+)   Cav1(+)   Cav1(+)  % of My32(+)   Cav1(+)Cav3(+)   % of My32(+)                          
My32(+)                                             My32(+)                                                    My32(+)      
2.30E+01  1.30E+01  2.70E+01   5.65E+01       0.00E+00  1.60E+01    0.00E+00           0.00E+00              0.00E+00 
4.80E+01  2.20E+01  3.30E+01   4.58E+01       0.00E+00  1.60E+01    0.00E+00           0.00E+00              0.00E+00 
7.10E+01  3.30E+01  4.90E+01   4.65E+01       1.00E+00  2.60E+01    1.41E+00           0.00E+00              0.00E+00 
7.70E+01  2.50E+01  3.50E+01   3.25E+01       1.00E+00  1.90E+01    1.30E+00           1.00E+00              1.30E+00 
4.40E+01  1.40E+01  2.50E+01   3.18E+01       0.00E+00  1.30E+01    0.00E+00           0.00E+00              0.00E+00 
5.20E+01  2.10E+01  7.00E+01   4.04E+01       3.00E+00  1.60E+01    5.77E+00           2.00E+00              3.85E+00 
5.70E+01  3.10E+01  5.10E+01   5.44E+01       3.00E+00  2.00E+01    5.26E+00           0.00E+00              0.00E+00 
6.50E+01  3.90E+01  5.80E+01   6.00E+01       2.00E+00  1.40E+01    3.08E+00           2.00E+00              3.08E+00 
7.80E+01  4.80E+01  6.50E+01   6.15E+01       3.00E+00  1.80E+01    3.85E+00           3.00E+00              3.85E+00 
5.20E+01  2.00E+01  3.60E+01   3.85E+01       2.00E+00  1.90E+01    3.85E+00           0.00E+00              0.00E+00 
4.20E+01  1.80E+01  3.40E+01   4.29E+01       0.00E+00  1.70E+01    0.00E+00           0.00E+00              0.00E+00 
4.00E+01  2.20E+01  4.20E+01   5.50E+01       2.00E+00  2.00E+01    5.00E+00           2.00E+00              5.00E+00 
Average      5.41E+01 2.55E+01  4.38E+01   4.71E+01      1.42E+00  1.78E+01    2.46E+00            8.33E-01              1.42E+00 
 384 
STDEV    1.64E+01 1.04E+01  1.48E+01    1.03E+01       1.24E+00  3.41E+00  2.26E+00          1.11E+00              1.94E+00 
St error    4.95E+00 3.14E+00  4.46E+00    3.10E+00       3.74E-01   1.03E+00  6.81E-01           3.36E-01                5.85E-01 
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Figure 6.14-6.18 Modulus of myotubes 
C2C12  C2C12-mCherry  C2C12  C2C12-mCherry  C2C12  C2C12-mCherry  C2C12-        dfd13 dfd13-mCherry  dfd13-  dfd13-mCherry  dfd13-   dfd13-mCherry  dfd13- 
-eGFP   -dsGFP(shag)  -Cav1eGFP   Cav1KD          -Cav3eGFP  Cav3KD   minidys-eGFP -eGFP   -dsGFP(shag) Cav1eGFP  Cav1KD         Cav3eGFP  Cav3KD  minidys-eGFP 
                    7.94E+03   3.01E+03      1.21E+04     1.92E+03             1.60E+04   1.66E+03     3.80E+03        2.72E+03    2.65E+03    5.21E+03    1.12E+03         5.15E+03   9.68E+03    4.54E+03 
7.24E+03   2.33E+03      2.37E+03     4.89E+03             2.30E+03   1.34E+03     8.37E+03        4.78E+03    2.85E+03    5.15E+03    2.96E+03         4.36E+03   2.34E+03    2.71E+03 
1.04E+04   1.33E+03      4.11E+03     5.55E+03             1.07E+04   4.58E+03     1.63E+04        3.34E+03    3.54E+03    5.68E+03    9.18E+02         3.85E+03   8.23E+03    4.21E+04 
9.95E+03   1.82E+03      2.44E+03     3.71E+03             6.61E+03   3.90E+03     3.34E+03        1.90E+03    2.97E+03    6.91E+03    5.42E+02         4.92E+03   6.94E+03    3.67E+03 
9.31E+03   3.86E+03      3.74E+03     4.16E+03             5.86E+03   2.11E+03     1.17E+03        1.58E+03    2.87E+03    3.22E+03    2.58E+02         4.02E+03   4.21E+03    9.05E+03 
5.38E+03   3.47E+03      3.30E+03     2.60E+03             4.18E+03   5.37E+03     7.78E+02        2.27E+03    5.45E+03    4.43E+03    3.08E+03         2.15E+03   5.46E+03    3.14E+03 
7.64E+03   4.70E+03      3.36E+03     2.12E+03             7.02E+03   8.12E+03     2.60E+03        6.86E+03    1.12E+03    7.47E+03    3.49E+02         3.08E+03   8.73E+03    5.59E+03 
4.88E+03   1.69E+03      6.45E+03     4.48E+03             1.01E+04   3.95E+03     2.39E+03        2.59E+03    4.17E+03    2.85E+03    2.40E+02         8.78E+03   4.07E+03    2.41E+03 
5.98E+03   1.72E+03      3.77E+03     5.68E+03             8.87E+03   4.08E+03     3.91E+03        1.36E+03    3.22E+03    6.77E+03    4.53E+02         1.32E+03   3.46E+03    3.38E+03 
6.51E+03   1.34E+03      2.76E+03     9.86E+03             4.61E+03   8.49E+03     7.25E+02        2.17E+03    3.42E+03    3.42E+03    5.85E+03         2.25E+03   9.93E+03    8.10E+03 
4.21E+03   3.19E+03      6.78E+02     6.70E+03             2.27E+04   4.78E+03     1.15E+03        2.44E+03    2.96E+03    9.66E+03    2.48E+03         1.81E+03   9.32E+03    2.70E+03 
3.34E+03   2.84E+03      1.46E+03     8.00E+03             8.04E+03   1.98E+03     1.07E+03        1.71E+03    4.65E+03    4.26E+03    1.44E+03         3.13E+03   7.48E+03    3.07E+03 
1.20E+04   3.52E+03      3.83E+03     2.08E+03             6.27E+03   9.88E+03     1.29E+03        1.21E+03    6.77E+03    5.49E+03    1.95E+03         3.42E+03   5.94E+03    1.49E+03 
8.61E+03   1.57E+03      2.32E+03     4.99E+03             1.03E+04   2.07E+03     1.99E+03        3.20E+03    3.22E+03    2.29E+03    4.25E+03         2.31E+03   6.30E+03    4.10E+03 
4.61E+03   3.96E+03      2.26E+03     6.02E+03             1.84E+04   2.22E+03     8.53E+02        2.14E+03    2.75E+03    9.74E+03    1.71E+03         2.32E+03   3.24E+03    1.51E+03 
4.31E+03   2.52E+03      5.34E+03     4.02E+03             6.35E+03   5.04E+03     4.54E+03        3.86E+03    5.61E+03    3.86E+03    1.92E+03         2.62E+03   7.54E+03    2.71E+03 
5.64E+03   2.43E+03      3.13E+03     3.16E+03             5.17E+03   7.37E+03     1.35E+03        2.12E+03    2.72E+03    2.31E+03    5.99E+02         8.90E+03   5.76E+03    3.28E+03 
7.81E+03   2.49E+03      2.00E+03     1.21E+03             4.60E+03   2.42E+03     9.68E+02        1.74E+03    3.18E+03    4.05E+03    1.25E+03         2.40E+03   7.16E+03    3.49E+03 
4.94E+03   2.92E+03      5.51E+03     4.56E+03             7.90E+03   1.09E+03     1.07E+03        1.47E+03    2.82E+03    1.43E+04    5.24E+03         2.19E+03   5.48E+03    2.32E+03 
2.97E+03   2.84E+03      1.89E+03     1.90E+03             6.85E+03   2.62E+03     3.16E+03        3.16E+03    5.53E+03    6.09E+03    3.66E+03         1.21E+03   5.27E+03    1.18E+03 
4.82E+03   3.41E+03      3.85E+03     1.22E+04             6.07E+03   2.20E+03     3.69E+03        1.58E+03    3.62E+03    6.85E+03    1.49E+03         2.32E+03   6.30E+03    1.52E+03 
2.19E+03   2.56E+03      2.31E+03     6.16E+03             7.67E+03   9.29E+02     1.18E+03        3.24E+03    2.88E+03    3.55E+03    9.94E+02         2.27E+03   7.94E+03    2.68E+03 
2.22E+03   3.30E+03      2.53E+03     8.95E+03             2.79E+03   2.31E+03     2.38E+03        2.01E+03    1.92E+03    2.51E+03    9.47E+02         5.18E+03   5.71E+03    1.20E+03 
2.14E+03   3.39E+03      1.53E+03     9.74E+03             1.68E+03   5.12E+03     9.15E+02        1.28E+03    4.75E+03    5.16E+03    2.24E+03         1.64E+03   7.35E+03    2.48E+03 
2.33E+03   2.61E+03      6.30E+02     1.16E+04             4.89E+03   8.22E+02     1.43E+03        2.15E+03    5.12E+03    2.39E+03    1.26E+03         1.04E+03   6.40E+03    1.28E+03 
2.40E+03   2.66E+03      3.73E+03     7.93E+03             4.22E+03   1.40E+03     1.36E+03        3.96E+03    3.84E+03    2.99E+03    1.60E+03         1.28E+03   5.16E+03    3.13E+03 
6.08E+03   2.37E+03      5.10E+03     7.79E+03             7.09E+03   4.75E+03     2.94E+03        1.44E+03    6.98E+03    2.60E+03    1.72E+03         1.46E+03   6.30E+03    3.35E+03 
3.02E+03   2.67E+03      3.10E+03     4.69E+03             6.96E+03   1.43E+03     1.12E+03        1.33E+03    7.84E+03    5.45E+03    2.20E+03         9.98E+02   9.05E+03    2.60E+03 
1.91E+03   3.13E+03      4.33E+03     5.42E+03             3.15E+03   3.68E+03     4.45E+02        3.08E+03    5.65E+03    6.96E+03    2.04E+03         5.00E+02   7.69E+03    5.37E+03 
1.10E+04   2.90E+03      8.04E+03     2.26E+03             4.65E+03   3.02E+03     7.18E+03        1.60E+03    3.15E+03    5.74E+03    1.96E+03         1.51E+03   4.63E+03    1.96E+03 
Average      5.72E+03   2.75E+03     3.60E+03     5.48E+03             7.40E+03   3.62E+03     2.78E+03        2.48E+03   3.94E+03    5.25E+03   1.89E+03         2.95E+03   6.44E+03    4.54E+03 
STDEV       2.92E+03   7.95E+02     2.29E+03    2.95E+03              4.62E+03   2.38E+03     3.16E+03       1.23E+03   1.57E+03     2.66E+03   1.40E+03         2.04E+03   1.95E+03    7.32E+03 
st error        5.41E+02  1.48E+02     4.26E+02     5.49E+02             8.58E+02   4.42E+02     5.87E+02        2.28E+02   2.92E+02    4.93E+02   2.60E+02         3.78E+02   3.61E+02    1.36E+03 
p value (vs.C2C12)                                                                                                                                             5.6E-07      4.77E-04      1.28E-02   1.62E-06           1.05E-05    5.50E-06     2.33E-01 
p value (vs.control)                            2.68E-03     8.56E-06              9.86E-02     6.20E-02      4.1E-04                                                 2.86E-06    1.30E-07           2.83E-01    1.03E-06     1.34E-01 
 
Figure 6.14-6.18 Modulus distribution of myotubes 
C2C12  C2C12-mCherry  C2C12  C2C12-mCherry  C2C12  C2C12-mCherry  C2C12-      dfd13   dfd13-mCherry  dfd13-  dfd13-mCherry   dfd13-       dfd13-mCherry  dfd13- 
-eGFP   -dsGFP(shag)    -Cav1eGFP   Cav1KD       -Cav3eGFP  Cav3KD   minidys-eGFP  -eGFP   -dsGFP(shag)    Cav1eGFP  Cav1KD      Cav3eGFP  Cav3KD       minidys-eGFP 
Modulous (Force) 
0                                                                      2                                                                 2             6                                                                                        9              2 
1                       1              6                             4                 3                           1                 5            12                      12               2                                           11             8                                               7   
2                       6             13                            8                 4                           2                 7             4                        9                9                        7                  5              9                       1                      8 
3                       2             10                            9                 2                           1                 4             5                        7                8                        4                  2              4                       2                      8 
4                       6              1                             2                 7                           6                 4             1                        1                3                        3                  1              3                       3                      2 
5                       3                                             3                 3                           2                 3                                                         5                        7                  2              2                       7                      2 
6                       2                                             1                 3                           6                                                          1                2                        5                                                           5 
7                       4                                                                3                           4                 1             1                                          1                        1                                                           6 
8                       1                                             1                 1                           2                 2             1                                                                                                         2                      2                      1 
9                       2                                                                2                                              1                                                                                   2                                                           4                      1 
10                     2                                                                                             3                 1 
11                     1                                                                1 
12                                                                                       1 
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13 
14                                                                                                                                                                                                                            1 
15                                                                                                                   1 
18                                                                                                                   1 
22                                                                                                                   1 
 
Figure 6.20-6.25  Mechanical test  
C2C12   C2C12mock  C2C12-mCherry  C2C12-eGFP  C2C12-mCherry  C2C12-Cav3eGFP  C2C12-mCherry C2C12-Cav1eGFP  C2C12-mCherry  C2C12-minidys-eGFP  
transfection                                                            -dsGFP(shag)                                            Cav3KO                                                Cav1KO 
2.82E+03   1.66E+03         4.41E+03            3.53E+03             3.23E+03                   3.85E+03               1.54E+03              3.26E+03                4.55E+03               1.73E+03 
6.82E+03   2.47E+03         6.52E+03            2.06E+03             1.88E+03                   3.94E+03               2.57E+03              2.85E+03                3.94E+03               1.70E+03 
4.03E+03   1.34E+03         3.99E+03            2.36E+03             2.89E+03                   5.58E+03               1.07E+03              4.59E+02                4.46E+03               2.06E+03 
2.65E+03   2.33E+03         3.40E+03            2.11E+03             3.75E+03                   4.34E+03               1.93E+03              2.74E+03                1.92E+03               2.21E+03 
3.12E+03   3.05E+03         5.76E+03            2.71E+03             1.76E+03                   3.81E+03               1.77E+03              2.99E+03                1.69E+03               1.88E+03 
4.12E+03   1.26E+03         4.13E+03            3.21E+03             1.99E+03                   4.81E+03               1.89E+03              3.95E+03                1.97E+03               1.72E+03 
2.73E+03   2.26E+03         6.60E+03            2.25E+03             4.26E+03                   3.05E+03               1.78E+03              2.35E+03                2.58E+03               3.18E+03 
4.11E+03   2.82E+03         3.47E+03            1.78E+03             3.15E+03                   3.16E+03               1.08E+03              2.78E+03                3.25E+03               1.95E+03 
3.89E+03   2.02E+03         9.77E+03            1.73E+03             3.30E+03                   6.21E+03               1.97E+03              3.18E+03                2.38E+03               1.86E+03 
4.13E+03   3.08E+03         4.53E+03            2.09E+03             1.69E+03                   3.99E+03               1.18E+03              5.73E+02                3.45E+03               4.29E+03 
3.55E+03   1.66E+03         7.21E+03            2.55E+03             3.77E+03                   8.89E+03               2.42E+03              2.76E+03                1.20E+03               4.27E+03 
2.68E+03   6.51E+03         5.58E+03            3.49E+03             3.65E+03                   6.04E+03               2.78E+03              3.72E+03                2.02E+03               4.49E+03 
4.85E+03   2.41E+03         5.63E+03            4.40E+03             3.00E+03                   6.39E+03               2.12E+03              2.21E+03                4.18E+03               5.06E+03 
3.17E+03   2.80E+03         8.18E+03            2.56E+03             4.09E+03                   4.59E+03               2.35E+03              4.74E+03                2.67E+03               3.34E+03 
4.16E+03   1.47E+03         1.03E+04            2.66E+03             4.52E+03                   7.50E+03               2.17E+03              2.39E+03                2.50E+03               4.61E+03 
3.52E+03   2.62E+03         1.37E+04            3.70E+03             3.76E+03                   5.62E+03               2.19E+03              2.62E+03                3.89E+03               1.15E+04 
4.68E+03   7.29E+03         8.72E+03            8.96E+03             3.18E+03                   1.13E+04               1.54E+03              1.60E+03                2.71E+03               2.63E+03 
4.11E+03   6.40E+03         7.23E+03            1.86E+03             2.73E+03                   1.78E+03               1.61E+03              1.99E+03                1.68E+03               3.49E+03 
2.76E+03   4.60E+03         4.74E+03            2.91E+03             3.40E+03                   3.48E+03               1.40E+03              2.87E+03                2.64E+03               6.87E+03 
6.86E+03   1.58E+03         6.39E+03            2.72E+03             3.33E+03                   1.04E+04               1.79E+03              1.25E+03                1.95E+03               1.88E+03 
5.21E+03   1.77E+03         9.94E+03            3.53E+03             2.74E+03                   5.23E+03               1.19E+03              6.53E+03                8.03E+03               9.07E+03 
4.51E+03   2.14E+03         9.63E+03            1.88E+03             2.93E+03                   6.35E+03               1.52E+03              5.49E+03                7.31E+03               7.11E+03 
7.70E+03   3.08E+03         5.03E+03            3.21E+03             4.96E+03                   3.44E+03               1.33E+03              6.33E+03                5.89E+03               1.22E+04 
3.92E+03   1.38E+03         5.37E+03            2.06E+03             3.52E+03                   8.32E+03               1.37E+03              6.12E+03                3.36E+03               8.88E+03 
3.86E+03   1.45E+03         4.79E+03            2.17E+03             3.85E+03                   6.64E+03               1.07E+03              3.88E+03                5.50E+03               8.55E+03 
4.26E+03   2.61E+03         8.79E+03            2.36E+03             4.47E+03                   3.64E+03               2.04E+03              7.85E+03                6.23E+03               7.58E+03 
6.08E+03   1.98E+03         9.02E+03            1.66E+03             3.11E+03                   3.92E+03               2.08E+03              5.68E+03                6.52E+03               2.83E+03 
3.06E+03   1.31E+03         5.65E+03            2.11E+03             5.45E+03                   4.55E+03               1.74E+03              3.15E+03                5.77E+03               4.40E+03 
7.67E+03   1.77E+03         4.58E+03            2.71E+03             3.10E+03                   9.61E+03               1.31E+03              4.54E+03                5.76E+03               7.07E+03 
3.23E+03   1.30E+03         4.57E+03            1.88E+03             3.53E+03                   3.99E+03               1.06E+03              2.81E+03                7.21E+03               5.45E+03 
Average (Pa)   4.28E+03   2.61E+03         6.59E+03            2.77E+03             3.44E+03                   5.48E+03               1.73E+03             3.03E+03               3.91E+03               4.79E+03 
STDEV            1.44E+03   1.58E+03         2.47E+03            1.35E+03            7.74E+02                    2.33E+03               4.77E+02             1.86E+03               1.94E+03               3.01E+03 
st error            2.67E+02   2.94E+02         4.59E+02            2.51E+02             1.44E+02                   4.33E+02               8.85E+01              3.46E+02               3.61E+02              5.60E+02 
p value (vs control)                                                                                                                                 8.74E-07                1.74E-12              1.00E-01                1.71E-01               1.41E-03 
vs dfd13           6.58E-02    8.26E-02          4.79E-04             7.97E-06              1.15E-01                    2.58E-08                3.57E-02               2.18E-02                5.68E-02                9.15E-01 
 
Figure 6.20-6.25  Modulus distribution of C2C12 myoblasts  
Modulous (Force) C2C12  C2C12-mCherry  C2C12-eGFP  C2C12-mCherry  C2C12-Cav3eGFP  C2C12-mCherry  C2C12-Cav1eGFP  C2C12-mCherry  C2C12-minidys-eGFP 
-dsGFP(shag)                                            Cav3KO                                                 Cav1KD 
0                                                                                                                                                                                                                2                     
1                                                                                    6                            4                            1                              21                            3                                6                                 7 
2                                  5                                               16                           5                                                              9                           11                               7                                 4 
3                                  9                  3                            6                           15                           11                                                            6                                5                                 3 
4                                10                  7                            1                            5                             4                                                             2                                3                                 5 
5                                 1                   6                                                          1                             3                                                             2                                4                                 2 
6                                 3                   3                                                                                         5                                                             3                                2                                 1 
7                                 2                   2                                                                                         1                                                             1                                2                                 3 
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8                                                      3                            1                                                           2                                                                                               1                                 2 
9                                                      4                                                                                         1                                                                                                                                  1 
10                                                    1                                                                                                                          1 
11                                                                                                                                               1                                                                                                                                  1 
12                                                                                                                                                                                                                                                                                   1 
13                                                   1 
Total                        30                 30                          30                          30                            30                              30                          30                               30                             30 
 
 
Figure 6.20-6.25  Cell heights of C2C12 myoblasts  
height (um)   C2C12   C2C12 mock   C2C12-mCherry  C2C12-eGFP C2C12-mCherry C2C12-Cav3eGFP  C2C12-mCherry C2C12-Cav1eGFP  C2C12-mCherry C2C12-minidys-eGFP 
 transfection                                                               -dsGFP(shag)                                             Cav3KD                                             Cav1KD 
0 
1                                                                          1 
2                           6                                             6                                                                                             3                                                        4                                                        2 
3                          13                7                         21                            2                           5                                                                4                         7                               6                       4 
4                           9                 7                         11                            4                           8                                 10                           7                         7                                8                      8 
5                          15              12                          9                             7                         12                                  3                           10                        3                                8                      6 
6                           3                4                                                          6                         10                                  3                             7                        7                                4                      4 
7                           2                1                           4                             8                          4                                   2                             5                                                          6                      4 
8                           1                2                                                          3                          5                                   2                                                                                         1                      3 
9                           1                1                                                          5                          8                                   2                             3                        1 
10                         1                1                                                          1                          3                                                                  2                        1                                2 
11                                                                                                       2                          3                                                                                                                              1                       2 
12                                                                                                       2                          3                                                                  1                                                          1                       1 
13                                           1                                                                                      1                                   13                           1 
14                                                                                                                                   1 
15                                                                                                                                   2 
16  
17                                                                                                                                   1 
Total                    51              36                            52                          40                      66                                  38                           40                       30                            37                   34 
 
Modulus distribution of dfd13 myoblasts  
dfd13  dfd13 mock  dfd13-mCherry  dfd13-eGFP  dfd13-mCherry  dfd13-mCherry  dfd13-Cav3eGFP  dfd13-mCherry  dfd13-Cav1eGFP  dfd13-minidyseGFP 
transfection                                                       -dsGFP(shag)            Cav3KD                                             Cav1KD 
0                                      1                                                                                                                                                                         2                          1 
1                       5            10                                                                             2                             15                       11                             5                          1 
2                       6             5                        4                          2                        8                             12                        9                             13                         6                             7 
3                       5             5                      12                         10                       8                              2                         5                              6                          5                             8 
4                       5             3                        2                          8                        6                                                         3                              4                        10                             5 
5                       4             3                        7                          4                        4                                                                                                                     2                             1 
6                       1             3                        2                          4                                                        1                                                                                     2                             2 
7                       3                                       1                                                                                                                                                                           1                             1 
8                       1                                       2                                                    1                                                                                                                     1                             4 
9                                                                                            1                        1                                                                                                                                                    1 
10                                                                                          1                                                                                                                   1                          2 
11                                                                                                                                                                                                                                                                          1 
Total              30            30                     30                          30                     30                            30                       30                            30                         30                          30 
 
Cell heights of dfd13 myoblasts  
Height (μm)   dfd13  dfd13 mock  dfd13-mCherry  dfd13-eGFP  dfd13-mCherry  dfd13-mCherry  dfd13-Cav3eGFP  dfd13-mCherry  dfd13-Cav1eGFP  dfd13-minidyseGFP 
transfection                                                       -dsGFP(shag)      Cav3KD                                                Cav1KD 
0 
1                                                                     1 
2                          7              4                         1                       4                       6                          2                             8                              9                          2                               5 
3                        14             15                       11                    18                      11                        11                           11                            13                        16                             10 
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4                          1              5                         9                     18                       9                         20                            9                              8                         10                              3 
5                                          4                         2                     10                       6                         14                            5                              1                         10                              3 
6                                          2                         2                       6                       1                           4                            5                              3                           1                              2 
7                         3               3                         1                       3                       2                           4                            2                              1                           2                              4 
8                                                                                              1                       1                           3                                                            2                           1                              1 
9                        1                                                                                                                                                                                        1                           3                              4 
10                      1                                                                                                                                                                                                                                                     5 
11                                                                                                                    2 
12 
13 
14                                                                                                                                                                                                                                                                             1 
Total                27              33                       27                    60                     38                         58                            40                           38                          45                           38 
Mechanical test of dfd13 myoblasts  
dfd13   dfd13 mock  dfd13-mCherry  dfd13-eGFP  dfd13-mCherry  dfd13-mCherry  dfd13-Cav3eGFP  dfd13-mCherry  dfd13-Cav1eGFP  dfd13-minidyseGFP 
transfection                                                     -dsGFP(shag)       Cav3KD                                                Cav1KD 
3.78E+03   1.54E+03      4.08E+03              4.14E+03        3.96E+03            1.79E+03             2.30E+03                  2.07E+03            3.69E+03              2.74E+03 
4.02E+03   6.38E+03      3.97E+03              4.50E+03        3.39E+03            1.31E+03             1.66E+03                  3.18E+03            4.55E+03              4.34E+03 
2.99E+03   5.19E+03      6.00E+03              5.43E+03        2.74E+03            6.12E+02             8.74E+02                  1.75E+03            5.30E+03              3.19E+03 
1.14E+03   3.37E+03      3.95E+03              3.34E+03        2.35E+03            1.97E+03             3.42E+03                  3.03E+03            3.60E+03              2.50E+03 
2.82E+03   4.58E+03      2.79E+03              3.73E+03        4.48E+03            2.15E+03             4.38E+03                  2.77E+03            5.93E+03              3.18E+03 
6.76E+03   3.90E+03      5.59E+03              4.38E+03        2.87E+03            1.78E+03             2.45E+03                  2.19E+03            6.98E+03              3.66E+03 
3.08E+03   6.09E+03      2.59E+03              4.41E+03        3.41E+03            1.69E+03             1.11E+03                  8.54E+02            1.66E+03              6.22E+03 
4.49E+03   6.22E+03      8.43E+03              3.49E+03        4.79E+03            1.78E+03             1.28E+03                  1.53E+03            4.67E+03              4.50E+03 
3.67E+03   5.16E+03      3.10E+03              6.50E+03        8.82E+03            2.02E+03             3.96E+03                  1.74E+03            4.74E+03              2.57E+03 
4.06E+03   5.68E+03      3.59E+03              4.47E+03        4.58E+03            2.08E+03             3.65E+03                  2.47E+03            6.09E+03              3.33E+03 
2.86E+03   4.59E+03      7.82E+03              3.33E+03        2.50E+03            3.19E+03             4.55E+03                  2.28E+03            2.58E+03              3.02E+03 
1.64E+03   2.84E+03      6.19E+03              2.46E+03        2.70E+03            2.21E+03             2.81E+03                  2.82E+03            4.13E+03              2.57E+03 
1.49E+03   3.62E+03      8.07E+03              3.42E+03        2.25E+03            2.71E+03             3.86E+03                  2.12E+03            2.68E+03              6.86E+03 
2.14E+03   1.59E+03      4.84E+03              5.86E+03        2.38E+03            2.96E+03             4.38E+03                  1.28E+03            2.36E+03              3.03E+03 
5.16E+03   1.48E+03      5.83E+03              5.20E+03        5.46E+03            2.41E+03             1.73E+03                  2.54E+03            4.09E+03              2.68E+03 
7.09E+03   1.64E+03      5.83E+03              3.45E+03        2.09E+03            3.20E+03             6.50E+02                  2.51E+03            4.38E+03              4.51E+03 
2.38E+03   8.94E+02      5.82E+03              6.96E+03        5.22E+03            1.80E+03             1.61E+03                  2.71E+03            7.46E+03              2.75E+03 
2.19E+03   1.73E+03      5.95E+03              3.67E+03        1.88E+03            1.83E+03             1.43E+03                  1.33E+03            2.42E+03              3.39E+03 
1.33E+03   1.90E+03      5.53E+03              3.34E+03        1.94E+03            1.61E+03             2.48E+03                  3.27E+03            8.85E+03              2.19E+03 
1.46E+03   1.71E+03      3.97E+03              4.56E+03        3.11E+03            2.92E+03             1.76E+03                  2.06E+03            1.40E+04              3.01E+03 
7.38E+03   1.22E+03      3.69E+03              9.17E+03        4.36E+03            1.78E+03             3.00E+03                  3.91E+03            3.42E+03              5.69E+03 
7.05E+03   1.94E+03      3.39E+03              3.58E+03        5.56E+03            1.65E+03             2.97E+03                  5.47E+03            2.50E+03              7.84E+03 
5.75E+03   2.48E+03      3.35E+03              5.77E+03        3.22E+03            2.39E+03             2.56E+03                  4.50E+03            3.17E+03              8.35E+03 
8.48E+03   1.18E+03      3.62E+03              6.95E+03        3.32E+03            1.44E+03             2.68E+03                  5.79E+03            2.73E+03              9.42E+03 
4.58E+03   2.53E+03      3.09E+03              6.29E+03        5.46E+03            1.99E+03             1.40E+03                  5.18E+03            4.81E+03              4.09E+03 
5.43E+03   3.63E+03      2.79E+03              2.90E+03        3.41E+03            1.19E+03             1.93E+03                  3.94E+03            4.78E+03              8.98E+03 
3.01E+03   2.85E+03      3.78E+03              4.62E+03        9.30E+03            1.77E+03             1.79E+03                  3.94E+03            4.75E+03              1.01E+04 
3.89E+03   2.89E+03      2.58E+03              4.49E+03        3.83E+03            2.10E+03             2.09E+03                  5.67E+03            4.52E+03              8.15E+03 
4.37E+03   3.15E+03      6.68E+03              3.57E+03        4.40E+03            2.26E+03             1.83E+03                  5.68E+03            1.06E+04              8.31E+03 
5.15E+03   4.10E+03      3.22E+03              1.08E+04        4.61E+03            2.05E+03             3.14E+03                  2.98E+03            3.26E+03              4.93E+03 
Average (Pa)   3.99E+03   3.20E+03      4.67E+03              4.83E+03        3.95E+03           2.02E+03             2.46E+03                  3.05E+03            4.82E+03              4.36E+03 
STDEV            1.99E+03  1.66E+03       1.69E+03              1.85E+03       1.78E+03            5.78E+02             1.09E+03                  1.42E+03            2.63E+03              2.32E+03 
st error             3.70E+02  3.09E+02      3.14E+02              3.44E+02        3.30E+02           1.07E+02              2.02E+02                  2.63E+02            4.89E+02             4.32E+02 
vs control                                                                                                                                   5.45E-07              1.19E-07                   3.56E-02             9.97E-01              9.36E-01 
 
 
